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ABSTRACT 
 
INTRODUCTION 
Low post-operative death rates after cardiac surgery make mortality an inadequate outcome 
measure. As post-operative morbidity is more common, its measurement would be more 
sensitive. Accurate identification and quantification might also allow its aetiology to be 
addressed. The nine domain Post-Operative Morbidity Survey (POMS)(1) is the only prospective 
tool for standardised morbidity measurement in general surgical patients. I sought to develop 
and validate such a tool (cardiac- or C-POMS) for cardiac surgery. 
 
METHODS 
Development: Morbidity was prospectively assessed in 450 cardiac surgery patients on post-
operative days 1, 3, 5, 8 and 15 using POMS criteria and cardiac-specific variables (from an 
expert panel). Other morbidities were noted as free-text and included if prevalence >5%, 
missingness <5% and mean expert-rated severity-importance index score >8. 
Reliability/validity: assessed by expert panel review, using Cronbach’s alpha (internal 
consistency) and linear regression to test the ability of C-POMS to predict length of stay (LOS). 
Clinical utility: assessed by multi-professional teams at two hospitals. 
 
RESULTS 
Development: Following item-reduction, C-POMS resulted in a 13 domain model. 
Reliability/validity: Internal consistency (>0.7) on D3-D15 permits use of C-POMS as a 
summative score of total morbidity burden. Mean C-POMS scores were 3.4 (D3), 2.6 (D5), 3.4 
(D8) and 3.8 (D15). Patient LOS was 4.6 (p=0.012), 5.3 days (p=0.001) and 7.6 days (p=0.135) 
longer in patients with (compared to without) morbidity on D3, D5, D8 and D15, respectively. For 
every unit increase in C-POMS summary score subsequent LOS increased by 1.7 (D3), 2.2 
(D5), 4.5 (D8) and 6.2 (D15) days (all p=0.000). Clinical utility: Demonstrated by C-POMS now 
being routinely collected at two hospitals. 
 
CONCLUSIONS 
C-POMS is the first validated tool for identifying total morbidity burden post cardiac surgery. C-
POMS identifies considerable morbidity in these patients and may assist in modelling causation 
and in identifying preventative and therapeutic targets.  
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ABBREVIATIONS 
Abbreviation Explanation 
ABG Arterial Blood Gas 
ACEI Angiotensin Converting Enzyme Inhibitor 
AMI Acute Myocardial Infarction 
APACHE Acute Physiology and Chronic Health Evaluation 
ASO  Arteriosclerosis Obliterans 
AVR Aortic Valve Replacement 
BIPAP Bi-level Positive Airway Pressure 
BMI Body Mass Index 
BP Blood Pressure 
BPM Beats Per Minute 
CABG Coronary Artery Bypass Graft 
CCSC Canadian Cardiovascular Society Classification 
CDMR Cochrane Database of Methodological Reviews 
CDR Clinical Data Repositiory 
CHB Complete Heart Block 
CHF Chronic Heart Failure 
CI Chief Investigator 
COPD Chronic Obstructive Pulmonary Disease 
CPAP Continuous Positive Airway Pressure 
CPB Coronary Pulmonary Bypass 
C-POMS Cardiac Post Operative Morbidity Survey 
CRD Centre for Reviews and Dissemination 
CRP C-Reactive Protein 
CRF Case Report Form 
CTT Classical Test Theory 
CV Cardiovascular 
CVA Cerebro-Vascular Accident 
CVI Content Validity Index 
CVP Central Venous Pressure 
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DIB Difficulty in Breathing 
DVT Deep Vein Thrombosis 
ECG Electrocardiogram 
EF Ejection Fraction 
FiO2 Fraction of Inspired Oxygen 
GCS Glasgow Coma Score 
GI Gastrointestinal 
HES Hospital Episode Statistics 
Hb Haemaglobin 
HR Heart Rate 
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IABP Intra-aortic Balloon Pump 
ICU Intensive Care Unit 
IDC In-Dwelling Catheter 
IDDM Insulin Dependent Diabetes Mellitus 
IHD Ischaemic Heart Disease 
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INR International Normalised Ratio 
IRS Item Reduction Strategy 
IRT Item Response Theory 
IV Intra-venous 
K Potassium 
LLL Left Lower Lobe 
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pCO2 Partial pressure of carbon dioxide 
PDA Personal Digital Assistant 
PDG Protocol Development Group 
PI Principle Investigator 
pO2 Partial pressure of oxygen 
POMS Post Operative Morbidity Survey 
POSSUM Physiologic and Operative Severity Score for the enUmeration of 
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RBC Red Blood Cell 
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TAVI TransCatheter Aortic Valve Implantation 
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UTI Urinary Tract Infection 
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1 INTRODUCTION 
 
1.1 INTRODUCTION 
Open heart surgery was first performed in 1952 in the United States of America (USA)(2). 
However, cardiac surgery was initially infrequently performed due to the high risk of mortality. 
Surgery became more frequent, particularly in the United Kingdom (UK), with the subsequent 
development of the heart-lung machine in 1953(2). This was considered safe to use with 
hypothermia on patients in 1960. The advantages were that slower flow rates could be induced, 
the operative fields were dry enabling increased visual inspection and that greater time 
allowances for completing the procedure were provided(3). Outcome measurement following 
cardiac surgery has been recorded in the UK for a period of nearly 35 years since the 
introduction of the UK national cardiac registry in 1977. At this time, 11,602 patients had heart 
surgery with a mortality rate of 9.8%(4). Currently, more than 25,000 patients have heart surgery 
each year in the UK with a mortality rate of approximately 2%(5). However, whilst mortality rates 
have declined, cardiac surgery is still associated with significant morbidity and hospital length of 
stay. 
 
The aim of this chapter is to explore the available evidence surrounding outcome measurement, 
and in particular morbidity outcome measurement, in patients undergoing cardiac surgery in the 
period leading to the commencement of this study. Firstly, the debate surrounding mortality and 
morbidity outcome measurement will be addressed. Secondly, the work of the national and 
international cardiac surgery societies in post-operative outcome measurement, both now and in 
the future, will be reviewed. Thirdly, I will critically evaluate the existing literature relating to pre-
operative risk assessment scores for post-operative morbidity outcome in patients undergoing 
cardiac surgery, particularly exploring the definitions of post-operative morbidity being utilised. 
Finally, I will explore morbidity measurement within other medical disciplines. 
 
1.2 MORTALITY VS MORBIDITY OUTCOME MEASUREMENT 
Mortality is the most commonly cited cardiac surgery outcome variable(6). This is because 
mortality is clearly an undesirable outcome, can be unequivocally defined(7, 8) and is easily 
measured(8, 9, 10). However, post-operative death has become increasingly infrequent(11), 
(currently 2% for isolated coronary artery bypass graft (CABG) surgery(5)), rendering mortality 
an insensitive general outcome measure or indicator of quality of care or performance(12). 
 
Post-operative morbidity, being more common than mortality, may be a more valid end-point(13), 
but only if inherent limitations such as subjectivity and imprecision(14) can be overcome. 
Surrogate markers of morbidity have been used (for example, length of intensive care unit (ICU) 
stay, length of post-operative stay), but although objective and readily available, are limited in 
their usefulness as they do not account for non-medical causes of prolonged stay (for example, 
bed availability on the ward or delay in discharge related to social, rather than medical, factors).  
Since  31% of general surgical patients(15) have been found to remain hospitalized for non-
medical reasons, the use of surrogate markers should be used cautiously. Additionally, these 
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markers provide no indication of the type or frequency of conditions contributing to the 
prolonged length of stay, limiting their usefulness in relation to risk assessment and optimization 
of care to reduce post-operative morbid conditions. 
 
It has further been suggested that mortality and morbidity should be considered independently 
since post-operative complication rate does not correlate well with mortality rate(16, 17) and 
hospital characteristics associated with higher quality of care were associated with lower 
mortality rates but higher complication rates(16). Additionally, pre-operative risk prediction 
models for mortality (Parsonnet(18), EuroSCORE(19) and Pons(9)) significantly underestimate 
post-operative morbidity(6).   
 
For all these reasons, although mortality has been the standard measure of quality of care to 
date(20), morbidity is now recognised as a complementary and independent component of quality 
of care.  However, standardised and uniformly applied definitions are required(14).   
 
 
1.3 OUTCOME MEASUREMENT AFTER CARDIAC SURGERY  
1.3.1 United Kingdom 
Investigation of outcome after cardiac surgery in the UK has been primarily driven and 
implemented by the Society of Cardiothoracic Surgery of Great Britain and Ireland (formerly the 
Society of Society of Thoracic and Cardiovascular Surgeons of Great Britain and Northern 
Ireland) (SCTS). To date, this has focused almost entirely on in-hospital mortality. 
 
1.3.1.1 Mortality 
Lead by Sir Terence English in 1976(21), the SCTS initiated a cardiac surgery register in 1977 for 
all National Health Service (NHS) units to voluntarily and anonymously submit their cardiac 
surgery activity data and 30 day mortality. Analysis within the first few years indicated a 
significant decline in mortality despite the increasing numbers of operations being performed(4), 
a trend which has continued to be observed (Figure 1-1).  
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Figure 1-1: Activity and mortality trends for isolated surgery (N=386,745) from 1977 to 2003(5). 
This figure was obtained from the SCTS. 
 
 
 
However, the main limitation of the register was the lack of ability to adjust results by case-mix. 
This was resolved through the establishment of the cardiac surgery database project in 1994, 
and ultimately the national SCTS database in 1996 by Professor Sir Bruce Keogh, which 
generated a more comprehensive dataset comprising pre-operative, operative and post-
operative information. This enabled national risk-adjusted in-hospital mortality analysis on all 
operative groups, on which the five published audit reports between 1999 and 2004(5, 22, 23, 24, 25) 
are based.  
 
1.3.1.2 Morbidity 
Three post-operative outcome variables (re-operation, new post-operative stroke and new 
haemofiltration/dialysis post-operatively) were included in the first SCTS database in 1996 and 
these remained the same until a decision to revise the dataset in 2003. However, in the latest 
audit report(5), the results for re-operation for post-operative bleeding were reported for the first 
time, albeit in only 21 hospitals due to missing or unsuitable data. The dataset revision is yet to 
go live and thus the changes, if any, to national morbidity outcome reporting are as yet 
unreported. 
 
1.3.2 International 
Many national cardiac surgical registers were established in Europe during the 1990’s including 
those in France, Belgium, Norway, Israel, Sweden, Germany, Denmark, Portugal and the Czech 
Republic, with varying degrees of detail collected. Where outcome data has been obtained this 
is usually restricted to 30 day mortality, and in some instances hospital length of stay. The 
European Cardiac Surgical Register (ECSUR), funded by the European Association for 
Cardiothoracic Surgery (EACTS), aimed to centralise cardiac surgical data from many European 
countries(26). In the year following inception of data collection (1997-1998) data were obtained 
from 30 countries, including national data from the UK, Norway and Belgium(26). However, the 
ECSUR minimum dataset, utilised by some countries, does not include any outcome data 
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variables. Although no further information is currently available from the year 2000, it appears 
that the aim is to negotiate with other countries to make additional information available in order 
to undertake European comparisons(26). 
In comparison, the STS (Society of Thoracic Surgeons) national database, established in 1990, 
is the largest database in America. In addition to mortality outcome variables, the STS database 
includes 24 post-operative complications (Table 1-1). These are primarily severe complications 
(for example, cardiac arrest, re-operation, central neurological deficit, coma >24 hours and 
multi-system failure), but some considered to be less serious (for example, urinary tract infection, 
transient neurological deficit, new atrial fibrillation (AF) or atrial flutter) are also included. 
 
Table 1-1: Post-operative complications in the STS dataset V2.52.1 (9th April 2004) 
Post-operative complication 
Bleed/tamponade Pneumonia 
Re-operation Renal failure 
Peri-operative MI New dialysis 
Deep sternal wound infection Dissection iliac/femoral arteries 
Infection in harvest site Limb ischaemia 
Septicaemia New heart block requiring permanent 
pacemaker 
Urinary Tract Infection (UTI) Cardiac arrest 
Central neurological deficit >72hrs Anticoagulation complication 
Transient neurological deficit Fluid in pericardial space 
Coma >24hrs GI complications 
Pulmonary insufficiency requiring ventilation Multi-system failure 
Pulmonary embolism New AF or atrial flutter 
 
Furthermore, efforts are underway between ECSUR and STS to create an international adult 
cardiac surgical dataset to enable international comparisons and the adoption of a world-wide 
standard(27). However, details of the minimum dataset (including those relating to post-operative 
morbidity variables) are not publically available. 
 
 
1.4 MORBIDITY OUTCOME AFTER CARDIAC SURGERY  
The Bristol Royal Infirmary Inquiry Final Report (recommendation 108) and the Department of 
Health Adverse Events Consultation Document (recommendation 7) emphasised the immediate 
need for basic research to investigate the incidence and nature of adverse events leading to 
significant morbidity in the post-operative period(28, 29).  Without a validated standard by which to 
assess morbidity, it remains impossible to investigate the mechanisms which might underlie 
morbidity and to accurately assess the impact of therapeutic or systematic interventions on such 
morbidity. Thus, the following literature review was undertaken with the primary aim of 
identifying any existing validated tools for the assessment of post-operative morbidity following 
cardiac surgery. 
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1.4.1 Aim 
To identify and critically evaluate the existing evidence regarding the development and 
validation of pre-operative risk assessment scores for post-operative morbidity in patients 
undergoing cardiac surgery. 
This will enable: 
 the identification of the definitions of post-operative morbidity following cardiac surgery  
 the identification of the incidence of post-operative morbidity following cardiac surgery 
 the identification of clinically applicable pre-operative risk assessment scores for predicting 
post-operative morbidity following cardiac surgery. Such pre-operative risk scores could be 
used to assess their predictive ability of a newly-defined post-operative morbidity tool. 
 
1.4.2 Methods 
1.4.2.1 Time-frame 
The literature review was conducted in July 2004. 
 
1.4.2.2 Centre for Reviews and Dissemination framework 
The basic framework for conducting systematic reviews from the Centre for Reviews and 
Dissemination(30) was utilised (Phases 0-7). 
 
STAGE I - PLANNING THE REVIEW 
Phase 0: Identification of the need for a review 
Phase 1: Preparation of a proposal for a systematic review 
Phase 2: Development of a review protocol 
 
STAGE II - CONDUCTING THE REVIEW 
Phase 3: Identification of research 
Phase 4: Selection of studies 
Phase 5: Study quality assessment 
Phase 6: Data extraction and monitoring progress 
Phase 7: Data synthesis 
 
1.4.2.3 Inclusion criteria 
Three methodological quality filters were utilised to determine inclusion of studies into the 
literature review: 
a) Study population: The study population was defined as an adult population undergoing any 
form of cardiac surgery (excluding transplantation). 
b) Data collection tool: Only methodologies that constructed a pre-operative risk assessment 
tool were included.  Those concentrating solely on intra-operative and/or post-operative 
variables were excluded. 
c) Outcomes: Valid outcomes were mortality and morbidity. Both mortality and morbidity 
definitions were taken as the definitions presented in the paper.  There were no exclusions 
on the basis of the definition of either outcome. 
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Furthermore, inclusion was limited to those publications available in the English-language for 
ease of interpretation. However, since English is the language required by internationally 
recognised journals, it was considered that this would not be a significant limiting factor to 
identifying the appropriate studies. Papers were not excluded on the basis of sample size, year 
of study or study design (retrospective or prospective). 
 
1.4.2.4 Searching for eligible papers 
In addition to publication databases (the National Centre for Biotechnology Information (NCBI), 
Entrez retrieval system (PubMed) and the Web of Science ISI Citation Databases) sources of 
ongoing and recently completed studies (The National Research Register, The Cochrane 
Library of Systematic Reviews) were also interrogated to identify eligible papers. 
 
1.4.2.4.1 The National Research Register  
The National Research Register (NRR) is a database of ongoing and recently completed 
research projects funded by, or of interest to, the UK's National Health Service (NHS).  It 
consists of The NRR Projects database (115,152 records from 350 organisations from 2000-
March 2004), The MRC Clinical Trials Directory (180 records), The Centre for Reviews and 
Dissemination (CRD) Register of Reviews (806 records) and Abstracts of Cochrane Reviews 
(1964 records). 
 
1.4.2.4.2 The Cochrane Library of Systematic Reviews 
The Cochrane Collaboration, founded in 1993, is an international, non-profit and independent 
organisation containing The Cochrane Database of Systematic Reviews (3,440 records), The 
Database of Abstracts of Reviews of Effectiveness (4,645 records), The Cochrane Controlled 
Trials Register (405,580 records), The NHS Economic Evaluation Database (13,828 records), 
Health Technology Assessment Database (3,848 records) and the Cochrane Database of 
Methodological Reviews (CDMR) (18 records).  All databases are regularly updated, evidence-
based and contain both published and unpublished work. 
 
1.4.2.4.3 PubMed and Web of Science ISI Citation Databases 
The indexing services utilised were the National Centre for Biotechnology Information (NCBI) 
Entrez retrieval system (PubMed 1966-) and the Web of Science ISI Citation Databases (1945-
).  NCBI Entrez PubMed is a text-based search and retrieval system that includes MEDLINE 
(National Library of Medicine bibliographic database covering medical, nursing, dentistry, and 
pre-clinical science disciplines).  In addition to access to MEDLINE’s 4,600 biomedical journals 
published from 71 countries and containing 11 million citations, PubMed provides over 14 
million citations dating back to the 1950’s, out-of-scope citations, citations that precede the date 
that a journal was selected for MEDLINE indexing and some additional life science journals.  
The Science Citation Index Expanded is a multidisciplinary database covering the journal 
literature of the sciences.  It indexes more than 8,400 major journals from over 3000 publishers 
in 60 nations across 164 scientific disciplines and contains a current total of 17 million records, 
with all cited (backward and forward) references captured.  As of January 1991 it contains 
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searchable, full-length, English-language author abstracts for approximately 70% of the articles 
in the database.  
 
Since the search ‘morbidity scores’ produced a significant number of potential papers in 
PubMed, combinations of keywords were utilised.  The title combinations employed were based 
on preliminary reading and the keywords associated with this study.  Table 1-2 highlights the 
searches undertaken in June 2004.  
 
Table 1-2: Initial keyword searches.   Values in bold are those where all titles/abstracts were 
read and assessed for relevance. 
Pubmed: limits Keywords 
None Title/ 
abstract 
word 
Title 
word 
NIHR Cochrane 
Collaboration 
(all databases) 
Morbidity scores 13,026 2,350 30 5 10 
Risk prediction score   1,033    796 16 0   0 
Cardiac surgery score      277    580 11 0   0 
Cardiac surgery risk score      143    285   4 0   0 
Preoperaive risk; cardiac surgery        33      94 33 0   0 
Risk prediction score; cardiac surgery        18      30   0 0   0 
 
However, very few potential studies were identified through the NRR or Cochrane Collaboration 
and hence additional, broader keyword searches were undertaken to ensure optimal study 
capture (Table 1-3). 
 
Table 1-3: Additional keyword searches conducted in NRR and the Cochrane Collaboration. 
Values in bold are those where all titles/abstracts searched for relevance. 
Keyword NRR Cochrane Collaboration 
Cardiac 3,578 15,425 
Cardiac surgery    554   1,891 
Cardiac surgery morbidity       0          0 
Cardiac surgery risk       0          0 
CABG   251   1,020 
CABG morbidity       0         1 
Surgery morbidity       4       20 
Surgery outcome     15       72 
 
Thus, overall the study titles and abstracts of the 1,067 potential eligible records identified 
through the keyword searches (all records highlighted in bold in Tables 1-2 and 1-3), were 
scrutinised in order to identify relevant studies fulfilling the review inclusion criteria.   
 
1.4.2.4.4 Backward citation tracking 
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The bibliographies of all relevant papers identified and retrieved were manually searched for 
additional relevant papers.   
 
1.4.2.4.5 Forward citation tracking 
Using the Science Citation Index, papers that had subsequently cited the relevant papers 
identified from the keyword literature search were reviewed. References which had not been 
previously identified from the primary or backward citation searches were recorded. 
 
1.4.2.4.6 Repeat backward and forward citation searches 
Backward and forward citation searches were conducted on all papers identified from the 
previous backward and forward citation tracking.  
 
1.4.2.5 Literature analysis 
Data extraction utilised a modified Ganong framework(31) encompassing descriptive issues (title, 
author, date), methodological issues (type of study, study characteristics, sample, data 
collection tool, validity/reliability), analysis (methods, results) and study evaluation (strengths, 
limitations, conclusions).  Non-quantitative analysis of extracted data were undertaken. 
 
1.4.3 Results 
1.4.3.1 Number of studies 
In total, 20 relevant studies were identified from the following sources: The NRR 0 (0%), The 
Cochrane Collaboration 0 (0%) PubMed 10 (50.0%); backward citation 6 (30.0%); forward 
citation 4 (20.0%). Full-text articles were retrieved on all studies (100%).  Table 1-4, Table 1-5 
and Table 1-6 show the results of the backward and forward citation searches. 
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Table 1-4: Backward and forward citation searches from relevant papers identified through the initial PubMed search  (new references appear only once - 
therefore duplicated new references not repeated if found in more than one paper).  
Paper 
identified 
through 
pubmed 
search and 
availability 
Backward 
citation: 
No of 
references 
cited 
Backward 
Citation: 
No of new 
references 
identified 
Backward Citation: 
Potential new 
references identified 
New score 
identified? 
If yes, 
state 
Forward 
Citation: 
No of 
times 
cited 
Forward 
Citation: 
No new 
references 
identified 
Forward Citation: Potential new 
references identified 
New score 
identified? If 
yes, state 
Parsonnet 
et al 
1989(18) 
81 6 Edwards et al 1988(32) 
Wright et al 1987(33) 
Junod et al 1987(34) 
Hlatky et al 1988(35) 
Horst et al 1987(36) 
Scott et al 1985(37) 
No.   
No  
No.   
No.   
No.   
No.   
220 16 Lippmann et al 1997(38) 
Martinez-Alario et al 1999(39) 
Daly et al 1993(40) 
Reed et al 2003(41) 
Schoepf et al 2002(42) 
Wagener et al 2001(43) 
Pons et al 1997(9) 
Junger et al 2002(44) 
Wyse et al 2002(45) 
Duncan et al 1995(46) 
Pliam et al 1997(47) 
Dupuis et al 1998(48) 
Daley et al 1994(49) 
Simchen et al 2000(50) 
Geraci et al 1993(11) 
Immer et al 2000(51) 
No  
No.   
No.   
No.   
No. 
No.  
No.  
No. 
No. 
No.  
No.   
No.  
No. 
No. 
Yes.  Own score 
No. 
Higgins et 
al 1992(52) 
35 2 Kennedy et al 1980(53) 
Paiement et al 1983(54) 
No.   
 
No.   
353 2 Baretti et al 2001(55) 
Smith et al 1996(56) 
No  
No  
Tuman et al 
1992(57) 
24 1 Hammermeister et al 
1990(58) 
No  89 5 Wong et al 1999(59) 
Heijmans et al 2003(60) 
Cortina et al 1998(61) 
Pinna-Pintor et al 2002(62) 
Yes.  Own score 
No.  
No. 
No  
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Tu et al 
1995(63) 
20 0 -  148 0 -  
Kurki and 
Kataja 
1996(64) 
23 1 Marshall et al 1994(65) No 41 1 Wouters et al 2002(66) Yes.  Own score.  
Higgins et 
al 1997(67) 
27 3 O’Connor et al 1992(68) 
Hattler et al 1994(69) 
 
Orr et al 1995(70) 
No.   
Yes.  Uses 
STS model 
No.   
41 0 -  
Staat et al 
1999(7) 
28 1 Magovern et al 1996(71) Yes. Own 
score 
6 0 -  
Dupuis et al 
2001(72) 
39 2 Urzua et al 1981(73) 
Pons et al 1998(74) 
No.   
No.  
14 0 -  
Huijske et 
al 2003(75) 
24 4 Bernstein et al 2000(76) 
Bridgewater et al 1998(77) 
Pitkanen et al 2000(78) 
 
Stoica et al 2002(79) 
No.  
No. 
Yes. Own 
score 
No  
0 0 -  
Janssen et 
al 2004(80) 
10 1 Kurki et al 2001(81) No.   0 0 -  
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Table 1-5: Relevant papers identified from backward citation searches from review papers identified from PubMed. New references appear only once - 
therefore duplicated new references are not repeated if found in more than one paper. 
Paper identified 
through 
backward/forward 
citation 
Backward 
citation: No 
of 
references 
cited 
Backward 
Citation: 
No of new 
reference
s 
identified 
Backward Citation: 
Potential new 
references 
identified 
New score 
identified? If 
yes, state 
Forward 
Citation: No 
of times cited 
Forward 
Citation: No 
new references 
identified 
Forward 
Citation: 
Potential new 
references 
identified 
New score 
identified? If 
yes, state 
Tremblay et al 
1993(82) 
26 1 Grover et al 1990(83) No.   19 
 
0 -  
Roques et al 1995(84) 17 0 -  20 0 -  
Eagle et al 1999(85) 0 0 -  70 1 Reed et al 
2003(86) 
No.   
Fortescue et al 
2001(87) 
28 0 -  2 1 -  
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Table 1-6: Backward and forward citation searches from relevant papers identified through backward and forward citation searches of papers identified 
on Pubmed or from review papers (new references appear only once - therefore duplicated new references s not repeated if found in more than one 
paper). 
Paper/Score 
identified through 
backward/forward 
citation 
Backward 
citation: No 
of 
references 
cited 
Backward 
Citation: No 
of new 
references 
identified 
Backward 
Citation: 
Potential new 
references 
identified 
New score 
identified? If 
yes, state 
Forward 
Citation: No 
of times cited 
Forward 
Citation: No 
new references 
identified 
Forward 
Citation: 
Potential new 
references 
identified 
New score 
identified? If 
yes, state 
Geraci et al 1993(11) 29 0 - - 51 0 - - 
Hattler et al 1994(69) 15 0 - - 29 0 - - 
Magovern et al 
1996(71) 
20 0 - - 42 0 - - 
Wong et al 1999(59) 33 0 - - 34 0 - - 
Pitkanen et al 2000(78) 20 0 - - 7 0 - - 
Wouters et al 2002(66) 11 0 - - 1 0 - - 
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1.4.3.2 Identification of the definitions of post-operative morbidity 
The analysis of the pre-operative risk assessment models for post-operative morbidity following 
cardiac surgery is summarised in Table 1-7, with the full version available in Appendix 1.  
Of the 20 pre-operative risk predictive models identified, 10 models specifically defined morbidity 
and mortality separately but included all outcomes in developing one model(11, 18, 52, 57, 63, 67, 71, 72, 82, 84) 
and 5 models included death within their definition of morbidity(7, 64, 69, 80, 87). Only 5 models defined 
mortality and morbidity separately and constructed separate models for each(59, 66, 75, 78, 85).  
Increased ICU stay(59, 63, 75, 78, 80) and increased hospital stay(18, 63, 64, 71, 72) were used as surrogate 
measures for morbidity with 4 models solely using these definitions for measuring post-operative 
morbidity(18, 63, 64, 80). The definition of morbidity used by year of study publication is summarised in 
Figure 1-2 highlighting that the earlier models included mortality and morbidity in one model with a 
trend towards separating mortality, morbidity and morbidity surrogate models appearing more 
recently. 
 
Figure 1-2: Definition of post-operative morbidity by year of study publication. (Some models used 
more than one definition and appear more than once). 
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1.4.3.3 The incidence of post-operative morbidity 
As detailed in Table 1-7, the reported incidence of post-operative morbidity varies from a minimum 
4.3%(87) to a maximum 36%(71). The wide range of reported morbidity rates (Figure 1-3) probably  
reflects the diverse definitions of morbidity used. 
 
 33
Figure 1-3: Mortality and morbidity rates observed in studies developing pre-operative risk 
assessment scores for morbidity outcome following cardiac surgery. 
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While the Fortescue model includes mortality, others including mortality have much higher 
incidences of morbidity 12.0%(80) and 23.0%(7). However, they report similar mortality rates of 
2.8%(80)  and 2.5%(7). Overall, definitions including surrogate measures of morbidity report a lower 
incidence of morbidity with 16.7%(59) to 20.0%(78) remaining in ICU for >2days and 12%(80) to 14%(75) 
>3days. 
 
1.4.3.4 Clinically applicable pre-operative risk assessment scores 
Although the majority of models include variables that are readily attainable in routine clinical care, 
the Magovern score is the only score with a wide definition of morbidity, including major and minor 
categories, that also does not include mortality(71). The full score is reported with definitive cut-offs 
differentiating between different levels of risk and the predictive power of the model for their defined 
morbidities is strong.   
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Table 1-7: Summary of pre-operative risk prediction scores for morbidity outcome in patients undergoing cardiac surgery (Full version available in 
Appendix 1). 
Primary 
author 
Year Country Method Year (data) Sample Sample size Outcome morbidity definitions Mortality rate (%) Morbidity rate (%) 
Parsonnet(18) 
 
Parsonnet 
score 
1989 USA Retrospective 1982-1987 Open-heart 
surgery 
Development: 
3,500;  
 
Validation: 300 
Operative mortality: any death occurring 
within 30days of surgery 
Post-operative complications: 
Not stated 
Length of hospital stay: 
Not stated 
8.9 23.5 
Higgins(52) 
 
Cleveland 
Clinical 
Severity 
Score 
1992 USA Retrospective 
development;  
 
Prospective 
validation 
1986-1988 CABG Development: 
5,051;  
 
Validation: 4,069
Mortality 
Not stated 
Morbidity: MI, IABP, mechanical ventilation 
>3 days, neurological deficit, oliguric or 
anuric renal failure, Serious infection 
2.5 13.5 
Tuman(57) 
 
Canadian 
Model 
1992 Canada Prospective   Development: 
3,156;  
 
Validation 394 
Morbidity :The presence of one or more of 
the following categories of complications: 
Cardiac, Pulmonary, Renal, Infectious, 
Neurologic 
Operative mortality:intra-operative death or 
death within 24hrs of surgery.  Death after 
this period was defined as post-operative 
mortality. 
6.2 22.2 
Geraci(11) 1993 USA Retrospective 1985-1986 CABG 2,213 Mortality: Death within 30days of 
admission.  
Non-fatal adverse event: 
New MI by ECG, Cardiorespiratory arrest, 
New CHF by CXR, Acute graft failure New 
onset thromboembolism, New onset stroke, 
Coma, Mechanical ventilation >48hrs, 
6.6 33.0 
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Wound infection, Bacteraemia, Acute renal 
failure (1st time dialysis or rise in creatinine 
to 442mmol/l), More than 6 units of blood or 
packed red blood cells, Unplanned return to 
surgery 
Tremblay(82) 
 
The Montreal 
Heart Institute 
Risk 
Assessment 
Classification 
1993 Canada Retrospective 
development; 
 
Prospective 
validation 
Development: 
1980;  
 
Validation 
1988-1990 
Cardiac 
surgery 
Development: 
500;  
 
Validation 2,029 
Mortality: Postoperative mortality during 
hospitalisation (1980 and 1990 populations) 
Length of stay in post-operative ICU 
(1990 population) 
Not stated 
Length of postoperative hospitalisation 
(1990 population) 
Not stated 
3.4 (1980) 4.9 
(1990) 
NS 
Hattler(69) 
 
STS Model 2 
1994 USA Prospective 1991-1993 CABG 728 Mortality 
Not stated 
Morbidity: Included: 
Re-operative bleeding, 
Perioperative MI 
Infection (mediastinal, septicaemia), Stroke 
(permanent/transient) 
Ventilator >5days, Renal failure (no dialysis)
Dialysis required, Heart block (permanent), 
Cardiac arrest, Anticoagulant complication, 
Tamponade, Gastrointestinal complication, 
Multisystem failure, In-hospital mortality 
3.98 NS 
Roques(84) 
 
Ontario 
Province Risk 
Score 
(French 
1995 France Prospective 1993 Cardiac 
surgery 
7,181 Mortality  
Not stated 
Mortality/severe morbidity: Reoperation 
for thoracic wound infection, Perioperative 
MI, Duration of intubation >48hrs, Severe 
infection, Reoperation with CPB, Low 
6.0 NS 
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Score) cardiac output, Cardiac massage, Low limb 
ischaemia, Ventricular arrhythmia, Renal 
failure, Stroke, Gastro-duodenal, 
hemorrhage, Insertion of IABP 
Tu(63) 
 
Tu Score 
1995 Canada Retrospective Development: 
1991-1992; 
Validation 
1992-1993 
Cardiac 
surgery 
Development: 
6,213;  
 
Validation 6,885 
Mortality 
In-hospital mortality 
Very long ICU LOS >6days 
Very long post-op LOS >17days 
3.7 NS states LOS 
Kurki(64) 
 
CABDEAL 
Score 
1996 Finland Retrospective 1990-1991 CABG 386 Prolonged hospital stay >12 days 
because of adverse events, transfer to 
another hospital for treatment of 
complications or death during hospital stay 
NS NS 
Magovern(71) 1996 USA Retrospective Development: 
1991-1992;  
 
Validation: 
1993-1994 
CABG Development: 
1,567;  
 
Validation: 1,235
Outcome: mortality or morbidity during the 
hospitalisation only. 
Mortality : Death at any time during the 
hospital stay 
Morbidity: An unexpected post-operative 
complication, major or minor, which resulted 
in the increase consumption of hospital 
resources owing to the required treatment.  
Full definitions of each major and minor 
complication stated. 
Major: 
cardiovascular failure, respiratory failure, 
acute renal failure, permanent cerebral 
deficit, major wound infection, pulmonary 
embolus, surgical intervention after CABG 
Minor: 
Temporary central nervous system deficit, 
acute renal insufficiency, atrial arrhythmias, 
ventricular arrhythmias, superficial wound 
3.8 (Development) 
3.0 (Validation) 
16 (major);  
36 (minor) 
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infection, respiratory insufficiency, pleural 
effusion, pneumothorax, systemic sepsis, 
gastrointestinal bleeding, post-operative 
mediastinal bleeding. 
Higgins(67) 1997 USA Prospective 1993-1995 CABG 
(alone or 
combined) 
Development: 
2,793;  
 
Validation: 2,125
Morbidity :The presence of one or more of 
the following during hospitalisation: Cardiac 
complication, prolonged ventilatory support, 
CNS complication, renal failure, serious 
infection, death. 
Mortality : All deaths during hospitalisation 
for the operation, regardless of length of 
stay. 
3.1 10.4 
Eagle(85) 
 
ACC/AHA 
Practice 
Guidelines 
1999 USA  1996-1998 CABG 7,290 Mortality: I-hospital mortality 
CVA : New focal neurological event 
persisting at least 24hrs. 
Mediastinitis: During index admission 
defined as a positive deep culture and/or 
Gram stain and/or radiographic findings 
indicating infection and requiring re-
operation. 
2.93 1.58 (CVA);  
1.19 (mediastinitus) 
Staat(7) 1999 France Retrospective 1996 CABG 679 Severe morbidity: Mortality or one of the 
following 10 non-fatal adverse events: Low 
cardiac output, IABP, MI 
Mechanical ventilation >48hrs, Serious 
pneumonia, Other serious infections, Acute 
renal failure, Excessive bleeding, Unplanned 
return to surgery, CNS complication 
2.5 23.0 
Wong(59) 1999 Canada Prospective 1995 CABG 885 Delayed extubation: >10hrs 
Prolonged ICU LOS: >48hrs 
Mortality: Death occurring within 30 days of 
hospital or during hospital stay 
2.6 NS states LOS 
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Pitkanen(78) 2000 Finland Retrospective 
development;  
 
Prospective 
validation 
Development: 
1992-1996;  
 
Validation 
1998-1999 
Cardiac 
surgery 
Development: 
4,592;  
 
Validation: 821 
Morbidity (overall) : 1 or more of the 
following: 
Haemodynamic problems (inotropic support, 
IABP), mechanical ventilation >24hrs, 
serious gastrointestinal complications, 
anuria, stroke multi-organ failure, 
resternotomy due to other cause than 
excessive bleeding, sepsis, pneumonia, 
mediastinitis, psychosis or remarkable 
confusion, readmission to the ICU or 
complicated clinical situation at discharge to 
another hospital. 
Morbidity: Length of ICU stay >2days. 
Mortality: Death occurring within 30 days 
from the operation. 
2.0 (Development) 
1.1 (Validation) 
22.0 (Development) 
18.4% (Validation) 
Dupuis(72) 
 
Cardiac 
Anaesthesia 
Risk 
Evaluation 
Score 
(CARE) 
2001 Canada Prospective Development: 
1996-1998;  
 
Validation 
1998-1999 
Cardiac 
surgery 
Development: 
2000;  
 
Validation: 1,548
Mortality: In-hospital death 
Morbidity: Complications in one or more of 
the following categories: cardiovascular, 
respiratory, neurological, renal, infectious, 
any other. 
Length of stay: If no morbidity data, 
prolonged post-operative LOS used as a 
surrogate. 
3.4 20.7 (Development); 
22.2 (Validation) 
Fortescue(87) 
 
QMMI Score 
2001 USA  1993-1995 CABG Development: 
6,237;  
 
Validation: 3,261
Major adverse outcome: Any of the 
following: 
Death, Renal failure, MI, Cardiac arrest, 
Stroke, Coma 
2.5 4.3 
Wouters(66) 
 
CORRAD 
Score 
2002 Netherlands Retrospective Development: 
1998;  
 
Validation: 
CABG Development: 
653;  
 
Validation: 969 
Early mortality: hospital mortality and 
cardiac-related mortality within the 6 month 
follow-up period. 
Morbidity:  hospital mortality and also the 
5.6 
(Development); 
5.3 (Validation) 
19.1 (Development); 
21 (Validation) 
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1999-2000 following complications resulting in a 
prolonged hospital stay: ventilatory support 
> 3days, sternal wound, nephrological, 
neurological, pulmonary, gastrointestinal, 
vascular problems  
Huijskes(75) 
 
Amphia 
Score 
2003 Netherlands  1997-2001 CABG 
and/or valve 
surgery 
7,282 Mortality: In-hospital mortality 
Major adverse cardiac event (MACE): in-
hospital death or peri-operative MI or VT/VF 
Extended length of stay: intensive care 
length of stay of at least 3 days or in-
hospital death.               
2.3 17 
Janssen(80) 2004 Netherlands Retrospective 2000-2001 CABG 888 Prolonged length of stay in ICU:  longer 
than 3 days.  Indications for prolonged 
length of ICU stay were: Prolonged 
ventilation, Low cardiac output defined as 
need for inotropic support and a cardiac 
index <2.2l/min per m2, Need for Swan 
ganz-catheter 
2.8 12 (LOS) 
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1.4.4 Discussion 
This review has identified that no consistent definition of post-operative morbidity has been used 
(for example, Higgins et al(52), Magovern et al(71), Wouters et al(66)).  Furthermore, some included 
death within the definition (for example, Staat et al(7), Fortescue et al(87)) and some defined 
morbidity using surrogate markers such as increased ICU (for example, Tu et al(63), Janssen et al(80)) 
or post-operative stay (Parsonnet et al(18), Magovern et al(71), Dupuis et al(72)). Since such varied 
definitions are used, it is unsurprising that such a range in morbidity rates are reported - from 
4.3%(87) to 40%(71). As highlighted previously, post-operative complication rate does not correlate 
well with mortality rate(16, 17), and although the Parsonnet score(18) is widely used in clinical practice 
for post-operative mortality risk assessment, its usefulness in assessing morbidity risk has been 
questioned(72, 88).  
 
The literature review identified 5 models that constructed morbidity models separately from 
mortality(59, 66, 75, 78, 85).  Of these, 2 models defined morbidity using a more general perspective(66, 78). 
However, neither model reported the origin of the definitions used. Furthermore, the Pitkanen pre-
operative risk score was not sensitive in predicting morbidity. This was considered to be due to the 
morbidity definition: generalisation of morbid events as opposed to considering an isolated morbid 
event, a limitation also echoed by Wouters and colleagues(66). Furthermore, the subjectivity of 
morbidity definition and their impact relating to treatment choices and length of stay is highlighted(66). 
 
Overall, the Magovern score, despite including mortality within the morbidity definition, has the most 
well-defined morbidity outcome encompassing major and minor definitions. The inclusion of minor 
morbidity explains the increased morbidity rate in comparison with other studies. Furthermore, the 
pre-operative risk assessment model contains easily attainable clinical variables with high predictive 
ability of subsequent post-operative morbidity. However, as with the Pitkanen and Wouters models, 
the origin of the morbidity outcome definitions in undefined and the study was only conducted in 
patients undergoing isolated CABG. 
 
1.4.5 Conclusion 
This review has demonstrated the diversity associated with attempting to measure morbidity which 
can lead to imprecise measurement and monitoring of events(14). Despite the limitations of the tools 
identified, no model is used in the UK for the assessment of post-operative morbidity after cardiac 
surgery. 
 
1.5 MORBIDITY ASSESSMENT IN OTHER SURGICAL DISCIPLINES 
Due to a lack of tools for general post-operative morbidity assessment in patients undergoing 
cardiac surgery, methods used by other surgical disciplines were explored.  As with cardiac surgery, 
studies in post-operative morbidity have generally been restricted to specific post-operative 
complications (for example infection, cardiac morbidity) or surrogate markers (for example length of 
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hospitalisation). However, the Post-Operative Morbidity Survey (POMS)(1) is the only published, 
prospective tool for assessing the incidence and pattern of post-operative morbidity in orthopaedic, 
urological, vascular, gynaecological and general surgical patients. POMS is a nine domain survey 
(Table 1-8) completed on all participants remaining in hospital on post-operative days 5, 8 and 15. 
 
Table 1-8: Post-Operative Morbidity Survey(1) 
Morbidity type Criteria 
Pulmonary The patient has developed a new requirement for oxygen or respiratory 
support 
Infectious Currently on antibiotics and/or has had a temperature of >38°C in the last 24 
hours 
Renal Presence of oliguria < 500ml/24hours, increased serum creatinine (>30% from 
pre operative level); urinary catheter in situ for non surgical reason 
Gastrointestinal Unable to tolerate an enteral diet for any reason including nausea, vomiting 
and abdominal distension 
Cardiovascular Diagnostic tests or therapy within the last 24 hours for any of the following: 1) 
new MI or ischaemia, 2) hypotension (requiring fluid therapy >200ml/hr or 
pharmacological therapy, 3) atrial or ventricular   arrhythmias, 4) cardiogenic 
pulmonary oedema, thrombotic event (requiring anticoagulation). 
Neurological New focal neurological deficit, confusion, delirium or coma 
Haematological Requirement for any of the following within the last 24 hrs: packed 
erythrocytes, platelets, fresh-frozen plasma, or cryoprecipitate 
Wound Wound dehiscence requiring surgical exploration or drainage of pus from the 
operation wound with or without isolation of organisms 
Pain New postoperative pain significant enough to require parenteral opioids or 
regional analgesia 
 
At study inception, POMS was being validated at University College London Hospitals, NHS Trust, 
London, UK by Grocott and colleagues who additionally collect POMS data on post-operative days 
1 and 3. 
 
1.6 OVERALL SUMMARY AND CONCLUSIONS 
Examination of the work of the SCTS in the UK, of other cardiac surgery societies internationally, 
and of the available published literature has highlighted that there is no uniformly applied definition 
of post-operative morbidity following cardiac surgery nor method for its measurement. The STS in 
the USA collects the greatest range of data relating to post-operative morbid events which is 
collectively reported but not at the patient level. The only instrument for post-operative morbidity 
assessment, at the patient level, is the POMS tool for general surgical patients(1). Thus, the 
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development of a tool, similar to POMS but specifically designed for the identification and 
quantification of post-operative morbidity following cardiac surgery, is indicated. 
 
 
1.7 THESIS PLAN 
My thesis aim was thus to develop and validate a tool, the Cardiac Post-Operative Morbidity Survey, 
(C-POMS), for the identification and quantification of post-operative morbidity after cardiac surgery. 
 
The ‘route-plan’ of the work undertaken is described below. However, Figure 2-1 in the methods 
chapter shows the overall architecture in more detail. 
 
Chapter 2: Methods 
This chapter describes the aims and objectives of the thesis and the main study methods, including 
the pilot study. 
 
Chapter 3: Data quality 
This chapter examines the necessity of strategies for maximising data quality and undertaking data 
quality assessments, which informs the error prevention strategies and data cleaning strategies 
undertaken in this study.  The results on data uniqueness, accuracy, completeness, consistency 
and validity of the study data are reported. 
 
Chapter 4: Results I: Pilot study 
Chapter 4 reports the results of the pilot study. These results informed changes to be made to the 
main study protocol in terms of routine data collection items which are also indicated in this chapter. 
 
Chapter 5: Results II: Baseline characteristics 
The inter-rater reliability test results, screening and recruitment characteristics and participant 
baseline characteristics are reported in this chapter. The baseline characteristics include 
demographic, pre-operative, intra-operative, immediate ICU and outcome characteristics of the 
participants of the main study. 
 
The following three results chapters are closely related and follow a process through model 
development, reliability and validity testing of the model and assessment of its use in clinical 
practice.  
 
Chapter 6: Results III: C-POMS development 
This chapter begins by examining the background to health indices model development exploring 
the theoretical background (psychometric and clinimetric theory;  classical test theory and item-
response theory), construction frameworks (the McMaster Framework(89) for constructing a health 
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indices) and item reduction strategies. The methods undertaken for developing C-POMS are then 
described and the results of each phase are reported. The resulting model is shown, while the 
discussion relating to the components of the final model being included in chapter 9. 
 
Chapter 7: Results IV: C-POMS reliability and validity testing 
The aim of this chapter is to assess the reliability and validity of the C-POMS tool. Firstly, the need 
for validity testing is examined. Then the specific aims and objectives of the content validity, 
reliability and construct validity testing are stated and the methods utilised, and results, for each are 
detailed. The strengths and weaknesses of the reliability and validity methods undertaken are 
evaluated and whether the results indicate if sufficient reliability and validity has been obtained is 
discussed. 
 
Chapter 8: Results V: Clinical utility of C-POMS 
The final results chapter focuses on the clinical utility of the C-POMS tool, both at an individual 
patient level and also as a potential tool to be administered to all patients undergoing cardiac 
surgery. Thus, the aims of this chapter are to identify and quantify post-operative morbidity as 
defined by C-POMS, to determine if C-POMS provides benefit over POMS in defining and 
quantifying post-operative morbidity in cardiac surgical patients and to explore the utility of C-POMS 
in clinical practice with multi-disciplinary clinical teams. The methods and results are reported and 
discussed.  
 
Chapter 9: Discussion 
This chapter aims to bring together the overarching discursive elements concerning this work. 
Firstly, an update on the work of the SCTS, international cardiac registries and the literature from 
the commencement of the study are considered to conclude on the current appropriateness of C-
POMS. The use of C-POMS as a morbidity outcome measure is then discussed, particularly 
exploring the C-POMS morbidity rate with morbidity rates reported in the literature, the 
independently predictive domains of subsequently length of stay and the newly derived domains. 
Consideration is also given to the uses of C-POMS ranging from the individual patient level to unit 
level and a national perspective, and to the limitations and strengths of C-POMS as a tool in 
addition to the methodological strengths and weaknesses of the study. Finally, future work is 
highlighted.   
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2 STUDY METHODS  
 
2.1 INTRODUCTION TO CHAPTER 
The aim of this chapter is to detail the aims and objectives of the work undertaken and to describe 
the methods utilised for the main study and pilot study data collection. To aid clarity of how this work 
progressed from inception to completion, a summary figure is included which details the process 
undertaken and where each key aspect is reported within this document.  
 
 
2.2 AIMS AND OBJECTIVES 
2.2.1 Aims 
The overall aim is to explore in-hospital morbidity outcome in patients undergoing cardiac surgery 
 
The specific aims are: 
1. To develop and validate a scoring system to assess in-hospital post-operative morbidity in 
patients undergoing cardiac surgery. 
 
2. To describe and quantify in-hospital post-operative morbidity experienced following cardiac 
surgery. 
 
2.2.2 Objectives 
The objectives are to: 
1. Develop and validate a cardiac POMS (C-POMS) from the components of the original POMS 
and cardiac-specific indices determined by an expert panel. 
 
2. Explore the applicability of POMS in describing and quantifying post-operative morbidity in 
patients undergoing cardiac surgery 
 
3. Assess the utility of a post-operative morbidity survey in the description of in-hospital morbidity 
following cardiac surgery  
 
 
2.3 ROUTE-MAP  
Figure 2-1 details the process of work undertaken in working towards the aims and objectives of this 
study, highlighting the chapter in which the steps are specifically described or discussed. 
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Figure 2-1: Route-map of work undertaken 
PDG meeting 1
23.08.2004
Approvals
22.09.2004-
01.12.2004
Inter-rater reliability 
testing
01.12.2004-
07.12.2004
Recruitment: Phase 
III
03.10.2005-
05.12.2005
Pilot Study: Phases I 
and II
10.01.2005-
28.03.2005
PDG meeting 2
27.07.2005
Data entry
24.01.2006-
21.03.2006
Recruitment: Phase 
IV
02.07.2007-
14.11.2007
Other clinical data 
collection
11.12.2007-
16.01.2008
Data entry
16.01.2008-
01.05.2008
PDG meeting 3
13.01.2009
Coding additional 
morbidities
05.11.2008-
14.11.2008
Data cleaning 
assessment
09.09.2008-
27.10.2008
Data cleaning 
strategy definition
07.05.2008-
24.07.2008
Item reduction 
strategy and final C-
POMS framework
19.05.2009-
14.07.2009
Inter-item 
correlation analysis
15.03.2009-
23.04.2009
Item reduction 
strategy defined
22.01.2009-
15.03.2009
Redefined dataset: 
C-POMS
September 2009
Chapter 2: 
Methods
Data preparation
21.09.2009-
28.11.2009
Reliability testing
28.11.2009
Validity testing
29.12.2009
Start write-up
January 2010
Further analysis
August-October 2010
PDG meeting 4: 
Clinical utility
11.03.2011
Meeting at London 
Chest Hospital: 
Clinical utility
19.04.2011
SCTS meeting: oral 
presentation
21.03.2011
Complete write-up
End of 2011
ESC meeting: post 
presentation
28.08.2011
Chapter 8: 
Clinical utility
Chapter 4: 
Pilot study 
results
Chapter 5: 
Baseline 
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Chapter 3: 
Data quality
Chapter 6: 
C-POMS 
development
Chapter 6: 
C-POMS 
development
Chapter 7: 
C-POMS 
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validity testing
 
 
 
2.4 MAIN STUDY METHODS 
2.4.1 Ethics committee approval and study registrations 
This study was registered with UCL Data Protection on September 24th 2004 (reference Z6364106 
Section 19, Research: medical research), received UCLH Research and Development approval on 
October 13th 2004 (reference 04/0165) and ethics approval from The Joint UCL/UCLH Committees 
on the Ethics of Human Research (Committee Alpha) on December 1st 2004 (reference 
04/Q0502/73). Table 2-1 details the relevant Ethics amendments submitted. 
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Table 2-1: Ethics committee amendments 
Number Reason for amendment Date 
approved 
Included in thesis 
1 Addition and removal of clinical data items 
following the pilot study 
25.07.2005 Yes 
2 The measuring of oxygen saturation 
levels using near-infra red spectroscopy 
on a sub-section of the cohort 
Full 
submission 
required 
Separate study 
conducted 
3 Genetics sample collection 03.08.2006 No 
4 Extension of study 26.04.2007 Yes 
5 Additional retrospective variables for 
blood storage study 
15.07.2008 No 
6 1-year mortality data from the NHS 
Information Centre 
15.07.2008 No 
 
2.4.2 Protocol Development Group  
A Protocol Development Group (PDG) was established to provide expert clinical opinion on the 
protocol throughout this study. Membership of the PDG included fifteen representatives from 
cardiac nursing, surgery, intensive care and anaesthesia, and also included representatives from 
the original POMS study(1). Table 2-2 provides a brief overview of the meetings undertaken.  
 
Table 2-2: Schedule of PDG meetings 
Meeting Date Purpose of meeting 
1 23.08.2004 Development of cardiac specific variables for inclusion in data 
collection 
2 27.07.2005 Presentation of pilot study results, to discuss the additional 
morbidities, review variables for ongoing data collection 
3 13.01.2009 Presentation of completed recruitment, present data quality 
assessments, to discuss the additional morbidities, discussion 
relating to item-reduction  
4 11.03.2010 Presentation of results, to discuss clinical utility of C-POMS 
 
The output of meeting 1 is detailed in section 2.4.5.2. 
 
2.4.3 Study design 
This study is a prospective, single-site (The Heart Hospital, UCLH NHS Foundation Trust, London, 
UK), observational cohort study. All the cardiothoracic consultant surgeons were approached prior 
to the study commencement and each provided written agreement that their patients could be 
approached for participation in this study. 
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2.4.4 Participants 
2.4.4.1 Inclusion and exclusion criteria 
Patients undergoing any form of cardiac surgery (for example, coronary artery bypass grafting 
(CABG), valve surgery, CABG plus valve, aortic root replacement) were eligible for the study.  
Patients under 18 years of age, undergoing emergency surgery (inadequate time to obtain informed 
consent), undergoing cardiac surgery for a grown-up congenital heart condition (complicated and 
sub-set specific co-morbidities), unable to give informed consent (severe mental illness or handicap, 
difficulties in understanding English language) and those involved in a clinical intervention trial (due 
to influencing patient outcome) were excluded. Furthermore, those who died within five days of 
surgery were also excluded in order that morbidity could be considered separately from factors 
affecting mortality in the immediate post-operative period. 
 
2.4.4.2 Identification, recruitment and informed consent 
All participants were screened and recruited from either the bi-weekly cardiothoracic pre-admission 
clinics or on admission to hospital (usually the day prior to surgery). Patients coming into hospital 
for surgery were identified through weekly operating timetables and through liaison with the Bed 
Management team and the operating theatre and surgical staff.  Written informed consent was 
obtained from each patient who agreed to participate and participants were re-consented if more 
than two weeks had lapsed between the clinic date and admission to hospital. Agreement to 
participate was documented in the medical notes. 
 
2.4.4.3 Sample size 
Using a sample size calculator from Creative Research Systems 
(http://www.surveysystem.com/sscalc.htm), based on a population of approximately 40,000 patients 
undergoing cardiac surgery annually in the UK and a 95% confidence level, a sample size of 450 
patients is required to detect a specific morbid event/variable occurring in 5% of the patients 
(CI±2%). 
 
2.4.5 Data variables  
2.4.5.1 POMS framework 
The morbidity types and individual criteria as detailed within POMS(1) were collected (Chapter 
1,Table 1-8). In participants with pre-operative morbidities present, the presence of the post-
operative morbidity in any of the post-operative days was only coded as ‘not new’ if exactly the 
same as in the pre-operative category.  For example, in these participants if the morbidity was more 
severe (nasal spec pre-op and CPAP post-op) or identified by a different criteria (GI: pre-op nausea 
only; post-op vomiting only) the morbidity was coded as ‘new’ 
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2.4.5.2 Cardiac specific data variables 
The PDG (meeting 1, Table 2-2) made the following recommendations: 
a) the POMS framework (Table 2-3) 
 
Table 2-3: PDG recommendation on additional data items relating to each POMS domain. 
POMS domain PDG recommendations for additional data collection 
Pulmonary  Is the patient intubated and ventilated?   Y/N 
 Is the patient on CPAP, BIPAP, O2 mask, nasal specs? Specify which 
 How much? 
 Record RR 
 Record FIO2 or SaO2  
Infectious  Treatment (antibiotics) Y/N 
 Is treatment routine/non-routine 
Renal  Is the patient currently receiving any renal replacement therapy?  Y/N 
 If yes, state:______________ 
 Add space for post-operative creatinine level on all post-operative days. 
Gastrointestinal Prior to 'unable to tolerate enteral diet (oral or tube feed)' add 
 Is the patient receiving nutritional support? Y/N 
 Specify TPN/NG feed 
 Is additional nutritional support due to GI disturbance?  Y/N 
 
In 'is the patient experiencing nausea, vomiting or abdominal disturbance?  
On anti-emetics?' specify which contributes to the scoring of the morbidity. 
Cardiovascular For each of the outcomes (new MI, Ischaemia or hypotension, atrial or 
ventricular arrhythmias, cardiogenic shock or non-routine anticoagulation) 
add in 
 Specify diagnostic test: 
 Diagnosis following diagnostic test: 
 Treated: Y/N 
 Specify treatment: 
Under atrial and ventricular arrhythmias add in: 
 Presence of any rhythm disturbance? Y/N 
 Paced?  Y/N 
 Specify rhythm 
 Treated? Y/N 
 Specify treatment 
 
Need to specify use of inotropes Y/N 
Neurological Specify between new confusion, delirium, focal deficit or coma. 
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Haematological State the number of units of each used 
Add Aprotinin and dose (indication of post-operative bleeding) 
Wound To 'has the patient experienced wound dehiscence requiring surgical 
exploration or drainage of pus from the operation wound with or without 
isolation of organisms?' add 
 Specify surgical intervention or drainage 
 Isolation of organism? Y/N state 
 Additional treatment? 
After 'has the patient experienced wound dehiscence requiring surgical 
exploration or drainage of pus from the operation wound with or without 
isolation of organisms?'  add 
 Has the patient experienced any wound complications? Y/N 
 If yes, specify whether sternal, L arm, R arm, L leg, R leg 
 Swab taken?  Y/N 
 Isolation of organisms? Y/N state: 
Pain Change to: Has the patient required parenteral opioids or regional 
analgesia? 
Specify method of medication of administration (PCA/Epidural/IV/IM) 
 
b) additional assessments at each time-point: ambulation assistance (wheelchair, zimmer frame, 
walking sticks etc), DVT (has the patient undergone a diagnostic test for suspected DVT in the last 
24 hrs or has the patient received treatment for suspected DVT in the last 24 hrs?) 
c) pre-operative assessment: Magovern score(71) as identified from literature review, Parsonnet 
score(18) and EuroSCORE(19) as used in clinical practice and POSSUM (physiological component 
only)(90) data variables  
d) intra-operative assessment: anaesthetic agents, cardioplegia method, circulatory arrest time, 
aortic cross clamp time, cardiopulmonary bypass details (used, time and temperature) 
e) theatre/ICU interface variables: APACHE II(91) and SOFA score (Sequential Organ Failure 
Assessment 1996,(92)) variables  
f) first recorded after 30 minutes stabilisation period: ventilator settings, arterial blood gas (ABG) 
results, BP, HR, temperature, MAP, CVP, urine output, fluids, level of inotrope use, drainage 
(mediastinal/pleural), intubation grade.  
g) other outcome measures: extubation time, hours ventilated, return to theatre, length of ICU stay, 
post-operative length of stay, total hospital length of stay, delayed discharge and reason. 
 
2.4.5.3 Other clinical data  
Pre-operative risk factors and relevant medical history, intra-operative details and post-operative 
outcome variables were extracted from the SCTS national audit minimum dataset, collected 
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routinely on all patients undergoing cardiac surgery at the Heart Hospital, by dedicated Information 
Nurses. Full details of the variables can be found in the SCTS data definition table (Appendix 2). 
 
2.4.5.4 Participant interviews 
To ensure that full coverage of all aspects of post-operative morbidity were identified, participants 
were asked at each time-point how they were feeling and to report all symptoms, regardless of their 
perception of severity, and any factors they felt were affecting or influencing their recovery. 
Responses that identified morbidities not encapsulated within the POMS framework were recorded 
as free-text. 
All participant interviews were conducted at a time convenient to the patient, in either a single or 
double patient room to provide a significant amount of privacy to discuss the symptoms/difficulties 
the patient may be experiencing post-operatively. 
 
2.4.5.5 Outcome variables 
The primary outcome measure which C-POMS will be validated against is post-operative length of 
stay.  
 
2.4.5.6 Data definitions  
Data definitions of all variables and normal clinical parameters can be found in Appendix 2. 
 
2.4.5.7 Data collection 
2.4.5.7.1 Reliability study  
To ensure reliability and consistency in POMS coding, prior to commencement of data collection an 
inter-rater reliability study was undertaken with the data collector for the POMS validation study 
conducted at UCLH(93).  During December 2004, 20 in-patients participating in the POMS validation 
study had repeat data collection on one of their post-operative time-points, excluding D1 as D1 data 
were not collected in the validation study.  
 
2.4.5.7.2 Time-points and time-frame 
Morbidity data were collected pre-operatively and on post-operative days 1 (D1), 3 (D3), 5 (D5), 8 
(D8) and 15 (D15) if the participant remained an in-patient, as per the POMS protocol(1). 
Data collection commenced on January 10th 2005 and was conducted in phases, due to the time 
commitment required, through to completion on November 14th 2007. 
 
2.4.5.8 Data collection tools 
All data were obtained from a) NHS electronic information systems: PAS (administrative and 
demographic data); CDR (blood results); PACS (radiographic data), PATS (SCTS data), b) the 
medical or nursing notes/charts, c) the patient, using a standardised Case Report Form (CRF):  
 V1 Sept 2004:    Completed after PDG meeting 1 
 51
 V2 March 2005:  Revised version after review of clinical variables Phase I pilot study 
 V3 July 2005:     Revised version after completion of pilot study (after PDG meeting 2) 
 
2.4.5.9 Data collector 
The SCTS data were collected by the Heart Hospital Information Nurses. All other data were 
collected by myself. 
 
2.4.5.10 Data custodian 
Professor Hugh Montgomery (as Chief Investigator (CI)/supervisor) and myself as the study 
Principle Investigator (PI) were named data custodians for this study. 
 
2.4.5.11 Data security and storage 
A pseudoanonymised system was required to enable ongoing data collection. At time of recruitment, 
participants were allocated a unique study number by which all clinical data collection was labeled. 
All CRFs and the study enrolment register (only place where patient name is recorded with the 
allocated study number) were stored in a locked metal filing cabinet within a locked office at UCL 
with access only allocated to the CI and PI.  All electronic data were stored on a double password 
protected database within a locked office at UCL, with access restricted to the PI. Patient 
identifiable information was stored separately from all other data, and only linkable through 
database manipulation. 
 
2.4.6 Ethical considerations 
This study was conducted under the Principles of the Declaration of Helsinki(94). In accordance with 
ethical principles as stated by American Nurses Association(95), and in addition to those already 
detailed (Right to privacy and dignity: section pt interviews 4.1.5.4; Right to anonymity and 
confidentiality: section Data security 4.1.6.6), the other principle ethical principles relevant to this 
study are: 
  
2.4.6.1 Right to self determination 
Patients must not feel coerced into participating in the study. Thus, particular emphasis was given 
during recruitment on not having to take part, being able to withdraw at any time, without giving a 
reason and that the decision to take part or not will not affect their care and management in any 
way. 
 
2.4.6.2 Right to fair treatment 
All participants were treated equally during the study, there were no payments or reimbursements 
made and there were no unequal distributions of risk between patients by participating in the study. 
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2.4.6.3 Right to protection from discomfort and harm 
There were no anticipated risks to the participant or researcher by participating in this study. 
 
2.4.7 Statistical methods 
All analyses were performed using SPSS V13. The Kappa statistic was utilised to establish the 
measure of agreement between the two raters. For the baseline descriptors of patients, categorical 
and continuous variables were analysed using basic descriptive analysis: frequencies and mean, 
minimum, maximum and standard deviation, as appropriate. 
 
2.5 PILOT STUDY 
2.5.1 Aim 
The purpose of the pilot study was to  
a) explore the initial applicability of POMS in describing and quantifying post-operative 
morbidity following cardiac surgery  
b) confirm the routine data collection variables required for the main study.  
 
2.5.2 Methods 
The pilot study emulated the study design, participants (excluding sample size), data variables, data 
collection (excluding reliability study and time-frame) and ethical considerations of the main study 
design, detailed in section 2.4. 
 
2.5.2.1 Sample size 
The pilot study consisted of a pre-determined sample size of 100 participants, which was deemed to 
be clinically appropriate by the PDG (meeting 1). 
 
2.5.2.2 Time frame 
The pilot study was conducted in two phases: a review of the routine data variables in the first fifty 
patients (Phase I) resulting in a revised CRF (V2 March 2005) for the remaining fifty patients (Phase 
II). 
 
2.5.2.3 Data collection Phase II 
Retrospective clinical data on the Phase I participants was obtained in order to complete routine 
clinical data following Phase I review.  Additionally, retrospective review of all chest x-ray reports 
using PACS on all patients was completed to ensure accurate identification of pneumothoraces, 
pulmonary oedema, left lower lobe (LLL) collapse and pleural effusions requiring drainage. 
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2.5.2.4 PDG review 
The PDG met post completion of the pilot study (meeting 2, Table 2-2) to evaluate the free-text 
additional morbidities (occurring in ≥5% of participants) from a clinical perspective to decide which 
were to be included as standard data items on the C-POMS CRF. 
 
2.5.2.5 Statistical methods 
All analysis was conducted in SPSS (V12.1).  The baseline descriptor analysis methods were 
identical to those used in the main study (section 2.4.7) 
 
2.5.2.5.1 Analysis of free-text entry 
Any symptoms/items identified to occur in more than 5% of patients were considered for inclusion in 
C-POMS.  Each morbidity identified through free-text data entry was entered into the Microsoft 
Access database into separate fields for every patient.  Thus, a patient with four additional post-
operative morbidities on day 1 and two on day 3 would have four free-text fields for day 1 and two 
for day 3.  Each free-text field was sorted into ascending order to identify each type of morbidity.  A 
new data table comprising of all patients and the identified morbidities was completed (where 1=yes 
for the presence of the morbidity at any point during the post-operative period).  The frequency of 
each morbidity was then calculated.  To identify the time-point specific frequency of each morbidity, 
each morbidity was allocated a code and the frequency of the code in each of the morbidity fields 
was calculated for each day. 
 
2.5.2.5.2 Acceptability and item frequency  
This was determined by examining distributions for item response frequencies and item non-
response, at all time-points.  Items with less than 5% completion were considered poorly performing 
and therefore redundant, items.  Items with less than 5% frequency were retained if considered by 
the PDG to have substantial clinical significance. Items occurring in more than 5% of patients were 
included in the final C-POMS data collection tool. 
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3 DATA QUALITY 
 
3.1 INTRODUCTION TO CHAPTER 
The validity of the conclusions reached depends on the quality of the data(96, 97).Thus, this chapter 
explores the concept of data quality, describes the methods used to devise and implement a data 
quality strategy and reports the data quality results of the data collected in the main study. 
 
 
3.2 INTRODUCTION TO DATA QUALITY 
All studies, no matter how well designed or implemented, have to deal with errors from various 
sources(98). However, while ‘quality’ data are not necessarily ‘perfect’ data(99) a lack of quality control 
can be detrimental to analysis and conclusions(97). Therefore, the validity of the conclusions reached 
depends partly on the accuracy of the data(96). Data quality issues can arise due to application 
errors, human errors and deliberate manipulations(100) and can be either random or systematic(101). 
Both error types can occur during data collection and data management but often can be identified 
and corrected(96).  Furthermore, multi-source datasets that require matching are vulnerable to 
naming and structural conflicts and also overlapping, contradicting and inconsistent data(102, 103).  
However, little guidance exists in the peer-reviewed literature on how to set up and carry out data 
quality strategies in an efficient way(98) and regulations and guidelines do not address minimum 
acceptable data quality levels for clinical trial data(104). Furthermore, since the majority of publication 
retractions are due to research error or inability to reproduce results(105), the growing importance of 
Good Clinical Practice guidelines and regulations(98) and the recommendation from the statistical 
societies that the description of data cleaning be a standard part of reporting statistical methods(106), 
greater emphasis on data quality in clinical studies is being made.  
 
The importance of a data quality strategy for this study is evident. Since the data quality process is 
unique for each study and particular to the data being analysed(102), the development of a data 
quality strategy specific to this study is required. Thus, this chapter will detail the development (from 
exploration of data quality and data quality strategies in the literature), implementation and reporting 
of a data quality strategy applied to the data in this study.  
  
 
3.3 AIMS 
The overall aim is to ensure a valid dataset containing minimal errors is produced. 
 
The specific aims and objectives are to: 
1. Develop a data quality strategy 
a. Explore the literature for existing methods and strategies 
b. Design a data quality strategy based on current evidence 
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2. Implement the data quality strategy 
3. Report and assess the results of the study’s data quality 
a. Report the data cleaning and screening procedures used 
b. Report the sources and assessed adequacy of the data 
 
 
3.4 EXPLORATION OF THE LITERATURE ON DATA QUALITY 
3.4.1 Defining data quality 
Data quality is a continuous and dynamic process of the operational checks to verify that clinical 
data are generated, collected, handled, analysed and reported accurately(96, 107). High levels of data 
quality are achieved when information is valid for the use for which it is applied(99, 108).  A review of 
the literature highlighted the components of data quality as detailed in Table 3-1. Other components 
identified were structure(109), value distribution(109), representativeness(110), integrity, cleanliness and 
correctness(100), where correctness and accuracy were stated as individual components. However, 
these components were ill-defined. 
 
3.4.2 Data quality strategies 
Data quality strategies comprise error prevention and data cleaning processes. Error-prevention 
strategies reduce many problems but cannot eliminate them and therefore data cleaning deals with 
data problems once they have occurred(98, 99). Known approaches to error prevention are detailed in 
Table 3-2. 
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Table 3-1: Components of data quality 
Component Reference Definition Measurement 
Uniqueness  
 
Orli 1996(99), 
Geiger 
2007(109) 
• The ability to establish the 
uniqueness of a data record (and 
data key values)  
• addresses the validity of the keys  
Quickly compare the number of 
records with distinct instances of the 
primary key  
Timeliness Orli 1996(99), 
Geiger 
2007(109) 
The extent to which a data item or 
multiple items are provided at the 
time required or specified.  A 
synonym for currency, the degree to 
which specified values are up to 
date  
 
Accuracy Orli 1996(99), 
Dongre 
2004(100), 
Geiger 
2007(109), 
Bethell 
2001(110) 
 
 The measure or degree of 
agreement between a data value 
(or set of values) and a source 
assumed to be correct and a 
qualitative assessment of freedom 
from error  
 addresses the correctness of the 
data  
A quick assessment can quickly see if 
you have numeric fields where they 
don't belong, negative values for a 
field that should only have positive 
values, future dates for past events 
and other data that is obviously 
incorrect. While it is possible to spot 
some accuracy problems quickly, 
others may require verification against 
known values  
Completeness Orli 1996(99), 
Dongre 
2004(100), 
Geiger 
2007(109), 
Bethell 
2001(110) 
 
 The degree to which values are 
present in the attributes that 
require them  
 addresses whether or not the field 
has a value  
This is quickly detected by looking at 
the percent null. Additionally, an 
examination of frequently occurring 
values (e.g., 1/1/1900 as a date) may 
indicate that the operational system 
inserted a default value for a null 
condition. Understanding the 
completeness of fields that may be 
used as a selection criterion in the 
data warehouse is crucial to ensure 
that when a user looks at data 
segmented by that criterion, all of the 
expected data is provided  
Consistency Orli 1996(99), 
Dongre 
2004(100), 
Data are maintained so they are free 
from variation or contradiction. The 
measure of the degree to which a 
set of data satisfies a set of 
constraints  
 
Validity  
 
Orli 1996(99) The quality of the maintained data is 
rigorous enough to satisfy the 
acceptance requirements of the 
classification criteria. A condition 
where the data values pass all edits 
for acceptability, producing desired 
results. 
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Table 3-2: Error prevention strategies (Roberts et al 1997(96), unless otherwise stated) 
 Error prevention strategy 
Data 
collection 
and coding  
1. If existing records are being used (lab value sheets) then the sequence on the 
CRF should follow the sequence of the existing record.  This helps to minimize 
systematic errors in data collection 
 2. Once data collection has begun, data should be coded soon after so that errors 
or questions can be corrected or subjects remeasured. 
 3. Coding should be present on CRF so the coder doesn’t have to go between the 
form and a code book.  Use of embedded coding instructions also facilitates data 
checking because data can be checked simultaneously with data entry. 
 4. There are coding schemes that also simplify later analysis. For example, 
dichotomous variables can be code as 0 and 1 to avoid recoding the variable 
 5. To minimize error coding should be performed by one person and checked by 
another. 
 6. Data collection points requiring calculations (eg mean BP) can be easily 
performed by a computer to avoid calculation errors on the part of the data 
collector. 
Data entry 7. When assigning variable names to items that make up a scale, using the same 2 
or 3 letters to start the variable names will ensure they appear sequentially in the 
list of variable names in the statistical software. 
 8. Hand-held computers can be used to eliminate the need for a paper record. This 
reduces the frequency with which the data can be manipulated and hence reduces 
the chance of error entering the data. 
 9. Appropriate design of the database schema and integrity constraints as well as of 
data entry applications are required(103). 
 10. All tools should be designed with data entry efficiency in mind.  Blocks of data 
items then a space will likely minimize misreading and incorrect key strokes 
because the values to be entered can be chunked(111). 
 11. Data errors are minimized when record lengths are kept short and multiple 
records per case are used.  Thus an ID number is required(111). 
 12. Can set up the ranges of values to be identified while the file is set up, thus 
entry of out of range data is prevented. 
 13. Using optical scanning technology(112). Although this technology reduces 
introduction of errors into data files it does not compensate for recording incorrect 
data on the instrument(113) and does introduce possible transcription errors. 
 14. Stats packages like SPSS can have a programme written to fill in logistical 
responses to questions and to skip items that are not relevant. 
 15. If data cleaning starts at same time as data collection, systematic     
   errors can be identified. 
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Data cleaning is the process of detecting, diagnosing and editing/removing faulty data(98). The goal 
is to obtain a set of data that contains a minimum of errors resulting from human factors in coding 
and data entry(114).  Data cleaning can also be used to determine the extent of error, where in the 
process the errors occurred, and whether the errors are systematic or random(96). 
 
Data cleaning is a time-consuming exercise which requires a sound methodological strategy(100). In 
addition to some practical data cleaning techniques (Table 3-3), a search of the literature identified 
three data cleaning frameworks(98, 99, 103), with Geiger(115) and Wright(116) describing the data profiling 
and error analysis components only, respectively. 
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Table 3-3: Data cleaning techniques 
 Data cleaning techniques 
Roberts et 
al 1997(96) 
1. The raw data should be copied into a data file for computation and analysis 
so if computational errors or computer problems the raw data remains 
unchanged. 
 2. Personnel who know the data well are instrumental in identifying potential 
errors and can be essential in resolving them 
 3. Data should be entered twice into 2 separate files which can then be 
compared to identify inconsistencies 
 4. Random samples of subjects can be drawn and the data entered compared 
with that on the CRF.  If multiple instruments for data collection are used, 
random samples should be drawn for each instrument to ensure thorough 
checking. 
 5. Each data collectors work should be checked 
Dongre 
2004(100) 
6. Examination of listings of the records: visual inspection of fields for the 
appropriateness of the content and the correctness of the value. 
 7. Frequency distributions:  Prior to doing them the researcher determines the 
upper and lower limits for the variables.  Also identifies illegitimate values 
(eg. Those as fractions when should be whole numbers) 
 8. Cross tabulations: when certain combinations of variables are illegitimate. 
 9. Examination of entire record: examines a sample of records.  Must make 2 
decisions.  The first is to determine the number of error-containing records 
that will be accepted before all records can be verified. The second is to 
determine the size of a sample of records that should be drawn and 
verified. 
 10. Multiple entry: constructing 2 duplicate data sets for comparison. Discrepant 
records are then verified against the original forms and the appropriate 
corrections made.  Is more efficient for large data sets (>250 records). 
Hayes 
2004(102) 
11. Descriptive analysis: identify missing information, incorrect coding, outliers 
and misaligned data.  These findings precipitate checks against the original 
hard copy – time consuming element. 
 12. Double verification of entered data 
 13. Random checks of individual subjects against original: Use cross-
tabulations  to show impossible or unlikely  combinations. 
Suter 
1986(111) 
14. Scatterplots highlight suspicious combinations of values. 
 15. Double entry for double checking 
 16. Handling missing data: leave blank (code as missing in SPSS). 
 17. Recoding variables (computing) to create new variables can introduce 
errors.  Frequency distributions on recoded and computed variables should 
always be inspected for errors. 
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The Rahm and Do model(103) deals exclusively with computational data cleaning. However, while 
Orli(99) highlight the need for individual projects to deal with existing data and the processes that 
causes those errors, only Van der Broeck 2005(98) comprehensively includes data quality as a 
continuous process from study design to completion, although is branded as a data cleaning 
framework (Figure 3-1).  
 
Figure 3-1: Van der Broeck 2005(98) Data cleaning framework 
 
 
The screening, diagnosis and editing steps can be initiated at any stage during the study process 
but do rely on insight into the sources and types of errors at all stages of the study. As detailed in 
Figure 3-1, the screening phase is to identify four types of potential error. The data range identified, 
and the diagnostic steps required (Figure 3-2) aim to provide clarity of the true nature of the 
potential error identified. Finally, the editing phase involves deciding how to deal with the error, 
either to correct, delete or leave unchanged. The general rules for the editing phase are that a) 
impossible values should never be left unchanged but should be deleted if the correct value cannot 
be obtained, b) for biological measurements some within-subject variation should be considered 
acceptable, c) additional individual and group investigation may be required for true extreme values 
and values that are still suspect after the diagnostic phase. 
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Figure 3-2: Data range in screening and diagnostic steps required to clarify diagnosis(98). 
 
 
 
3.5 METHODS 
3.5.1 Design 
A modified Van der Broeck(98) framework (Figure 3-1) was utilised incorporating specific practical 
strategies from a variety of other sources (Figure 3-3). 
 
Figure 3-3: Data quality strategy 
Design
Collect 
and Enter
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Editing
•Correct
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3.5.2 Time-points 
Error prevention strategies were employed at the Design and Collect/enter phase following 
completion of the Pilot study. Some data cleaning occurred at the Collect/enter phase at the end of 
pilot phases I and II (uniqueness, accuracy of coding, completeness: not reported here) with the 
most extensive data cleaning being commenced at the end of all data entry following completion of 
Phase IV recruitment. Subsequent data errors noted during the Explore/Analyse steps of the study 
process were also noted, diagnosed and treated.  
 
3.5.3 Error prevention strategy 
The error prevention strategies 1-4 and 6-12 detailed in Table 5.2 were employed within the Design 
and Collect/enter I steps of the study process. Strategies 13 and 14 were not appropriate as optical 
scanning techniques were not utilised in the study and Microsoft Access (not SPSS) was used for 
data storage, respectively. Strategy 5 was also not applicable as I was a lone researcher, resulting 
in strategy 15 not being able to commence at start of data collection, but was delayed until the end 
of Phase I of the pilot study data collection.  Furthermore, while in accordance with strategy 3 most 
coding was present on the CRF, some coding of free-text fields (for example, additional morbidities, 
pre-operative medications) occurred at the end of the pilot study which was as the earliest 
opportunity, as suggested within strategy 2.  The CRF was designed with variables blocked in 
accordance to flow of data collection (administrative information, pre-operative information, intra-
operative information and post-operative days in date order) and, within that, sources of data 
collection (for example, all drugs grouped together for collection from the drug chart). The database 
mirrored the data collection flow with each time-point entered into a separate data entry table to 
ease data entry and minimise errors (strategies 9-11). Additionally, data validation rules were 
constructed in the database, where appropriate, in accordance with strategy 12. 
 
3.5.4 Data cleaning strategy 
3.5.4.1 Screening 
To identify 3 of the 4 types of potential errors (lack/excess of data; outliers/inconsistencies; strange 
patterns), exploration of the components of data quality (Table 3-1) was undertaken using the 
strategies 3-17 (excluding 5) detailed in Table 3-3.  Strategy 5 was not relevant since there was 
only one data collector, and the assessment of timeliness was not applicable as all data were 
collected at the appropriate times. The suspect analysis errors are detailed in section 5.3.3.4.  All 
tasks were conducted in Microsoft Access through frequency distributions and data query functions 
and all assessments were done in the order indicated below, as each had the potential to affect the 
next. 
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a) Uniqueness 
The distinct instances of the primary key (unique study identifier) was assessed in each of the data 
tables within the database by ensuring the correct frequency of records were present and whether 
duplicates of the primary key existed (Microsoft Access ‘Find duplicates query wizard’) 
 
b) Accuracy 
The accuracy of the data was assessed individually for each data variable within each data table. 
Pre-defined quality criteria were that all clinical variables and blood results would be considered 
within acceptable range if within two-times the upper/lower normal range, as defined by centre 
norms (Appendix 2).  Visual assessments included that the type of information in the field was 
correct, of expected length (decimal places or characters) and that the information was within the 
expected range (either coding range or clinically reasonable). Those considered suspect or 
impossible were indicated to establish diagnosis.  
Using a random number generator in Microsoft Excel, (where column A is the patient number 
between 1-464 (=FLOOR(1+A$1*RAND(),1), column B is section in C-POMS 
(=FLOOR(1+B$1*RAND(),1) and where F9 refreshes the list) 10 participants were identified for 
each data table for multiple entry (one repeat data entry by data enterer), 5 for the examination of 
the entire record and 10 for random checks between the CRF and database entries. 
 
c) Completeness 
The completeness of the data was assessed for each data variable within each data table 
individually. For variables attributable to an indicator field, data completeness was related to the 
indicator field and not the dataset overall.  Incompleteness was defined as the percentage null or 
coded as not stated (not stated in medical notes) or missing (missing in CRF). The residual 
incompleteness was defined as overall incompleteness (include not stated/not done) not only 
dataset incompleteness. The pre-defined quality criteria was that 0% incompleteness should be 
attempted for all variables, thus all variables above this threshold were subject to re-exploration.  
 
d) Consistency 
Consistency assessments were undertaken in variables where it was possible: 
a) Unique identifier across all data tables 
b) Dates across all post-operative data tables from day of operation. For example DODay1-
DOOP should be 1, DODay3-DOOP should be 3 
c) Neurological history: consistency between C-POMS and SCTS data 
d) Pulmonary disease history: consistency between C-POMS and SCTS data 
e) C-POMS coding of categories: 
I. The coding of each variable within each category was checked. 
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II. Each post-operative day compared against pre-operative coding for each variable to 
ensure consistency in coding for morbidity ‘new’ or ‘not new’.  Exception to this rule 
was ‘ischaemia/MI’ in the cardiovascular category and the haematological category 
 
e) Validity 
The representativeness of the population characteristics of those who did and did not participate in 
the study was assessed. Cross tabulation for categorical variables and comparing means of 
continuous variables in SPSS was conducted. Statistical significance was taken at the p<0.05 level. 
The results of all the data quality assessments were considered by the PDG (meeting 3) to 
determine if the data were ‘fit for purpose’. 
 
3.5.4.2 Diagnosis 
A 2-tier level to confirm diagnosis was employed on all variables indicated as potential errors. Firstly 
all suspect, impossible or missing variables were checked in the CRF and, if not resolved, the 
medical records were then examined. A diagnosis of missing, erroneous (incorrect/wrong) true 
extreme, true normal (prior expectation was incorrect), idiopathic (unknown) was applied to all 
indicated potential errors. 
 
3.5.4.3 Editing 
Prior to any data editing, a copy of the raw data was saved as a separate file, as per strategy 1 
(Table 3-3). The treatment plan options were correcting, deleting and leaving unchanged. 
Pre-defined quality criteria are that any missing values subsequently identified are corrected, true 
extreme and true normal values are left unchanged and idiopathic errors are deleted and then 
become a missing value.  
 
3.5.4.4 Suspect analysis/results 
These data errors, their diagnosis and treatment, were identified during data analysis. 
 
 
3.6 RESULTS 
3.6.1 Uniqueness 
Each data table had the required number of records and were without duplicate unique study 
identifiers. 
 
3.6.2 Accuracy 
Of the 1234 data fields, 138 (11.2%) were assessed as having potential inaccuracies affecting 532 
entries of which 259 (48.7%) were erroneous, 251 (47.2%) were true extreme and 21 (3.9%) were 
true normal. The true extreme and true normal values were left unchanged and 5 (1.9%) of the 
erroneous values were deleted as subsequently diagnosed as idiopathic. The remaining erroneous 
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values were corrected.  Summary details for the accuracy assessments in each data table are 
detailed in Table 3-4. 
 
Table 3-4: Summary of accuracy assessment results. Values are n(%). 
Table % pre-screening potential 
inaccuracy (mean) 
Erroneous 
(n=259 
entries) 
True 
extreme 
(n=251 
entries) 
True normal 
(n=21 
entries) 
Admin 0.004   1   (0.4)   2  (0.8)   1   (4.8) 
Pre-operative  0.18 99 (38.2) 20  (8.0)   2   (9.5) 
Intra-operative 0.04 33 (12.7) 15   (6.0)   0   (0.0) 
C-POMS D1 0.10 28 (10.8)   2   (1.2)   0   (0.0) 
C-POMS D3 0.09 18   (6.9) 38 (15.1)   0   (0.0) 
C-POMS D5 0.05   5  (1.9) 27 (10.8)   0   (0.0) 
C-POMS D8 0.13 28 (10.8) 61 (24.3)   0   (0.0) 
C-POMS D15 0.10   0  (0.0) 73 (29.1)   0   (0.0) 
Outcome 0.24 26 (10.0)   0   (0.0)   0   (0.0) 
SCTS 0.13 21 ( 8.1) 13   (5.2) 18 (85.7) 
 
The accuracy assessments also highlighted that some fields required further coding (Additional 
DOOP comments, Other infusions, D1 comments, DC services comments) and that some fields 
were redundant (pre-operative creat >50% in the pre-operative table, as irrelevant pre-operatively; 
wound culture treatment on D3, D5, D8 and D15 in the C-POMS tables, as will be defined within 
antibiotic field in the infectious POMS domain.) 
 
3.6.2.1 Multiple entry 
Overall, 81 (6.9%) of fields in the dataset had discrepancies (Table 3-5).  Sixty-eight (84.0%) of 
those fields had errors in one pair of entries, 8 (9.9%) had errors in 2 pairs of entries, 2 (2.5%) had 
errors in 3 pairs of entries and 3 (3.7%) had errors in all 5 pairs.    
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Table 3-5: Summary of multiple entry errors 
Table Total number of fields Fields with errors n(%) 
Admin   19 (not incl NHS no)   0     (0) 
Pre-operative (including C-POMS) 225   6   (2.7) 
Intra-operative 172 11   (6.4) 
C-POMS D1 143   7   (4.9) 
C-POMS D3 142 17 (12.0) 
C-POMS D5 152   7   (4.6) 
C-POMS D8 151 15   (9.9) 
C-POMS D15 150 14   (9.3) 
Outcome 23   4 (17.4) 
Total 1177 81   (6.9) 
 
Table 3-6 details the specific results. Thirty-four (38.3%) and 40 (49.4%) of the errors were 
attributed to the first and second entry, respectively, with 4 (4.9%) of errors being attributable to 
either entry and in 3 (3.7%) where the fields in the whole dataset need re-examination (D1 wound 
drain, D1 wound complication, D1 assisted ambulation type).  These errors were attributable to 
incorrect value/code/data entry errors (n=36, 44.4%; 3.0% of all variables), an incorrect indicator 
field code (n=20, 24.7%), data being obtained from different source (not CRF) (n=13, 16.0%), field 
introduction after pilot study/change in data collection during study (n=5, 6.2%) and the presence of 
mixed results within field (n=4, 4.9%). 
Errors attributed to the first entry were examined individually in the database.  Eleven (32.4%) were 
already corrected within the database from data cleaning efforts.  23 (67.6%) remained inaccurate 
and were changed in the database of which 20 (58.8%) were erroneous inliers and 3 (8.8%) were 
changed from missing. 
 
3.6.2.2 Examination of entire records 
Examination of the entire record of CP161, CP261, CP271, CP319, CP361 detected no errors.  
 
3.6.2.3 Random checks 
Examination of records CP100 (pre-operative data), CP106 (CPOMS D1 and D8), CP165 (intra-
operative data), CP282 (C-POMS D3 and D5) and CP454 (administrative and outcome data) 
detected no errors.  C-POMS D15 data were not checked as no numbers were generated for 
participants still an inpatient on D15.
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Table 3-6: Detailed results of discrepancies detected during multiple entry 
Table Field Error (number of 
pairs) 
Discrepancy check Reason for discrepancy *First entry errors checked in 
database 
Pre-operative DOpreopCXR 1 (CP313) Error on 2nd entry Data from different source (not on CRF)  
 COPD 2 (CP056, CP313) CP056: Error on 1st entry 
CP313: Error on 2nd entry 
Incorrect code Already changed in database 
 Pre albumin 1 (CP056) Error on 2nd entry Incorrect value  
 H2 agonsist 1 (CP207) Error on 1st entry  Not routine variable in 1st entry.  Coded at end of 
study 
Already changed in database through 
data cleaning methods 
 Other2 state dose 1 (CP207) Error on either Monday dose stated in entry 1 and combined 
weekly dose coded on entry 2 
 
 Other3 state drug 1 (CP207) Error on either Too many drugs to enter  
Intra-operative Anaes room time 1 (CP377) Error on 2nd entry Data from different source (not on CRF)  
 Anaes start 1 (CP377) Error on 2nd entry Data from different source (not on CRF)  
 Enter theatre 1 (CP377) Error on 2nd entry Data from different source (not on CRF)  
 Skin prep 1 (CP377) Error on 2nd entry Data from different source (not on CRF)  
 Op end 1 (CP377) Error on 2nd entry Data from different source (not on CRF)  
 Leave theatre 1 (CP377) Error on 2nd entry Data from different source (not on CRF)  
 PORR vent or ext 1 (CP125) Error on 2nd entry Incorrect code  
 Temp (1st) 1 (CP125) Error on 1st entry Incorrect value (coding Fields for first entries 
changed to 1st and highest during study). 
Changed in database to correct entry 
 Temp (high) 2 (CP123, CP125) Both: Error on 1st entry Incorrect value (coding Fields for first entries 
changed to 1st and highest during study) 
Changed in database to correct entry 
 D1 heart rhythm 1 (CP377) Error on 2nd entry Incorrect coding  
 D1 heart rhythm 
other 
1 (CP377) Error on 2nd entry Error related to incorrect code in indicator field  
C-POMS D1 D1 Oxy Supp? 1 (CP212) Error on 1st entry Incorrect code Changed in database to correct entry 
 D1 Renal new 1 (CP212) Error on 2nd entry Incorrect code  
 D1 IV frusemide 1 (CP082) Error on 2nd entry Incorrect code  
 D1 creat >30% 3 (CP212, CP273, Error on 2nd entry Data from different source (not on CRF)  
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CP423) 
 D1 wound drain 5  To check whole dataset  
 D1 wound compl 5  To check whole dataset  
 Assisted 
ambulation type 
5  To check whole dataset  
C-POMS D3 D3 ward transfer 1 (CP021) Error on 1st entry Incorrect code Changed in database to correct entry 
 D3 How much 
oxy? 
2 (CP021, CP027) Both: Error on 2nd entry:  Incorrect value  
 D3 Fragmin 1 (CP021) Error on 2nd entry Incorrect code  
 D3 Frusemide 1 (CP098) Error on 2nd entry Incorrect code  
 D3 creat >30% 2 (CP242, CP349) Both: Error on 2nd entry  Data from different source (not on CRF)  
 D3 hypotension 1 (CP349) Error on 1st entry Incorrect code Changed in database to correct entry 
 D3 Hypo new? 1 (CP349) Error on 1st entry Error related to incorrect code in indicator field Changed in database to correct entry 
 D3 Hypo test 1 (CP349) Error on 1st entry Error related to incorrect code in indicator field Changed in database to correct entry 
 D3 Hypo diag 1 (CP349) Error on 1st entry Error related to incorrect code in indicator field Changed in database to correct entry 
 D3 Hypo treated 1 (CP349) Error on 1st entry Error related to incorrect code in indicator field Changed in database to correct entry 
 D3 Hypo Rx 1 (CP349) Error on 1st entry Error related to incorrect code in indicator field Changed in database to correct entry 
 D3 Arrhy treated 1 (CP021) Error on 2nd entry Incorrect code  
 D3 Assisted 
ambulation 
1 (CP021) Error on 2nd entry Incorrect code  
 D3 Assisted ambul 
new? 
1 (CP021) Error on 2nd entry Error related to incorrect code in indicator field  
 D3 Assisted ambul 
type 
1 (CP021) Error on 2nd entry Error related to incorrect code in indicator field  
 D3 Hypotension 
(fluid) 
1 (CP027) Error on 1st entry Pilot study: Field introduced after pilot study and 
data merged at end of study 
Already changed in database through 
data cleaning methods 
 D3 Hypotension 
comments 
1 CP027) Error on 1st entry Error related to incorrect code in indicator field Already changed in database through 
data cleaning methods 
C-POMS D5 D5 How much 
oxy? 
1 (CP181) Error on 1st entry Incorrect code Already changed in database through 
data cleaning methods 
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 D5 state inotropes 1 (CP181) Error on 1st entry Incorrect code Already changed in database through 
data cleaning methods 
 D5 Wound culture 1 (CP181) Error on 2nd entry Data from different source (not on CRF)  
 D5 Wound culture 
results 
1 (CP181) Error on 2nd entry Error related to incorrect code in indicator field  
 D5 Social reasons 1 (CP127) Error on 2nd entry Incorrect code  
 D5 Other medical 1 (CP255) Error on 1st entry Incorrect code Changed in database to correct entry 
 D5 Other medical 
state 
1 (CP255) Error on 1st entry Error related to incorrect code in indicator field Changed in database to correct entry 
C-POMS D8 D8 ward transfer 2 (CP032, CP043) Both: Error on 1st entry Incorrect value Changed in database to correct entry 
 D8 How much 
oxy? 
1 (CP043) Error on 2nd entry Incorrect value  
 D8 SaO2 1 (CP349) Error on 2nd entry Incorrect value  
 D8 wound 
complication 
1 (CP281) Error on 1st entry Incorrect code Changed in database to correct entry 
 D8 Pul 
oed/anticoag 
1 (CP032) Error on 2nd entry Data from different source (not on CRF)  
 D8 Pul 
oed/anticoag 
new? 
1 (CP032) Error on 2nd entry Error related to incorrect code in indicator field  
 D8 Pul 
oed/anticoag test 
1 (CP032) Error on 2nd entry Error related to incorrect code in indicator field  
 D8 Pul 
oed/anticoag diag 
1 (CP032) Error on 2nd entry Error related to incorrect code in indicator field  
 D8 Neuro state 1 (CP032) Error on 1st entry Incorrect code Changed in database to correct entry 
 D8 Neuro 
comments 
1 (CP032) Error on 1st entry Error related to incorrect code in indicator field Changed in database to correct entry 
 D8 Assisted 
ambulation type 
1 (CP032) Error on 1st entry Incorrect code Changed in database to correct entry 
 D8 IV Frusemide 1 (CP043) Error on 1st entry Pilot study: Field introduced after pilot study and Already changed in database through 
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given data merged at end of study. data cleaning methods 
 D8 IV Frusemide 
comment 
1 (CP043) Error on 1st entry Error related to incorrect code in indicator field Already changed in database through 
data cleaning methods 
 D8 INR 1 (CP349) Error on 1st entry Field introduced after pilot study and data 
merged at end of study. 
Changed in database to correct entry 
 D8 Periph oed 1 (CP349) Error on 1st entry Field introduced after pilot study and data 
merged at end of study. 
Changed in database to correct entry 
C-POMS D15 D15 SaO2 1 (CP128) Error on 1st entry Incorrect value Changed in database to correct entry 
 D15 wound site 1 (CP154) Error on 1st entry Incorrect code Changed in database to correct entry 
 D15 Wound 
culture 
1 (CP154) Error on 2nd entry Data from different source (not on CRF)  
 D15 Wound 
culture result 
1 (CP154) Error on 2nd entry Error related to incorrect code in indicator field  
 D15 intol type ent 
diet 
1 (CP154) Error on 2nd entry Incorrect value  
 D15 Dysrhythm 
treated 
1 (CP418) Error on 1st entry Incorrect value Already changed in database through 
data cleaning methods 
 D15 Dysrhtyhm Rx 2 (CP264, CP418) Both: Error on 1st entry 
 
CP418: Error related to incorrect code in 
indicator field 
CP264: Incorrect text (Data in wrong field) 
Already changed in database through 
data cleaning methods 
 D15 Hypertension 
Rx 
1 (CP154) Error on 1st entry Incorrect code Already changed in database through 
data cleaning methods 
 D15 Hypertension 
comments 
1 (CP154) Error on 1st entry Error related to incorrect code in indicator field Already changed in database through 
data cleaning methods 
 D15 INR 1 (CP156) Error on 2nd entry Incorrect code  
 D15 Incr wt 1 (CP156) Error on 2nd entry Incorrect code  
 D15 Incr wt 
comments 
1 (CP156) Error on 2nd entry Error related to incorrect code in indicator field  
 D15 Other medical 1 (CP128) Error on 1st entry Incorrect code (not reason for delayed 
discharge) 
Changed in database to correct entry 
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 D15 Other medical 
comments 
1 (CP128) Error on 1st entry Error related to incorrect code in indicator field Changed in database to correct entry 
Outcome Dest from ICU 1 (CP006) Error on 2nd entry Data from different source (not on CRF)  
 DC services 3 (CP006, CP060, 
CP189) 
CP006: Error on 2nd entry 
CP060: Error on 2nd entry 
CP189: Error on 1st entry 
CP006: Field introduced after pilot study and 
collected retrospectively thus data from different 
source (not on CRF) 
CP060 and CP189: Incorrect coding 
 
 DC DN 2 (CP006, CP060) CP006: Error on 2nd entry 
CP060: Error on 2nd entry 
CP006: Field introduced after pilot study and 
collected retrospectively thus data from different 
source (not on CRF) 
CP060: Error related to incorrect code in 
indicator field 
 
 DC SS 2 (CP006, CP060) CP006: Error on 2nd entry 
CP060: Error on 2nd entry 
CP006: Field introduced after pilot study and 
collected retrospectively thus data from different 
source (not on CRF) 
CP060: Error related to incorrect code in 
indicator field 
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3.6.3 Completeness 
Prior to data cleaning, the mean incompleteness of the dataset was 2.8%, reducing to 1.4% 
post-cleaning (Table 3-7). All data tables had over 93% completeness post-cleaning, with admin, 
intra-op, C-POMS D1-D15 all exhibiting over 99% completeness. Overall, 52.8% and 77.9% of 
variables were 100% and >99% complete, respectively pre-cleaning, increasing to 67.7% and 
90%, respectively post-cleaning. The SCTS database was the poorest performing with overall 
incompleteness of 6.8% and only 30.4% of variables with 100% completeness and 48.2% of 
variables with >99% completeness while 7 of the other 9 data tables exhibited >99% 
completeness in more than 92% of variables post-cleaning.  
 
Table 3-7: Summary of data completeness 
 Descriptives (mean% 
± SD) 
Variables with 100% 
completeness 
Variables with >99% 
completeness 
 Screen  Post-
cleaning 
 
Screen Post-
cleaning 
Screen Post-
cleaning 
Admin 0.2 ±4.8 0.18 ± 4.8   17 (85.0)   17 (85.0)   19 (95.0)   19 (95.0) 
Pre-op 2.5 ± 6.6 2.23 ± 6.4 133 (59.1) 151 (67.1) 189 (84.4) 194 (86.2) 
Intra-op 1.1 ± 5.5 0.9 ± 5.5   78 (45.3)   94 (54.7) 155 (90.1) 159 (92.4) 
CPOMS D1 2.6 ± 6.5 0.4 ± 1.1   72 (50.3)   81 (56.6) 119 (83.2) 134 (93.7) 
CPOMS D3 2.9 ± 6.9 0.8 ± 3.4   69 (48.6)   94 (66.2) 118 (83.1) 133 (93.7) 
CPOMS D5 3.0 ± 8.1 1.0 ± 5.7   85 (55.9) 126 (82.9) 125 (82.2) 142 (93.4) 
CPOMS D8 2.4 ± 6.1 1.0 ± 4.6   88 (58.3)   94 (62.3) 121 (80.1) 140 (92.7) 
CPOMS D15 2.4 ± 6.1 1.0 ± 4.6   90 (60.0) 144 (96.0)   90 (60.0) 144 (96.0) 
Outcome 3.1 ± 11.8 2.7 ± 11.2   14 (60.9)   17 (73.9)   16 (69.6)   19 (82.6) 
SCTS 7.8 ± 18.9 6.8 ± 19.2     6 (10.7)   17 (30.4)     8 (14.3)   27 (48.2) 
All 2.8 ± 7.8 1.4 ± 6.5 652 (52.8) 835 (67.7) 960 (77.9) 1111 
(90.0) 
 
Despite some records exhibiting significant amounts of residual incompleteness (Table 3-8), no 
records were deleted since only sections of the data, and not the whole record, were affected in 
each case. 
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Table 3-8: Records with high residual incompleteness 
Study 
number 
Reason Table Residual missing 
in indicator field 
n(%) 
CP004 No anaesthetic chart, ICU charts for 
DOOP/D1 in notes 
Intra-op  
CPOMS D3  
39 (42.4) 
40 (66.7) 
CP035 No D1 ICU chart Intra-op 12 (13.0) 
CP059 Notes not received Intra-op 11 (12.0) 
CP065 Notes received but no notes pertaining to 
this admission 
CPOMS D8 52 (77.6) 
CP122 Notes received but no ICU/drug charts CPOMS D1 22 (36.1) 
CP123 Notes not received CPOMS D1 20 (32.8) 
CP196 Obs chart missing in medical notes Pre-op   5   (5.6) 
CP215 Notes not received Pre-op 
CPOMS 
  5   (5.6) 
CP238 No D1 ICU chart in notes Intra-op,  
CPOMS D1 
18 (19.6) 
51 (83.6) 
CP245 Notes received but no notes for that day (? 
Transferred o/n) 
CPOMS D5 11 (16.4) 
CP297 Drug related fields only as no drug charts 
and medical notes not received 
Pre-op 31 (34.4) 
 
Cause of death, days ventilated and circulatory arrest time, all variables from the SCTS 
database, had 100%, 41.6% and 99.1% incompleteness, respectively and ASA (intra-operative 
table) had 55.3% missing data. Thus, each was deleted from analysis. 
 
3.6.4 Consistency 
3.6.4.1 Unique identifier 
With the exception of the administrative table, complete consistency across all tables was 
identified with the unique study number. The administrative table contained the 14 participants 
who gave consent to participate but did not complete the study. 
 
3.6.4.2 Dates throughout all data tables 
Complete data consistency of dates was observed on D8, with <1% error identified at all other 
post-operative time-points (Table 3-9). All errors were erroneous and corrected, thus resulting in 
100% consistency on all days. 
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Table 3-9: Date inconsistencies on post-operative data time-points from day of operation. 
Table Screen 
(% 
inaccurate) 
Diagnosis Treatment 
plan 
Comments 
C-POMS 
D1 (n=450) 
0.4 Erroneous Correct CP180 (DOOP) CP439 
(DODay1): Correct from CRF. 
Corrected from CDR 
C-POMS 
D3 (n=450) 
0.2 Erroneous Correct CP180: Corrected DOOP from 
CDR 
C-POMS 
D5 (n=426) 
0.7 Erroneous Correct CP012, CP224: Corrected from 
CRF. CP180: Corrected DOOP 
from CDR,  
C-POMS 
D8 (n=181) 
0.0 Erroneous Correct  
C-POMS 
D15 (n=48) 
0.2 Erroneous Correct CP385: Correct from CRF. 
Corrected from CDR. 
DOOP = Date of operation; DODay1 = date of D1; CDR = Clinical Data Repository; CRF = Case 
Report Form. 
 
3.6.4.3 Neurological history 
A neurological history was recorded in 32 (7.1%) participants in C-POMS and 31 (6.9%) in 
SCTS. Agreement was observed in 28 participants (87.5%) while there were 4 (12.5%) 
participants identified that had a neurological history identified in C-POMS but not SCTS and 3 
(9.4%)  that had a neurological history recorded in SCTS but not C-POMS (Table 3-10).  The 
medical notes of each of the 7 discrepancies were requested but were unavailable.  Thus, it was 
concluded that those in C-POMS but not SCTS would remain in the database as there was 
enough information for the entry to be valid and unlikely to be due to data entry.  However, 
those in SCTS but not C-POMS were not added since without verification from the medical 
notes there was insufficient information not to exclude data entry error. Furthermore, there was 
sufficient confidence in the C-POMS data collection to be assured that it ws unlikely those cases 
were missed. 
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Table 3-10: Consistency between C-POMS and SCTS data collection of neurological history 
 C-POMS database Checked with 
medical notes 
SCTS 
database 
Checked with 
medical notes 
Those with 
neurological 
history in C-
POMS but not 
SCTS (to 
check medical 
notes) 
CP039: slight TIA 
10yrs ago 
CP364: L cortical 
infarct 2002 
CP384: ?? TIA 
CP402:TIA 3yrs 
ago, complete 
recovery 
CP039: medical 
notes not received 
CP364: medical 
notes not received 
CP384: medical 
notes not received 
CP402: medical 
notes not received 
-  
Those with 
neurological 
history in 
SCTS but not 
C-POMS (to 
check medical 
notes) 
- - CP038: TIA 
or RIND 
CP186: TIA 
or RIND 
CP221: CVA 
with full 
recovery 
CP038: medical 
notes not 
received 
CP186: medical 
notes not 
received 
CP221: medical 
notes not 
received 
 
3.6.4.4 Pulmonary disease 
A history of pulmonary disease was recorded in 62 (13.8%) participants in C-POMS and 45 
(10%) in SCTS. All those identified within SCTS were observed in C-POMS. Of the 17 identified 
in C-POMS but not SCTS, 6 were erroneous data entries and were corrected.  
 
3.6.4.5 POMS coding of categories 
Erroneous errors were detected in POMS coding on D1 (0.7%), D3 (1.6%), D5 (2.4%), D8 
(1.1%) and D15 (1.1%) (Table 3-11). All treatment plans were to correct, which were 
implemented leaving no residual POMS coding errors. 
 
3.6.5 Validity 
Overall, those participating in the study were significantly older with a higher percentage of 
Caucasians and hypertensive patients in comparison to those who didn’t participate in the study 
(Table 3-12). Those in C-POMS also had a lower EuroSCORE with lower mean ICU and post-
operative length of stay.  When comparing the characteristics of those who did and did not 
participate in the CPOMS study during each of the recruitment phases (Table 3-13) there were 
no significant differences during phase I and II.  During Phase III there were significantly more 
Caucasians in the study and a lower mean EuroSCORE was observed overall in the study 
group.  During Phase IV again there were more Caucasians, more hypertensives and more 
single procedure surgery than those not in the study with an overall reduced mean length of ICU 
stay in the study group. 
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On review of the data quality strategy and results, the PDG deemed sufficient face validity was 
observed that the data did accurately represent the data aimed to be collected, with sufficient 
accuracy for decision making to be made on this data. 
 77
Table 3-11: Consistency of POMS domain coding 
 Pre-operative CPOMS D1 CPOMS D3 CPOMS D5 CPOMS D8 CPOMS D15 
 Screen 
(n) 
Comments Screen 
(n) 
Comments Screen 
(n) 
Comments Screen 
(n) 
Comments Screen 
(n) 
Comments Screen 
(n) 
Comments 
Pulmonary 13 Correct 449 Correct 303 Correct 113  50 CP002: 
corrected to 
‘not new’ 
14 Correct 
Supplementary 
oxygen 
13 Correct 373 Correct 303 CP159 
corrected to 
‘new’ 
113 CP199 
corrected 
coding of 
type of suppl 
50 CP419, 
CP443: 
checked but 
correct 
14 Correct 
Infectious 12 Correct 376 Correct 109 Correct 154 CP258: 
Corrected 
coding. 
CP168: 
Corrected to 
new 
99 CP168: 
corrected to 
‘new’. CP397: 
Corrected 
coding as 
antibiotics 
present (99 to 
100) 
28 Correct 
Antibiotics 11 Correct 376 CP063 changed 
to ‘not new’ 
109 CP062 
corrected to 
‘new’ 
152 Correct 100 Correct 28 Correct 
Temperature 1 Correct 19 Correct 21 Correct 5 Correct 2 Correct 1 Correct 
Renal 12 Correct 44 CP429 corrected 154 CP297: 
corrected 
coding 
67 Correct 45 Correct 18 Correct 
Oliguria 6 Correct 11 CP004, CP386: 
Checked but 
correct 
15 Correct 11 Correct 4 Correct 1 Correct 
Creatinine NA Correct 26 Correct 56 Correct 25 Correct 21 Correct 5 Correct 
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Catheter 4 Correct 448 CP429 as 
missing in renal 
142 Correct 61 Correct 33 CP263: not 
coded as ‘not 
new’ as pre-op 
catheter not a 
long-term 
catheter 
13 Correct 
RRT 7 Correct 8 Correct 11 CP004: 
corrected 
from ‘no’ to 
‘missing’ 
12 Correct 5 Correct 1 Correct 
Gastrointestinal 10 Correct 230 Correct 112 Correct 93 CP058: 
Corrected 
coding 
38 Correct 8 Correct 
Nausea 7 Correct 224 Correct 92 Correct 75 Correct 31 CP107: 
corrected to 
‘not new’ 
5 Correct 
Vomiting 2 Correct 80 Correct 21 Correct 11 Correct 2 Correct 0 Correct 
Abdominal 
distension 
1 Correct 1 Correct 20 Correct 22 CP158, 
CP235, 
CP285, 
CP446: 
Corrected to 
‘new’ 
8 Correct 7 4 not new: 
all 
erroneous 
and 
corrected 
Cardiovascular 66 Correct 223 Correct 196 Correct 184 Correct 104 Correct 28 Correct 
Ischaemia/MI 9 Correct 15 Correct 4 Correct 0 Correct 0 Correct 0 Correct 
Hypotension 1 Correct 132 Correct 37 Correct 15 Correct 5 Correct 5 Correct 
Arrhythmias 38 
(corrected 
to 42 after 
post-op 
Correct 93 32 checked: all 
correct 
152 CP106, 
CP123, 
CP341: 
Corrected 
162 CP295, 
CP420, 
CP422: 
Corrected to 
86 Correct 25 CP013: 
corrected 
to ‘new’ 
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checks) pre-op 
coding 
‘not new’ 
Pulmonary 
oedema/anticoag 
53 Correct 44 Correct 60  Correct 56 Correct 41 CP273: check 
Factor V 
Laden 
8 Correct 
Neurological 1 Correct 69 Correct 80 Correct 45 Correct 27 Correct 8 Correct 
Focal deficit 0 Correct 2 Correct 6 Correct 7 Correct 7 Correct 2 Correct 
Confusion 1 Correct 35 Correct 25 Correct 18 Correct 14 Correct 5 Correct 
Delirium 0 Correct 27 Correct 44 Correct 17 Correct 4 Correct 0 Correct 
Coma 0 Correct 2 Agitated = 3 1 Agitated = 4 1 Agitated = 2 1 Agitated =1. 4 Correct 
Haematological 2 Correct 67 Neither pre-op in 
this group 
12 Correct 6  8  4 Correct 
RBC 1 Correct 63 Correct 11 Correct 6 Correct 8 Correct 4 Correct 
Platelets 1 Correct 3 Correct 1 Correct 0 Correct 0 Correct 0 Correct 
FFP 0 Correct 10 Correct 0 Correct 0 Correct 0 Correct 0 Correct 
Cryoprecipitates 0 Correct 2 Correct 0 Correct 0 Correct 0 Correct 0 Correct 
Wound 0 Correct 449 Correct 11 Correct 7 Correct 12 Correct 11 Correct 
Surgical 0 Correct 1 Correct 0 Correct 2 Correct 3 Correct 0 Correct 
Drainage 0 Correct 449 Correct 11 Correct 7 Correct 11 Correct 11 Correct 
Pain 2 Correct 430 CP036, CP038: 
checked but 
correct 
9 Correct 11 Correct 9 Correct 3 Correct 
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Table 3-12: Comparison of patients who did and did not participate in the study. Values are n(%) 
unless otherwise stated. 
 In C-POMS 
(n=450) 
Not in C-POMS 
(n=298) 
p 
Age (mean/years) 66.5 64.1 0.01 
Gender (female)   93 (20.7)   77 (25.8) 0.06 
Ethnicity -     Caucasian 
- Asian 
- Black 
- Other 
384 (86.1) 
  39   (8.7) 
  16   (3.6) 
    7   (1.6) 
198 (74.4) 
  37 (13.9) 
  19   (7.1) 
  12   (4.5) 
0.001 
Hypertension 332 (73.8) 196 (66.7) 0.02 
Diabetes 105 (23.3)   68 (23.0) 0.49 
Smoking -    Current 
- Ex 
- Never 
  49 (10.9) 
250 (55.6) 
151 (33.6) 
  37 (12.6) 
151 (51.4) 
106 (36.1) 
0.51 
LVEF     -     Good 
- Fair 
- Poor 
327 (74.1) 
  90 (20.4) 
  24   (5.4) 
206 (71.8) 
  62 (21.6) 
  19   (6.6) 
0.72 
EuroSCORE (mean) 4.2 5.0 0.00 
Op Type -     CABG 
- AVR 
- MVR 
- CABG + AVR 
- CABG + MVR 
- AVR and MVR 
- CABG 
+AVR+MVR 
- Other 
301 (66.9) 
  61 (13.6) 
  11   (2.4) 
  37   (8.2) 
    1   (0.2) 
    3   (0.7) 
    2   (0.4) 
  34   (7.6) 
178 (60.5) 
  34 (11.6) 
  14   (4.8) 
  23  (7.8) 
    4  (1.4) 
    6  (2.0) 
    2  (0.7) 
33  (11.2) 
0.06 
ICU LOS (mean/nights) 2.1 2.8 0.05 
Post-op LOS (mean/days) 9.6 10.5 0.27 
 
 81
Table 3-13: Comparing patients that did and did not participate in the study in each of the three recruitment phases.  Values are n(%) unless otherwise stated. 
 Phase I and II (n=230) Phase III (n=180) Phase III (n=338) 
 In C-POMS 
(n=100) 
Not in C-
POMS 
(n=130) 
p In C-POMS 
(n=100) 
Not in C-
POMS 
(n=80) 
p In C-POMS 
(n=250) 
Not in C-
POMS 
(n=88) 
p 
Age (mean/years) 66.9 64.1 0.07 66.5 63.8 0.17 66.3 64.4 0.18 
Gender (female) 23 (23.0) 30 (23.1) 0.56 26 (26.0) 27 (33.8) 0.17 44 (17.6) 20 (22.7) 0.18 
Ethnicity – Caucasian 
- Asian 
- Black 
- Other 
85 (86.7) 
  7   (7.1) 
  3   (3.1) 
  3   (3.1) 
94 (76.4) 
19 (15.4) 
  7   (5.7) 
  3   (2.4) 
0.19 90 (90.0) 
  8   (8.0) 
  2   (2.0) 
  0   (0.0) 
49 (74.2) 
  8 (12.1) 
  6   (9.1) 
  3   (4.5) 
0.01 209 (84.3) 
  24   (9.7) 
  11   (4.4) 
    4   (1.6) 
55 (71.4) 
10 (13.0) 
  6   (7.8) 
  6   (7.8) 
0.02 
Hypertension 75 (75.0) 95 (73.6) 0.47 71 (71.0) 47 (59.5) 0.07 186 (74.4) 54 (62.8) 0.03 
Diabetes 22 (22.0) 31 (24.0) 0.42 18 (18.0) 17 (21.3) 0.36   65 (26.0) 20 (23.0) 0.34 
Smoking – Current 
- Ex 
- Never 
11 (11.0) 
64 (64.0) 
25 (25.0) 
19 (14.7) 
66 (51.2) 
44 (34.1) 
0.15   9   (9.0) 
54 (54.0) 
37 (37.0) 
  5   (6.3) 
39 (49.4) 
35 (44.3) 
0.56   29 (11.6) 
132 (52.8) 
  89 (35.6) 
13 (15.1) 
46 (53.5) 
27 (31.4) 
0.62 
LVEF – Good 
- Fair 
- Poor 
66 (67.3) 
24 (24.5) 
  8   (8.2) 
85 (67.5) 
31 (24.6) 
10   (7.9) 
1.0 68 (69.4) 
23 (23.5) 
  7   (7.1) 
61 (77.2) 
15 (19.0) 
  3   (3.8) 
0.44 193 (78.8) 
  43 (17.6) 
    9   (3.7) 
60 (73.2) 
16 (19.5) 
  6   (7.3) 
0.34 
EuroSCORE (mean) 4.1 4.6 0.24 4.0 5.1 0.02 4.2 5.5 0.00 
Op Type – CABG 
- AVR 
- MVR 
- CABG + AVR 
- CABG + MVR 
- AVR and MVR 
- CABG +AVR+MVR 
- Other 
72 (72.0) 
11 (11.0) 
  3   (3.0) 
  6   (6.0) 
  0   (0.0) 
  1   (1.0) 
  1   (1.0) 
  6   (6.0) 
87 (68.5) 
  9   (7.1) 
  7   (5.5) 
12   (9.4) 
  1   (0.8) 
  1   (0.8) 
  1   (0.8) 
  9   (7.1) 
0.82 
 
65 (65.0) 
13 (13.0) 
  1   (1.0) 
  9   (9.0) 
  1   (1.0) 
  2   (2.0) 
  1   (1.0) 
  8   (8.0) 
45 (56.3) 
13 (16.3) 
  2   (2.5) 
  4   (5.0) 
  3   (3.8) 
  2   (2.5) 
  0   (0.0) 
11 (13.8) 
0.51 164 (65.6) 
  37 (14.8) 
    7   (2.8) 
  22   (8.8) 
    0   (0.0) 
    0   (0.0) 
    0   (0.0) 
  20   (8.0) 
46 (52.9) 
12 (13.8) 
  5   (5.7) 
  7   (8.0) 
  0   (0.0) 
  3   (3.4) 
  1   (1.1) 
13 (14.9) 
0.01 
ICU LOS (mean/nights) 2.0 2.3 0.47 2.4 3.0 0.53 2.0 3.4 0.02 
Post-op LOS (mean/days) 9.8 9.4 0.79 10.1 11.3 0.49 9.4 11.5 0.10 
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3.7 DISCUSSION 
3.7.1 Summary of findings 
The aim of a data quality strategy is to ensure that the data collected are valid for the purpose to 
which they are intended and of sufficient quality to minimise the impact of any errors on the study 
results(98). The implementation of a data quality strategy has highlighted that the data collected for 
this study has: a) complete uniqueness across all data tables, b) only five data entries were deleted 
due to erroneous, but unverifiable values, c) >99% completeness in >92% variables, with only 1.4% 
incompleteness overall, d) <1% consistency error relating to dates in the data flow and high levels 
of consistency with the SCTS dataset in other clinical variables e) demonstrated overall 
representativeness with those patients who didn’t participate in the study, following consideration of 
the study’s exclusion criteria: the observed lower EuroSCORE, mean ICU and post-operative length 
of stay and more single procedure surgery in patients participating in the study can be explained by 
the inclusion of only non-emergency surgery. All those undergoing emergency surgery, by definition, 
have a higher level of pre-operative risk, would be expected to have more complicated surgery and 
are likely to require longer in ICU and hospital. Thus, while the development and implementation of 
a data quality strategy has highlighted that the data remains imperfect, undertaking the process has 
improved the accuracy (identified 259 erroneous data entries and corrected 254 (98.6%) of them) 
and completeness (decreased overall from 2.8% to 1.4%, alerted to records and fields with high 
levels of residual incompleteness) of the data. Furthermore, the erroneous inliers identified would 
have remained undetected without the accuracy (in particular the multiple entry and random 
examination) and consistency (specifically pulmonary disease and POMS coding) assessments. 
 
3.7.2 Random and systematic errors 
As highlighted by Barhyte and Bacon(114), most errors are due to human factors in coding and data 
entry, which was evident in this study.  Most of the errors were random(101) and attributable to 
genuine errors in these processes. However, there were some systematic errors due to design 
discrepancies that were also emphasised through data quality assessments. For example, some 
medications, highest temperature, and ward were added after the pilot study and not available on 
all patients retrospectively and there was recoding of ‘creatinine >30% pre-operative value’ and also 
the overall renal domain on each post-operative day from missing (if blood sample not taken) to no 
morbidity). 
 
3.7.3 Missing data 
Missing data poses a threat to a study’s validity(117); as the percentage of missing values increases, 
so too does the level of potential bias(118), particularly if the missingness is completely not at 
random(119). The missingness in this study is, in the majority, missing completely at random. 
However, what is considered an acceptable level of missingness is undetermined and is context 
specific(120). Thus, some judgments relating to which values are missing and what their expected 
impact on the results may be are required(117). While missing baseline data do not usually lead to 
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bias(121), missing outcome data will, unless only a few observations are missing or unless values are 
missing completely at random(119).  Complete case analysis is appropriate when missingness is 
completely random, it does reduce the statistical power of the study(118) and is generally not 
acceptable as the primary approach to data analysis on exploratory studies(122). Furthermore, 
analysis of only observed data can in itself produce a biased result(123). In this study, following 
recoding of the creatinine and renal POMS variables, missing outcome data is minimal in the POMS 
tables, although a little higher in the SCTS table. Although sensitivity analysis is recommended 
when a substantial proportion of missing outcome data is apparent(124) for complete assurity of non-
bias, a sensitivity analysis comparing those with and without missing values could be conducted 
when using these variables. However, in accordance with the strategies for addressing missing 
data(119), variables with many missing values were deleted (ASA, cause of death, days ventilated 
and circulatory arrest time).  
 
3.7.4 Strengths and weaknesses 
Although little guidance exists on what to include in(114) and how to conduct a data quality 
strategy(98), a specific strength is that not only has a systematic approach been employed to both 
minimise errors and increase data quality through a structured data cleaning framework, but that a 
transparency of the methods used, error types and rates, and decision rules applied during the 
editing phase have been detailed, in accordance with current recommendations(98). Furthermore, 
consistent with the American Statistical Association guidelines(106), these processes and results 
have been reported. Secondly, as proposed in the literature(96, 107, 109), a proactive and continuous 
approach to data quality has been employed, including error prevention strategies incorporated at 
study design, early preliminary data quality assessments at completion of the pilot study to identify 
systematic and random problems early and also accounting for problem identification through 
preparation for and conducting analysis(111). 
 
However, as it is impossible to ensure 100% quality data(99) and since the data quality process is 
unique to each study(102) it is inevitable that limitations, either due to the nature of the data or the 
strategy employed, exist. In this study three main limitations have been identified. Firstly, there was 
a distinct lack of predefined quality expectations and validity criteria on which to assess the data 
quality assessment results. A hospital setting is considered an uncontrolled environment exhibiting 
a high degree of subject and environmental variability resulting in a increased likelihood of errors in 
data collection(96). Additionally, there is a lack of published guidance on the minimum acceptable 
data quality levels for clinical data(104) and a distinct lack of data quality reporting in the literature(98). 
Thus, there were no standards on which to base defining any realistic or appropriate quality 
objectives(99) or validity acceptability criteria(98). Consequently, no specific quality objectives were 
set (only that as near to 100% accuracy, completeness, uniqueness and consistency as possible be 
attained) and validity criteria were based purely on face validity and subjective assessment by the 
PDG. Whilst this was less than scientific a lack of experience in this area dictated this an 
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appropriate starting point. Since none of the key data items (POMS criteria) exhibited a high level of 
residual incompleteness, inaccuracy or inconsistency in coding, and those errors that were 
identified were corrected, further decision-making on the quality of the data were not warranted. 
Had significant issues relating to data quality been highlighted, then, retrospectively, validity criteria 
judgments would have been required. 
Secondly, despite it being recommended that data coding be performed by one person and 
checked by another to minimise errors, and that data cleaning be started at the same time as data 
collection so as to reduce systematic errors(96), this was not done since it was only possible for data 
collection and entry to be undertaken by one person. Additionally, although adequate numbers of 
skilled human resources should be available for collecting and maintaining data(125), it is also 
imperative that personnel involved in the data are involved in identifying and resolving errors(96). 
Thus, while this provides further indication that a data quality strategy was necessary, it also 
illustrates not only the required trade-off between optimum requirements and rate-limiting 
practicalities but also that this strategy was appropriate: the person most knowledgeable of the 
study data conducted the data quality assessments, diagnosis and treatment.   
Finally, the use of a single-person strategy resulted in a significant amount of time being devoted to 
the implementation of the data quality programme. While the STS(126) reported 15% of time was 
spent on data cleaning, approximately 18% of time was required overall in this study.  More time-
efficient strategies could have been considered, for example a) establishing critical and non-critical 
errors (those requiring and not requiring cleaning)(100), b) prioritisation of critical errors(98), c) the use 
of hand-held computer to eliminate the need for a paper record and reducing the potential for data 
entry error(96), d) the use of automated as well as manual data cleaning techniques(100) and e) the 
use of computer with built-in mechanisms to check completeness and validity continuously(125). 
While the former strategies (a-c) would have been beneficial, the latter (d-e) are outside the scope 
and expertise of this PhD (although some validation rules were applied to some variables), and are 
more properly assigned to larger studies where difficulties exist in maintaining procedures(102). 
Nevertheless, in this study the majority of data cleaning could only be done manually, and this is a 
time consuming process(102).  Despite error prevention strategies being employed in order to assist 
in minimising the amount of data cleaning necessary, substantial time was still required and thus 
time was the most expensive resource of this process in this instance. In the vast majority of other 
studies this will be a monetary expense and thus data cleaning, and utilising the most effective and 
efficient strategies, becomes a due consideration for study resources(103). 
 
 
3.8 CONCLUSION 
Despite the time-commitment involved, developing and implementing a data quality strategy 
increased the accuracy and completeness of the data, reducing potential analysis bias and 
improving the validity of the data.  
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4 RESULTS I: PILOT STUDY 
 
 
4.1 INTRODUCTION TO CHAPTER 
This chapter reports the results of the pilot study, including the screening and recruiting figures and 
participant baseline characteristics. The applicability of POMS to cardiac surgical patients in the 
pilot study is assessed and the changes required for the main study are highlighted.  
 
 
4.2 TIMEFRAME 
Phase I and Phase II were conducted between 10th January 2005 – 9th February 2005 (50 patients) 
and 7th March 2005 – 28th April 2005 (50 patients), respectively.   
 
 
4.3 PARTICIPANTS: SCREENING AND RECRUITMENT 
In total, 230 patients underwent cardiac surgery of whom 124 patients (54%) were screened for the 
study and 106 patients (46%) were missed.  The breakdown of reasons why patients were missed 
are detailed in Table 4-1. 
 
Table 4-1: Reasons why patients were missed for screening (n=106).  Values are n(%). 
Reason  Number of patients 
(%) 
Monday surgery 46 (43.4) 
General researcher unavailability  44 (41.5) 
Saturday surgery   7   (6.6) 
Sunday surgery   3   (2.8) 
Theatre list changed overnight   1   (0.9) 
Patient not on original theatre list   1   (0.9) 
Theatre list not confirmed   1   (0.9) 
Emergency surgery   1   (0.9) 
Late transfer from NHS general hospital (1st on list)   1   (0.9) 
Not required as had 100 patients for pilot at that time   1   (0.9) 
 
Of the 124 patients that were screened, 104 (84% of those screened and 45% of total population) 
gave consent to participate and 100 patients completed the study.  The breakdown of reasons why 
the 20 patients who were screened did not participate, and why the 4 patients who consented but 
did not complete the study are detailed in Table 4-2 and Table 4-3, respectively.   
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Table 4-2: Reasons why patients who were screened but did not participate in the study (n=20). 
Values are n(%). 
Reason Number of patients 
(%) 
Declined to participate 8 (40.0) 
Participating in an intervention study 5 (25.0) 
Unable to consent (lack of English and no translation available) 3 (15.0) 
Too anxious to provide informed consent 2 (10.0) 
Emergency surgery 1   (5.0) 
Inappropriate (drug abuser) 1   (5.0) 
 
Table 4-3: Reasons why patients who gave consent did not complete the study (n=4).  Values are 
n(%). 
Reason Number of patients 
(%) 
Surgery cancelled (1x leg wound, 1x lack of ITU beds) 2 (50.0) 
Died on return to theatre on day of surgery 1 (25.0) 
No longer appropriate for surgery 1 (25.0) 
 
 
4.4 PARTICIPANT BASELINE CHARACTERISTICS 
4.4.1 Pre-operative and surgical details 
Of the 100 participants 77% were male, the majority were White British, and the mean age was 67 
years. Five percent had cardiac surgery previously, 74% underwent elective surgery and overall 
participants had a medium operative risk (mean EuroSCORE 4.12). A summary of the pre-operative 
and operative details are shown in Table 4-4. Data completeness was >93% in all variables except 
liver disease (92%) and pre-operative temperature (74%). 
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Table 4-4: Baseline characteristics of the study population (n=100).  Values are stated as n, or 
mean, range and standard deviation (SD). 
Variable Frequency/
% or mean  
Range SD 
Medical history    
Non-cardiac history    
Neurological dysfunction**   6    
Pulmonary disease 10   
Liver disease   0   
GI  14   
Renal*   5      
Hypothyriodism   6   
Varicose veins  17   
Immunosuppresive medication   0   
Cardiac history    
Previous MI 37   
Previous PCI    6   
Congestive cardiac failure 13   
Cardiogenic shock   0   
Atrial arrhythmia   8   
Symptoms    
NYHA class – I 
- II 
- III 
- IV 
21 
42 
26 
  7 
  
CCSC score –  0 
 - I 
 - II 
 - III 
 - IV    
22 
17 
28 
18 
11 
  
Cardiac risk factors    
Smoking  -Current 
                -Ex 
                -Never 
11 
63 
25 
  
Hypertension 74   
Hypercholesterolaemia 84   
Diabetes 21   
Family history of IHD  50   
Examinations and investigations    
Number of diseased vessels – 0 
- 1 
16 
  6 
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- 2 
- 3 
20 
56 
LMS >50% stenosis 21   
LV function – Good (≥50%) 
                     -Fair (30%-49%) 
      -Poor (<30%) 
66 
23 
 8 
  
Cardiomegaly  3   
Systolic blood pressure (mean/mmHg) 133.8  90.0-183.0 18.2 
Heart rate (mean/bpm) 68.6  48.0-133.0 13.4 
Respiratory rate (mean/breathspm) 18.9 10.0-27.0 2.8 
Oxygen saturation (mean/%) 97.4 94.0-100 1.6 
Temperature (mean/0C) 36.4  36.0-38.0 0.4 
Height (mean/cm) 169.4  144.0-197.0 10.37 
Weight (mean/kg) 78.9  46.0-127.0 16.0 
BMI (mean/kg/m2) 27.5  18.5-38.8 40.62 
Glasgow coma score (mean) 15  15-15 0.0 
Creatinine (mean/umol/l) 96.9  46.0-321.0 36.3 
Urea (mean/mmol/l) 6.6  3.0-14.0 2.5 
Potassium (mean/mmol/l) 5.0   3.3-48.0 4.4 
Sodium (mean/ mmol/l) 138.0  128.0-148.0 3.4 
Haemaglobin (mean/g/dl) 13.5  9.2-16.2 1.5 
White cell count (mean/x109/l) 7.8  3.1-14.5 2.1 
Albumin (mean/g/l) 43.3  32.0-51.0 3.7 
Pre-operative risk assessment    
Parsonnet score (mean) 11.0  0.0-33.0 8.1 
EuroSCORE (mean) 4.1  1.0-10.0 2.68 
POSSUM score (physiological component) 
(mean) 
19.2  
 
12.0-40.0  
Operation details    
Surgical procedure – CABG 
- AVR 
- MVR 
- CABG + AVR 
- AVR + MVR 
- CABG + AVR +MVR 
- Other 
73 
11 
  3 
  6 
  1 
  1 
  5 
  
*Renal: no patients require dialysis; **neurological dysfunction: 2 patients with CVA, 4 patients with 
TIA;   
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4.4.2 Outcome characteristics 
Table 4-5 shows the outcome characteristics.  Data completeness was >94% in all variables except 
number of hours ventilated (89%) and discharge services required (71%) due to incompleteness of 
reporting in the medical notes. 
The mean length of ventilation was 5.8 hours (3 participants were extubated in theatres while 
waiting for a bed to become available on ICU) with participants spending an average of 2 days on 
ICU and 9.8 days in the operating hospital. Fourteen percent of patients were transferred to an NHS 
hospital and overall the average length of post-operative hospital stay was 12.2 days. However, the 
most commonly observed outcome was a ventilation of 5.0 hours, one night spent on the ICU, a 
post-operative stay of 5.0 days in the operating hospital, with this increasing to 6.0 days when 
including the additional hospital stay of patients transferred to another NHS hospital. In total, two 
participants died. 
 
Table 4-5: Outcome characteristics. (n=100).  Values are stated as n, or mean, mode, range and 
standard deviation (SD). 
 Frequency/mean  Mode Range  SD 
Length of ventilation (hours) 5.8  5.0 0.0-22.0 2.5 
Length of ICU stay (nights)  2.0  1.0 0.0-11.0 1.9 
Return to theatre 3    
Readmitted to ICU 7    
Length of hospital stay (HH) 
(days) 
9.8 5.0 3.0-123.0 13.1 
Discharge destination – home 
- NHS hospital 
- Convalescence home 
- Other (died) 
83 
14 
1 
2 
   
Total length of post-operative 
hospital stay (days) 
12.3 6.0 4.0-176.0 22.1 
Discharge services 32    
In-hospital death 2    
 
 
4.5 APPLICABILITY OF POMS TO CARDIAC SURGERY PATIENT 
4.5.1 POMS framework 
All patients were in-hospital on post-operative days 1 and 3 with 95%, 33% and 10% remaining an 
in-patient on post-operative days 5, 8 and 15, respectively.  The frequency of each POMS morbidity 
type is shown in Table 4-6. 
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Table 4-6: Frequency of original POMS items in C-POMS population.  Data is 100% complete.  
Values stated as n (new morbidity). 
POMS 
morbidity type 
Frequency of items  
 Pre-op 
(n=100) 
D1 
(n=100) 
D3 
(n=100) 
D5 
(n=95) 
D8 
(n=33) 
D15 
(n=10) 
Pulmonary 2 100 (100) 56 (56) 25 (25)   8   (8) 4 (4) 
Infectious 3   81   (78) 21 (18) 28 (27) 16 (16) 6 (6) 
Renal 2 100 (100) 30 (30) 14 (13)   9   (9) 6 (6) 
Gastrointestinal 5   48   (47) 20 (17) 17 (16)   8   (8) 2 (2) 
Cardiovascular 10   48   (45) 36 (33) 36 (31) 20 (17) 8 (6) 
Neurological 0   16   (16) 18 (18)   9  (9)   6   (6) 2 (2) 
Wound 
complication 
0 100 (100)   0  (0)   0  (0)   3   (3) 2 (2) 
Haematological    0 10     (10)    0  (0)  0   (0)   2   (2) 1 (1) 
Pain 2 95     (93)    3  (1)  5   (3)   2   (1) 1 (0) 
 
While there were no patients in hospital on D15 that did not have at least one POMS morbidity 
criteria present, 34.7% of patients on D5 and 9.1% of patients on D8 remained in-hospital on these 
days but had no POMS-defined morbidity. However, over a third of these patients did remain in 
hospital for a medical reason. Table 4-7 identifies the reasons for patients remaining in hospital on 
D5 and D8, when no POMS-defined morbidities were present. 
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Table 4-7: Reasons for remaining in hospital when no POMS morbidity present. Values are n(%). 
 Post-operative 
D5 (n=95) 
Post-operative 
D8 (n=33) 
No POMS-defined morbidity 33 (34.7) 3   (9.1) 
Discharge planned for today 11 (31.7) 1 (33.3) 
Social reasons   2   (6.1) 0   (0.0) 
Equipment needed at home   0   (0.0) 0   (0.0) 
Mobility (ongoing physio/occupational therapy needs)   6 (18.2) 1 (33.3) 
Institutional failure (transport not booked/out-patient 
appointment not arranged) 
  0   (0.0) 0   (0.0) 
Delayed discharge (lack of bed/rehab)   3   (9.1) 0  (0.0) 
*Other medical reason: 
    Hypertension 
    ACEI commenced 
    Discharge planned for next day 
    Uncontrolled diabetes 
    Increased INR 
    Awaiting haematological out-patient review 
    Due to extra post-op respiratory requirements 
    Increased weight 
    Awaiting echocardiography 
    Pleural effusion awaiting drainage (INR) 
12 (36.4) 
  1   (3.0) 
  1   (3.0) 
  3   (9.1) 
  3   (9.1) 
  2   (6.1) 
  1   (3.0)  
  1   (3.0) 
  2   (6.1) 
  2   (6.1) 
  1   (3.0) 
1 (33.3) 
 
 
 
 
1 (33.3) 
 
4.5.2 Additional morbidities identified by free text 
In total there were 73 additional morbidities identified that were not captured within POMS 
(Appendix 3), with 20 occurring in ≥5% patients (Table 4-8). 
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Table 4-8: Additional morbidities not captured by the POMS occurring in ≥5% patients. Values n(%). 
 Frequency 
Morbidity All patients 
(n=100) 
D1 
(n=100) 
D3  
(n=100) 
D5  
(n=95) 
D8  
(n=33) 
D15  
(n=10) 
Blood sugar control (actrapid 
infusion/uncontrolled diabetes) 
97 (97) 88 (88) 26 (26) 11 (11.6) 4 (12.1) 3 (30.0) 
Potassium supplements 83 (83) 73 (73) 22 (22) 13 (13.7) 3   (9.1) 1 (10.0) 
IV Furosemide (stat/infusion) 41 (41) 36 (36) 6    (6) 5    (5.3) 2   (6.1) 1 (10.0) 
Magnesium supplements 34 (34) 27 (27) 9    (9) 2    (2.1) 0   (0.0) 0   (0.0) 
Salbutamol or atrovent nebs 29 (29) 18 (18) 15 (15) 7   (7.4) 3   (9.1) 1 (10.0) 
Hypertension 27 (27) 19 (19) 10 (10) 7   (7.4) 0   (0.0) 0   (0.0) 
Chest drains remain insitu 17 (17) 17 (17) 1    (1) 0   (0.0) 1   (3.0) 0   (0.0) 
Inotropic support 17 (17) 16 (16) 3    (3) 0   (0.0) 0   (0.0) 0   (0.0) 
Hypotension (fluid/omit 
medication/drink) 
15 (15) 10 (10) 9    (9) 3   (3.2) 0   (0.0) 0   (0.0) 
*Pleural effusion  15 (15) 1    (1) 7    (7) 10 (10.5) 0   (0.0) 0   (0.0) 
LLL collapse 13 (13) 11(11) 0    (0) 1    (1.1) 0   (0.0) 0   (0.0) 
Constipation 11 (11) 0    (0) 5    (5) 6    (6.3) 2   (6.1) 0   (0.0) 
Untherapeutic INR 9    (9) 0    (0) 1    (1) 6    (6.3) 5 (15.2) 1 (10.0) 
Diarrhoea 8    (8) 0    (0) 3    (3) 3    (3.2) 2   (6.1) 0   (0.0) 
Low Hb (ferrous sulphate) 7    (7) 0    (0) 2    (2) 4    (4.2) 2   (6.1) 1 (10.0) 
Peripheral oedema 6    (6) 1    (1) 1    (1) 2    (2.1) 2   (6.1) 2 (20.0) 
Blurred vision/visual disturbances 
(not delirium) 
5    (5) 0    (0) 3    (3) 1    (1.1) 1   (3.0) 0   (0.0) 
Increased weight (medical treatment) 5    (5) 0    (0) 2    (2) 4    (4.2) 0   (0.0) 0   (0.0) 
Pneumothorax 5    (5) 4    (4) 2    (2) 1    (1.1) 0   (0.0) 0   (0.0) 
Sputum spec/productive cough 5    (5) 3    (3) 3    (3) 2    (2.1) 0   (0.0) 0   (0.0) 
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Of the 20 morbidities, 5 (25%) did not corresponded to an existing POMS morbidity type. These 
were blood sugar control, chest drains in situ, untherapeutic INR, peripheral oedema and 
increased weight requiring medical treatment. This suggests that new morbidity domains are 
required to accurately describe and quantify post-operative morbidity following cardiac surgery. 
All the 15 (75%) additional morbidities that could be corresponded to an existing POMS 
morbidity type, contributed independently to their morbidity type (Table 4-9). For example, of the 
73 patients requiring potassium supplements on D1, only 33 (78.8%) already had a 
cardiovascular morbidity, as defined by POMS. If any of the morbidities were not contributing to 
the morbidity type and were reflecting a criterion already measured, then all the percentages 
over each of the post-operative days would be 100. However, since each of the additional 
morbidity were found to be contributing above and beyond that already measured within POMS, 
modification to the existing POMS criteria may be required. 
 
 
4.6 CONFIRMING THE ROUTINE DATA COLLECTION ITEMS FOR THE MAIN STUDY 
Review of the routine data collection variables following Phase I was conducted with study 
supervisors and the PDG reviewed all pilot data results at meeting 2 on 27th July 2005. 
 
4.6.1 Routine data items 
Following completion of Phase I of the pilot study a review was undertaken of the routine data 
variables being collected, resulting in V2 (March 2005) of the CRF. The amendments agreed 
are detailed in Table 4-10. 
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Table 4-9: The contribution of the additional morbidities to the corresponding POMS morbidity type. Values n(%). 
  Frequency 
Morbidity Corresponding 
POMS category 
D1 
(n=100) 
POMS 
category 
already 
present 
(D1) 
D3 
(n=100) 
POMS 
category 
already 
present 
(D3) 
D5 (n=95) POMS 
category 
already 
present  
(D5) 
D8 (n=33) POMS 
category 
already 
present 
(D8) 
D15 
(n=10) 
POMS 
category 
already 
present 
(D15) 
Potassium supplements CV  73 33 (78.8) 22 12 (54.5) 13 8 (61.5) 3 2 (66.7) 1 1 (100) 
IV Frusemide 
(stat/infusion) 
Renal 36 36 (100) 6   4 (66.7) 5 3 (60.0) 2 1 (50.0) 1 1 (100) 
Magnesium supplements CV  27   9 (33.3) 9   7 (77.8) 2 0   (0.0) 0 - 0 - 
Salbutamol or atrovent 
nebs 
Pulmonary 18 18 (100) 15 14 (93.3) 7 5 (71.4) 3 2 (66.7) 1 1 (100) 
Hypertension CV 19  8 (42.1) 10 2 (20.0) 7 4 (57.1) 0 - 0 - 
Inotropic support CV 16  2 (12.5) 3 1 (33.3) 0 -  0 - 0 - 
Hypotension (fluid/omit 
medication/drink) 
CV 10  5 (50.0) 9 4 (44.4) 3 1 (33.3) 0 - 0 - 
*Pleural effusion  Pulmonary 1  1 (100) 7 6 (85.7) 10 5 (50.0) 0 - 0 - 
LLL collapse Pulmonary 11  1 (100) 0 - 1 1 (100) 0 - 0 - 
Constipation GI 0 - 5 2 (40.0) 6 2 (33.3) 2 0 0 - 
Diarrhoea GI 0 - 3 3  (100) 3 2 (66.7) 2 1 (50.0) 0 - 
Low Hb (ferrous sulphate) Haem 0 - 2 2  (100) 4 0   (0.0) 2 1 (50.0) 1 0 (0.0) 
Blurred vision/visual 
disturbances (not delirium) 
Neuro 0 - 3 0   (0.0) 1 0   (0.0) 1 1 (50.0) 0 - 
Pneumothorax Pulmonary 4 4 (100) 2 2  (100) 1 0   (0.0) 0 - 0 - 
Sputum spec/productive 
cough 
Pulmonary 3 3 (100) 3 2 (66.7) 2 1 (50.0) 0 - 0 - 
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Table 4-10: Data collection amendments following Phase I 
Data Table Change 
Admin  Add if participating in intervention trial 
 State date of transfer and transferring hospital  
Pre-operative  Exclude duplication of fields (creatinine and haemaglobin) 
 Add list of co-morbidities 
 Add NYHA class: easier that waiting for it in SCTS database 
 Add date of blood results: for quality assessments 
Intra-operative 
and immediate 
post-op 
 Collect surgiserve data: from sheets in theatre not database: 
unable to get response from database owner 
 Add any other medications given 
 Remove estimated blood loss: not recorded in theatre as too 
complicated due to CPB 
 Add tick boxes for operation performed: for ease of 
documentation 
 Add type of valve inserted, if appropriate: mechanical or tissue 
 Add whether participant was intra-operatively paced 
 Add free-text space for other comments 
 Add 12 hour summary for blood loss, urine output, total fluid, 
sedation score, potassium/magnesium supplements 
 Add list of infusions, doses and time started and discontinued. 
C-POMS D1-15  Pulmonary: record highest level of support required during the 
course of the day 
 Renal: record furosemide treatment separately as free-text. 
 Pain: do not record routine medications unless participant 
remaining in hospital due to pain. 
Outcome  Add destination from discharge from ICU 
 Add post-operative day of discharge from ICU and hospital 
 Add discharge services as a tick-box field 
 
It was decided not to include separate sections for blood test results, medications or referrals as 
routine data collection variables since any abnormalities/requirements outside the norm would be 
picked up either within the POMS domains, or can be recorded separately in the free-text if 
contribute to a prolonged period of hospitalisation. 
 
There were no changes to the routine data variables following completion of Phase II. 
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4.6.2 POMS  
Although, wound complications and haematological complications on D3 and D5 were present in 
<5% of the participants, it was agreed that no redundancy of items was to occur following the pilot 
study so as to permit full exploration of the applicability of POMS in the main study. 
 
4.6.3 Additional morbidities 
The PDG reviewed the 20 additional morbidities confirming whether or not each additional morbidity 
should be a routine data collection item for the main study (Table 4-11).  
 
Table 4-11: PDG decision on inclusion of additional morbidity present in ≥5% patients as routine 
data item. 
To include as routine data collection  Not to include as routine morbidity items 
(reason) 
Treatment for blood sugar control Potassium supplements (not morbidity or 
indicative of morbidity on own) 
IV furosemide for low urine output Magnesium supplements (not morbidity or 
indicative of morbidity on own) 
Hypertension LLL collapse (all patients have some degree of 
this, thus non-discriminatory) 
Chest drains in situ beyond day 1 Constipation (if severe enough to be a 
morbidity patient will experience nausea and/or 
abdo distension in GI category) 
Inotropic support Low Hb (not severe enough to be morbidity.  If 
severe will require blood transfusion and be 
picked up by haematological category) 
Hypotension (fluids/omit medication) Sputum specimen/productive cough (not 
morbidity on own.  If becomes a morbidity will 
be picked up in respiratory or infectious 
categories). 
Pleural effusion requiring drainage Diarrhoea (if severe enough to be a morbidity 
patient will experience abdominal distension in 
GI category) 
Untherapeutic INR Salbutamol nebulisers (not a morbidity in own 
right) 
Peripheral oedema  
Blurred vision/visual disturbances  
Increased weight (requiring treatment)  
Pneumothorax – note presence and severity  
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4.7 CONCLUSION OF THE PILOT STUDY 
The PDG concluded it was appropriate to conduct the full study. Furthermore, it was indicated that 
the pilot study participants data could be included in the main study since few protocol changes 
occurred as a result of the pilot study. 
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5 RESULTS II: BASELINE CHARACTERISTICS  
 
 
5.1 INTRODUCTION TO CHAPTER 
This chapter reports the baseline characteristics of the main study.  
 
 
5.2 INTER-RATER RELIABILITY   
Rater comparisons for 6 participants on D3 and 9, and 2 on D5, D8 and D15, respectively identified 
excellent agreement on 5 POMS domains (Table 5-1). Kappa statistics for the cardiovascular, 
neurological, wound complication and haematological domains was not generated since there were 
no events identified by either rater. 
 
Table 5-1: Inter-rater comparisons of POMS data collection 
POMS domain Kappa p 
Pulmonary 0.77 0.00 
Infectious 1.00 0.00 
Renal 0.80 0.00 
Gastrointestinal 0.79 0.00 
Cardiovascular - - 
Neurological - - 
Wound complication - - 
Haematological - - 
Pain 1.00 0.00 
 
 
5.3 SCREENING AND RECRUITMENT CHARACTERISTICS 
5.3.1 Timeframe 
Phase I and Phase II were conducted between 10th January 2005 and 9th February 2005 and 7th 
March 2005 – 28th April 2005, respectively.  Phase III was conducted between 3rd October 2005 and 
3rd December 2005 while Phase IV was completed between 2nd July and 15th November 2007. 
 
5.3.2 Participants: screening and recruitment 
During all the study phases 748 patients underwent cardiac surgery of whom 520 (69.5%) were 
screened and 464 (89.2%) subsequently consented to participate (Table 5-2). The majority of 
patients (55.6%) were recruited during Phase IV which had the highest percentage of patients seen 
compared to Phases I/II and III (83.1% v 53.9% v 63.9%, respectively), highest screening to 
recruitment rate (91.1% v 83.9% v 90.4%) and the lowest withdrawal rate (2.4% v 3.8% v 3.8%). 
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Table 5-2: Recruitment summary of each phase of data collection. 
 Phase I and II  
(n=100) 
Phase III  
(n=100) 
Phase IV  
(n=250) 
Overall 
(n=450) 
No of cardiac surgery cases 230 180 338 748 
No of participants missed 106 65   57 228 
No of participants screened 124 115 281 520 
% patients seen* 53.9% 63.9% 83.1% 69.5% 
No participants recruited 104 104 256 464 
Screening to recruitment rate 83.9% 90.4% 91.1% 89.2% 
No participants completed 
study 
100 100 250 450 
Withdrawal rate 3.8% 3.8% 2.4% 3.0% 
 
The majority of patients that were missed was due to researcher unavailability, particularly in 
relation to Monday surgery in Phase I/II where patients require consenting on a Sunday if not pre-
consented in pre-admission clinic (Table 5-3). Overall, 21 (9.2%) missed patients were missed due 
to hospital operational reasons (changes to operation list, late transfer from other hospital). 
 
Table 5-3: Reasons why patients were missed (n=228).  Values are n(%). 
Reason  Phase I and 
II (n=106) 
Phase III 
(n=65) 
Phase IV 
(n=57) 
Overall 
(n=229) 
Monday surgery 46 (43.4) 23 (35.4) -   69 (30.1) 
Break in recruitment/ 
researcher unavailability 
37 (34.9) 31 (47.7) 41 (71.9) 110 (48.0) 
Weekend surgery  17 (16.0)   1  (1.5) -   18  (7.9) 
Patient not on list/list changes   3   (2.8)   4  (6.2)   2   (3.4)     9  (3.9) 
Emergency case   1   (0.9) -   8 (13.8)     9  (3.9) 
Late transfer and 1st on op list   1   (0.9)   5  (7.7)   6 (10.3)   12  (5.2) 
Not required (100 in pilot)    1   (0.9) - -     1  (0.4) 
Not known -   1  (1.5) -     1  (0.4) 
 
Of the 56 patients that were screened but did not participate, 64.3% declined to participate while 
8.9% were already involved in an interventional trial (Table 5-4). Some judgments were required on 
the appropriateness of obtaining informed consent in 10 (17.9%) cases, resulting in non-inclusion in 
the study. 
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Table 5-4: Reasons why patients who were screened did not participate (n=56). Values are n(%). 
Reason Number of patients (%) 
Declined to participate 36 (64.3) 
Unable to consent    8 (14.3) 
Participating in an intervention study   5  (8.9) 
Late transfer and 1st on operation list   2  (3.6) 
Researcher decision   1  (1.8) 
Didn’t want to sign consent form   1  (1.8) 
Not appropriate to approach   1  (1.8) 
Operation list changed   1  (1.8) 
Emergency operation   1  (1.8) 
 
Of the 464 patients who gave consent to participate, 14 patients (3.0%) did not complete the study 
because they no longer fulfilled the inclusion criteria: 6 (42.9%) died within 5 days of surgery, 7 
(50.0%) did not undergo surgery and 1 (7.1%) participated in an intervention trial post consenting to 
C-POMS (Table 5-5). No participants withdrew their consent. 
 
Table 5-5: Reasons patients who gave consent did not complete the study (n=14).  Values are n(%). 
Reason Number of patients (%) 
Died within 1 week of surgery 6 (42.9) 
Surgery suspended 2 (14.3) 
Surgery cancelled: too high risk 2 (14.3) 
Surgery cancelled and not done within study time-frame (pilot 
study) 
2 (14.3) 
Took part in an intervention study post-recruitment 1   (7.1) 
Patient refused surgery 1   (7.1) 
 
 
5.4 PARTICIPANT BASELINE CHARACTERISTICS 
5.4.1 Demographic characteristics 
Of the 450 participants completing the study, 357 (79.3%) were male and the mean age was 66.5 
years (range 19-91). The majority were White British (384, 86.1%), with 39 (8.7%), 16 (3.6%) and 7 
(1.6%) of Asian, Black or other background, respectively.  Three hundred and twernty-three (71.8%) 
were admitted from home while 117 (26.0%) were admitted from another NHS hospital and 10 (2.2) 
from another source. 
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5.4.2 Pre-operative characteristics  
Table 5-6 details a summary of the participants’ pre-operative baseline characteristics (full version 
in Appendix 4: Pre-operative baseline and immediate post-operative characteristics). While 17 
(3.8%) had a history of CVA and 7 (1.6%) had a history of renal dialysis, 149 (33.1%), 36 (8.0%) 
and 19 (4.0%) had a previous MI, PCI and cardiac surgery, respectively. 105 (23.3%) were diabetic 
and the majority were ex-smokers (250, 55.6%), hypertensive (306, 68.0%) with 
hypercholesteraemia (347, 77.1%) and were overweight (mean BMI 28.5 kg/m2). However, only 277 
(61.6%), 104 (23.1) 24 (5.3%) were on a statin, nitrate and ACE inhibitor, respectively.  Although 
the majority had triple vessel disease (245, 54.4%) and a good LVEF (327, 72.7%), 80 (17.8%) had 
no coronary disease and a poor LVEF was observed in over 5%. Overall, participants were of 
moderate mortality risk (mean EuroSCORE and Parsonnet score 4.2 and 11.3, respectively).  
 
Table 5-6: Pre-operative baseline characteristics (n=450). Values are n(%) or mean, range and 
standard deviation (SD) as appropriate. 
 Frequency/mean Range SD 
Medical history    
Non-cardiac history    
Cerebrovascular disease 
- CVA 
32  ( 7.1) 
17   (3.8) 
  
Renal 
     - Dialysis 
12   (2.7) 
 7   (1.6) 
  
    
Cardiac history    
History of previous MI 149 (33.1)   
Number of previous MIs – 1 
                                       -  2 
119 (79.9) 
  30 (20.1) 
  
Previous PCI   36   (8.0)   
Re-operation 
Number of previous operations -1 
                                                  -2 
  19   (4.2) 
  16   (3.6) 
    3   (0.7) 
  
    
Symptoms    
NYHA Class -I 
- II 
- III 
- IV 
116 (25.8) 
207 (46.0) 
102 (22.7) 
  23   (5.1) 
  
CCSC – 0 
- I 
- II 
  86 (19.1) 
  93 (20.7) 
114 (25.3) 
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- III 
- IV 
  85 (18.9) 
  44   (9.8) 
    
Cardiac risk factors    
Smoking – Current 
- Ex 
- Never 
  49 (10.9) 
250 (55.6) 
151 (33.6) 
  
Hypertension 306 (68.0)   
Hypercholesteraemia 347 (77.1)   
Diabetes 105 (23.3)   
    
Current medication     
ACEI   24   (5.3)   
Beta Blocker 219 (48.7)   
Nitrate 104 (23.1)   
Statin 277 (61.6)   
    
Examination and Investigation    
Number of diseased vessels -0 
- 1 
- 2 
- 3 
  80 (17.8) 
  36   (8.0) 
  80 (17.8) 
245 (54.4) 
  
LVEF – Good (≥50%) 
- Fair (30%-49%) 
- Poor (<30%) 
327 (72.7) 
  90 (20.0) 
  24   (5.3) 
  
Potassium (mmol/L) 4.4 3.3-6.3 0.4 
Sodium (mmol/L) 139.6 128.0-148.0 3.2 
Haemaglobin (g/dL) 13.3 7.9-17.3 1.6 
White cell count (x109L) 1.13 1.0-4.0 0.4 
Creatinine (mmol/L) 99.9 46.0-838.0 66.2 
Systolic blood pressure (mmHg) 133.3 90.0-212.0 19.0 
Heart rate (bpm) 69.5 44.0-150.0 13.9 
Respiratory rate (breaths/min) 19.2 10.0-30.0 2.1 
Temperature (oC) 36.5 36.0-38.0 0.4 
BMI (kg/m2) 28.5 18.3-62.9 5.6 
    
Pre-operative risk assessment    
Parsonnet 11.3 0-37 8.1 
EuroSCORE 4.2 1-14 2.8 
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POSSUM 19.5 12-40 5.0 
 
5.4.3 Intra-operative characteristics 
315 (70%) of participants had elective surgery with 77 (17.1%) having multi-procedure surgery 
(Table 5-7). Cardiopulmonary bypass (CPB) was used in 418 (92.9%) of cases and lasted on 
average 79.5 minutes. In those having a valve replacement, a tissue value was implanted in the 
majority of cases. RBC, platelet and FFP transfusions were required in 37 (8.2%), 9 (2.0%) and 10 
(2.2%), respectively requiring up to 5, 2 and 6 units, respectively. Approximately a quarter of 
participants required enoximone, vasoconstrictors and tranexamic acid with nearly all participants 
receiving intra-operative antibiotics. Only 1 participant (0.2%) had an intra-operative balloon pump 
inserted. 
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Table 5-7: Intra-operative characteristics (n=450). Values are n(%) or mean, range and standard 
deviation (SD) as appropriate. 
 Frequency/mean Range SD 
Intra-operative details    
Operative priority – Elective 315 (70.0)   
Operation performed - CABG 
             -AVR 
             -MVR 
             -CABG + AVR 
             -CABG + MVR 
             -AVR + MVR 
             -CABG + AVR + MVR 
             -Other 
301 (66.9) 
  61 (13.6) 
  11   (2.4) 
  37   (8.2) 
    1   (0.2) 
    3   (0.7) 
    2   (0.4) 
  34   (7.6) 
  
Mechanical valve   65 (14.4)   
Total number of grafts 
- SVG 
- arterial 
2.7 
1.8 
0.9 
1.0-5.0 
0.0-4.0 
0.0-3.0 
0.9 
0.8 
0.3 
CPB used 418 (92.9)   
Length of CPB (mins) 79.5 0.0-314.0 35.9 
Length of aortic cross clamp (mins) 51.33 0.0-226.0 25.2 
Operation length (mins) 224.5 105.0-515.0 54.1 
    
Intra-operative medication    
RBC 
  - number of units (mean/patient) 
37 (8.2) 
2.0 
 
1.0-5.0 
 
0.9 
Platelets 
  - number of units (mean/patient) 
9 (2.0) 
1.2 
 
1.0-2.0 
 
0.4 
FFP 
  - number of units (mean/patient) 
10 (2.2) 
0.6 
 
1.0-6.0 
 
1.5 
Cryoprecipitate 0 (0.0)   
Aprotinin 155 (34.4)   
Enoximone 121 (26.9)   
Inotropes   51 (11.3)   
Vasoconstrictors 124 (27.6)   
Tranexamic acid 119 (26.4)   
Antibiotics 421 (93.6)   
    
IABP     1   (0.2)   
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5.4.4 Immediate ICU characteristics 
A summary of the participants’ characteristics during the immediate post-operative period through to 
D1 are detailed in Table 5-8 (full details in Appendix 4: Pre-operative baseline and immediate post-
operative characteristics).  In the first 12 hours following surgery 100 (22.2%), 35 (7.8%) and 38 
(8.4%) required RBC (mean 1.9 units), platelet (mean 1.3 units) and FFP (mean 3.1 units) 
transfusions, respectively. The mean drainage was 485.6mls (maximum 3035mls) with 52 (11.6%) 
requiring aprotinin. As would be expected almost all participants received GTN, actrapid, propofol 
and morphine infusions with 133 (29.6%) and 139 (30.9%) requiring some inotropic or vasodilator 
support, respectively.  Overall, haemodynamic variable means were within expected parameters, 
almost three quarters were in sinus rhythm, 131 (29.1%) required pacing and mean temperature 
increased from 35.8 to 36.9oC during this period. 
 
Table 5-8: Immediate ICU characteristics (n=450). Values are n(%) or mean, range and standard 
deviation (SD) as appropriate. 
 Frequency/mean Range SD 
Immediate post-operative medication     
RBC 
  - number of units (mean/patient) 
100 (22.2) 
1.9 
 
1.0-9.0 
 
1.6 
Platelets 
  - number of units (mean/patient) 
  35   (7.8) 
1.3 
 
1.0-5.0 
 
0.8 
FFP 
  - number of units (mean/patient) 
  38   (8.4) 
3.1 
 
1.0-11.0 
 
2.1 
Cryoprecipitate     0   (0.0)   
Aprotinin   52 (11.6)   
Enoximone   62 (13.8)   
Inotropes   71 (15.8)   
Vasoconstrictors 139 (30.9)   
Morphine 437 (97.1)   
Propofol 441 (98.0)   
GTN 422 (93.8)   
Actrapid 444 (98.7)   
    
Immediate post-operative measurements 
and examinations (12 hrs) 
   
Heart rhythm*  - Sinus rhythm 321 (71.3) ,  
Paced 131 (29.1)   
Total drainage (ml) 485.64 70.0-3035.0 366.1 
Heart rate (bpm) 87.5 50.0-180.0 14.7 
Systolic blood pressure (mmHg) 138.7 70.0-188.0 19.3 
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Diastolic blood pressure (mmHg) 61.8 35.0-100.0 9.9 
Respiratory rate (bpm) 12.2 8.0-26.0 1.7 
First temperature (oC) 35.8 32.0-38.0 0.9 
Highest temperature (oC) 36.9 36.0-38.0 0.4 
CVP (mmHg) 14.8 3.0-29.0 3.7 
MAP (mmHg) 85.0 60.0-130.0 10.3 
    
Day 1 medication    
RBC 
  - number of units (mean/patient) 
63 (14.0) 
1.4 
 
1.0-5.0 
 
0.7 
Platelets 
  - number of units (mean/patient) 
  3  (0.7) 
1.0 
 
1.0-1.0 
 
0.0 
FFP 
  - number of units (mean/patient) 
10 (2.2) 
2.3 
 
1.0-4.0 
 
1.1 
Cryoprecipitate 
  - number of units (mean/patient) 
  2 (0.4) 
10.0 
 
10.0-10.0 
 
0.0 
Aprotinin     6   (1.3)   
Enoximone   68 (15.1)   
Inotropes   53 (11.8)   
Vasoconstrictors   93 (20.7)   
Furosemide   25   (5.6)   
Morphine 423 (94.0)   
Propofol   38   (8.4)   
GTN 400 (88.9)   
Actrapid 438 (97.3)   
    
Day 1 examinations    
Drains out 381 (84.7)   
Heart rhythm* - Sinus rhythm 289 (64.2)   
Heart rate (bpm) 90.6 30.0-190.0 17.3 
Systolic blood pressure (mmHg) 142.2 90.0-215.0 19.2 
Diastolic blood pressure (mmHg) 63.5 42.0-100.0 9.9 
Respiratory rate (breathspm) 22.4 10.0-47.0 5.0 
Temperature (oC) 37.1 35.6-38.6 0.5 
CVP (mmHg) 16.1 0.0-30.0 4.6 
*Heart rhythm was taken as that reported by ICU nursing staff 
 
The day following surgery only slightly less participants required inotropic (26.9%) or vasodilator 
support (20.7%) although 25 (5.6%) required furosemide infusion. The proportion of participants in 
 107
sinus rhythm and atrial fibrillation decreased and increased, respectively, and the mean of all 
haemodynamic parameters increased on D1 in comparison to day of surgery but remained within 
expected clinical limits. 
 
5.4.5 Outcome characteristics 
Overall, participants stayed on ICU for an average of 3 days (but most commonly 1 day) with 31.6% 
discharged from ICU to a monitored bed (Table 5-9).  23 (5.1%) and 16 (3.6%) participants returned 
to theatre and ICU, respectively. On average, participants remained in the operating hospital for 9.6 
days with the vast majority being discharged home (382, 84.9%) and with 27.5% of those requiring 
discharge services. Fifty-five (12.2%) participants were transferred to another NHS hospital 
increasing the average length of total post-operative hospital stay to 11 days. However, the most 
frequently observed length of stay was 5.0 days in the operating hospital and 6.0 days when 
including additional stay at other NHS hospitals for patients who were transferred. Four patients 
died in the operating hospital, and a further 2 patients died in the hospital they were transferred to. 
Thus, the overall in-hospital mortality rate was 1.3%. 
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Table 5-9: Outcome characteristics (n=450). Values are n(%) or mean, range and standard 
deviation (SD) as appropriate. 
 Frequency/ 
mean 
Mode Range SD 
Length of ventilation (hours) 9.8 5.0 0.0-1152.0 57.7
Length of ICU stay (days)  3.0 1.0 1.0-29.0 2.6 
Destination from ICU  
-Acute coronary ward (cardiology 
monitored bed) 
-3rd Floor (cardiothoracic ward, monitored 
bed) 
-3rd Floor (cardiothoracic ward) 
-4th Floor (cardiothoracic ward) 
-Other 
 
  69 (15.3) 
  
 73 (16.2) 
 
154 (34.2) 
140 (31.1) 
  14   (3.1) 
   
Return to theatre   23   (5.1)    
Readmitted to ICU   16   (3.6)    
Length of hospital stay (HH) (days) 9.6 5.0 3.0-123.0 10.6
Discharge destination – home 
- NHS hospital 
- Convalescence home 
- Other (died) 
382 (84.9) 
  55 (12.2) 
    9  (2.0)  
    4  (0.9) 
   
Total length of post-operative hospital stay 
(days) 
11.2 6.0 4.0-176.0 15.4
Discharge services 
- District nurse 
- Social services 
- Other 
105 (23.3) 
  68 (64.8) 
  11 (10.5) 
  26 (24.8) 
   
In-hospital death     6   (1.3)    
 
 
5.5 DISCUSSION 
With the exception of patients <18 years of age and patients undergoing emergency or GUCH 
surgery, all patients undergoing cardiac surgery were eligible for inclusion in this study. Such 
inclusiveness was intended to ensure the full range of potential morbidities, which might vary with 
factors such as patient risk or surgical procedure, would be identified so that bias (and ultimately 
over- or under-representation of the scope or prevalence of post-operative morbidity) could be 
avoided. Furthermore, if C-POMS development is based on a population representative of the UK 
cardiac surgical population, this will enhance it’s generalisability and role in clinical and research 
practice. 
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This is evaluated in the following text where the degree to which the study population is 
representative of current national data (where possible) is addressed. In addition, some key areas 
raised by the results, the limitations and strengths of the recruitment process, and the data 
collection process are discussed. 
 
5.5.1 Representativeness of study population 
The study population was similar to the UK cardiac surgery population with respect to gender, age, 
proportion of diabetics and proportion of isolated CABG operations (SCTS data: 80% male, mean 
age 63years, 21.8% diabetic, 68.5% CABG 5). A higher average Parsonnet (11.3 v 7) and 
EuroSCORE (4.2 v 3.4) was observed in my study compared to that observed nationally(5), a finding 
likely to be attributable to the fact the SCTS data relate to mean scores for isolated CABG patients 
and this study includes all cardiac surgery (except emergency cases). All the mean pre-operative 
measures were generally within normal clinical range except for a low white cell count (1.13 vs 
normal range 3.0-10.0 x109/L), creatinine at the upper normal limit (99.9 vs normal range 49-112 
umol/L) and an elevated BMI in the ‘overweight’ category (28.5 vs normal range 18.5-25 kg/m2). 
However, given that 46.9% of patients undergoing cardiac surgery in the UK are classified as 
overweight(5), this is not an unusual finding.  
 
The in-hospital mortality rate is lower in the study (1.3% v 2% for isolated CABG, 4.2% isolated 
valve, 7.2% CABG and valve) than reported in the UK 2003 national data(5) and the re-operation 
rate (5.1%) is similar (3.0-3.5% for isolated CABG and 5% for isolated valve and mixed CABG and 
valve surgery). However, Keogh and colleagues only reported re-operation for bleeding while all 
causes are included in the study. Average post-operative length of stay is slightly higher than 
reported in 1999 data (9.6 days v 9.0 days)(5) but considerably higher if the patient being transferred 
from the operating hospital to another NHS hospital is taken into account (11.2 days).  Thus, the 
post-operative length of stay reported nationally appears to underestimates total length of post-
operative stay. 
 
5.5.2 Factors that may influence morbidity outcome 
Non-white patients undergoing cardiac surgery have similar in-hospital mortality(127), but have a 
poorer post-operative course with longer hospital stay than White patients(128). Since the vast 
majority of the study population were of White British background (86.1%), specific morbidities 
reported by patients from other ethnic backgrounds potentially may be under-represented in this 
study. Furthermore, ethnicity may be a confounder in future post-operative morbidity and hospital 
length of stay comparisons with hospitals with considerably more ethnic diversity.  
 
Pre-operative statin(129) and beta-blocker(130) use has been reported to decrease complications after 
cardiac surgery, and the effect of ACE inhibitors for left ventricular dysfunction in patients with 
cardiovascular disease on outcome is well-reported(131, 132). Thus, medication use may play an 
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important role in morbidity after cardiac surgery. Overall,  the proportion of patients receiving a pre-
operative statin and beta-blocker appeared lower than would be expected (61.1%, 48.7%, 
respectively) given the National Service Framework (NSF) targeted that 80-90% of patients with an 
MI to be on a statin and beta-blocker by 2002(133). Of the study participants with a previous MI, 
66.4% were on a statin, 56.4% were taking a beta-blocker and 25.5% were taking both. Similarly, 
16.7% of participants did not have any surgery for coronary artery disease and when exploring only 
CABG patients, 70.5% of patients were receiving statin therapy. Considering coronary risk as 
defined by the Sheffield tables(134) it would be expected that all cardiovascular patients should 
probably be on a statin. 
 
Only a small proportion of patients (7.1%) had surgery conducted without extracorporeal circulation 
(off-CPB), which is considerably lower than the 17% undergoing off-CPB surgery in the UK(5). Off-
CPB surgery, when compared to on-CPB surgery (with extracorporeal circulation) is associated with 
fewer in-hospital complications and reduced hospital stay(135, 136). This is an area of comparison that 
can be made using C-POMS once it has been developed and validated. 
 
5.5.3 Limitations and strengths of the recruitment and data collection process 
A limitation of this study is that recruitment of participants occurred in four phases over three years. 
This could introduce distortion since patients were not recruited consecutively and that clinical 
practices may have changed during the course of the study. Although phase IV of participant 
recruitment had the highest proportion of available patients screened (83.1%), this proportion was 
relatively modest overall (69.5%). This was solely due to researcher availability as a consequence 
of this being a single-researcher study. The limitations of this have already been discussed in the 
data quality chapter (Chapter 3, section 3.7.4). Also, as explored in the previous chapter, the overall 
representativeness of the patients recruited into the study, compared to those that were not, was 
good. Differences that were observed can, in part, be explained by the exclusion of emergency 
surgery patients. However, the overall representativeness of the baseline characteristics of the 
study population compared with those not participating in the study and compared with UK statistics 
is indeed a study strength. Other strengths include the excellent inter-rater agreement of the POMS 
data collection and that no participants withdrew consent from the study. 
 
5.6 CONCLUSION 
Despite the recruitment limitations, the study population appears representative of the UK cardiac 
surgical population. Ethnicity, medication use and off-CPB surgery are areas for potential 
comparison following final development and validation of the C-POMS tool. 
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6 RESULTS III: C-POMS DEVELOPMENT 
 
6.1 INTRODUCTION TO CHAPTER 
This aim of this chapter is to explore the theoretical background to developing health measurement 
tools; to describe the methods utilised to develop C-POMS and to report the results of each phase 
of the process, resulting in the final C-POMS model. 
 
 
6.2 INTRODUCTION 
6.2.1 Background to model development: Psychometrics and Clinimetrics 
Health outcome measures can be developed within psychometric or clinimetric theory. Table 6-1 
provides a summary of each approach. Psychometric theory primarily refers to the measurement of 
a single psychological phenomenon using multiple items(137), while clinimetric tools aim to measure 
multiple constructs within a single index(138). Opinion is divided as to whether psychometrics and 
clinimetrics are indeed isolated phenomena(139, 140) or whether clinimetrics is merely a sub-section of 
psychometrics(138).  However, since the approach undertaken does influence which items are 
included in a model(141, 142, 143), the choice of approach undertaken is important. 
 
Most measurement scales in psychometric theory are developed and validated using classical test 
theory (CTT)(144, 145) although item-response theory (IRT) methods are being used on a rapidly 
increasing basis(146). While both CTT and IRT aim to ‘measure a single attribute by means of 
several variables that are related to but do not have influence on the construct (indicator 
variables)’(145, p9) both have their advantages and disadvantages (Table 6-1). Despite IRT being 
considered the more favourable approach(147), it is much more mathematically complex. Current 
opinion is that they should be viewed as complementary approaches(148) since little difference has 
been observed following comparison(143, 149). 
In contrast, the clinimetric approach measures multiple constructs within a single index, may include 
causal variables, is constructed with emphasis on what patients and clinicians consider to be 
important and describes or measures symptoms, physical signs and other distinctly clinical 
phenomena in clinical medicine(150) (Table 6-1). The most widely known example of a clinimetric 
index is the Apgar score(151), where the rating of the presence or absence of five clinical signs (heart 
rate, respiratory effort, reflex irritability, muscle tone and color) are noted to evaulate newborn 
infants. It has also been suggested that clinically important items should be included in a disease-
specific measure, irrespective of their statistical associations(141). Juniper et al(141) identified that 
three items of greatest importance to patients would have been excluded from the Asthma Quality 
of Life questionnaire if they had only used psychometric methods and that not all the items derived 
through psychometric methods made clinical sense. Thus, in clinical research, psychometric 
methods without clinimetric integration may give misleading results(152). Such perspectives lend to 
the argument that clinimetrics is, therefore, not a unique entity but a subset of psychometrics(138).
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Table 6-1: Comparison of psychometric theory (CTT and IRT) with clinimetric theory. Sources: 12, 139, 145, 146, 148, 147, 149, 150, 153. 
 Psychometric theory 
 Classical Test Theory (CTT) Item Response Theory (IRT) 
Clinimetric theory 
Principles  Unidimensional scale with multiple items that are 
substantially correlated to each other  
 The theoretical value of the construct can be 
measured through components which are closely 
related to it 
 Individuals are able to distinguish between different 
grades of intensity, to which a numeric value 
(score) is assigned 
 The sum of the scores (total score) represents the 
construct’s value plus random error 
 Has circular dependency in that the quality of the 
measure is dependent on the response sample 
and the respondent scores are dependent on the 
quality of the items making up the measure. 
 Primary emphasis is on items as a group, thus 
often referred to as scales  
 The scale items only assess one trait 
(scale is unidimensional) 
 The probability of answering any given 
item positively is independent of that of 
answering any other item positively  
 There are essentially 4 unidimensional 
models characterised by the number of 
parameters in the model. 
 
 Multidimensional indexes 
 Indexes or rating scales designed to 
describe or measure a variety of clinical 
phenomena: symptoms, progression of 
illness, co-morbidities, functional capacity, 
reasons for medical decisions, for example 
 Include clinical phenomena that are 
observed, judged and decided by 
clinicians 
 Combines different symptoms and 
characteristics 
 Constructed on what the patients or 
clinicians consider to be important 
 May include causal variables 
Validation Mainly based on correlation (scaling assumptions, 
internal consistency, reproducibility and construct 
validity)  
 
Based on logit ‘which represents the 
transformation of probability values in a linear 
continuum. The relationship between the 
individual’s ability and the underlying trait is 
represented by a curve, typically s-shaped’. 
Construct validity of tool, in the absence of a 
gold standard, relies on the acceptance or 
rejection of hypotheses, which can be 
subjective  
 
Advantages  Principles are easy to understand   High reliability and consistency of the  Clinical data is essential for evaluation of 
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 Statistic measures require little mathematical 
knowledge  and are widely available 
 Based on relatively weak assumptions that are 
easy to meet with real data and modest sample 
sizes  
 The underlying model fits certain types of 
instruments fairly well, for example, a scale that 
adds together the scores from items designed as 
roughly equivalent indicators of a common 
underlying principle  
 The individual items do not need to be optimal: 
items that relate only modestly to the underlying 
variable can be used successfully by having many 
of them  
selected items 
 Data furnished on an interval level of 
measurement 
 Measurement error is more accurately 
adjusted for 
 Sample independence 
 A diversity of generalised IRT linear 
models and statistical methods exists, with 
the models being dependent on the item-
response options (dichotomous or 
polytomous) 
 Provides context and meaning to score 
change as opposed to the aggregate 
score from the CTT approach  
patient care strategies where randomised 
controlled trials are inappropriate 
 Unlike statistical indexes, the major 
contributions are clinical phenomena to 
diagnostic and therapeutic procedures 
Limitations  Presumed random distribution of the error  
 Independence of the error of the true value 
 Homogenous contribution of items to the final 
score 
 Impossibility of testing person ability and item 
difficulty separately Statistics describing items and 
ratings are sample-dependent  
 Scales are often long and items often seem quite 
similar   
 Difficulty in understanding its postulates 
 Complex methodology which requires 
large samples, training in analysis and 
specific statistical programs 
 In practice the independence of the 
sample is not always confirmed 
 It is not appropriate for causal variables 
and complex latent traits 
 Clinical data are often considered ‘too soft’ 
compared to scientific evidence 
 There are no standardised methods or 
procedures for identifying clinical 
information obtained from observation, 
conversation or decision-making practices 
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6.2.2 Model development framework 
The McMaster Framework 1985(89), updated in 1992(154) following publication of Feinstein’s 1987 
book, is the most comprehensive and commonly cited methodological framework for 
constructing and assessing health indices providing frameworks for discriminative, predictive 
and evaluative instruments (Appendix 5: The McMaster Framework for discriminative, predictive 
and evaluative tools(89)). All three measures have item selection, item scaling, items reduction, 
reliability, validity and responsiveness steps, differing only in their step definition. C-POMS by 
design and function is a discriminative instrument. Table 6-2 details the step definitions for 
discriminative instruments. 
 
While item selection was detailed in section 2.4.5 and the determination of reliability and validity 
is detailed in the following chapter, this chapter details the item scaling and item reductions 
steps undertaken to enable production of a proposed C-POMS model. 
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Table 6-2: McMaster Framework for discriminative instruments(89,154). Text in italics refers to 
1992 updates.  
Step in framework Step definition for ‘discriminative instrument’ 
Item selection  Tap important components of the domain 
 Universal applicability to respondents 
 Stability over time 
Item scaling  
(ie, options available 
for answering each 
question) 
Response options 
Short response sets which facilitate uniform interpretation  
(dichotomous responses are appropriate for a discriminative 
instrument) 
Item reduction Internal scaling or consistency 
Comprehensiveness and reduction of random error vs respondent 
burden 
Delete redundant items (high inter-item correlations) 
1. Choose items based on item frequency and importance  
2. Look at discriminative ability of each of the items – those items 
to which most or all of the respondents give similar or identical 
answers are of no use 
3. Idiosyncratic items must be excluded 
4. Identify and exclude items in which most of the between person 
variance is accounted for by other factors 
Determination of 
reliability 
Reproducibility 
Large and stable inter-subject variation: correlation between 
replicate measures 
 
Signal: between subject differences (validity) 
Noise: within subject differences (measurement error: random and 
systematic error) 
Signal to noise ratio: reliability measured by reliability coefficient 
Determination of 
validity 
 
Cross-sectional construct validity: relationship between index and 
external measures at a single point in time 
(Content  and construct validity are appropriate for discriminative 
instruments) 
Determination of 
responsiveness 
Not relevant 
 
6.2.3 Item reduction strategies 
The utility of C-POMS being administered routinely in clinical practice is reliant on it not being 
burdensome in terms of time and complexity(155, 156, 157) while retaining its measurement 
properties(158) and rigor(157). Thus, application of an appropriate item-reduction strategy (IRS) is 
paramount. Whether theoretically based in psychometrics or clinimetrics there are many 
methods for item reduction. While the McMaster Framework for discriminative instruments(89) 
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provides some indication of process, the specific methods have to be determined. Previous 
clinical studies have used a variety of methods including Rasch or alternative methods of 
statistical modelling(159, 160, 161), item importance and frequency as determined by patient and/or 
expert ratings using Likert scales(162), patient rankings of severity and importance(142), content 
validity index assessment by clinician judgment using Likert scale(163), patient questionnaires 
and subsequent correlation of scores(164) and mixed-method approaches(143, 165). These mixed-
method approaches used a combination of factor analysis, item frequency and expert review(165) 
and inter-item correlations, factor analysis and Rasch analysis(143). Therefore, overall, there is 
little uniformity in IRS approaches applied to clinical studies. 
 
This purpose of this chapter is to detail the item scaling and reduction processes undertaken 
and the results which culminate in the production of the C-POMS model. 
 
 
6.3 METHODS 
6.3.1 Overall theoretical theory and methods  
6.3.1.1 Theoretical approach 
Although C-POMS contains attributes of CTT, the clinimetric approach is employed since it 
encompasses clinical opinion as well as statistical assessment. 
 
6.3.1.2 McMaster Framework for discriminative instruments 
A summary of the process undertaken for these steps in the McMaster framework are indicated 
in Figure 6-1. The terms additional morbidity and item are used synonymously throughout this 
chapter. 
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Figure 6-1: Summary of the methods undertaken in relation to the McMaster Framework for 
discriminative instruments.  
McMaster Framework for discriminative 
instruments
ITEM SELECTION
ITEM SCALING
ITEM REDUCTION
DETERMINATION OF RELIABILITY
AND VALIDITY
•Standardised variable definitions
•Recoding of free-text additional morbidities (items)
(n=138) into dichotomous responses
•Allocation of items into POMS domains/derivation 
of new domains (n=175 total items)
•Delete redundant items (inter-item/domain correlations)
•Define each item frequency, missingness (from data) and 
importance (Expert panel ratings meetings 1 and 2)
•Determine items that are accounted for by other factors and 
exclude (Expert panel ratings meetings 1 and 2)
•Exclude idiosyncratic items (Expert panel)
•Identify items that meet a minimum of 2 of the inclusion 
criteria for consideration for entry into C-POMS (prevalence 
>5%, missingness <5%, mean SI score >8, likelihood to be 
captured by POMS mean rating <4 and <80% captured in the 
data)
See methods chapter 
See model validation chapter 
Methods used for C-POMS model development
 
 
6.3.2 Item scaling 
As previously indicated, POMS items have standardised definitions and are indicated by either a 
present or absent (ie dichotomous) response. Thus, re-coding of the 138 additional morbidities 
from free-text to a dichotomous present/absent response for each participant on each post-
operative day was undertaken. Each additional morbidity/item was allocated to a corresponding 
POMS domain and/or a newly derived domain. This lead to some of the morbidities being 
allocated to more than one domain and hence increased the number of items under 
consideration from 138 to 175. 
 
6.3.3 Item reduction  
The 175 items identified underwent an item reduction strategy (IRS) process as indicated in 
Figure 6-2. 
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Figure 6-2: Item reduction strategy process  
138 additional morbidities/175 
items (incl repeat items in 
different domain)
Inter-item and inter-domain 
correlations (Phi correlation)
Expert panel meeting 1
Expert panel meeting 2
Exclude items with >0.8 
correlation with clinical face 
validity
Questions to expert panel for rating on a 5 point likert scale:
Q1 Considering each item individually what is the likelihood it would be 
captured within the existing POMS criteria? [for likelihood of being 
captured by POMS]
Q2 Considering each item individually, if in isolation, what is the 
likelihood that the patient would remain in hospital/require specialist care? 
[for SI score]
Q3 Considering each item individually, how important is the item in 
describing or quantifying post-operative morbidity for clinical 
management following cardiac surgery? [for SI score]
INCLUSION CRITERIA FOR CONSIDERATION OF ITEM ENTRY INTO C-POMS
1. Prevalence >5%
2. Missingness <5%
_________________________________________________________
3. Expert panel consideration on whether likely to be captured by POMS
4. Mean severity importance (SI) score >8
Determined from data
Re-rate 
inconsistent 
ratings
Identify items that meet a 
minimum of 2 inclusion criteria
 
 
6.3.3.1 Delete redundant items  
A correlation matrix of all 138 additional morbidities against each other plus POMS categories 
was conducted (10,143 correlation) using Phi correlation (both variables are dichotomous). A 
correlation of >0.8 was imposed for consideration for the deletion of an item, based on the 
clinical face validity of the association. 
 
6.3.3.2 Item selection criteria 
Following deletion of redundant items, the item selection criteria for potential entry into C-POMS 
was defined as: 
 Prevalence >5%  
 Missingness <5% 
 Consideration on whether likely to be captured by POMS: mean rating <4 and <80% likely 
to be captured by POMS domain. 
 Mean severity-importance (SI) score >8  
It was decided a priori that a minimum of two criteria had to be met for consideration into C-
POMS. Section 6.3.3.3 defines the methods applied for each of these inclusion criteria.  
 
6.3.3.3 Item selection criteria methods 
6.3.3.3.1 Inclusion criteria for potential entry into C-POMS 
The prevalence and missingness criteria were derived from gold standard psychometric 
principles(166) and previous application(167, 168) and were calculated from the data.  Consideration 
of whether the item is likely to be captured by POMS was taken from both Expert Panel opinion 
and the data. An Expert Panel independently rated the following question for each item on a 5 
point Likert scale (1=<20%, 2=20-40%, 3=40-60%, 4=60-80%, 5=>80%): 
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 Question 1: Considering each item individually what is the likelihood it would be captured 
within the existing POMS criteria?  
The mean rating of ≤4 and the likelihood that <80% of the item was captured by the 
corresponding POMS domain (i.e. the percentage of occasions in which the item was captured 
by another criterion within the item’s corresponding POMS domain) were both required for the 
item to be considered for inclusion into C-POMS. 
The SI score is the most popular clinimetric method for item reduction(169) and has been used 
extensively to develop variety of health outcome measures. For example, in quality of life(162) 
and critical care(163) outcomes. The SI score is based on the ratings of patients or clinicians of 
both the severity and importance of each item under consideration for inclusion into the health 
outcome tool. For C-POMS, the mean SI score was calculated from responses from an Expert 
Panel to the following questions, members of which independently rated each item on a  5 point 
Likert scale (1=none, 2=a little, 3= moderately, 4=a lot, 5=extremely): 
 Question 2: Considering each item individually, if in isolation, what is the likelihood that the 
patient would remain in hospital/require specialist care? 
 Question 3: Considering each item individually, how important is the item in describing or 
quantifying post-operative morbidity for clinical management following cardiac surgery? 
A SI score per item per rater was calculated as the sum of the rating for severity (question 2) 
and the rating for importance (question 3)(142). A mean SI score was calculated. 
 
The consistency of the ratings for each question and for each item was examined. An item was 
reconsidered/re-rated by the expert panel when the range of ratings across raters bridged the 1-
3 or 4-5 boundary.  
 
6.3.3.3.2 Expert panel  
A minimum of five raters is recommended for an expert panel rating items on a Likert scale(170). 
Thus, a five-member expert panel was convened consisting of Consultant Cardiothoracic 
Surgeons (2) and Anaesthetist (1), a Consultant Intensivist (1) and the database lead for the 
SCTS/Clinical Director for the National Institute for Clinical Outcomes Research (NICOR) (1). 
These individuals were invited to participate to give a balance of clinical expertise from surgery, 
anaesthetics, intensive care and also from a national data perspective. As previously stated, the 
three questions were applied to each additional morbidity and independently rated each on a 5 
point Likert scale. Consistent with the Delphi Method(171), the questionnaires were completed 
anonymously and underwent controlled feedback whereby a second expert panel meeting was 
convened to re-rate and discuss specific items that had shown poor agreement from raters 
following the initial rating process. 
 
 
6.4 RESULTS 
6.4.1 Item scaling 
All items were re-coded successfully and allocated to POMS and/or new domains as detailed in 
Appendix 6: Categorisation of additional morbidities/items into POMS and/or new domains. 
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6.4.2 Item reduction 
6.4.2.1 Delete redundant items: inter-item/domain correlations 
Three correlations with r value >0.8 were identified  (bronchoscopy v haemothorax =1.0; 
decreased heart rate v pus from tooth = 1.0; eye infection v aortic dissection = 1.00). None hold 
face validity of being correlated. Repeat correlations with the 138 additional morbidities with the 
overall prevalence (excluding post-operative D1) were conducted.  No correlations >0.8 were 
identified. Overall, no items were deleted due to item redundancy. 
 
6.4.2.2 Item frequency and importance 
6.4.2.2.1 Item frequency and missingness  
Figure 6-3 shows that that all POMS domains have overall prevalence of >5%.  
 
Figure 6-3: Prevalence of POMS domains 
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However, the haematological, wound and pain domains have <5% prevalence on D3 (2.7%, 
2.4% and 2.0%, respectively) and D5 (1.4%, 1.6% and 2.6%, respectively) with only the 
haematological domain having <5% prevalence on D8 (4.4%) (Figure 6-4). 
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Figure 6-4: POMS domain prevalence by post-operative day 
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Renal is the only POMS domain with missing data in >5% patients on post-operative days 3-15 
(Figure 6-5), which is wholly attributable to creatinine levels not being measured on these days 
for all patients. In all other domains missingness is ≤0.2%. 
 
Figure 6-5: Percentage missingness of each POMS domain on each post-operative day. 
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There were 20 additional morbidities captured by free-text data collection (thus level of 
missingness is not indicated for these items) occurring in >5% of the study population (Table 
6-3). 
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6.4.2.3 Item importance 
6.4.2.3.1 Captured within POMS 
Of the 175 additional morbidity items, 63 (36.0%) could not be assigned to a POMS domain and 
thus were excluded from this specific analysis. Of the remaining 112 items that were assigned 
to a corresponding POMS domain, 56 (50.0%) were inconsistently rated by the expert panel and 
only 15 (26.8%) matched the data, ie had a mean rating of <4 and <80% captured by the other 
criteria within the corresponding POMS domain. Due to the overall lack of consistency, all 112 
items were collectively re-considered by the expert panel at the second meeting having access 
to both the initial mean rating and the percentage captured by the other criteria within the 
corresponding POMS domain (Table 6-3). 
 
This discussion process by the expert panel led to two decisions: 
 Redefine the POMS pain domain definition to replace the word ‘new’ with 
‘unexpected/continuing/escalated beyond day 5’ and also to remove ‘regional analgesia’ as 
not applicable to cardiac surgery. 
 Redefine the POMS neurological domain definition to remove the word ‘focal’. This will 
enable lack of coordination, drowsy/slow to wake, poor swallow, blurred vision, sedated 
and changing loss of consciousness to be automatically included within the domain. 
These changes mean that out of the 175 additional items under consideration, 36 (20.6%) are 
accounted for in the change of POMS pain domain definition and a further 7 (4.0%) from 
redefining the POMS neurological domain.  
 
6.4.2.3.2 Mean SI scores 
Mean SI scores were calculated for each item. However, 60/175 (34.3%) and 54/175 (30.9%) 
items did showed poor agreement between raters for question 2 and question 3, respectively. 
The 39 items having inconsistent ratings for both questions were returned to the expert panel for 
collective re-rating and subsequent recalculation of the SI score. The final mean SI scores for all 
items are included in Table 6-3. 
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Table 6-3: Summary of the item-reduction strategy results for each inclusion criteria for all additional morbidities (n=175). The shaded cells indicate those that satisfy 
the inclusion criteria. 
 Inclusion criteria Prevalence Mean SI score Unlikely to be captured in CPOMS 
  Frequency 
(prevalence) 
 a) Likelihood of 
being in POMS (data)
b) Likelihood of 
being in POMS 
(mean Q1 rating) 
Unlikely  to be captured by POMS 
POMS/potential 
new category 
Additional morbidity Inclusion >5% Inclusion >8 Inclusion <80% Inclusion <4 Expert panel collective decision 
Anticoag Bleeding with Rx 1 (0.2) 9.6 NA - -
Anticoag Clotting coagulopathy 1 (0.2) 9.2 NA - -
Anticoag Platelet abnormalities 4 (0.9) 7.4 NA - -
Anticoag Untherapeutic INR 102 (22.7) 8.2 NA - -
Blood sugar Blood sugar treatment 438 (97.3) 8.2 NA - -
Blood sugar Previous diabetic ulcers 1 (0.2) 4.6 NA - -
CV Inotropes 113 (25.1) 10.0 92.9 5.0 No
CV Hypotension (meds/fluid) 49 (10.9) 9.0 71.4 3.8 Yes
CV K abnormalities  7 (1.6) 8.2 85.7 2.2 No
CV PW remain insitu 11 (2.4) 6.8 63.6 3.0 Yes
CV Tamponade ?echo 1 (0.2) 10.0 100 4.6 No
CV Lactate abnormalities 1 (0.2) 9.0 100 3.4 No
CV Hypertension 104 (23.1) 7.0 64.4 1.8 Yes
CV Cold extremities 1 (0.2) 6.8 100 2.4 No
CV Aortic dissection? 1 (0.2) 10.0 100 4.2 No
CV Pericardial effusion 1 (0.2) 8.6 100 2.6 No
CV Large heart on CXR 1 (0.2) 6.8 100 2.2 No
CV Vasovagal 2 (0.4) 5.8 100 2.6 No
CV Dizzy 12 (2.7) 5.8 83.3 2.8 No
CV Tamponade ?theatre 1 (0.2) 10.0 100 5.0 No
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CV HR decreased 1 (0.2) 8.4 100 3.6 No
CV Pericarditis? 1 (0.2) 9.0 100 4.0 No
Death Death 7.33 NA - -
Gen pain pain around ears 2 (0.4) 4.6 NA - -
Gen pain Swollen knee 2 (0.4) 5.0 NA - -
Gen pain R pleural chest pain 1 (0.2) 7.4 NA - -
Gen pain Kidney pain 1 (0.2) 6.0 NA - -
Gen pain Pain in foot 1 (0.2) 4.8 NA - -
Gen pain Wound tightness 1 (0.2) 3.4 NA - -
Gen pain Ileostomy pain 1 (0.2) 4.8 NA - -
Gen pain Shoulder pain 12 (2.7) 4.6 NA - -
Gen pain Headache 5 (1.1) 4.6 NA - -
Gen pain Pericarditis 1 (0.2) 9.2 NA - -
Gen pain General pain 9 (2.0) 4.6 NA - -
Gen pain Wound pain 19 (4.2) 6.2 NA - -
Gen pain Back pain 6 (1.3) 4.6 NA - -
Gen pain Sore throat 27 (6.0) 4.4 NA - -
GI Ischaemic bowel 3 (0.7) 10.0 66.7 5.0 No
GI PR Bleed 3 (0.7) 8.6 100 2.2 No
GI Gastric reflux 1 (0.2) 5.6 100 2.2 No
GI Incontinence 9 (2.0) 7.0 55.6 1.6 Yes
GI GI bleed 4 (0.9) 9.8 100 3.8 Yes (although captured not identified specifically)
GI Constipated 19 (4.2) 4.4 73.7 1.6 No (normal to get constipated after surgery)
GI Stomach ache 2 (0.4) 7.4 50 2.8 Yes
GI NBM for procedure 13 (2.9) 7.25 53.8 2.2 No (NBM is not a morbidity)
GI Decreased appetite 13 (2.9) 4.6 92.3 2.8 No
GI Indigestion  2 (0.4) 5.0 100 2.2 No
GI Diarrhoea 51 (11.3) 8.2 76.5 2.0 Yes
GI NG tube 10 (2.2) 9.0 90 3.8 Yes
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Hypovol CVP/Fluid challenge 1 (0.2) 9.4 NA - -
Hypovol UO decreased 66 (14.7) 9.2 NA - -
Hypovol Thirsty 17 (3.8) 4.4 NA - -
Hypovol Na abnormalities 7 (1.6) 8.4 NA - -
Hypovol Positive fluid balance 4 (0.9) 6.4 NA - -
Hypovol Overfilled 4 (0.9) 8.0 NA - -
Hypovol IV fluids/hydration 8 (1.8) 9.4 NA - -
Hypovol U and E abnormalities 14 (3.1) 8.6 NA - -
Infectious UTI 1 (0.2) 6.8 100 3.4 No
Infectious Pyrexia <38 5 (1.1) 6.0 40.0 - Yes (but debated)
Infectious Fungal infection under 
breast 
1 (0.2) 4.2 100 1.8 No
Infectious Eye infection 1 (0.2) 6.4 100 2.8 No
Infectious WCC/CRP abnormalities 18 (4.0) 8.6 66.7 3.6 Yes
Infectious ?MRSA +VE 4 (0.9) 7.0 100 2.8 No
Infectious Abscess 3 (0.7) 9.2 100 4.2 No
Infectious Infected venflon site 10 (2.2) 7.0 77.8 2.8 No
Infectious Hot/sweaty 20 (4.4) 8.0 60.0 3.6 No
Infectious Shivery 1 (0.2) 8.8 100 4.0 No
Infectious Shingles 1 (0.2) 7.2 100 2.8 No
Infectious Pus from tooth 1 (0.2) 6.6 100 2.6 No
Infectious Oral thrush 2 (0.4) 4.6 50.0 2.4 No
Liver Decreased liver function 2 (0.4) 8.8 NA - -
Liver ALT increased 1 (0.2) 8.0 NA - -
Liver Vitamin B 1 (0.2) 4.0 NA - -
Misc Increased sense of smell 1 (0.2) 2.4 NA - -
Misc Nose bleed 1 (0.2) 4.6 NA - -
Misc Daxamethasone (?why 
given) 
1 (0.2) 6.4 NA - -
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Misc Collapse (no obvious 
cause) 
3 (0.7) 9.0 NA - -
Misc Nicotine patches 2 (0.4) 2.6 NA - -
Misc Femoral line 2 (0.4) 8.4 NA - -
Mobility OT assistance 1 (0.2) 6.2 NA - -
Mobility Fall 7 (1.6) 8.4 NA - -
Mobility Mobility encouragement 27 (6.0) 3.8 NA - -
Neuro Cerebral irritation 4 (0.9) 9.8 100 4.4 Included automatically following new neuro definition
Neuro Lack of coordination 6 (1.3) 8.4 33.3 4.2 Included automatically following new neuro definition
Neuro Weird dreams 37 (8.2) 2.8 35.1 1.2 No
Neuro Blurred vision 61 (13.6) 6.6 34.4 3.0 Included automatically following new neuro definition
Neuro Panic attack 5 (1.1) 3.8 60 1.8 No
Neuro Dizzy 12 (2.7) 6.5 8.3 2.0 No
Neuro Changing LOC 1 (0.2) 10.0 100 4.6 Included automatically following new neuro definition
Neuro Pressure in head 1 (0.2) 5.0 0 2.0 No
Neuro Tinnitus 1 (0.2) 3.8 0 1.8 No
Neuro Sedated 32 (7.1) 8.2 53.1 2.8 Included automatically following new neuro definition
Neuro Insomnia 3 (0.7) 2.8 100 1.4 No
Neuro Depression 1 (0.2) 5.0 100 2.0 No
Neuro Drowsy/slow to wake 11 (2.4) 9.4 45.5 3.8 Included automatically following new neuro definition
Neuro Poor swallow 4 (0.9) 8.0 50.0 3.4 Included automatically following new neuro definition
Neuro Feels weak/tired 1 (0.2) 6.0 33.3 1.3 Yes
Overload Peripheral oedema 368 (81.8) 7.2 NA - -
Overload Increased weight 14 (3.1) 6.2 NA - -
Overload Overfilled 4 (0.9) 8.0 NA - -
Overload Whole body oedema 6 (1.3) 9.0 NA - -
Pain General pain  9 (2.0) 4.8 0 2.0 Included automatically following new pain definition
Pain Wound tightness 1 (0.2) 4.0 0 1.8 Included automatically following new pain definition
Pain Kidney pain 1 (0.2) 7.4 0 3.0 Included automatically following new pain definition
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Pain Pericarditis 1 (0.2) 9.2 0 3.6 Included automatically following new pain definition
Pain R pleural chest pain 1 (0.2) 8.2 0 3.2 Included automatically following new pain definition
Pain Stomach ache 2 (0.4) 6.0 0 2.6 Included automatically following new pain definition
Pain Sore throat 27 (6.0) 3.8 9.1 1.6 Included automatically following new pain definition
Pain Ileostomy pain 1 (0.2) 6.0 0 2.2 Included automatically following new pain definition
Pain Swollen knee 2 (0.4) 5.4 0 2.0 Included automatically following new pain definition
Pain Back pain 6 (1.3) 4.4 0 2.0 Included automatically following new pain definition
Pain Pain from chest drains 2 (0.4) 6.4 0 3.2 Included automatically following new pain definition
Pain Headache 5 (1.1) 4.4 0 2.4 Included automatically following new pain definition
Pain Pain around ears 2 (0.4) 5.4 0 2.4 Included automatically following new pain definition
Pain Shoulder pain 12 (2.7) 4.4 0 2.2 Included automatically following new pain definition
Pain Pain in foot 1 (0.2) 4.8 0 2.2 Included automatically following new pain definition
Pain Wound pain 19 (4.2) 7.6 25.0 2.8 Included automatically following new pain definition
Pulmonary Bronchoscopy 1 (0.2) 8.0 100 4.0 No
Pulmonary Pneumothorax 15 (3.3) 9.6 90.9 4.0 No
Pulmonary Surgical emphysema 5 (1.1) 9.2 100 4.0 No
Pulmonary Pleural effusion 59 (13.1) 9.2 94.6 4.0 No
Pulmonary Saline/other nebs 210 (46.7) 7.75 87.5 4.0 Yes (include nebulisers within the definition)
Pulmonary DIB/pain from chest 
drains 
2 (0.4) 7.8 0 3.0 No
Pulmonary Haemothorax 1 (0.2) 9.2 100 4.0 No
Pulmonary Phrenic nerve palsy 1 (0.2) 7.2 100 3.0 No
Pulmonary SOB after medication 1 (0.2) 7.8 0 3.4 No
Pulmonary Ventilation difficulties 1 (0.2) 9.4 100 5.0 No
Pulmonary Chest physio 3 (0.7) 7.8 66.7 3.0 Yes
Pulmonary Reintubated 4 (0.9) 9.4 100 5.0 No
Pulmonary Aspiration Pneumonia 1 (0.2) 9.8 100 5.0 No
Pulmonary Respiratory acidosis 1 (0.2) 9.6 100 4.6 No
Pulmonary Hiccups 3 (0.7) 3.2 66.7 1.2 No
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Renal Haematuria 4 (0.9) 7.8 75.0 2.2 No
Renal Lactate abnormalities 1 (0.2) 9.4 100 2.6 No
Renal IV Frusemide 191 (42.4) 9.6 92.9 4.0 No
Renal Polyuric 14 (3.1) 8.8 84.6 3.0 No
Renal Na abnormalities 7 (1.6) 8.6 50.0 2.4 Yes
Renal IDC bypassing 3 (0.7) 7.6 100 2.4 No
Renal UO decreased 66 (14.7) 9.4 100 4.2 No
Renal K abnormalities 7 (1.6) 9.4 83.3 2.8 Yes (add as requiring treatment)
Renal Phosphate infusion (low) 5 (1.1) 8.6 50.0 2.0 Yes
Renal Increased BE 4 (0.9) 9.0 100 3.0 No
Renal U and E abnormalities 14 (3.1) 9.2 78.6 3.8 Yes
Renal ATN 3 (0.7) 10.0 100 5.0 No
Renal Cramps 1 (0.2) 4.8 0 1.4 No
Renal Kidney pain 1 (0.2) 7.4 0 2.4 No
Renal Prostate problems 3 (0.7) 5.5 33.3 2.25 No
Renal Urinary retention 8 (1.8) 8.6 87.5 3.0 No
Renal UTI 1 (0.2) 8.2 100 2.4 No
Renal Incontinence 9 (2.0) 6.0 55.6 1.8 Yes
Review Aortic dissection? 1 (0.2) 9.2 NA - -
Review For review 35 (7.8) 6.6 NA - -
Review Tamponade ? Echo 1 (0.2) 9.6 NA - -
Review For 
investigation/procedure 
23 (5.1) 7.4 NA - -
Review WCC/CRP abnormalities 18 (4.0) 8.2 NA - -
Review Rtn to theatre 6 (1.3) 9.4 NA - -
Review D1 post-procedure 33 (7.3) 6.5 NA - -
Review D2/3 post procedure 13 (2.9) 6.0 NA - -
Review Bronchoscopy 1 (0.2) 8.4 NA - -
Review Tamponade ? Theatre 1 (0.2) 9.6 NA - -
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Review Pericarditis? 1 (0.2) 9.2 NA - -
Review NBM for procedure 13 (2.9) 7.6 NA - -
Skin Itchy 1 (0.2) 5.2 NA - -
Skin Severe bruising 2 (0.4) 6.2 NA - -
Skin Iodine burns 2 (0.4) 7.4 NA - -
Skin Rash 3 (0.7) 5.6 NA - -
Skin Blisters 1 (0.2) 5.4 NA - -
Skin Allergic reaction 1 (0.2) 7.6 NA - -
Wound Chest drains 449 (99.8) 7.6 100 1.8 No
Wound Wound pain 19 (4.2) 6.0 25.0 2.6 Yes
Wound Chest support insitu 2 (0.4) 5.2 0 2.4 Yes
Wound Wound tightness 1 (0.2) 4.0 0 1.8 No
Wound Sternal click 1 (0.2) 6.0 0 2.6 No
Wound Numbness of donor site 17 (3.8) 3.2 16.7 1.4 No
Wound Return to theatre 6 (1.3) 10.0 100 3.2 No
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There were 21 rating inconsistencies for question 2: 18 items had 1 rater inconsistency, 2 items 
had considerable disagreement and 1 item had a high level of missing ratings. For the 18 items 
with 1 rater inconsistencies, a mean SI score excluding the inconsistent rating, was re-
calculated. No items met the inclusion criteria (>8) initially and then had SI <8 following 
recalculation (ie dropped out after recalculation) but 3 items had a mean score of <8 initially and 
then had an SI >8 following recalculation (Table 6-4). 
 
Table 6-4: Differences in mean SI score (affecting inclusion into C-POMS) following exclusion of 
rating not in agreement with other raters. 
Item Mean SI 
score 
Recalculated mean SI 
(excluded out of range rater) 
Expert panel 
review 
DIB/pain from chest drains 7.8 8.25 
Kidney pain 7.4 8 
Right pleural chest pain 7.4 8 
Collate all 
pain items  
* DIB: difficulty in breathing 
 
For the remaining 3 items with question 2 rating inconsistencies, a collective re-rating by the 
expert panel was undertaken and a revised mean SI score was calculated (Table 6-5) 
 
Table 6-5: Collective re-rating by the expert panel for question 2 on items with initial rating 
inconsistencies. 
Item Re-rating of Q2 by 
expert panel 
Recalculated mean SI 
score 
Prostate problems 1 5.5 
Constipated 1 4.4 
Feels weak/tired (delaying discharge) 5 6.0 
 
There were 15 items that only had rating inconsistencies in question 3.  Following the 
recalculation of the mean SI score, excluding the inconsistent rating, no items dropped out of 
potential inclusion into C-POMS (initial mean SI score >8 initially and <8 after re-calculation), 
but 2 items changed from <8 to >8 (ie potentially to add in) (Table 6-6). The expert panel 
decided that shortness of breath after medication and chest physiotherapy should be exclude 
and included for consideration into C-POMS, respectively. 
 
Table 6-6: Items changing SI score inclusion status from inconsistent ratings 
Item Mean SI 
score 
Recalculated mean SI 
(excluded out of range rater) 
Expert panel 
review 
Short of breath after medication 7.8 8.5 Exclude 
Chest physiotherapy 7.8 8.25 Include 
 
Figure 6-6 provides a summary of the results of the expert panel rating process.  
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Figure 6-6: Expert panel rating process results 
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175 additional morbidities 
Expert panel meeting 1: 
Individual rating of Q1, Q2 and 
Q3 
Q2: Agreement on ratings 
(n=175) 
Q1: Agreement on ratings 
(n=112) 
Q3: Agreement on ratings 
(n=175) 
n=56 (50.0%) n=56 (50.0%) n=115 (65.7%) n=60 (34.3%) 
Agreement with Q3 
n=121 (69.1%) n=54 (30.9%) 
Agreement with Q2 
n=21 (12.0%) n=39 (22.3%) 
For collective re-rating by expert panel
n=15 (8.6%) 
Recalculated mean SI score 
excluding rater who disagreed 
Recalculated mean SI score 
excluding rater who disagreed
Expert panel meeting 2: 
Reviewed by expert panel for 
collective decision using 
empirical evidence from the 
study 
Expert panel meeting 2: 
Reviewed by expert panel for 
collective decision on Q2 rating
Expert panel meeting 2: 
Collective re-rating by expert 
panel for both Q2 and Q3 
Expert panel meeting 2: 
Reviewed by expert panel for 
collective decision on Q3 rating
Change in mean SI 
score from <8 to >8 
n=2 
Change in mean SI score 
from >8 to <8 
n=0 
Use original mean SI score 
Change in mean SI 
score from <8 to >8 
n=3 
Change in mean SI score 
from >8 to <8 
n=0 
Use original mean SI score 
FOR CONSIDERATION UNDER THE INCLUSION CRITERIA FOR ENTRY INTO C-POMS 
1. Mean SI score >8,  2. Prevalence >5%,  3. Missingness <5% , 4. Expert panel consideration on whether likely to be captured by POMS 
Recalculated SI score based 
on new ratings
Recalculated SI score based 
on new ratings
Questions to expert panel for rating on a 5 point likert scale: 
Q1 Considering each item individually what is the likelihood it would be 
captured within the existing POMS criteria?  
Q2 Considering each item individually, if in isolation, what is the likelihood that 
the patient would remain in hospital/require specialist care? 
Q3 Considering each item individually, how important is the item in describing 
or quantifying post-operative morbidity for clinical management following 
cardiac surgery? 
The Severity Index score is the addition of the mean rating for Q2 and the 
mean rating for Q3. Criteria for inclusion to C-POMS is mean SI score>8 
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6.4.3 Item reduction and C-POMS inclusion criteria 
Table 6-3 summarises the results of the inclusion criteria for all 175 items.  Overall, of the 175 
additional morbidity items, 43 (24.6%) were removed following re-definition of the POMS 
neurological (7 items) and pain (36 items) domains during the second expert panel meeting. Of 
the 132 remaining items, 18 (13.6%) had a prevalence of >5%, 21 (15.9%) were judged as 
unlikely to be captured within POMS and 75 items (56.8%) had a mean SI score of >8. Figure 
6-7 shows the distribution of number of the items meeting the criteria for consideration into C-
POMS. 
 
Figure 6-7: The frequency of items meeting all, 2, 1 or none of the inclusion criteria following the 
item reduction process 
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Thus, there were 26 items meeting the minimum standard of meeting 2 or more criteria. 
Decreased urine output and potassium abnormalities requiring treatment were present under 2 
domains and thus one of each was made redundant to prevent duplication of data collection. 
Table 6-7 summarises the 24 items for inclusion into C-POMS. 
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Table 6-7: Summary of the 24 items for inclusion into C-POMS. 
New morbidity criteria Overall prevalence 
(inclusion criteria 
>5%) 
Mean SI 
score 
(inclusion 
criteria >8) 
Likelihood of being 
captured in POMS  (mean 
Q1 score) (inclusion 
criteria <4) 
Number 
of 
inclusion 
criteria 
met 
Comments 
Pulmonary 
Pleural effusion requiring 
drainage 
Chest physio 
 
59 (13.1) 
   
3   (0.7) 
 
9.2 
 
7.8 
 
4.0 
 
3.0 
 
2 
 
2 
 
Infectious 
WCC/CRP level requiring 
review 
 
18   (4.0) 
 
8.6 
 
3.6 
 
2 
 
Renal 
IV Furosemide 
Decreased UO 
Urinary incontinence 
Serum K (K abnormalities) 
 
191 (42.4) 
  66 (14.7) 
    9   (2.0) 
    7   (1.6) 
 
9.6 
9.2 
6.0 
9.4 
 
4.0 
NA 
1.6 
2.8 
 
2 
2 
2 
 
 
 
Included faecal incontinence in IRS 
Gastrointestinal 
NG tube 
GI Bleed 
Diarrhoea 
 
10   (2.2) 
  4   (0.9) 
51 (11.3) 
 
9 
9.8 
8.2 
 
3.8 
3.8 
2.0 
 
2 
2 
3 
 
Cardiovascular 
Inotropic therapy 
 
113 (25.1) 
 
10.0 
 
5.0 
 
2 
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Pacing wires 
Hypotension 
Hypertension 
12    (2.7) 
 49 (10.9) 
104 (23.1) 
6.8 
9.0 
7.0 
3.0 
3.8 
1.8 
2 
3 
2 
Haematological 
Untherapeutic INR 
 
102 (22.7) 
 
8.2 
 
NA 
 
2 
 
Wound complication 
Chest drains 
Wound pain 
 
449 (99.8) 
  19   (4.2) 
 
7.6 
6.0 
 
1.8 
2.8 
 
2 
2 
 
Endocrine (new domain) 
Blood sugar management 
 
438 (97.3) 
 
8.2 
 
NA 
 
2 
 
Electrolyte (new domain) 
Sodium 
Potassium 
Urea 
Phosphate 
 
  7 (1.6) 
  7 (1.6) 
14 (3.1) 
  5 (1.1) 
 
8.4 
9.4 
9.2 
8.6 
 
2.4 
2.8 
3.8 
2.0 
 
2 
2 
2 
2 
 
Review (new domain) 
Further review 
Investigation or procedure 
 
  3 (8.2) 
23 (5.1) 
 
6.6 
8.4 
 
NA 
NA 
 
 
2 
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6.4.4 The C-POMS tool 
The C-POMS model with morbidity type and criteria definitions is stated in Table 6-8. C-POMS 
includes all POMS morbidity types and definitions in addition to the 24 items identified through 
the IRS, resulting in modified POMS domains and three new domains.  As indicated previously, 
(Methods chapter section 2.4.5.2), ambulation was requested as a routine data collection 
domain by the PDG and thus inclusion was mandatory. No amendments to the domain criteria 
were recommended by the expert panel.   Furthermore, in addition to C-POMS all non-C-POMS 
related reasons for delayed discharge on D5, D8 and D15 are to be documented as part of 
routine C-POMS data collection (Table 6-9), as also decided by the PDG. 
 
Overall, C-POMS can be used as crude presence/absence of each of the morbidity types or 
detailed collection of individual definition items. Each is documented as a new morbidity or an 
escalating morbidity from pre-operative assessment.   
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Table 6-8: Final tool: C-POMS morbidity types and definitions 
Morbidity type C-POMS criteria 
Pulmonary Presence of one or more of the following: 
 New requirement for oxygen or respiratory support (including nebuliser therapy or request for chest physiotherapy on or 
after D5);  
 pleural effusion requiring drainage 
Infectious Presence of one or more of the following: 
 Currently on antibiotics  
 has had a temperature of >38°C in the last 24 hours  
 has a white cell count/CRP level requiring in-hospital review or treatment 
Renal Presence of one or more of the following: 
 Presence of decreased urine output requiring intervention (including IV furosemide),  
 increased serum creatinine (>30% from pre operative level);  
 urinary catheter in situ;  
 new urinary incontinence;  
 serum potassium abnormalities* requiring treatment 
Gastrointestinal Presence of one or more of the following: 
 Unable to tolerate an enteral diet for any reason including nausea, vomiting and abdominal distension;  
 the presence of a nasogastric tube;  
 diagnosis of a gastrointestinal bleed;  
 presence of diarrhoea  
Cardiovascular Presence of one or more of the following: 
 The use of inotropic therapy for any cardiovascular cause;  
 the presence of pacing wires (on or after D5) and/or requiring temporary or new permanent pacing**;  
 diagnostic tests or therapy within the last 24 hours for any of the following: 1) new MI or ischaemia, 2) hypotension 
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(requiring fluid therapy, pharmacological therapy or omission of pharmacological therapy 3) atrial or ventricular  
arrhythmias***, 4) cardiogenic pulmonary oedema, thrombotic event (requiring anticoagulation), 5) hypertension 
(pharmacological therapy or omission of pharmacological therapy)  
Neurological New neurological deficit (including confusion, delirium, coma, lack of coordination, drowsy/slow to wake, poor swallow, blurred 
vision, sedated, changing loss of consciousness) 
Haematological Presence of one or more of the following: 
 Untherapeutic INR requiring pharmacological therapy or omission of pharmacological therapy;  
 Requirement for any of the following within the last 24 hrs: packed erythrocytes, platelets, fresh-frozen plasma, or 
cryoprecipitate 
Wound Presence of one or more of the following: 
 Wound dehiscence requiring surgical exploration or drainage of pus from the operation wound with or without isolation of 
organisms;  
 presence of chest drains;  
 wound pain significant enough to require continuing or escalating analgesic intervention 
Pain Postoperative pain significant enough to require parenteral opioids and/or continuing or additional analgesia.  
Endocrine New or additional requirements for blood sugar management 
Electrolyte *Electrolyte (including sodium, urea, phosphate) imbalance requiring oral or intravenous intervention (NB not including 
potassium as included in Renal category) 
Review Remaining in hospital for further review, investigation and/or procedure 
Assisted 
ambulation 
A new or escalated post-operative requirement for mobility assistance (including wheelchair, crutches, zimmer frame, walking 
sticks, or assistance) 
*Where abnormalities refer to the local clinical ranges. 
**Protocol development group (PDG) meetings prior to collection of data requested identification of pacing (temporary or new permanent). Thus, added to 
CV category. 
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Table 6-9: Non-C-POMS related reasons for delayed discharge on D5, D8 and D15 which the PDG decided should also be routine data collection in C-
POMS on these days. 
Non-
morbidity 
reason for 
delayed 
discharge 
POMS criteria (UCLH validation study) C-POMS criteria 
Delayed 
discharge 
Where POMS is ‘0’ but the patient remains in hospital, 
state the reason for lack of discharge: 
 
Social reasons 
Equipment at home 
Mobility (ongoing physo and OT needs) 
Institutional failure (transport not booked, OPA or follow-
up not arranged)  
Delayed discharge (lack of rehab or other bed) 
Discharge planned for today 
Other medical reason  
Where C-POMS is ‘0’ but the patient remains in hospital, state the 
reason for lack of discharge: 
 
Social reasons  
Equipment at home  
Mobility (ongoing physo and OT needs)  
Institutional failure (transport not booked, OPA or follow-up not 
arranged)  
Delayed discharge (lack of rehab or other bed)  
Discharge planned for today  
Other medical reason 
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7 RESULTS IV: C-POMS RELIABILITY AND VALIDITY 
 
7.1 INTRODUCTION TO CHAPTER 
This chapter will describe the aims, methods and results of the reliability and validity testing of the 
C-POMS tool. 
 
 
7.2 INTRODUCTION: THE NEED FOR MODEL VALIDATION 
Validity refers to whether an instrument measures what it purports to measure(166). There are 
several methods of validity assessment which are undertaken by a process of hypothesis testing: 
content validity, construct validity and criterion validity. Content validity, ‘the degree to which the 
elements of an assessed instrument are relevant to and representative of the targeted construct for 
a particular assessment purpose’(172 p238), is a component of construct validity. Construct validity is 
‘the degree to which an assessment instrument measures the targeted construct’(172 p239) and is 
assessed in the absence of an existing gold standard by which to compare the instrument (criterion 
validity). As a gold standard for post-operative morbidity in cardiac patients does not exist, construct 
validity testing of C-POMS is required. Since clinical judgments are influenced by the construct 
validity of an instrument(172) construct validation is an essential process in the development of C-
POMS.  
 
The importance of the use of a conceptual framework in instrument development has been 
highlighted(173). As stated previously, the McMaster Framework for discriminative instruments(89, 154) 
has been used in the development of C-POMS and the validation steps as set out by this 
framework will be described in this chapter. Furthermore, the most commonly cited content validity 
framework(172) will also be used to assess the content validity of C-POMS. 
 
 
7.3 AIMS 
The aim of this chapter is to assess the reliability and validity of C-POMS. The objectives are to 
assess the: 
a) Content validity of C-POMS using the Haynes et al content validity framework(172) 
b) Internal consistency of C-POMS to determine if C-POMS can be used as a summary score 
to denote total morbidity burden 
c) Construct validity of C-POMS by testing the following hypotheses: 
I. C-POMS predicts post-operative length of stay 
II. Existing pre-operative risk assessment scores (EuroSCORE, Parsonnet score and 
Magovern score) predict C-POMS  
III. C-POMS domain frequencies are higher in patients with greatest post-operative risk 
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IV. No participants will remain in hospital with a C-POMS score of zero and that no 
participants will be discharged home with a C-POMS score of ≥1 on D5, D8 and D15 
and to 
V. Determine the independent predictive power of each domain on subsequent length of 
stay. 
 
7.4 METHODS 
7.4.1 Model development framework 
As detailed in the previous chapter, the model development framework being utilised for the 
development and validation of C-POMS is the McMaster Framework published in 1985(89) and 
updated in 1992(154) for discriminative instruments. The framework steps relating to model validation 
are detailed in Table 7-1. 
 
Table 7-1: Validation steps of the McMaster Framework for discriminative instruments(89, 154) 
Step in framework Step definition for ‘discriminative instrument’ 
Determination of 
reliability 
Reproducibility 
Large and stable inter-subject variation: correlation between replicate 
measures 
Signal: between subject differences (validity) 
Noise: within subject differences (measurement error: random and 
systematic error) 
Signal to noise ratio: reliability measured by reliability coefficient 
Determination of 
validity 
 
Cross-sectional construct validity: relationship between index and 
external measures at a single point in time 
(Content  and construct validity are appropriate for discriminative 
instruments) 
 
7.4.2 Content validity  
The procedure and sequence of assessing content validity was conducted using the Haynes et al 
content validity framework(172) (Table 7.2). 
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Table 7-2: Haynes et al content validity framework(172) 
Steps in the framework: Procedure and sequence of content validation  
1. Specify the construct(s) targeted by the instrument 
a) Specify the domain of the construct 
(i) What is to be included 
(ii) What is to be excluded 
b) Specify the facets and dimensions of the construct 
(i) Factors of the construct to be covered 
(ii) Dimensions (e.g. rate, duration and magnitude) 
(iii) Mode (e.g. thoughts and behaviours) 
(iv) Temporal parameters (response interval and duration of time sampling) 
(v) Situations 
2. Specify the intended functions of the instrument (e.g. brief screening, functional 
analysis and diagnosis) 
3. Select assessment method to match targeted construct and function of assessment 
4. Initial selection and generation of items from: 
a) rational deduction 
b) clinical experience 
c) theories relevant to the construct 
d) empirical literature relevant to the construct (e.g. studies on construct validity of potential 
items) 
e) other assessment instruments (e.g. borrowing items from other instruments that have 
demonstrated validity) 
f) suggestions from experts 
g) suggestions from target populations 
5. Match items to facets and dimensions 
a) use table of facets to insure coverage (include all relevant dimensions, modes, temporal 
parameters and situations) 
b) generate multiple items for each facet 
c) insure proportional representation of items across facets (i.e. the relative number of items 
in each facet should match the importance of that facet in the targeted construct) 
6. Examine structure, form, topography and content of each item 
a) appropriateness of item for the facet of construct 
b) consistency and accuracy, specificity and clarity of wording and definitions 
c) remove redundant items 
7. Establish quantitative parameters  
a) response formats and scales 
b) time-sampling parameters (sampling intervals and durations) 
8. Construct instructions to participants 
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a) match with domain and function of assessment instrument 
b) clarify: strive for specificity and appropriate grammatical structure 
9. Establish stimuli used in assessment (e.g. social scenarios, and audio and visual 
presentations) to match construct and function 
10. Have experts review the results of methods 1-3 and 5-9 
a) quantitative evaluations of construct definition, domain, facets, mode and dimensions 
b) quantitative evaluation of the relevance and representativeness of items and stimuli 
c) quantitative evaluation of response formats, scales, stimuli, situations, time-sampling 
parameters, data reduction and aggregation 
d) match of an instrument attributes to it’s function 
e) qualitative evaluation: suggested additions, deletions and modifications 
11. Have target population sample the results: review quantitative and qualitative 
evaluation of items, stimuli and situations 
12. Have experts and target population sample re-review the modified assessment 
instrument 
13. Perform psychometric evaluation and contingent instrument refinement: criterion-
related and construct validity, and factor analysis. 
 
7.4.3 Reliability: Reproducibility 
Due to the nature of the study, repeat measure analysis was not appropriate, since morbidity issues 
would change over time. Additionally, since this study was conducted by one person, there was no 
available person to undertake inter-rater reliability testing of the final C-POMS tool. 
 
7.4.4 Reliability: Internal consistency  
The extent to which the C-POMS tool comprises a scale that measures the same underlying 
construct was calculated using Cronbach’s alpha(174). The minimum standard to indicate a sufficient 
level of homogeneity among the domains to regard the survey as a scale was taken as 0.70(175). 
Descriptive statistics (minimum, maximum, median and standard deviation) were used to describe 
the resulting summary scores for each post-operative day that demonstrated at least the minimum 
standard for homogeneity.  
 
7.4.5 Construct validity 
7.4.5.1 C-POMS summary score and subsequent length of stay  
The frequencies of those with and without C-POMS defined morbidity on each post-operative day 
were calculated. The predictive validity of C-POMS on subsequent post-operative length of stay 
was explored using a) univariate analysis using t-tests to compare the mean subsequent length of 
post-operative stay between those with and without -CPOMS defined morbidity, b) linear regression 
to test the predictive ability of C-POMS summary score on subsequent post-operative length of stay.  
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7.4.5.2 The ability of EuroSCORE, POSSUM and Magovern score to predict C-POMS 
summary score  
Linear regression was performed to determine the predictive ability of EuroSCORE, POSSUM and 
Magovern scores on C-POMS summary score for each post-operative day.  
 
7.4.5.3 Domain level analysis: Are C-POMS domain frequencies higher in patients with 
greatest risk of post-operative morbidity?  
The Chi-square statistic was used to determine if C-POMS domains frequencies were higher in 
patients with greatest risk of post-operative morbidity as defined by EuroSCORE, the physiological 
component on POSSUM and the Magovern score. Categorisation of low and high risk of each of 
the pre-operative risk assessment scores was divided at the median score within the dataset. Thus, 
for EuroSCORE the median score was 4.0 (low risk = 0-4; high risk = 5-14), the physiological 
component on POSSUM the median score was 18 (low risk = 12-18, high risk = 19-40) and the 
Magovern score the median score was 5.0 (low risk = 0-5, high risk 6-18).  
 
7.4.5.4 Remaining in hospital with a C-POMS score of zero and those discharged home with 
a C-POMS score of ≥1 
The frequency of the social, organisational and/or medical reasons for remaining in hospital on D5, 
D8 and D15 when C-POMS is ‘0’ but the patient is still an in-patient was examined. Additionally, the 
frequency and reasons why participants with a C-POMS score ≥1 who are discharged on these 
days was also explored. 
 
7.4.5.5 Multivariate analysis: Independent predictive power of each domain on subsequent 
length of stay. 
Multivariate linear regression analysis was performed to determine the independent strength of 
each C-POMS domain on subsequent length of stay for each post-operative day. 
 
In all statistical tests statistical significance was taken at p<0.05 level. 
 
 
7.5 RESULTS 
7.5.1 Content validity  
Table 7-3 shows the process undertaken for each of the McMaster framework steps. 
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Table 7-3: Process undertaken for each of the content validity steps 
Steps in the framework: Procedure and sequence of 
content validation  
Details within C-POMS 
1. Specify the construct(s) targeted by the 
instrument 
1. Specify the domain of the construct 
(i) What is to be included 
(ii) What is to be excluded 
b. Specify the facets and dimensions of the construct 
(i) Factors of the construct to be covered 
(ii) Dimensions (e.g. rate, duration and 
magnitude) 
(iii) Mode (e.g. thoughts and behaviours) 
(iv) Temporal parameters (response interval and 
duration of time sampling) 
(v) Situations 
Construct: survey of in-hospital post-operative morbidity 
in patients undergoing adult cardiac surgery 
a) Domain: in-hospital post-operative morbidity 
(i) Included: All morbidity requiring treatment or 
extending hospital stay 
(ii) Excluded: any morbidity leading to death within 5 
days of surgery 
 
b) Facets and dimensions 
(i) Factors: POMS framework dimensions, new 
dimensions as identified by prospective research 
(ii) Dimensions: POMS framework dimensions on post-
operative days 1, 3, 5, 8 and 15 
(iii) Mode: see ‘factors’ 
(iv) Temporal parameters: NA 
(v) Situations: NA 
2. Specify the intended functions of the instrument 
(e.g. brief screening, functional analysis and diagnosis) 
 
1. Identify and quantify post-operative morbidity burden 
in patients undergoing cardiac surgery 
3. Select assessment method to match targeted 
construct and function of assessment 
See methods chapter 
 
1-3 REVIEWED BY EXPERT PANEL PRE-STUDY 
4. Initial selection and generation of items from: 
a) rational deduction 
b) clinical experience 
c) theories relevant to the construct 
d) empirical literature relevant to the construct (e.g. 
studies on construct validity of potential items) 
e) other assessment instruments (e.g. borrowing items 
from other instruments that have demonstrated validity) 
f) suggestions from experts 
g) suggestions from target populations 
a) Rational deduction: Based on clinical 
experience/observation  
b) clinical experience: C-POMS study 
c) Theory: POMS. No others 
d) Literature review: Pre-op risk assessment models for 
post-operative morbidity 
e) Other assessment instruments: POMS 
f) Suggestions from experts: PDG meetings/Expert panel 
review 
g) Suggestions from target populations: Patient 
interviews in C-POMS study 
 
REVIEWED BY EXPERT PANEL PRE-STUDY, POST 
PILOT STUDY AND POST STUDY (PRELIMINARY 
RESULTS) 
5. Match items to facets and dimensions 
a) use table of facets to insure coverage (include all 
relevant dimensions, modes, temporal parameters and 
situations) 
b) generate multiple items for each facet 
c) insure proportional representation of items across 
facets (i.e. the relative number of items in each facet 
should match the importance of that facet in the targeted 
For morbidities identified outside of POMS framework: 
a) Group items relating to domain: group according to 
POMS domain or construct new dimensions as 
appropriate 
b) Ensure newly developed domains contain multiple 
items 
c) NA: Domains generated according to item generation 
results and not predetermined 
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construct) d) NA: each dimension given equal importance  
6. Examine structure, form, topography and content 
of each item 
a) appropriateness of item for the facet of construct 
b) consistency and accuracy, specificity and clarity of 
wording and definitions 
c) remove redundant items 
See item-reduction strategy detailed in model 
development chapter 
 
 
 
REVIEWED BY EXPERT PANEL POST PILOT STUDY 
AND POST-STUDY 
7. Establish quantitative parameters  
a) response formats and scales 
b) time-sampling parameters (sampling intervals and 
durations) 
a) Defined by POMS framework and PDG/Expert panel 
pre-study 
b) Modified parameters in POMS study (post-operative 
D1, D3, D5, D8 and D15) to also include a pre-operative 
assessment: PDG/Expert panel questioned usefulness of 
D1 but kept in study design to accurately assess 
usefulness/clinical discriminative usefulness on D1 
 
DEFINED BY EXPERT PANEL PRE-STUDY AND 
REVIEWED POST PILOT STUDY 
8. Construct instructions to participants 
a) match with domain and function of assessment 
instrument 
b) clarify: strive for specificity and appropriate 
grammatical structure 
Instructions to participants: NA 
Instructions to data collector (single): 
 Standardisation of data variable definitions: Data 
definition tables for each variable constructed 
 Standardisation of data collection: Standardised CRF 
constructed  
 
DEFINED PRE-STUDY, REVIEWED MID PILOT STUDY 
AND BY EXPERT PANEL AT END OF PILOT STUDY 
9. Establish stimuli used in assessment (e.g. social 
scenarios, and audio and visual presentations) to 
match construct and function 
NA: no need to additional stimuli and data collected by 
experienced research nurse and a simple checklist for 
data collection is being used with clear definitions for 
each variable  
10. Have experts review the results of methods 1-3 
and 5-9 
a) quantitative evaluations of construct definition, 
domain, facets, mode and dimensions 
b) quantitative evaluation of the relevance and 
representativeness of items and stimuli 
c) quantitative evaluation of response formats, scales, 
stimuli, situations, time-sampling parameters, data 
reduction and aggregation 
d) match of an instrument attributes to it’s function 
e) qualitative evaluation: suggested additions, deletions 
and modifications 
Expert panel to review a) – e) pre-study, end of pilot 
study, end of data collection (preliminary results)  
In addition: 
 Administrative burden: length of tool; ease of 
completion; number of assessment points(173)/Utility 
assessment of instrument(176) 
 
11. Have target population sample the results: 
review quantitative and qualitative evaluation of 
items, stimuli and situations 
UNDERTAKEN AS THE PILOT STUDY 
12. Have experts and target population sample re-
review the modified assessment instrument 
REVIEWED BY EXPERT PANEL POST PILOT STUDY. 
EXPERT PANEL REVIEWED FINAL MODEL. 
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13. Perform psychometric evaluation and contingent 
instrument refinement: criterion-related and 
construct validity. 
Criterion validity 
Most powerful method but no gold standard is available 
and thus unable to assess 
 
Construct validity 
As detailed in this chapter 
 
7.5.2 Reliability: Internal consistency  
The frequencies of those with and without C-POMS defined morbidity on each post-operative day 
are shown in Table 7-4. 
 
Table 7-4: Frequencies of those with and without C-POMS defined morbidity (n=450). Values are 
stated at n(%). 
Post-operative day Without C-POMS  With C-POMS Missing data 
D3 35   (7.8)  412 (91.5) 3 
D5 57 (13.4)  367 (86.1) 1 
D8   9   (2.0) 171 (94.4) 1 
D15   0   (0.0) 48    (100) 0 
 
Excluding D1, C-POMS has sufficient internal consistency (>0.7) on D3, D5, D8 and D15 such that 
a summary score for each C-POMS post-operative day can be calculated (Table 7-5).  
 
Table 7-5: Internal consistency of C-POMS 
 
 
 
 
 
 
 
 
For C-POMS, a summary score was then calculated for each participant for post-operative days 3, 
5, 8 and 15. Figure 7-1 shows the frequency of each summary score 0-13 on each post-operative 
day.  
 
 
 
 
 
 
Post-operative 
day 
Internal consistency  
D1 0.19 
D3 0.67 
D5 0.66 
D8 0.69 
D15 0.74 
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Figure 7-1: C-POMS summary score frequencies. 
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Overall, the mean C-POMS scores for D3, D5, D8 and D15 were 3.4, 2.6, 3.4 and 3.8, respectively. 
The maximum score of any participant was 11 on D3, D8 and D15 and 10 on D5 which was 
observed in one participant on D3, D5 and D15 and 3 (1.7%) on D8. The score with the highest 
frequency was 2 on D3 (18.8%) and D8 (19.9), a score of 1 for D5 (24.9%) and on D15 the same 
highest frequency was observed for a score of 1 and 2 (20.8%). No C-POMS recorded morbidity 
was identified in 7.8% on D3, 13.6 on D5, 5.0% on D8 and no participants on D15.  
 
7.5.3 Construct validity 
7.5.3.1  C-POMS summary score and subsequent LOS 
Those with C-POMS-defined morbidity on post-operative D3, D5 and D8 remain in hospital for an 
additional 4.6 (p=0.012), 5.3 days (p=0.001) and 7.6 days (p=0.135), respectively, when compared 
to those without (Figure 7-2). There were no patients without C-POMS defined morbidity on D15. 
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Figure 7-2: The mean length of post-operative length of stay between those with and without C-
POMS defined morbidity (n=450). 
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For every unit increase in C-POMS summary score there is a 1.7, 2.2, 4.5 and 6.2 day increase in 
subsequent length of stay on post-operative D3, D5, D8 and D15, respectively (Table 7-6). 
 
Table 7-6: Subsequent length of stay per unit increase in C-POMS summary score 
 Subsequent length 
of stay (days) 
p 95%CI 
D3 (n=450) 1.7 0.000 1.284-2.099 
D5 (n=426) 2.2 0.000 1.770-2.640 
D8 (n=181) 4.5 0.000 2.711-4.268 
D15 (n=48) 6.2 0.000 4.004-8.351 
 
7.5.3.2 EuroSCORE, POSSUM and Magovern score  
Table 7-7 shows the ability of EuroSCORE, POSSUM and Magovern scores to predict C-POMS 
summary score on each post-operative day. The ability to predict C-POMS summary score is only 
small in all measures on D3 and D5 and additionally with EuroSCORE on D8. On D3 for every unit 
increase in EuroSCORE, POSSUM and Magovern score there was a 0.32, 0.17 and 0.17 increase 
in C-POMS summary score, respectively (all p=0.000) while on D5 a 0.23, 0.14 and 0.15 increase 
in C-POMS summary score is observed for each of the scores, respectively (all p=0.000). 
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Table 7-7: Predictive power of EuroSCORE, POSSUM and Magovern scores on C-POMS summary 
score. 
 Level of predicting C-
POMS summary score  
p 95%CI 
EuroSCORE    
D3 (n=450) 0.32 0.000 0.245-0.384 
D5 (n=426) 0.23 0.000 0.161-0.303 
D8 (n=181) 0.19 0.003 0.065-0.320 
D15 (n=48) 0.04 0.743 -0.187-0.260 
POSSUM    
D3 (n=450) 0.17 0.000 0.127-0.206 
D5 (n=426) 0.14 0.000 0.103-0.183 
D8 (n=181) 0.06 0.061 -0.003-0.126 
D15 (n=48) 0.03 0.651 -0.100-0.158 
Magovern     
D3 (n=450) 0.18 0.000 0.104-0.233 
D5 (n=426) 0.15 0.000 0.083-0.211 
D8 (n=181) 0.12 0.057 -0.003-0.213 
D15 (n=48) 0.10 0.393 -0.138-0.341 
 
 
7.5.3.3 Domain level analysis:  
Tables detailing the full results are detailed in Appendix 7: C-POMS domain level analysis.. 
 
7.5.3.3.1 EuroSCORE 
With the exception of the infectious domain, the frequency of each domain was higher in those with 
greatest surgical risk as defined by EuroSCORE. Significant differences were observed on D3 
(64.0% vs 80.8%, p=0.000) and D5 (30.3% vs 46.7%, p=0.001) in the pulmonary domain and on D3, 
D5 and D8 in the renal (D3: 24.7% vs 54.6%, p=0.000; D5: 12.7% vs 24.2%, p=0.003; D8:18.8% vs 
35.6%, p=0.013) and cardiovascular (D3: 46.1% vs 60.4%, p=0.002; D5 42.6% vs 57.7%, p=0.002); 
D8: 50.0% vs 73.0%, p=0.002) domains. While assisted ambulation was significantly higher in those 
with predicted higher risk on all days (D3: 33.5% vs 63.7%, p=0.000; D5: 17.2% vs 41.8%, p=0.000; 
D8: 27.5% vs 46.0%, p=0.013; D15: 12.5% vs 53.1%, p=0.011), significant gastrointestinal (24.0% 
vs 38.5%, p=0.001) and endocrine (25.8% vs 37.2%, p=0.007) differences were observed on D3 
only. 
 
7.5.3.3.2 POSSUM 
With the exception of wound complication domain, the frequency of each domain was higher in 
those with greatest risk as defined by POSSUM. A significant difference was observed on both D3 
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and D5 in the pulmonary (D3: 62.2% vs 79.3%, p=0.000; D5: 26.7% vs 48.5%, p=0.000), renal (D3: 
19.4% vs 51.4%, p=0.000; D5: 8.1% vs 26.7%, p=0.000), cardiovascular (D3: 44.1% vs 59.6%, 
p=0.002; D5: 38.8% vs 57.9%, p=0.000), endocrine (D3: 22.5% vs 39.2%, p=0.000; D5: 7.6% vs 
14.4%, p=0.039) and assisted ambulation (D3: 28.8% vs 63.5%, p=0.000; D5: 16.2% vs 39.1%, 
p=0.000) domains. Assisted ambulation also had a significantly higher frequency in those with 
greater risk on D15 (13.3% vs 50.0%, p=0.023) while the infectious domain only observed a 
significantly higher frequency in those with higher risk on D8 (68.3% vs 50.0%, p=0.025). 
 
7.5.3.3.3 Magovern score 
In those with greatest risk of post-operative morbidity, as defined by the Magovern score, higher 
frequencies were not observed in at least two C-POMS domains on each post-operative day. These 
were neurological and wound domains on D3, haematolgical and wound complication domains on 
D5, infectious, haematological, wound complication and electrolyte domains on D8 and infectious, 
and haematological and wound complications on D15. However, none were statistically significant. 
All other domains did have a higher frequency in those with greatest risk on all post-operative days. 
Those with a significant difference were pulmonary, renal, cardiovascular, endocrine and assisted 
ambulation on D3 (63.6% vs 79.9%, p=0.002; 22.3% vs 47.0%, p=0.000; 46.2% vs 60.4%, p=0.011; 
19.6% vs 39.3%, p=0.000; 32.8% vs 58.4%, p=0.000, respectively) and D5 (28.0% vs 45.6%, 
p=0.001; 8.9% vs 27.2%, p=0.000; 45.2% vs 57.1, p=0.042; 3.6% vs 15.6%, p=0.000; 13.2% vs 
42.2%, p=0.000, respectively), with renal and assisted ambulation on D8 (renal: 9.4% vs 33.3%, 
p=0.002; assisted ambulation: 21.2% vs 42.3%, p=0.014) and pulmonary and assisted ambulation 
on D15 (pulmonary: 9.1% vs 47.4%, p=0.049; assisted ambulation: 0.0% vs 36.8%, p=0.029). 
 
7.5.3.4 Remaining in hospital with a C-POMS score of zero and those discharged home with 
a C-POMS score of ≥1 
There were 58 out of the 426 in-patients on D5 (13.6%) and 9 out of 181 (5.0%) in-patients on D8, 
that had a C-POMS score of ‘0’. There were no in-patients with a C-POMS score of ‘0’ on D15. As 
shown in Figure 7-3, the majority of the participants were discharged on D5 and D8 (42/58 (72.4%) 
and 8/9 (88.9%), respectively). Of those remaining in hospital (16 on D5 and 1 on D8), social and 
organisational factors delayed discharge for 9 (56.3%) on D5 and in 1 (100.0%) on D8.  
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Figure 7-3: Reasons for non-discharge in participants with a C-POMS score of 0. 
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However, while C-POMS encompassed all the medical reasons for remaining in hospital on D8, 7 of 
the 58 participants (12.1%) with a zero C-POMS score on D5, remained in hospital for a medical 
reason. These reasons were increased weight requiring treatment (2), ‘discharge planned for 
tomorrow’ (2), peripheral oedema requiring observation (1) and increased blood sugar 
measurement (but no additional treatment prescribed) (1). One participant refused to go home. 
 
Overall, on D5, D8 and D15, 55/426 (12.9%), 26/181 (14.4%) and 6/48 (12.5%) participants, 
respectively, with a C-POMS score of ≥1 were discharged from the hospital where the surgery was 
undertaken. Of those, 2/55 (3.6%) on D5, 2/26 (7.7%) on D8 and 4/6 (66.7%) on D15 were either 
transferred to another NHS hospital or discharged to a convalescence/nursing home. One 
participant with a C-POMS score of 5 died on D8. The remaining participants were discharged 
home. There were 53/426 (12.4%), 23/181 (12.7%) and 2/48 (4.2%) participants with a C-POMS 
score of ≥1 that were discharged home on D5, D8 and D15, respectively. Figure 7-4 shows the 
proportion of participants with each summary score by discharge day. 
 
 
 
 
 
 
 
 
 
 152
Figure 7-4: The proportion of participants that were discharged home while having a C-POMS score 
of ≥1. 
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Of the participants with a C-POMS score of 1 (Figure 7-5), the majority discontinued the treatment 
they were receiving (oxygen supplementation, antibiotics, pacing wires were removed), or were 
prescribed medications to be taken on discharge (antibiotics, pain (wound) medication, anti-emetics 
(GI)). There were no participants with a score of 1 that was attributable to a renal, haematological or 
electrolyte domain morbidity. 
 
Figure 7-5: C-POMS domains that were present in participants that were discharged home while 
having a C-POMS score of 1. 
0
10
20
30
40
50
60
70
80
90
100
Pu
lm
on
ary
Inf
ec
tio
us
Re
na
l GI CV
Ne
uro
Ha
em
Wo
un
d
En
do
cri
ne
Ele
ctr
oly
te
Re
vie
w
Pa
in
As
s A
mb
ula
tio
n
C-POMS domains
Pr
op
or
tio
n 
of
 p
ar
tic
ip
an
ts
 w
ith
 C
-
P
O
M
S 
sc
or
e 
>1 D5 (n=35)
D8  (n=8)
D15 (n=1)
 
The combinations of domains present for those discharged home with a C-POMS score of 2, 3 or 4 
are shown in Table 7-8. 
 
 
 
 153
Table 7-8: C-POMS domains and criteria present for participants that were discharged home with a 
C-POMS score of 2, 3 or 4. 
 Frequency 
C-POMS score 2 D5 D8 D15 
Pulmonary (O2) + Infection (antibiotics) 3 1  
Infection (antibiotics) + CV (arrhythmia) 1   
Infection (antibiotics) + GI (nausea) 1   
Infection (antibiotics) + Ambulation (sticks) 1   
Infection (antibiotics) +  Pain  1   
GI (diarrhoea) + CV (arrhythmia) 1   
GI (nausea) + CV (arrhythmia) 2   
GI (abdominal) + Neurological (blurred vision) 1   
CV (arrhythmia) + Neurological (confusion) 1   
Neurological (delirium) + Pain (continued) 1   
Pulmonary (O2 and nebs) + CV (paced)  1  
Infection (antibiotics) + CV (pulmonary oedema)  1  
CV (paced and pulmonary oedema) + Haematological (INR)  1  
CV (arrhythmia) + Renal (abnormal potassium level)  1  
Infection (antibiotics) + Haematological (INR)  1  
CV (arrhythmia) + Neurological (blurred vision)  1  
GI (nausea and diarrhoea) + CV (arrhythmia)  1  
GI (vomiting) + Endocrine  1  
Renal (creatinine) + CV (paced and arrhythmia)   1 
C-POMS score 3    
Pulmonary (O2 and nebs) + Infection (antibiotics) + GI (nausea) 1   
Pulmonary (pleural effusion) + Infection (antibiotics) + GI (abdominal) 1   
Pulmonary (O2 and nebs) + Infection (antibiotics) + CV (arrhythmia) 1   
Infection (antibiotics) + CV (arrhythmia) + Haematological (INR) 1 1  
GI (nausea) + Endocrine + Review (further review) 1   
Infection (antibiotics) + GI (diarrhoea) + Electrolyte (sodium)  1  
Infection (antibiotics) + GI (nausea and abdominal) + Endocrine  1  
Infection (antibiotics) + CV (paced, arrhythmia, pulmonary oedema) + 
Haematological (INR) 
 1  
Infection (antibiotics) + GI (nausea) + CV (arrhythmia)  1  
C-POMS score 4    
Pulmonary (O2) + Infection (antibiotics) + CV (pulmonary oedema) + 
assisted ambulation (walking sticks) 
 1  
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Overall, there were 29 domain-criteria combinations, with only 2 combinations occurring in more 
than one participant. The wound complication morbidity type was the only domain not to be present 
in any participant. 
 
7.5.3.5 Multivariate analysis 
Five domains on D3 were independently predictive of subsequent length of stay (Table 7-9). Those 
with, renal, gastrointestinal, neurological, haematological and wound complications have an 
additional 3.0, 2.2, 2.5, 3.2 and 8.4 days in hospital (post D3) than patients without those 
morbidities, regardless of whether or not they have other types of morbidity.  
 
Table 7-9: Independent predictive strength of each C-POMS domain on D3 (n=450). 
D3: C-POMS domains Adjusted difference 
in subsequent length 
of stay (days) 
p 95%CI 
Pulmonary 1.1 0.358 -1.236-3.415 
Infectious 1.5 0.175 -0.670-3.661 
Renal 3.0 0.015 0.583-5.503 
Gastrointestinal 2.2 0.034 0.175-4.310 
Cardiovascular -0.1 0.960 -2.181-2.073 
Neurological 2.5 0.026 0.309-4.765 
Haematological 3.2 0.032 0.271-6.150 
Wound complication 8.4 0.001 3.658-13.237 
Pain -2.9 0.403 -9.610-3.868 
Endocrine 0.8 0.487 -1.478-3.097 
Electrolyte -1.7 0.589 -7.977-4.535 
Review 3.4 0.222 -2.067-8.869 
Assisted ambulation 1.2 0.351 -1.278-3.589 
  
On D5 the pulmonary, renal, neurological, pain and endocrine domains were independently 
predictive of subsequent length of stay (post D5) with an extra 2.3, 3.9, 5.4, 3.7 and 3.5 days in 
hospital, respectively, for those with these morbidities than those without them (Table 7-10). 
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Table 7-10: Independent predictive strength of each C-POMS domain on D5 (n=426). 
D5: C-POMS domains Adjusted difference 
in subsequent length 
of stay (days) 
p 95%CI 
Pulmonary 2.3 0.048 0.017-4.643 
Infectious 0.6 0.535 -1.389-2.670 
Renal 3.9 0.013 0.837-7.007 
Gastrointestinal 0.5 0.634 -1.650-2.708 
Cardiovascular 0.8 0.465 -1.304-2.850 
Neurological 5.4 0.000 2.370-8.351 
Haematological 1.5 0.273 -1.168-4.128 
Wound complication 1.2 0.633 -3.769-6.194 
Pain 3.7 0.039 0.189-7.302 
Endocrine 3.5 0.040 0.157-6.915 
Electrolyte 5.4 0.101 -1.071-11.953 
Review -0.6 0.737 -4.835-3.101 
Assisted ambulation 1.7 0.202 -0.925-4.353 
 
Three domains on D8 are independently predictive of subsequent length of stay (Table 7-11). 
Those with renal, haematological or wound complications, compared to those who do not, have an 
additional 6.5, 5.7 and 24.7 days (post D8), respectively, in hospital. 
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Table 7-11: Independent predictive strength of each C-POMS domain on D8 (n=181). 
D8: C-POMS domains Adjusted difference 
in subsequent length 
of stay (days) 
p 95%CI 
Pulmonary 1.2 0.602 -3.393-5.839 
Infectious 2.4 0.194 -1.246-6.095 
Renal 6.5 0.015 1.299-11.791 
Gastrointestinal 2.5 0.252 -1.813-6.870 
Cardiovascular -1.8 0.382 -5.863-2.259 
Neurological 3.4 0.200 -1.826-8.679 
Haematological 5.7 0.01 1.382-10.084 
Wound complication 24.7 0.000 16.056-33.280 
Pain -1.8 0.652 -9.566-6.002 
Endocrine 2.7 0.435 -4.038-9.342 
Electrolyte 3.4 0.453 -5.535-12.355 
Review 0.8 0.800 -5.287-6.843 
Assisted ambulation 1.8 0.440 -2.802-6.411 
 
There were four domains that were independently predictive of subsequent length of stay on D15 
(Table 7-12).  Those with renal, pain and electrolyte morbidities had an additional 10.7, 77.4 and 
74.1 days in hospital than those that did not have those morbidities. Those with an endocrine 
morbidity on D15 had 15.1 days less in hospital than those without the morbidity. 
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Table 7-12: Independent predictive strength of each C-POMS domain on D15 (n=48). 
D15: C-POMS domains Adjusted difference 
in subsequent length 
of stay (days) 
p 95%CI 
Pulmonary 4.1 0.413 -6.075-14.415 
Infectious 6.8 0.126 -2.030-15.673 
Renal 10.7 0.049 0.063-21.357 
Gastrointestinal 2.7 0.623 -8.521-14.002 
Cardiovascular -7.3 0.111 -16.284-1.766 
Neurological -1.6 0.793 -13.889-10.700 
Haematological 1.8 0.709 -8.128-11.822 
Wound complication 5.2 0.356 -6.095-16.460 
Pain 77.4 0.000 45.917-108.989 
Endocrine -15.1 0.034 -28.908-1.235 
Electrolyte 74.1 0.000 43.265-104.840 
Review 0.7 0.925 -13.750-15.091 
Assisted ambulation 8.3 0.124 -2.406-19.092 
 
Overall, C-POMS defined morbidity explains 16.5%, 22.3%, 43.1% and 82.0% of the variance in 
subsequent length of post-operative stay on D3, D5, D8 and D15, respectively. 
 
7.6 DISCUSSION 
7.6.1 C-POMS defined morbidity and increased length of stay 
As hypothesised, participants with C-POMS defined morbidity remained in hospital longer than 
those who did not have C-POMS defined morbidity on D3 (+ 4.6 days), D5 (+ 5.3 days) and D8 (+ 
7.6 days), while no participants were without C-POMS defined morbidity on D15.  Thus, those 
without C-POMS-defined morbidity on D3 had on average a further 2.3 days in hospital, while those 
without C-POMS-defined morbidity on D5 and D8 were likely to be discharged on D5 and D8, 
respectively. This shows that the C-POMS model does appear to exhibit construct validity when 
comparing the length of subsequent stay in those with and without C-POMS defined morbidity. 
 
7.6.2 C-POMS summary score 
C-POMS also demonstrated sufficient internal consistency to be used as a summary score on D3, 
D5, D8 and D15. While a score of 1 or 2 was observed in the majority of participants on each day, a 
score of 6 or more was observed in approximately 20% of participants on D3, D8 and D15 with 
2.8% and 4.2% experiencing morbidity in 10 or more C-POMS domains on D8 and D15, 
respectively. This substantial burden of morbidity has implications not only for the patient but for the 
clinical service since a 1.7, 2.2, 4.5 and 6.3 day increase in subsequent length of stay per unit 
increase in C-POMS on D3, D5, D8 and D15, respectively, was identified. However, this will be 
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discussed in further detail later (section 9.5.6). The finding that C-POMS did not have sufficient 
internal consistency on D1 to be used as a summary score is unsurprising due to the extent of 
routine requirements in the immediate post-operative period (for example, supplementary oxygen 
support, administration of antibiotics, urinary catheter insitu, chest drains insitu, assisted ambulation) 
that would register a minimum C-POMS score of 5 for all patients on D1. This is consistent with the 
original POMS(1) and POMS validation study(93) that do not report D1 results for this reason. 
 
7.6.3 Association of pre-operative risk assessment scores on C-POMS 
EuroSCORE, POSSUM and Magovern score were only modestly associated with C-POMS 
summary score on D3 and D5 and with EuroSCORE only on D8. Such a result is consistent with 
what would be anticipated from any of the three instruments due to their limitations and the lack of 
an overall gold standard. EuroSCORE is a pre-operative risk assessment tool for post-operative 
mortality. Since complication rate does not correlate well with mortality rate(16, 17) and pre-operative 
risk prediction models for mortality significantly underestimate post-operative morbidity(6), greater 
prediction of C-POMS was not expected. The POSSUM score is used to predict post-operative 
morbidity risk but the morbidity complications included in devising the morbidity risk were arbitrarily 
set and then categorised to those having a complicated or uncomplicated recovery(90). Furthermore, 
it was developed and validated on patients undergoing general surgery only. In contrast, the 
Magovern score was developed and validated on cardiac surgical patients with a number of well-
defined major and minor morbidity outcomes. Although this score was developed in a single site 
and was unvalidated at time of publication, greater prediction of C-POMS was anticipated. Potential 
reasons for not observing this are that construct validity can vary across populations and since 
Magovern’s sample consisted of CABG only patients, was conducted in the USA, and developed 
and validated 10 years prior to C-POMS, strong associations perhaps cannot be expected. 
However, the most likely explanation is that although the Magovern score used a number of well-
defined morbidities to construct their pre-operative risk assessment score, the morbidities were not 
similar enough to those included in C-POMS, for the Magovern score to be able to accurately 
predict C-POMS. 
 
As hypothesised, C-POMS domain frequencies are higher in patients with greatest post-operative 
risk as defined by EuroSCORE (except infectious), POSSUM (except wound complication) and 
Magovern score (except neurological, wound, haematological, infection and electrolyte domains on 
certain days). Since EuroSCORE contains pre-operative pulmonary disease, renal dysfunction and 
cardiovascular conditions, it is unsurprising that significant differences were observed in the 
frequency of the pulmonary, renal and cardiovascular domains. This also applies to the POSSUM 
physiological score (which includes pulmonary, renal, cardiovascular and infection items and it was 
in these domains that a significantly higher frequency was observed in those with greatest surgical 
risk) and the Magovern score (significantly higher frequency in pulmonary, renal, cardiovascular and 
endocrine domains with items relating to these domains within the model). 
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7.6.4 New derived C-POMS domains 
Of the new domains in C-POMS, endocrine (D3 EuroSCORE and D3, D5 POSSUM and Magovern 
score) and assisted ambulation (all days EuroSCORE and Magovern score, D3, D5 and D15 
POSSUM) were also significantly higher in the higher surgical risk groups. In patients undergoing 
isolated CABG, the proportion of diabetics has increased by 33% between 2001 and 2008(25) with 
diabetes being a recognised risk factor for poorer outcome amongst patients undergoing cardiac 
surgery. Diabetics have a greater mortality rate (1.9% v 1.3 %)(25), a longer ICU(177) and post-
operative stay (9.7days v 8.2 days)(25) and a significantly higher incidence of post-operative delirium, 
peri-operative stroke, renal dysfunction, sternal instability/infection and post-operative 
reintubation(177). While 21% of patients undergoing non-cardiac surgery have undiagnosed 
diabetes(178), the proportion for those undergoing cardiac surgery is unknown. However, such 
patients will also contribute to those who exhibit endocrine domain morbidity post-operatively. 
Despite diabetes/endocrine function not being included in EuroSCORE or POSSUM, diabetic status 
does feature in the Magovern and Parsonnet(18) scores. Assisted ambulation, on the other hand, is 
only included within the neurological dysfunction definition within EuroSCORE as ‘neurological 
dysfunction severely affecting ambulation or day-to-day functioning’. Interestingly, although both 
EuroSCORE and Magovern include cerebrovascular disease in their models the C-POMS 
neurological domain was not observed to have significantly higher frequencies in those with 
greatest surgical risk. This is possibly due to the different definitions used by EuroSCORE (stated 
above) and Magovern score (‘focal brain injury documented by scan with a permanent functional 
deficit’) compared with the C-POMS definition, which includes more transient neurological 
morbidities in addition to the permanent neurological morbidities. 
 
7.6.5 Domains independently predictive of post-operative stay 
Overall, nine of the thirteen C-POMS domains (five domains on D3 (renal, GI, neurological, 
haematological, wound) and D5 (pulmonary, renal, neurological, pain, endocrine), three on D8 
(renal, haematological, wound) and four on D15 (renal, pain, endocrine, electrolyte)) independently 
predicted subsequent length of stay. Furthermore, the renal domain was independently predictive of 
subsequent length of stay at all post-operative time-points. While the results themselves are 
unsurprising, as these physiological complications are well documented in terms of prolonging 
hospital stay, this gives some assurance that the definitions used within C-POMS are producing 
expected results. The interesting aspect lies in that different domains independently predict 
subsequent length of stay on different post-operative days. There may be scope to further analyse 
this to ascertain if the presence of certain domains, or combinations of domains, in the early post-
operative period lend to a particular subsequent post-operative recovery path. Currently, the 
possibility of this is being explored with Professor John Shawe-Taylor, Head of the Department of 
Computer Science at UCL. 
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7.6.6 Extent to which C-POMS explains length of stay 
It was found that C-POMS-defined morbidity explained the variance in subsequent length of post-
operative stay by 16.5%, 22.3%, 43.1% and 82.0% on D3, D5, D8 and D15, respectively. Thus, 
other factors not accounted for within C-POMS are influencing post-operative length of stay, 
particularly on D3 and D5.  Four such influences might be suggested. Firstly, C-POMS does not 
assess patients every day and therefore some short-lived morbidities may not be identified or 
tracked. Secondly, human factors (doctor/nurse preferences, simple mistakes, minor delays) may 
also have some part in explaining the variance. Thirdly, not all morbidities may be accounted for in 
C-POMS. There were 7 (12.1% of those remaining in hospital on D5 with a C-POMS score of 0) 
with a C-POMS score of zero that remained in hospital due to a morbidity not identified by C-POMS, 
but none on D8. Finally, non-medical reasons are also likely to contribute to increased length of 
stay, since between 31%(15) and 53.9%(93) of general surgical patients have been found to be 
hospitalised for non-medical reasons. In this study it was found that 9 participants on D5 and 1 on 
D8 remained in the hospital they underwent surgery due to social or organisational reasons, 
indicating that while early discharge planning is still indicated, fewer patients remained in hospital 
due to social or organisational factors in this study.  
 
Conversely, it was found that 12.4%, 12.7% and 4.2% of participants that were in hospital on D5, 
D8 and D15 were discharged home with C-POMS-defined morbidity on those days. If C-POMS 
were a perfect measure of morbidity it would be expected that no patients would be discharged with 
any C-POMS defined morbidity. However, no instruments will measure a health-related concept 
with 100% accuracy and anomalies will always be present. For example, in terms of mortality 
prediction, the additive EuroSCORE has been found to underestimate(179), the Parsonnet score has 
been found to over estimate(180) and both scores have been found to discriminate well overall 
between favourable/non-favourable outcome but not on individual predictions(62). Furthermore, the 
predictive ability of EuroSCORE has been reported as an area under the receiver curve of between 
0.7-0.8(62, 181), indicating a fair test but not perfect which would produce an area under the receiver 
curve of 1. Other considerations are that the presence of some morbidity is acceptable to be 
discharged home with (for example, antibiotics for an infection, anti-emetics for nausea, anti-
arrhythmics for an arrhythmia) or that there is potentially some degree of unrequired treatment in 
hospital on those days (for example, a significant proportion of participants were receiving oxygen 
supplementation of the day of discharge).  
 
7.6.7 Limitations and strengths of the validation process 
The limitations in the validation process are threefold.  Firstly, the C-POMS summary score was 
derived on the basis of the internal consistency, as measured using Cronbach’s alpha, reaching the 
minimum acceptable standard of internal consistency, as described by Nunnally 1978(175). Not only 
was this minimum standard only just met but the definition itself has been contested despite it being 
commonly accepted and widely used. Such criticisms include the lack of rationale for defining 0.7 as 
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the minimum(182, 183) and that a greater number of items can artificially increase Cronbach’s alpha 
when no substantial consistency exists between items(183, 184). In light of these criticisms, it has been 
suggested that the minimum standard should not be used as a definitive rule but that researcher 
discretion be applied(183). Furthermore, it is also recognised that high alpha coefficients in a newly 
developed model may reflect the inclusion of redundant items(185). Since inter-item correlations were 
conducted to delete redundant items prior to testing the internal consistency, such items are not 
likely to be enhancing the alpha coefficient in C-POMS and thus the internal consistency identified 
for C-POMS is likely to reflect the best estimate of it’s reliability. Secondly, although indicated within 
the McMaster Framework as a necessary step in the validation of a health indices(154), the 
reliability/reproducibility step was not able to be conducted in this study. This was due to the lack of 
available personnel that could have undertaken inter-rater reliability testing. Additionally, test-retest 
reliability could not be conducted due to the changes that would occur in the participant morbidity 
profile once enough time had elapsed for such testing to be repeated. This could only have been 
achieved if the repeat data had been obtained retrospectively from the participant medical records. 
Since C-POMS is intended as a prospective model true results would potentially not be obtained. 
However, reliability/reproducibility testing would be an essential training step prior to data collection 
in the clinical setting if adopted as a routine data collection tool. Finally, although C-POMS currently 
exhibits construct validity, content validity decreases over time as new data and theories evolve(170). 
Thus, future construct validity assessments will be necessary which will potentially identify a need 
for revisions to C-POMS in order for it to remain an appropriate measure of post-operative 
morbidity(172). Methods to do this include the calculation of a content validity index (CVI) of each 
item(170, 186) or for the overall instrument(170). However, calculating the CVI in the validation of C-
POMS was unnecessary since part of C-POMS construction was based on expert panel judgments 
on the severity and importance of the morbidity items for inclusion into the model. 
 
There are also several strengths of this validation process. Conceptual frameworks were used(173), 
which included recommended content validation methods(172) that assessed both the overall 
instrument as well as each individual facet(166). Furthermore, sufficient data were collected to permit 
determination of the reasons for delayed discharge when participants remained in hospital when 
having no C-POMS defined morbidity. This enabled further exploration of the construct validity of C-
POMS and also provides useful clinical information with regards to organisational and social issues 
related discharge planning. 
 
 
7.7 CONCLUSION 
C-POMS has sufficient internal consistency to be used as a summative score to denote total 
morbidity burden on post-operative D3, D5, D8 and D15 and also appears to exhibit construct 
validity, as assessed by pre-defined hypotheses. 
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8 RESULTS V: CLINICAL UTILITY OF C-POMS 
 
8.1 INTRODUCTION TO CHAPTER 
For C-POMS to be adopted within the clinical environment, the case must be made that no existing 
tools adequately address the phenomenon under consideration(173) and that C-POMS has clinical 
utility(163). This chapter will explore both concepts in relation to C-POMS by presenting the results of 
C-POMS in quantifying post-operative morbidity, comparing C-POMS and POMS as morbidity 
outcome tools in patients undergoing cardiac surgery, and exploring the clinical utility with multi-
professional teams at 2 cardiac surgical centres.  
 
 
8.2 INTRODUCTION TO THE CLINICAL UTILITY OF C-POMS 
Although a plethora of outcome measurement instruments exist(12), the POMS tool is the only 
prospective tool for the description and quantification of post-operative morbidity identified in the 
literature (chapter 1 section 1.4). My pilot data (chapter 4) indicate that POMS may underestimate 
post-operative morbidity in patients undergoing cardiac surgery and certainly, the generalisability of 
POMS to cardiac surgery patients remains unclear(93).  Furthermore, multifactorial models are 
generally poorly integrated into clinical practice(72) due to their complexity and requirement on 
clinical variables that are not readily attainable(57, 72) making them impractical to use. Nonetheless, 
whilst efforts were made to try to maintain simplicity, the clinical utility of C-POMS (in terms of 
length and ease of completion(173)), both on an individual patient level and as a tool to be 
administered for all patients undergoing cardiac surgery, requires assessment. 
 
 
8.3 AIMS 
a. To quantify post-operative morbidity after cardiac surgery using the C-POMS tool 
b. To determine whether C-POMS does provide benefit over POMS in defining and quantifying 
post-operative morbidity in cardiac patients, by 
i. assessing the construct validity of POMS on the study population 
ii. comparing the results of C-POMS (chapter 7) and POMS 
c. To explore the utility of C-POMS in clinical practice, by 
i. exploring the potential use of C-POMS as a routine data collection tool with 
the PDG (described chapter 2 section 2.4.2) 
ii. obtaining the opinions of others at the 2011 annual scientific meeting of the 
SCTS, following presentation of the results. 
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8.4 METHODS 
8.4.1 Quantifying post-operative morbidity using C-POMS 
The proportion of participants with the presence of each C-POMS domain and criteria, on each 
post-operative day, was calculated. 
 
8.4.2 Applying POMS to the study population 
The internal consistency and construct validity analysis applied to C-POMS, as detailed in the 
model validation chapter, were applied to POMS. 
 
8.4.3 To explore the utility of C-POMS in clinical practice 
The utility of C-POMS in clinical practice was explored through a variety of meetings:  
o with the PDG,  
o at the London Chest Hospital, London, UK. 
 
 
8.5 RESULTS 
8.5.1 Quantifying post-operative morbidity using C-POMS 
The proportion of participants with the presence of each C-POMS domain is shown in Figure 8-1. 
The full breakdown of the proportion of participants with the presence of each C-POMS criterion is 
shown in Table 8-1. 
 
Figure 8-1: Proportion of participants with the presence of each C-POMS domain. 
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Table 8-1: Proportion of patients with each C-POMS criteria. Values are n(%). Criteria defining the morbidity types are not mutually exclusive. 
Morbidity type and criteria      
 Post-op D1 
(n=450) 
Post-op D3 
(n=450) 
Post-op D5 
(n=426) 
Post-op D8 
(n=181) 
Post-op D15 
(n=48) 
Pulmonary 
       Supplementary oxygen or support  
       Pleural effusion requiring drainage 
449 (99.8) 
449 (99.8) 
   4    (0.9) 
318 (70.7) 
304 (67.6) 
  14   (3.1) 
159 (37.3) 
139 (32.6) 
  38   (8.9) 
  68 (37.6) 
  64 (35.4) 
  12   (6.6) 
  19 (39.6) 
  19 (39.6) 
    1   (2.1) 
Infectious 
       Antibiotics 
       Pyrexia (>380C) 
       WCC/CRP level requiring review 
380 (84.4) 
376 (83.6) 
  19   (4.2) 
    0   (0.0) 
121 (26.9) 
109 (24.2) 
  21   (4.7) 
    9   (2.0) 
155 (36.4) 
152 (35.7) 
    5   (1.2) 
    5   (1.2) 
102 (56.4) 
100 (55.2) 
    2   (1.1) 
    6   (3.3) 
  28 (58.3) 
  28 (58.3) 
    1   (2.1) 
    0   (0.0) 
Renal 
       Decreased urine output 
       Creatinine >30% pre-op) 
       Urinary catheter insitu 
       Urinary incontinence 
       Serum K level requiring treatment 
449 (99.8) 
207 (46.0) 
  26   (5.8) 
448 (99.6) 
    0   (0.0) 
    1   (0.2) 
160 (35.6) 
  53 (11.8) 
  56 (12.4) 
142 (31.6) 
    4  (0.9) 
    0  (0.0) 
  75 (17.6) 
  31   (7.3) 
  25   (5.9) 
  61 (14.3) 
    3   (0.7) 
    1   (0.2) 
  51 (28.2) 
  14   (7.7) 
  21 (11.6) 
  33 (18.2) 
    3   (1.7) 
    2   (1.1) 
  19 (39.6) 
    6 (12.5) 
  10 (20.8) 
  13 (27.1) 
    0   (0.0) 
    3   (6.3) 
Gastrointestinal 
       Nausea 
       Vomiting 
       Abdominal distention 
       NG tube 
       GI bleed 
       Diarrhoea 
235 (52.2) 
223 (49.6) 
  79 (17.6) 
    6   (1.3) 
  10   (2.2) 
    1   (0.2) 
    0   (0.0) 
134 (29.8) 
  92 (20.4) 
  21   (4.7) 
  20   (4.4) 
  20   (4.4) 
    1   (0.2) 
  22   (4.9) 
116 (27.2) 
  75 (17.6) 
  11   (2.6) 
  22   (5.2) 
  18   (4.2) 
    1   (0.2) 
  21   (4.9) 
  50 (27.6) 
  31 (17.1) 
    2   (1.1) 
    8   (4.4) 
  12   (6.6) 
    0   (0.0) 
    9   (5.0) 
  13 (27.1) 
    5 (10.4) 
    0   (0.0) 
    8 (16.7) 
    7 (14.6) 
    1   (2.1) 
    2   (4.2) 
Cardiovascular 318 (70.7) 233 (51.8) 208 (48.8) 113 (62.4)   31 (64.6) 
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       Inotropic therapy 
       Paced 
       Pacing wires 
       MI or ischaemia 
       Hypotension 
       Atrial or vent arrhythmia 
       Cardiogenic pulmonary oedema  
       Hypertension  
111 (24.7) 
114 (25.3) 
NA 
  15   (3.3) 
142 (31.6) 
  93 (20.7) 
  44   (9.8) 
  82 (18.2) 
  31   (6.9) 
  42   (9.3) 
NA  
    4 (40.9) 
  58 (12.9) 
152 (33.8) 
  60 (13.3) 
  22   (4.9) 
    7   (1.6) 
  30   (7.0) 
    9   (2.1) 
    0   (0.0) 
  26   (6.1) 
162 (38.0) 
  56 (13.1) 
  16   (3.8) 
    3   (1.7) 
  21 (11.6) 
    1   (0.6) 
    0   (0.0) 
    9   (5.0) 
  86 (47.5) 
  41 (22.7) 
    4   (2.2) 
    0   (0.0) 
    6 (12.5) 
    1   (2.1) 
    0   (0.0) 
    6 (12.5) 
  25 (52.1) 
    8 (16.7) 
    1   (2.1) 
Neurological 
       Confusion 
       Delirium 
       Focal deficit 
       Coma 
       Agitated 
       Lack of coordination 
       Drowsy/slow to wake 
       Poor swallow 
       Blurred vision 
       Sedated 
       Changing level of consciousness 
116 (25.8) 
  35  (7.8) 
  29  (6.4) 
    2  (0.4) 
    2  (0.4) 
    8  (1.8) 
    6  (1.3) 
    7  (1.6) 
    1  (0.2) 
  26  (5.8) 
  16  (3.6) 
    0  (0.0) 
108 (24.0) 
  26   (5.8) 
  44   (9.8) 
    6   (1.3) 
    1   (0.2) 
  10   (2.2) 
    3   (0.7) 
    1   (0.2) 
    1   (0.2) 
  23   (5.1) 
    8   (1.8) 
    1   (0.2) 
  58 (13.6) 
  18   (4.2) 
  19   (4.5) 
    7   (1.6) 
    1   (0.2) 
    0   (0.0) 
    4   (0.9) 
    0   (0.0) 
    0   (0.0) 
    8   (1.9) 
    6   (1.4) 
    0   (0.0) 
  37 (20.4) 
  15   (8.3) 
    4   (2.2) 
    7   (3.9) 
    1   (0.6) 
    3   (1.7) 
    0   (0.0) 
    1   (0.6) 
    1   (0.6) 
    5   (2.8) 
    8   (4.4) 
    1   (0.6) 
  10 (20.8) 
    5 (10.4) 
    0   (0.0) 
    0   (0.0) 
    1   (2.1) 
    0   (0.0) 
    0   (0.0) 
    2   (4.2) 
    0   (0.0) 
    0   (0.0) 
    2   (4.2) 
    0   (0.0) 
Haematological 
       Untherapeutic INR       
       RBC 
       Platelets 
       FFP 
127 (28.2) 
  70 (15.6) 
  63 (14.0) 
    3   (0.7) 
  10   (2.2) 
  59 (13.1) 
  49 (10.9) 
  11   (2.4) 
    1   (0.2) 
    0   (0.0) 
  70 (16.4) 
  65 (15.3) 
    6   (1.4) 
    0   (0.0) 
    0   (0.0) 
  48 (26.5) 
  40 (22.1) 
    8   (4.4) 
    0   (0.0) 
    0   (0.0) 
    9 (18.8) 
    5 (10.4) 
    4   (8.3) 
    0   (0.0) 
    0   (0.0) 
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      Cryoprecipiate     2   (0.4)     0   (0.0)     0   (0.0)     0   (0.0)     0   (0.0) 
Wound complication 
       Surgical exploration 
       Drainage 
       Chest drains 
       Wound pain 
449 (99.8) 
    1   (0.2) 
449 (99.8) 
449 (99.8) 
  18 (4.0) 
  19   (4.2) 
    0   (0.0) 
  11   (2.4) 
  10   (2.2) 
    8   (1.8) 
  17   (4.0) 
    2   (0.5) 
    7   (1.6) 
    6   (1.4) 
  10   (2.3) 
  13   (7.2) 
    3   (1.7) 
  11   (6.1) 
    4   (2.2) 
    2   (1.1) 
  12 (25.0) 
    0   (0.0) 
  11 (22.9) 
    0   (0.0) 
    1   (2.1) 
Pain 430 (95.6)     9   (2.0)   33   (7.7)   14   (7.7)     3   (6.3) 
Endocrine 436 (96.9) 137 (30.4)   48 (11.3)   26 (14.4)   10 (20.8) 
Electrolyte 
       Na 
       Urea 
       Phosphate 
    4  (0.9) 
    1  (0.2) 
    0  (0.0) 
    3  (0.7) 
  10   (2.2) 
    0   (0.0) 
    9   (2.0) 
    1   (0.2) 
    9   (2.1) 
    3   (0.7) 
    6   (1.4) 
    0   (0.0) 
    8   (4.4) 
    4   (2.2) 
    4   (2.2) 
    0   (0.0) 
    1   (2.1) 
    0   (0.0) 
    1   (2.1) 
    0   (0.0) 
Review 
       Clinical review 
       Investigation or procedure 
    0 (0.0) 
    0 (0.0) 
    0 (0.0) 
  13   (2.9) 
    9   (2.0) 
    4   (0.9) 
  25   (5.9) 
  15   (3.5) 
  10   (2.3) 
  18   (9.9) 
  10   (5.5) 
    8   (4.4) 
    6 (12.5) 
    4   (8.3) 
    3   (6.3) 
Ambulation 
       Wheelchair 
       Crutches 
       Zimmer frame 
       Walking sticks 
       Bedbound 
       With assistance 
       Attached to equipment 
448 (99.6) 
    1   (0.2)  
    0   (0.0) 
    0   (0.0) 
    0   (0.0) 
  29   (6.4) 
418 (95.9) 
    0   (0.0) 
205 (45.6) 
    0   (0.0) 
    0   (0.0) 
    5   (1.1) 
  10   (2.2) 
  78 (17.3) 
  99 (22.0) 
  13   (2.9) 
118 (27.7) 
    0   (0.0) 
    0   (0.0) 
  10   (2.3) 
  17   (4.0) 
  40   (9.4) 
  44 (10.3) 
    7  (1.6) 
  68 (37.6) 
    0   (0.0) 
    0   (0.0) 
  10   (5.5) 
    8   (4.4) 
  27 (14.9) 
  19 (10.5) 
    4   (2.2) 
  19 (39.6) 
    0   (0.0) 
    0   (0.0) 
    3   (6.3) 
    6 (12.5) 
  10 (20.8) 
    3   (6.3) 
    0   (0.0) 
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Overall, D1 is a poor discriminator in 7 domains (pulmonary, infectious, renal, wound complication, 
pain, endocrine and ambulation) primarily due to routine care requirements. For example, oxygen 
supplementation and the presence of a urinary catheter are standard on D1, hence pulmonary and 
renal domains are present in 99.8% of participants. The highest level of morbidity on D3 was 
observed in the pulmonary domain (70.7%), on D5 and D8 in the cardiovascular domain (48.8% 
and 62.4%, respectively) and on D15 in the infectious domain (58.3%). Unsurprisingly, the 
proportion of participants requiring further review increased steadily over the post-operative stay 
(D3 2.9%, D5 5.9%, D8 9.9% and D15 12.5%). GI complications were seen in just over a quarter of 
patients on D3-D15, mainly attributable to nausea on D3-D8, and abdominal distention and the 
presence of an NG tube on D15. For the other domains, the criteria that considerably contributed to 
each were supplementary oxygen (pulmonary), antibiotic use (infectious), urinary catheter in situ 
(renal), MI/ischaemia (D3) and atrial/ventricular arrhythmias (D5-D15) (cardiovascular), 
untherapeutic INR (haematological), drainage (wound complication), urea abnormalities (electrolyte), 
clinical review (review) and with a requirement for assistance with mobilisation/bedbound 
(ambulation). The proportion of the presence of the neurological domain criteria were much more 
spread, although confusion and delirium did contribute to at least half of the identified neurological 
domain morbidity. 
 
8.5.2 Applying POMS to the study population and comparison with C-POMS 
8.5.2.1 Internal consistency 
The frequency of those with and without POMS-defined morbidity on each post-operative day is 
shown in Table 8-2. 
 
Table 8-2: Frequency of those with and without POMS-defined morbidity. Values are stated at n(%). 
Post-operative day Without POMS  With POMS Missing data 
D3 (n=450)   58 (12.9) 390 (86.7) 2 (0.4) 
D5 (n=426) 110 (25.8) 316 (74.2) 0 (0.0) 
D8 (n=181)   21 (11.6) 159 (87.8) 1 (0.6) 
D15 (n=48)     4  (8.3)   44 (91.7) 0 (0.0) 
 
As expected, since all POMS domains and criteria were included in C-POMS, there were fewer 
participants with POMS-defined morbidity on each post-operative day. Conversely, that means that 
on each post-operative day a greater proportion of in-patient participants (up to 25.8% on D5) had 
no-recorded morbidity.  
 
Only D15 for POMS shows minimum level of internal consistency (≥0.7) (Table 8-3).  
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Table 8-3: Internal consistency of POMS. 
 
 
 
 
 
 
 
 
For POMS, a summary score was then calculated for each participant for post-operative D15 only. 
Table 8-4 shows the frequency of each summary score. 
 
Table 8-4: POMS summary score frequencies. Value n(%). 
Score Frequency 
0   4   (8.3) 
1 14 (29.2) 
2 13 (27.1) 
3   4   (8.3) 
4   4  (8.3) 
5   3  (6.2) 
6   3  (6.2) 
7   3  (6.2) 
8   0  (0.0) 
9   0  (0.0) 
 
The maximum POMS score of any participant was 7, with the highest frequency of participants 
having one recorded morbidity. The mean score was 2.5 and there were 8.3% of participants with 
no POMS-defined morbidity.  
 
8.5.2.2 Construct validity 
8.5.2.2.1 POMS summary score and subsequent LOS 
Participants with POMS-defined morbidity on post-operative D3, D5 and D8 remain in hospital for an 
additional 4.8 (p=0.001), 5.1 days (p=0.000) and 6.9 days (p=0.047), respectively, compared to those 
without such morbidity on those days (Figure 8-2). No significant difference was observed between 
those with and without POMS-defined morbidity on D15 (p=0.296). 
 
 
 
Post-operative day POMS  
D1 0.07 
D3 0.49 
D5 0.56 
D8 0.63 
D15 0.66 
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Figure 8-2: Subsequent length of post-operative stay comparing those with an without POMS 
defined post-operative morbidity. 
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For every unit increase in POMS summary score on D15 there is an 8.2 day (95% CI 5.223-11.213, 
p=0.000) increase in subsequent length of stay. 
 
8.5.2.2.2 EuroSCORE, POSSUM and Magovern score  
Table 8-5 shows that EuroSCORE, POSSUM and Magovern scores do not predict POMS summary 
score on D15. A negative relationship between EuroSCORE and POSSUM with POMS summary 
score on D15 is observed (for every unit increase in EuroSCORE or POSSUM there is a 0.03 or 
0.20 decrease in POMS summary score, respectively) while for every unit increase in Magovern 
score a statistically non-significant 0.013 increase in POMS score is observed. 
 
Table 8-5: Predictive power of EuroSCORE, POSSUM and Magovern scores on POMS summary 
score.  
 Level of predicting POMS 
summary score  
p 95%CI 
EuroSCORE    
D15 -0.03 0.684 -0.198-0.131 
POSSUM    
D15 -0.20 0.676 -0.116-0.076 
Magovern     
D15 0.013 0.889 -0.174-0.200 
 
8.4.1.1.1 Domain level analysis:  
Tables detailing the full results are detailed in Appendix 8: POMS domain level analysis.. 
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8.5.2.2.2.1 EuroSCORE 
The frequency of each domain was higher in those with greatest surgical risk as defined by 
EuroSCORE with the exception of the infectious domain on D3, D5 and D8, the cardiovascular 
domain on D3 and D15, the wound complication domain on D8 and D15 and the neurological 
and haematological domains on D15. Significant differences were observed on D3 in the 
pulmonary (79.9% vs 59.2%, p=0.000), renal (50.0% vs 23.6%, p= 0.000), gastrointestinal 
(32.4% vs 19.9%, p=0.003) and haematological domain (4.9% vs 1.1%, p=0.017), on D5 in the 
pulmonary (36.3% vs 19.3%, p=0.000), renal (22.0% vs 11.1%, p=0.003) and cardiovascular 
domain (51.6% vs 36.9%, p=0.003) and on D8 in the cardiovascular domain only (65.0% vs 
48.8%, p=0.034). However, on D3 the highest frequency of cardiovascular morbidity as defined 
by POMS was observed in those with lowest pre-operative risk as defined by EuroSCORE 
(53.6% vs 50.0%, p=0.026) and there were no significant differences observed on D15. 
 
8.5.2.2.2.2 POSSUM 
The frequency of each domain on D3 and D5 was higher in those with higher risk as defined by 
the POSSUM physiological score and significantly higher on both days in the pulmonary (D3: 
77.9% vs 42.3%, p=0.000; D5: 36.1% vs 17.1%, p=0.000), renal (D3: 50.5% vs 36.1%, p=0.003; 
D5: 24.8% vs 6.2%, p=0.000) and cardiovascular domains (D3: 50.5% vs 36.1%, p=0.003; D5: 
50.5% vs 34.8%, p=0.001) and in the neurological domain on D3 only (22.1% vs 14.1%, 
p=0.033). A higher frequency was observed in those with greatest risk in all domains on D8 and 
D15, with the exception of the cardiovascular domain (D15), wound complication domain (D8 
and D15) and the infectious domain (D8 and D15) which was significantly different on D8 
(66.7% vs 49.1%, p=0.037). 
 
8.5.2.2.2.3 Magovern score 
A higher frequency of each domain was observed in those with greatest risk as defined by the 
Magovern score with the exception of the pulmonary and neurological domains on D3, 
infectious, and wound complications domains on D8 and the infectious, gastrointestinal, 
cardiovascular and haematological domains on D15. Significant differences were observed in 
the renal domain on D3, D5 and D8 (45.0% vs 21.7%, p=0.000; 25.2% vs 7.1%, p=0.000; 
28.2% vs 9.4%, p=0.014, respectively), pulmonary domain on D5 and D15 (36.7% vs 17.9%, 
p=0.000; 36.8% vs 0.0%, p=0.029, respectively) and also on D3 although the higher frequency 
was observed in the lower risk group (55.3% vs 44.7%, p=0.000).  
 
8.5.2.3 Remaining in hospital with a POMS score of zero and those discharged home with a 
POMS score of ≥1 
On D15, there were 4 (8.3%) participants that had a POMS score of zero but remained in hospital. 
One participant was discharged to a nursing home on D15 while 3 participants were transferred on 
D16, D20, D22 to their local hospitals, having a total length of hospital stay of 18 days, 21 days and 
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57 days, respectively. Conversely, on D15 2 (4.2%) participants were discharged home with a POMS 
score of ≥1. One participant scored 1 (cardiovascular domain) and 1 participant scored 2 
(cardiovascular and renal domains).  
 
Due to the lack of sufficient internal consistency to calculate a POMS summary score on D5 and D8, 
comparisons can only be made in those with and without POMS-defined morbidity. It was observed 
that of those with no POMS-defined morbidity 110 (25.8%) and 21 (11.6%) remained in hospital on 
D5 and D8, respectively. The reasons for remaining in hospital are detailed in Figure 8-3. 
 
Figure 8-3: Reasons for non-discharge in participants with no POMS-defined morbidity. 
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Furthermore, 42 (9.9%) and 21 (11.6%) of participants were discharged home on D5 and D8, 
respectively, that were suffering from some POMS-defined morbidity. 
 
8.5.2.4 Multivariate analysis 
Three domains on D3 were independently predictive of subsequent length of stay (Table 8-6). 
Those with renal, haematological and wound complication morbidities as defined by POMS have an 
additional 3.8, 10.1 and 11.8 days in hospital (post D3) than participants without those morbidities.  
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Table 8-6: Independent predictive strength of each POMS domain on D3. 
D3: POMS domains Adjusted difference 
in subsequent 
length of stay 
(days) 
95% CI P  
Pulmonary 2.1 -0.028-4.243 0.053 
Infectious 2.0 -0.166-4.140 0.070 
Renal 3.8 1.638-6.038 0.001 
Gastrointestinal 1.5 -0.599-3.633 0.160 
Cardiovascular 0.076 -1.906-2.058 0.940 
Neurological 1.6 -0.898-4.000 0.214 
Haematological 10.1 4.165-16.048 0.001 
Wound complication 11.8 5.464-18.122 0.000 
Pain -4.395 -11.198-2.408 0.205 
  
On D5, the pulmonary, renal and neurological domains are independently predictive of subsequent 
length of stay (post D5) with an extra 3.8, 5.9 and 5.6 days in hospital, respectively, for those with 
these morbidities than those without them (Table 8-7). 
 
Table 8-7: Independent predictive strength of each POMS domain on D5. 
D5: POMS domains Adjusted difference 
in subsequent 
length of stay 
(days) 
95% CI p 
Pulmonary 3.8 1.249-6.345 0.004 
Infectious 0.7 -1.356-2.689 0.517 
Renal 5.9 2.774-8.958 0.000 
Gastrointestinal 0.6 -1.713-2.817 0.632 
Cardiovascular 0.5 -1.538-2.446 0.654 
Neurological 5.6 2.425-8.761 0.001 
Haematological -0.1 -8.126-7.895 0.977 
Wound complication 10.9 2.625-19.215 0.10 
Pain 7.2 1.050-13.414 0.22 
 
Three domains are independently predictive of subsequent length of stay post D8 (Table 
8-8).Those with renal, haematological and wound complications, as defined by POMS, have an 
additional 5.9, 32.2 and 21.5 days in hospital, respectively, when compared to those participants 
where these morbidities were not observed. 
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Table 8-8: Independent predictive strength of each POMS domain on D8. 
D8: POMS domains Adjusted difference 
in subsequent 
length of stay 
(days) 
95%CI p 
Pulmonary -0.4 -5.104-4.245 0.856 
Infectious 2.6 -0.573-5.865 0.106 
Renal 5.9 1.289-10.586 0.013 
Gastrointestinal 1.4 -2.448-5.297 0.469 
Cardiovascular -0.5 -3.683-2.704 0.762 
Neurological 4.5 -0.174-9.266 0.059 
Haematological 32.2 23.531-40.908 0.000 
Wound complication 21.5 13.251-29.757 0.000 
Pain 1.6 -7.197-10.299 0.727 
 
On D15, the pulmonary and pain domains were independently predictive of subsequent length of 
stay with an additional 22.2 and 46.8 days in hospital, respectively, when compared to those 
without these morbidities on D15 (Table 8-9) 
 
Table 8-9: Independent predictive strength of each POMS domain on D15. 
D15: POMS domains Adjusted difference 
in subsequent 
length of stay 
(days) 
95%CI p  
Pulmonary 22.2 7.403-37.026 0.004 
Infectious 4.5 -6.673-15.668 0.420 
Renal 2.2 -12.020-16.498 0.752 
Gastrointestinal 12.4 -5.082-29.796 0.159 
Cardiovascular -4.3 -15.337-6.810 0.440 
Neurological -1.1 -15.554-13.453 0.884 
Haematological -3.7 -21.825-14.372 0.679 
Wound complication 8.7 -7.357-24.673 0.280 
Pain 46.8 9.787-83.906 0.015 
 
Overall, POMS-defined morbidity explains the variance in subsequent length of post-operative stay 
by 16.8%, 21.7%, 55.1% and 62.4% on D3, D5, D8 and D15, respectively. 
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8.5.3 To explore the utility of C-POMS in clinical practice 
8.5.3.1 The PDG  
The PDG thought C-POMS was fundamentally useful. The PDG recognised the potential of C-
POMS in the hospital, departmental and individual quality profile and as a patient outcome measure, 
where the identification of the presence and frequency of each domain is as useful as using the 
overall score. It was agreed that C-POMS should be a routine data collection tool at the Heart 
Hospital, and thus the discussion mainly focused on how this could be achieved. Consideration was 
given to data collection personnel, data quality, database management and the longer-term 
sustainability of the routine collection of C-POMS data on all cardiac surgical patients. For this long-
term strategy it was suggested that the Hospital Directors would need to be persuaded of the 
usefulness of the tool in order to gain support, and in particular, funding for a dedicated data 
collector. To achieve this, it is necessary to provide evidence of C-POMS being successfully 
integrated into clinical practice, with demonstrable application. Thus, in the short-term it was agreed 
that the data would be collected by the Senior House Officer allocated to audit each week and to 
ease the administrative burden, data would be entered directly onto a PDA (Personal Digit 
Assistant), supported through departmental funds. Data quality would be overseen by Dr Andrew 
Smith, who would lead on this initiative at the Heart Hospital. Support was formally given by the 
Heart Hospital Clinical Director and work is currently underway to commence data collection in the 
near future. 
 
8.5.3.2 London Chest Hospital, London, UK. 
Following my oral presentation at the SCTS 2011 meeting, discussion was initiated with 
representatives from the London Chest Hospital, who have developed a Microsoft Access database 
to collect ICU outcome data. For example, on a daily basis and for each patient, if a patient is 
considered by the Consultant to be following a routine recovery trajectory then no data are collected. 
For patients not considered not to be following a normal post-operative course, the reasons for this 
assessment are selected from a defined list. Furthermore, the database programme provides 
summary data ‘at the click of a button’.  It was agreed that a pilot study merging the C-POMS tool 
onto the London Chest Hospital database and to commence data collection at the London Chest 
Hospital, led by Dr Alex Shipolini, would be advantageous. Initial work on adding C-POMS to the 
database is underway, with Figure 8-4 showing a screen shot of the progress made thus far. 
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Figure 8-4: Screenshot of C-POMS database. 
 
 
8.5.3.3 The Heart Hospital and London Chest Hospital collaboration 
Discussions concluded that the London Chest Hospital would be happy to collaborate with the 
Heart Hospital and provide them with a copy of the database so that data is collected identically at 
each site. Furthermore, it was agreed that anonymised merged data from both sites would be used 
for analysis, particularly in relation to determining pre-operative risk factors of C-POMS. 
 
 
8.6 DISCUSSION  
8.6.1 Applying POMS to cardiac patients 
Comparison of the results from the construct validity of C-POMS (chapter 7) and POMS (this 
chapter) suggests that the POMS has noticeably less construct validity than C-POMS when applied 
to patients undergoing cardiac surgery. Firstly, as summarised in Figure 8-5, there are considerably 
more participants without POMS defined morbidity remaining in hospital than C-POMS defined 
morbidity on D3, D5, D8, and D15.  
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Figure 8-5: Proportion of participants without POMS and C-POMS-defined morbidity. 
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Furthermore, whist those without POMS-defined morbidity on D15 remained in hospital due to non-
medical reasons, POMS failed to capture all relevant morbidity on D5 and D8, with 33.6% and 
28.6%, respectively, remaining in hospital for a medical reason. In contrast, C-POMS captured all 
the morbidity in 87.9% and 100% of in-patients on D5 and D8, respectively. Secondly, while C-
POMS had sufficient internal consistency on D3, D5, D8 and D15 to be used as a summary score, 
POMS only exhibited sufficient internal consistency on D15. As expected, due to the proportion of 
medical reasons for remaining in hospital not accounted for in POMS, the comparison of C-POMS 
and POMS summary scores on D15 highlights that fact since C-POMS has a higher mean summary 
score (3.8 vs 2.5) and higher maximum score (11 vs 7). However, although there was no predictive 
power of EuroSCORE, POSSUM or Magovern score on D15 POMS summary score, this was also 
true for D15 C-POMS summary score, despite a small predictive ability being observed from the 
three pre-operative risk assessment scores on the other assessment days. Thirdly, while similar 
results were observed between POMS and C-POMS in the domain level analysis for the domains 
observed in both models, significant differences were also observed in the newly constructed 
endocrine and assisted ambulation C-POMS domains across EuroSCORE, POSSUM and 
Magovern score. Fourthly, the domains that were independently predictive of subsequent length of 
stay using POMS and C-POMS tools were the same for D8 (renal, haematological and wound 
complication) and similar for D3 (renal, haematological and wound complications), D5 (pulmonary, 
renal and neurological) and D15 (pain). Additionally, the following C-POMS domains were also 
being independently predictive: Gastrointestinal (D3), neurological (D3), pain (D5), endocrine (D5, 
D15), renal (D15) and electrolyte (D15).  Finally, whilst C-POMS- and POMS-defined morbidity 
explain similar variance in subsequent length of stay on D3 (16.5% vs 16.8%) and D5 (22.3% vs 
21.7%), C-POMS-defined morbidity explains considerably more of the variance than POMS-defined 
morbidity on D15 (82.0% vs 62.4%) but less on D8 (43.1% vs 55.1%). 
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While POMS alone exhibits some features of being a useful tool in describing and quantifying post-
operative morbidity in cardiac surgery patients, POMS does appear to underestimate post-operative 
morbidity in cardiac patients and has considerably less construct validity than C-POMS. However, 
POMS domains and criteria were deliberately retained within the C-POMS model in order to benefit 
from the advantages of both generic and disease-specific instruments in the clinical environment. 
This allows the use of POMS as a generic tool that permits comparison across different patient 
populations(166). For example, POMS has been used and validated in urological, orthopaedic and 
general surgery patients(93), while the cardiac-specific amendments included to create C-POMS 
provide the greater specificity of a condition specific instrument(187). This has use in assessing 
changes over time(188), accurately predicting outcomes and utilization of health services(189). 
 
8.6.2 Clinical utility of C-POMS 
One of the most useful aspects of C-POMS when compared to POMS is the ability to use it as a 
summary score on D3, D5, D8 and D15, compared with only D15 for POMS. Summary scales 
provide an easy method of scoring and are readily interpretable(173). The Heart Hospital and London 
Chest Hospital recognised the usefulness of this characteristic and the potential such a tool 
provides in morbidity measurement after cardiac surgery. Both hospitals agreed to use C-POMS as 
a routine data collection tool for post-operative morbidity and to collaborate by analyzing 
anonymised joint data. Furthermore, if other hospital sites were interested in using C-POMS the 
package of C-POMS on the pre-developed database would be offered. Overall, there was 
considerable enthusiasm for piloting C-POMS in clinical practice at these sites and to work 
collaboratively. Thus, at this early stage, C-POMS has been well received within the cardiac 
surgical profession. Further analysis of this will occur over time as the pilot data is collected, and if 
other surgical units come on board. Ultimately, if C-POMS continues to be well received and its 
usefulness demonstrated, the aim would be for C-POMS data collection to be included in the SCTS 
dataset in all UK cardiac surgical centres. 
 
8.7 CONCLUSION 
C-POMS has greater construct validity and more appropriately identifies and quantifies post-
operative morbidity than POMS after cardiac surgery. C-POMS has been evaluated favorably from 
a clinical perspective with efforts now underway to introduce C-POMS as a routine data collective 
tool at two hospitals. 
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9 DISCUSSION  
 
9.1 INTRODUCTION TO CHAPTER 
This chapter aims to bring together the overarching discursive elements concerning this work. 
However, a summary of the work undertaken will first be provided. This will be followed by an 
update on the work conducted by the SCTS, international cardiac registries and the literature since 
commencement of the study. The use of C-POMS as a morbidity outcome measure will be 
discussed, as will the limitations and strengths of C-POMS as a tool, the methodological strengths 
and weaknesses of the study and potential future work. Finally, the overall conclusions reached 
from this work will conclude the chapter.  
 
 
9.2 SUMMARY OF THESIS 
Post-operative morbidity, being more common than mortality, may be a more valid outcome 
measure. However, there has been very little emphasis placed on morbidity outcome measurement 
after cardiac surgery, both nationally and internationally. Primarily this is due to the difficulty in 
defining post-operative morbidity thus making its measurement difficult. However, morbidity is now 
recognised as a complementary and independent component of quality of care.  Despite this, the 
POMS tool(1) is the only published prospective tool for assessing the incidence and pattern of post-
operative morbidity in orthopaedic, urological, vascular, gynaecological and general surgical 
patients. Hence, the aims and objectives of this thesis were to: 
• Develop and validate a system (C-POMS) to describe and quantify in-hospital post-
operative morbidity in patients undergoing cardiac surgery,  
• Explore the applicability of POMS in describing and quantifying post-operative morbidity in 
patients undergoing cardiac surgery and  
• Assess the utility of a post-operative morbidity survey for the description of in-hospital 
morbidity following cardiac surgery.  
 
9.2.1 Development of C-POMS 
The development of C-POMS was established using clinimetric principles through prospective data 
collection of 450 patients undergoing cardiac surgery between 2005-2007. Data collection 
comprised POMS criteria, cardiac specific indices determined by a PDG and free-text for 
morbidities not captured by the POMS criteria and was collected on D1, D3, D5, D8 and D15, if they 
remained an in-patient on those days. Analysis of the free-text identified 175 additional morbidities 
that went through an item reduction process using inter-item and inter-domain correlations, and an 
inclusion criteria of: prevalence >5%, missingness <5%, a mean severity-importance score  ≥8 and 
expert panel consideration of whether the item would be identified by a POMS criteria. POMS 
criteria and Items that met at least two of the criteria were considered for entry into C-POMS. The 
result was a 13 domain tool.  
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9.2.2 Reliability and validity testing of C-POMS 
Reliability testing of C-POMS demonstrated sufficient internal consistency to be used as a summary 
score to denote total morbidity burden on D3, D5, D8 and D15. The mean C-POMS score for D3, 
D5, D8 and D15 was 3.4, 2.6, 3.4 and 3.8, respectively and for every unit increase in C-POMS 
summary score there is a 1.7 (D3), 2.2 (D5), 4.5 (D8) and 6.2 (D15) day increase in subsequent 
length of stay (all p=0.000). Due to lack of a gold standard, construct validity was assessed through 
the testing of 5 hypotheses. The key findings were that those with C-POMS-defined morbidity on 
post-operative D3, D5 and D8 remain in hospital for an additional 4.6 (p=0.012), 5.3 days (p=0.001) 
and 7.6 days (p=0.135), respectively, when compared to those without. There were no patients 
without C-POMS defined morbidity on D15. Existing pre-operative risk assessment scores 
(EuroSCORE, POSSUM and Magovern) only had a small predictive ability to predict C-POMS 
summary score. However, higher C-POMS domain frequencies were observed in those with 
greatest surgical risk, as defined by these scores, in all but the infectious (EuroSCORE) and wound 
complication (POSSUM) domains. Overall, C-POMS-defined morbidity explains the variance in 
subsequent length of post-operative stay by 16.5%, 22.3%, 43.1% and 82.0% on D3, D5, D8 and 
D15, respectively. Potentially, social and organisational factors may also contribute to variations in 
length of post-operative stay. Of those patients remaining in hospital with a C-POMS score of zero, 
social and organisational factors accounted for 100% of reasons on D8 and 56.3% on D5, while 
only 7 (12.1%) remained in hospital for a medical reason not captured by C-POMS on D5. Overall, 
nine of the thirteen C-POMS domains (renal, GI, neurological, haematological, wound on D3, 
pulmonary, renal, neurological, pain, endocrine on D5, renal, haematological, wound on D8 and 
renal, pain, endocrine, electrolyte on D15) independently predicted subsequent length of stay with 
between 2.2 to 77 extra days in hospital. Thus, C-POMS appears to exhibit construct validity, as 
assessed by pre-defined hypotheses. 
 
9.2.3 The applicability of POMS to cardiac surgical patients 
In exploring the applicability of POMS to cardiac surgical patients, POMS appears to underestimate 
the post-operative morbidity experienced. Furthermore, POMS only exhibited sufficient internal 
consistency to be used as a summary score on D15 where for every unit increase in POMS 
summary score on D15 there was an 8.2 day (95% CI 5.223-11.213, p=0.000) increase in 
subsequent length of stay. However, EuroSCORE, POSSUM and Magovern scores do not predict 
POMS summary score on D15 and less domains than C-POMS exhibited the highest frequency in 
those with greatest risk as defined by these score. Furthermore, POMS failed to capture all relevant 
morbidity on D5 and D8. 
 
9.2.4 The utility of C-POMS in clinical practice 
The utility of C-POMS in clinical practice was considered by the PDG at the Heart Hospital and also 
the London Chest Hopsital and both thought that C-POMS was fundamentally useful for hospital, 
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departmental and individual quality profiles and as a patient outcome measure. Both have agreed to 
use C-POMS as a routine data collection tool, and have agreed to collaborate, sharing anonymised 
data, for analysis purposes. The London Chest Hospital currently collect data electronically using a 
purpose-built database to which they are adding the C-POMS data fields to. This database will be 
shared with the Heart Hospital, and potentially other hospitals who are interested. 
 
9.3 UPDATE: UK, INTERNATIONAL AND LITERATURE 
9.3.1 UK update 
Although the SCTS are leading on outcome measurement compared with other countries(190) and 
other medical disciplines, since this study started the focus has remained primarily on mortality. In 
response to recommendation 155 (outcomes of Trust, units and consultant team should be 
available to the public) of the Bristol Royal Infirmary report(28), the SCTS have published mortality 
rates at the hospital level and whether the mortality standard (defined as crude mortality within 
99.99% CIs of the national mean for isolated coronary artery surgery(5) was achieved at the named 
consultant surgeon level. However, while the debate continues as to the appropriateness of 
publishing named surgeons’ results(25, 191), the choice currently rests with the individual unit(192).  
In terms of morbidity, there has been some consideration of morbidity outcome since this study 
commenced. The revision of the SCTS dataset, which went live in April 2010, contained additional 
post-operative outcome measures which included return to theatre, deep sternal wound infection, 
new post-operative neurological dysfunction and new haemofiltration/dialysis post-operatively. 
However, data incompleteness for post-operative complications is considerably higher than for 
operative risk stratification variables (15% vs <5%, respectively), although this is declining(192). 
Currently, morbidity is of particular interest following the publication of Darzi’s 2008 report ‘high 
quality care for all’(193) as it is recognised that alone mortality is an inadequate quality indicator(57).  
 
9.3.2 International update 
It has been challenging to identify international changes that have occurred since this study 
commenced. Although the first and 2nd EACTS database reports appear not to be publically 
available, the third report in 2007(194) contains data from 260 hospitals in 22 countries. However, the 
outcome data reported (post-operative length of stay and mortality) is presented only as aggregate 
data and not by country. Similarly, in the 4th 2010 report which referred to over 1 million patients 
from 366 hospitals in 29 countries, epidemiological data, mortality (2.2% for isolated CABG) and 
post-operative length of stay (median 7 days, range 5-11 days) only are reported(195). Nevertheless, 
the ultimate aim of this database is to measure quality of care across the whole patient pathway(196). 
Furthermore, since updates relating to the progress of the international STS-ECSUR database have 
not been reported, calls for an international database remain(197). However, the Belgian National 
Cardiac Surgical Register are expanding the dataset from 1st January 2012 to include 4 post-
operative complications (re-operation, new post-operative stroke, new post-operative dialysis and 
multi-system failure using STS definitions), while the Swedish national register has included quality 
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of life measures since 2005.  Additionally, revisions to the STS database in relation to post-
operative morbidity outcome have also occurred. From January 2011 the STS database contains 
49 variables related to post-operative events with new post-operative complications including 
paralysis, pleural effusion requiring drainage, aortic dissection, laryngeal nerve injury and an ‘other’ 
category for complications not defined within the dataset. 
 
9.3.3 Update from the literature 
At the start of this work there was no standardised definition of post-operative morbidity or method 
for its measurement in cardiac surgery patients. To assess whether this remains true, an update on 
the literature review was conducted using the same methods, excluding backward citation tracking, 
as detailed previously (section 1.4.2). The forward citation search of the pre-operative risk 
assessment scores identified through the literature review was conducted in September 2010, while 
the keyword searches were conducted July 2011.  Since the initial review, the NRR has been 
archived (October 2007) and only contains records up to September 2007. Furthermore, both 
PubMed and the Cochrane Library now contain considerably more records, with over 20 million 
citations and over 28,000 contributors from more than 11 countries, respectively. 
 
A total of 734 forward citations since 2004 were identified from the 20 pre-operative risk 
assessment models for post-operative morbidity identified in the literature review. Figure 9-1 details 
the number of forward citations identified from each of the pre-operative risk assessment models. 
The abstract/record details of each forward citation was assessed for relevance. 
 
Figure 9-1: Number of forward citations since 2004 of the pre-operative risk assessment models for 
morbidity identified in the literature review. 
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Table 9-1 details the number of papers that were identified through the keyword searches. The 
abstracts of those highlighted in bold were assessed for relevance. 
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Table 9-1: Keyword searches for literature review update. 
Keywords  PubMed  
(limit to 
title word) 
NIHR archive 
 
Cochrane Library (all 
databases)  
(limit to title, abstract and 
keyword) 
Morbidity score 67  67 
Risk prediction score 102  119 
Cardiac surgery score 48  2 
Cardiac surgery risk score 20  1 
Preoperaive risk; cardiac 
surgery 
64  2 
Risk prediction score; cardiac 
surgery 
2  4 
Cardiac 144,681 1,560 144 
Cardiac surgery 12,699 6,760 43 
Cardiac surgery morbidity 123 1,786 14 
Cardiac surgery risk 792 3,106 28 
CABG 973 18 11 
CABG morbidity 9 214 2 
Surgery morbidity 857 1,284 167 
Surgery outcome 3,476 2,184 567 
 
As identified in the original literature review, models were identified that only explored a particular 
post-operative event (for example, renal complications(198, 199, 200) or post-operative bleeding(201)), 
defined morbidity by using a surrogate marker  (ICU LOS)(202, 203), or were based exclusively on 
mortality outcome(204). However, four new models of pre-operative risk assessment of overall post-
operative morbidity were identified. Both Biagioli and colleagues(205) and Cevenini and 
colleagues(206) used Higgins et al(52) definition of morbidity, which included death, while the Syntax 
score defined morbidity as cardiovascular events(207) only. Finally, the Toronto Risk score(208) was 
established to assess risk for post-operative adverse events, defined as death, MI, low cardiac 
output syndrome, post-operative renal failure, stroke or deep wound infection.   
 
Since the commencement of the work on C-POMS, the Post-operative Quality Recovery Scale has 
been published(209). This was developed principally in general surgical patients, although 5% of 
patients did undergo cardiac surgery. It is a six domain (physiology, nociceptive, emotional, 
activities of daily living, cognitive and overall patient perspective) tool comprising a mix of patient-
reported outcomes and researcher-led tests, in all but the physiological domain. The variables are 
collected pre-operatively, at a time when anaesthesia is no longer required (T0), at 15 and 40 
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minutes after T0, on D1 and D3 after surgery and at 3 months after surgery. However, the authors 
recognise that for cardiac surgery, the earlier time-points may not be appropriate and that the scale 
is also limited by the burden of undertaking the tests, preferably by one dedicated person. Although, 
like C-POMS, the PQRS tool is a multi-dimensional tool to assess post-operative recovery, they are 
very different instruments in relation to content, with the PQRS not containing easily or readily 
available variables. Nevertheless, the PQRS tool may be a useful as a complementary tool to C-
POMS, particularly in relation to patient-reported outcomes and should be explored further. 
 
Thus, overall, this literature update revealed that there continues to be no standardised definition of 
post-operative morbidity or method for its measurement in patients having cardiac surgery.  Despite 
the development of the PQRS scale, it is not possible to compare it with C-POMS in the study 
population due to the variables that comprise the scale . Therefore, C-POMS remains relevant with 
the nearest tool to compare with continuing to be POMS. 
 
9.3.4 Conclusions  
Following review of the progress on post-operative morbidity outcome measurement since 
commencement of this work, it is apparent that in the continued absence of a standardised method 
to measure morbidity outcome, a place for C-POMS is still apparent. 
 
 
9.4 C-POMS AS A MORBIDITY OUTCOME MEASURE 
9.4.1 C-POMS vs. POMS  
As already discussed (section 8.6.1 and section 9.2.3) POMS appears to underestimate post-
operative morbidity in cardiac surgery patients and has noticeably less construct validity than C-
POMS when applied to this patient group. In brief: 
• POMS failed to capture all relevant morbidity on D5 and D8 while C-POMS captured all  
the morbidity in 87.9% and 100% of in-patients, respectively.  
• While C-POMS had sufficient internal consistency to be used as a summary score on  
D3, D5, D8 and D15, POMS only exhibited sufficient internal consistency on D15  
• Although C-POMS and POMS defined morbidity explained a similar variance in  
subsequent length of stay on D3 (16.5% v 16.8%) and D5 (22.3% v 21.7%), C-POMS  
defined morbidity explained considerably more of the variance than POMS defined 
morbidity on D15 (82.0% v 62.4%).  
Thus, the cardiac-specific amendments included to create C-POMS appear to provide the greater 
specificity of a condition specific instrument(187). 
 
9.4.2 Comparing morbidity rate with the existing literature 
The frequency of morbidity reported is affected by the definition of morbidity used(7, 11). As 
highlighted in section 1.4.4, the diverse methods previously used to define morbidity makes 
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comparisons of morbidity rates difficult. In these studies the incidence of morbidity ranged from 
4.3%(87) to 36%(71) compared with 92.2%, 86.4%, 95% and 100% on D3, D5, D8 and D15, 
respectively, by C-POMS. This difference in morbidity prevalence is likely to be attributable to C-
POMS assessing total morbidity burden while other studies limited their definition to consist of only 
major/specific complications, surrogate markers of morbidity or included mortality within the 
morbidity definition. Since C-POMS retains the properties of POMS, comparison of POMS in 
cardiac patients with other published in reports in other surgical populations(93) is possible (Figure 
9-2).  
 
Figure 9-2: Comparison of morbidity rates using POMS criteria across different patient populations. 
Orthopaedic, general and urology figures obtained from Grocott et al 2007(93). 
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As shown in Figure 9-2 above, patients having cardiac surgery have less POMS-defined morbidity 
than general or urology patients on D3, similar levels to those seen in general surgical patients on 
D5, but considerably more than that in all the other patient groups on D8 and D15. Overall, 
orthopaedic surgical patients have the least POMS-defined morbidity on each post-operative day.  
Exploring this in terms of domain frequencies highlights that for orthopaedic patients the most 
common POMS-defined morbidities are pulmonary and pain on D3 and infection on D5, D8 and 
D15, while for general surgical patients GI complication is the most prevalent on all post-operative 
days (Table 9-2). Renal and infection domains on D3, GI on D5 and D8 and infection on D15 have 
the highest frequency for urology patients while for cardiac patients the most common domains are 
pulmonary on D3, CV on D5, and both infection and CV on D8 and D15. Thus, while infection is a 
main course of morbidity in all surgical groups, cardiac patients have the lowest infection and pain 
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rates on D3 of all surgical groups. They also have considerably less GI POMS-defined morbidity 
than general or urology surgical populations and the lowest level of haematological complications 
on D3 but highest on D8. However, cardiac patients have the highest level of POMS-defined 
cardiovascular and neurological morbidity on all post-operative days and in all domains except GI 
on D15. 
 
Table 9-2: Comparison of POMS domain frequencies in different surgical populations. 
 D3 D5 
 Orthopa
edic 
General Urology Cardiac Orthop
aedic 
General Urology Cardiac 
Pulm 30.1 58.4 36.7 67.3 7.3 19.8 22.4 26.5 
Infect 26.6 43.6 59.2 25.1 21.5 28.7 36.7 36.2 
Renal 24.9 39.6 53.1 34.2 8.7 21.8 30.6 15.7 
GI 20.1 92.1 51.0 24.9 15.9 65.3 40.8 21.8 
CV 0.7 3.0 2.0 43.6 1.4 4.0 2.0 43.2 
Neuro 1.7 3.0 0 17.8 0.7 2.0 0 10.6 
Wound 1.7 0 0   2.7 5.5 1.0 2.0  1.4 
Haem 7.3 4.0 16.3   2.4 2.4 2.0 2.0  1.6 
Pain 30.8 58.4 49.0   2.0 4.2 24.8 20.4  2.6 
 D8 D15 
 Orthopa
edic 
General Urology Cardiac Orthop
aedic 
General Urology Cardiac 
Pulm 2.4 12.9 8.2 27.6 1.7 5.9 6.1 29.2 
Infect 14.5 18.8 14.3 55.2 7.6 11.9 16.3 58.3 
Renal 2.8 5.9 10.2 24.9 1.0 3.0 4.1 37.5 
GI 7.3 37.6 18.4 21.0 1.0 25.7 10.2 16.7 
CV 0.3 1.0 0 57.5 0 1.0 0 58.3 
Neuro 0.3 0 4.1 14.9 0 0 0 16.7 
Wound 5.9 6.9 4.1   6.7 2.4 6.9 4.1   8.3 
Haem 1.0 1.0 0   4.4 0.3 0 0 22.9 
Pain 1.4 10.9 2.0   5.0 0.7 5.9 2.0   6.3 
Abbreviations: Pulm=pulmonary, Infect=infection, GI=gastrointestinal, CV=cardiovascular, 
Neuro=neurological, Haem=haematological 
 
Overall, this comparison provides a new insight into post-operative morbidity across different 
surgical groups and highlights that different surgical groups do exhibit different morbidity events 
post-surgery and in different frequencies. In particular, cardiac patients have higher levels of 
morbidity than other surgical groups, despite POMS underestimating post-operative morbidity in 
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comparison to C-POMS. In the future such information may potentially have use in planning and 
delivering health services and in a hospital quality report (see section 9.5.6) 
 
9.4.3 Independently predictive domains of subsequent length of stay 
As shown in chapter 7 section 7.5.3.5, nine of the thirteen domains were independently predictive of 
subsequent length of stay on at least one post-operative day: Pulmonary (D5), renal (D3, D5, D8, 
D15), gastrointestinal (D3), neurological (D3, D5), haematological (D3, D8), wound complications 
(D3, D8), pain (D5, D15), endocrine (D5, D15) and electrolyte (D15). Direct comparisons with 
existing literature unfortunately cannot be made as there are no other post-operative morbidity 
assessment tools with which to compare. Nevertheless, the independent predictive nature of these 
domains, with the exception of GI, pain and electrolyte, is unsurprising as these physiological areas 
have previously been shown to be pre-operatively predictive of ICU LOS and post-operative 
morbidity (Chapter 1 section 1.4.3.2) in cardiac surgical patients.  Pre-operative renal predictors of 
ICU LOS include LVEF and a history of renal dysfunction(210, 211, 212, 213), while pulmonary predictors 
include a history of pulmonary disease(80, 213, 214) and NYHA class(210). Additionally, neurological 
predictors include a history of cerebrovascular disease(210) with diabetes also being associated with 
ICU LOS(210, 211). ICU LOS is also independently predicted by receiving any red blood cell (RBC) 
transfusion(215, 216) while for patients newly started on warfarin, untherapeutic INR delays hospital 
discharge in 30%(217). Furthermore, post-operative deep sternal wound infections is associated with 
significantly increased hospital length of stay(218, 219). However, in contrast, pain has been found not 
to increase ICU LOS(220), and no studies were found that identified gastrointestinal or electrolyte 
complications as predictors of post-operative stay in cardiac surgical patients.  
The findings in the literature review (chapter 1 section 1.4.3.2) similarly show that areas within these 
physiological domains pre-operatively predict post-operative morbidity, despite the diverse 
definitions of morbidity utilised. Figure 9-3 summarises the proportion of studies in the literature 
review (all variables detailed in Appendix 1) that contain areas in each of the domains that were 
independently predictive of subsequent length of stay in C-POMS, with the exception of the 
cardiovascular domain. 
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Figure 9-3: The proportion of studies identified in the literature review that contain areas of the 
domains in C-POMS found to be independently predictive of subsequent length of stay. 
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The cardiovascular domain was not independently predictive on any post-operative day.  This was 
unexpected given that pre-operative cardiac-related factors such as rhythm disturbances(80, 221), 
MI(213, 222) and hypertension(211) are known to be predictive of increased length of ICU stay, and 
78.9% of the pre-operative risk assessment tools for post-operative morbidity in the literature review 
contained cardiovascular variables (Figure 9-3, above) . However, it is likely that the cardiovascular 
domain was not independently predictive of subsequent length of stay due to the overall high 
proportions of participants experiencing a cardiovascular morbidity. It is possible that sub-analysis 
of this domain may identify that individual criteria are predictive of subsequent length of stay, as 
suggested in the literature. 
 
9.4.4 New domains 
9.4.4.1 Assisted ambulation 
Assisted ambulation, defined as ‘a new or escalated post-operative requirement for mobility 
assistance (including wheelchair, crutches, zimmer frame, walking sticks, or ‘assistance’), was 
requested by the PDG as a routine data collection variable prior to commencing the study. Assisted 
ambulation was present in 99.6%, 45.6%, 27.7%, 37.6% and 39.6% on D1, D3, D5, D8 and D15, 
respectively, and mobility-related issues were the reason for non-discharge in 18.2% on D5 and 
28.6% of patients with no POMS-defined morbidity. Thus, mobility at a reduced pre-operative 
capacity has been identified in a considerable proportion of patients, delaying discharge and hence 
increasing hospital costs. Possible causes of this reduced mobility capacity are acquired muscle 
weakness in the ICU(223), neurological impairment, worsened cardiac output and/or general 
confounders (difficult to walk with catheter/drains/attached to cardiac monitor). However, whatever 
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the reason, mobility is still a useful marker of patient recovery and since in-hospital mobility 
following cardiac surgery has only been included as an outcome measure in only a few studies (for 
example, Izumi et al 2010(224)), the inclusion of this domain in C-POMS has merit. Furthermore, 
assisted ambulation fits well within the clinimetric principle by which C-POMS was developed since 
clinimetrics by definition can include such clinical phenomena such as functional capacity 
ailments(150).  
 
9.4.4.2 Review 
The newly generated ‘review’ domain is defined as ‘remaining in hospital for further review, 
investigation and/or procedure’ and was present in 0.0%, 2.9%, 5.9%, 9.9% and 12.5% on D1, D3, 
D5, D8 and D15, respectively. While this domain could be criticised for being more a measure of 
system failure than morbidity, the inclusion of reasons for medical decisions, as in the ‘review’ 
criteria, is a legitimate characteristic of clinimetric measures(150). Furthermore, such judgmental 
decisions are a routine feature of clinical practice that are rarely measured(150). If patients require 
further investigations or procedures that are necessary prior to discharge, the ‘investigation and/or 
procedure’ criteria can be a measure of system failure (delay due to organisational factors) and 
morbidity (delay due to medical reasons), both of which will prolong time to discharge. Subsequent 
analysis of the individual criteria will distinguish between the two reasons and provide useful 
information for clinical management.  
 
9.4.4.3 Electrolytes 
Patients undergoing cardiac surgery are at high risk of developing electrolyte depletion(225), a risk 
factor for a range of clinical symptoms including arrhythmias(226, 227), respiratory complications and 
muscle weakness(228).  In this study, electrolyte disturbances were defined as an imbalance 
(depletion and elevation) in serum electrolyte concentrations (including sodium, urea, phosphate 
but not potassium as included within renal domain) requiring oral or intravenous intervention’ and 
overall were observed in 0.9% on D1, 2.2% D3, 2.1% D5, 4.4% D8 and 12.5%on D15. Individually, 
sodium, urea and phosphate imbalances were observed only in 1.6%, 3.1% and 1.1% of 
participants, respectively, but all had a mean severity-importance (SI) score (defined within chapter 
6 section 6.3.3.3.1) of greater than 8 and were considered by the expert panel not likely to be 
captured within the POMS criteria. Thus, overall the inclusion of electrolyte abnormalities was 
attributable to the ratings of the expert panel, providing an example of how clinically important items 
should be included in a disease-specific measure, irrespective of their statistical associations(141). 
Furthermore, this domain was found to be independently predictive for subsequent length of stay on 
D15 (74.1 extra days, p=0.000, 95%CI 43.265-104.840) providing statistical justification for the 
inclusion of the domain in C-POMS. 
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9.4.4.4 Endocrine 
The proportion of diabetic patients undergoing isolated CABG surgery has increased from 18% to 
24% between 2001 and 2008 (p<0.001) (25). Furthermore, diabetic patients have an increased 
length of hospital stay, currently an additional 1.5 days, than non-diabetic patients (Figure 9-4(25)). 
 
Figure 9-4: Post-operative length of stay in diabetic and non-diabetic patients undergoing isolated 
CABG(25). This figure was obtained from the SCTS. 
 
However, poor glycaemic control following surgery is associated with increased mortality and 
morbidity (including MI, infection, renal and pulmonary complications) in both diabetics and non-
diabetics(229, 230, 231). Furthermore, 48.2% of patients with poorly controlled post-operative blood 
glucose and 68.5% of patients with moderately controlled post-operative blood glucose being pre-
operatively defined as non-diabetic. In the C-POMS study, although the incidence of diabetes was 
23.3%, the proportion of non-diabetics requiring blood sugar management was 96.8%, 19.7%, 4.6%, 
6.2% and 16.7% on D1, D3, D5, D8 and D15, respectively. Additionally, the presence of this 
domain was an independent predictor of subsequent length of stay on D5 (3.5 extra days, p-0.04, 
95%CI 0.157-6.915) and D15 (-15.1 days, p=0.034, 95%CI -28.908-1.235). Thus, a domain that 
notes new or additional requirements for blood sugar management in both diabetic and non-diabetic 
patients is clinically useful.  
 
 
9.5 USES OF C-POMS 
9.5.1 Standard outcome measure for post-operative morbidity following cardiac surgery 
Since C-POMS is the only validated measure of post-operative morbidity following cardiac surgery, 
C-POMS can be used as a standard outcome measure to describe and quantify post-operative 
morbidity and total morbidity burden. Once applied as a standard outcome measure C-POMS might 
thus have use in identifying those at greatest risk of post-operative morbidity, in guiding clinical 
decision making, as a prognostic indicator, in quality assurance (audit and performance/quality of 
care indicator) processes, in the optimising the utilisation of health services and in cost analysis. 
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9.5.2 Identifying those at risk of post-operative morbidity 
Risk factors associated with C-POMS- (and C-POMS summary score-) defined post-operative 
morbidity, and those which might be causal, can be sought. Since risk assessment can change from 
the pre-operative period to that immediately following surgery, factors associated with pre-operative 
risk and then subsequent risk on arrival on ICU should be explored(67). This would aid patient group 
and individual risk stratification(64) and permit new therapeutic or preventative strategies to be 
implemented to specifically address the risk factors identified. 
 
9.5.3 Clinical decision making and informed consent 
Although the ability to predict mortality following surgery is important to patient and their families it is 
an incomplete method for assessing surgical outcome(71). It has been reported that four times as 
many patients undergoing cardiac surgery were concerned about surgery-related stroke rather than 
death and that 80% wanted to be informed of all the risks associated with having the operation(232). 
Furthermore, the General Medical Council guidance on obtaining patient consent states that 
patients should be told about ‘less serious side effects and complications’(233). The identification of 
risk factors for total morbidity burden and the associated prediction of subsequent length of stay can 
be used for improved pre-operative risk assessment and information provision for patients and their 
families.  
 
9.5.4 Prognostic indicator 
Potentially, C-POMS summary score could be used  as a prognostic indicator for longer-term 
morbidity and particularly within the first year of surgery. However, while this is an area we are 
exploring (see section 9.8.2), currently there is a lack of information on morbidity outcome beyond 
initial hospitalisation period. Thus, further work in this area is required for C-POMS to be used in 
this way. 
 
9.5.5 Quality assurance 
9.5.5.1 Clinical audit  
The C-POMS tool provides a framework by which changes in post-operative morbidity over time 
(level and type; following interventional strategies and processes; in unit and between centres) can 
be measured. The assessment of such changes over time highlights the potential use of C-POMS 
as a performance indicator/quality of care assessment tool at individual, departmental and 
institutional levels. 
 
9.5.5.2 Performance indicator/quality of care assessment tool. 
Quality of care as a concept in the NHS is not new. However, Lord Darzi’s 2008 report ‘high quality 
care for all’ emphasised the need to bring clarity to quality, to measure and publish quality 
performance and to recognise and reward quality(193).  This led to the establishment of the National 
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Quality Board in 2009 to drive the quality agenda throughout the NHS. Since little correlation has 
been found between quality of care and mortality(234), it is now acknowledged that mortality is only 
one aspect of overall healthcare quality(235) and consequently alone is an inadequate quality 
indicator(57, 236). Thus, morbidity outcome, along with clinical process evaluation(236, 237), has become 
important in this quality initiative. Since C-POMS offers clarity of definition and a tool for the 
measurement of post-operative morbidity, C-POMS has potential use as a tool in the quality 
assessment of cardiac surgery at both departmental and institutional level. If C-POMS data could 
be collected nationally, or in a number of diverse institutions, a national reference for comparing 
morbidity results between centres could be created(52). The publication of such quality assessment 
is likely to have particular usefulness in the assessment of the future procurement of cardiac 
surgical services by GPs and by patients in an era of patient choice. The Bristol Royal Infirmary 
Inquiry recommendation 153 states that performance indicators should be understandable by the 
public as well as by the healthcare profession(28). C-POMS as a summary score and by morbidity 
domain are likely to be understandable to the lay person due to its simplicity. Nevertheless, formal 
lay person review would be required prior to publication. Furthermore, since there is also a 
professional responsibility to monitor surgical performance(238), and especially with the introduction 
of revalidation for doctors in late 2012(239), C-POMS could also be utilised for individual quality 
performance assessment/evidence of practice. 
 
9.5.6 Utilisation of health services 
C-POMS has potential use in decisions relating to the utilisation of health services. As highlighted in 
chapter 7 section 7.5.2, a C-POMS summary score of 6 or more was observed in approximately 
20% of participants on D3, D8 and D15 with 2.8% and 4.2% experiencing morbidity in 10 or more 
C-POMS domains on D8 and D15, respectively. This is a considerable amount of morbidity and has 
implications for the clinical service since a 1.7, 2.2, 4.5 and 6.3 day increase in subsequent length 
of stay per unit increase in C-POMS on D3, D5, D8 and D15, respectively, was identified. Since 
post-operative morbidity increases length of hospitalisation it obstructs patient through-put(80). Using 
C-POMS summary score to predict subsequent length of stay might thus help in modelling (and 
better managing) patient flow. Furthermore, once pre-operative predictors of C-POMS-defined 
morbidity are determined, services for those at high risk can be planned accordingly. Conversely, 
following exploration on whether C-POMS summary score predicts post-operative morbidity 
following the initial hospitalisation period, rehabilitation and follow-up services could be determined 
and tailored accordingly. 
 
9.5.7 Cost analysis 
Increased length of stay caused by post-operative morbidity has considerable economic importance 
due to the greater utilisation of resources required(71, 240). This is particularly pertinent for extended 
ICU stays since ICU is the most expensive clinical area(80). Although EuroSCORE can predict direct 
hospital costs(241), unsurprisingly it a poor predictor of total hospital costs(242). Thus, while C-POMS 
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can be used in calculating total hospital resource utilisation, pre-operative and post-surgical risks for 
C-POMS should provide a more accurate mechanism for predicting hospital costs. 
 
 
9.6 LIMITATIONS  
9.6.1 Generalisability 
C-POMS was designed specifically to describe and quantify morbidity following cardiac surgery. 
Therefore, C-POMS is unlikely to be generalisable to other surgical populations. However, the 
inclusion of the POMS domains and criteria does permit comparison of the POMS components with 
general, urological and orthopaedic surgery populations, in which POMS has been validated(93). In 
such circumstances the limitations of POMS in cardiac patients would need to be considered. The 
applicability of POMS to other surgical populations is currently unknown.  
 
C-POMS was developed within one institution and may only reflect the population on which it is 
based(243). For example, patient demographics, disease acuity and incidence of co-morbidities(71) as 
well as organisational factors such as intensivist-model ICUs(244, 245) can influence outcome and 
differ across institutions. Thus, the validity of C-POMS in other cardiac surgical centres is required. 
Currently, this is underway at the Heart Hospital and The London Chest Hospital. However, it is 
anticipated that C-POMS will be widely applicable since the case-mix is similar in many centres, 
and the study population characteristics remain comparable to the characteristics of cardiac surgical 
patients in the UK (see section 9.6.4).  
 
9.6.2 Methodological and data  considerations 
The limitations relating to internal consistency and reliability methods have been discussed 
previously in chapter 7 section 7.6.7. 
 
9.6.2.1 Inclusion of symptoms and interventions 
C-POMS could be criticised for including symptoms (for example, wound pain criteria; the pain 
domain) which, by their subjective nature, will vary in intensity between patients(173). While this 
would have greater influence in quality of life assessments, the aim of C-POMS is to identify only 
whether the morbidity is present or absent. However, using symptoms within a clinimetric approach 
is appropriate since clinimetrics is defined by the use of symptoms in addition to pathophysiologic 
findings, disease status and severity to measure a clinical phenomena(150). Furthermore, the pain 
domain was found to have construct validity and was an independent predictor of subsequent 
length of stay on D5 and D15.  
 
C-POMS could also be criticised for including interventions (for example, supplementary oxygen, 
pleural effusion requiring drainage, urinary catheter in situ) for two reasons. Firstly, an intervention 
assumes a level of severity. This is masked in the initial post-operative days, especially D1, by 
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routine treatments that become documented as ‘morbidity’ (for example, antibiotic use, urinary 
catheter in situ, new or additional requirements for blood sugar management). As highlighted in 
chapter 6 section 6.4.2.2.1, on D1 pulmonary, renal, wound, pain, endocrine and assisted 
ambulation domains showed almost 100% prevalence. Since C-POMS only had sufficient internal 
consistency to be used as a summary score on D3, D5, D8 and D15 it does reduce the influence 
this will have in C-POMS since all routine interventions would be expected to be discontinued by D3. 
However, C-POMS could be introduced on other post-operative days, and this should be 
considered on D2 where only escalated interventions above the routine protocol may need to be 
recorded. Secondly, the inclusion of interventions does assume competency of the institution to 
correctly recognise and treat morbidities(93). As acknowledged in chapter 7 section 7.6.6, human 
factors (doctor/nurse preferences, simple mistakes, and minor delays) are inevitably going to 
contribute to some degree in the variance. However, it is possible that those hospitals recording the 
lowest morbidity levels provide a lower standard of care. Comparison of C-POMS on early post-
operative days with routine care pathways would assist in establishing the effect of this potential 
bias. 
 
9.6.2.2  ‘Lost’ data 
C-POMS was developed on data collected on D1, D3, D5, D8 and D15 and thus some transient 
morbidities would not have been identified on intervening days and fluctuations could not be tracked. 
The administrative burden of C-POMS may prevent daily completion depending on the infra-
structure at each site. For example, the Heart Hospital will not collect C-POMS data daily until an 
electronic system for data collection is established, whereas The London Chest Hospital have such 
a system already established and hence will collect C-POMS daily there. 
Additionally, when continuous or discrete variables are changed into binary data, some information 
can be lost(7). However, this is a necessary compromise when attempting to develop as simple as 
possible and clinically usable tool. 
 
9.6.3 Validity and reliability 
There is no gold standard by which to assess the criterion validity of C-POMS, and validity 
assessment of discriminative instruments thus relies on construct validity(89). Although C-POMS 
currently exhibits construct validity, content validity decreases over time due to the dynamic nature 
of construct definitions and content validity(172). Thus, future construct validity assessments will be 
necessary which will potentially identify a need for revisions to C-POMS in order for it to remain an 
appropriate measure of post-operative morbidity(172). Methods to do this include the calculation of a 
content validity index (CVI) of each item(170, 186) or for the overall instrument(170). However, 
calculating the CVI in the validation of C-POMS was unnecessary since part of C-POMS 
construction was based on expert panel judgments on the severity and importance of the morbidity 
items for inclusion into the model. Furthermore, since content validity is conditional for the targeted 
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population(246) this reinforces C-POMS as condition-specific tool unlikely to have generalisability to 
other surgical populations. 
 
9.6.4 Clinical utility 
Data collection for this study started in 2005, and thus considerable time has evolved since this 
study was commenced. However, compared to the UK cardiac surgery population(25), the population 
on which C-POMS was developed remains representative in terms of gender (female: 19.3% vs 
20.7%), age (66 years vs 66.5 years), the proportion of patients returning to theatre (4.9% vs 5.1%) 
and in mortality rate (1.5% vs 1.3%). The fact that C-POMS population remains representative is 
useful when introducing C-POMS as a tool into clinical practice.  
Since this study was conducted, some changes have occurred that are of interest. Firstly, the 
proportion of patients undergoing off-CPB isolated CABG has stabilised at 17% in the UK(25), 
compared with 7.1% in this study. Since off-CPB surgery has since been shown to be associated 
with lower morbidity and reduced hospital stay(247), additional analysis comparing C-POMS-defined 
morbidity outcome between patients having surgery on- and off-CPB could now be explored. 
Secondly, further research evidence is now available suggesting that medications do affect 
outcome following cardiac surgery. Pre-operative statin use has been shown to enhance recovery 
after cardiac surgery(248), particularly for all-cause mortality, atrial fibrillation and stroke(249) while a 
combination of statin and beta-blockers have been shown to protect against stroke after CABG(250). 
However, there was no effect of pre-operative statins on MI or renal failure(249). Thirdly, although in-
hospital mortality appears not to be affected by ethnic background, non-whites have been found to 
have a longer hospital stay(251). Thus, it may be useful to undertake further analysis to determine if 
there are ethnicity differences in C-POMS-defined morbidity outcome. 
 
Since multifactorial  models are generally poorly integrated into clinical practice(72) due to their 
complexity(57, 72), the routine use of C-POMS in clinical practice is reliant on it not being burdensome 
in terms of time and complexity(155, 156, 157) while retaining its measurement properties(158) and 
rigor(157).To assist ease of completion the presence or absence of each domain can be recorded 
without presence or absence of the individual criteria being documented to enable the summary 
score to be calculated and each variable is readily available. Furthermore, consideration of the 
resources required and of the personnel available to obtain the data is required. Since 
recommendation 145 of the Bristol Royal Infirmary Inquiry report(28) suggests that participation in 
audit should be mandatory for all healthcare professionals providing clinical care, there should be 
sufficient resources available. However, in practice the reverse if often true. Nevertheless, two 
London hospitals have considered C-POMS and have concluded that the benefits of using C-POMS 
outweighs any administrative burden. Future assessment of the practicalities of using C-POMS in 
clinical practice in these sites will be reviewed. 
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9.7 STRENGTHS 
9.7.1 Methodological strengths 
9.7.1.1 Comprehensive frameworks 
As discussed in chapter 7 section 7.2, it is important to use a conceptual framework for credible 
instrument development(173). Three frameworks were utilised in the development and validation of 
C-POMS: A modified Van den Broeck framework(98) was used to minimise data errors and improve 
data quality; C-POMS was developed utilising the McMaster Framework for constructing and 
assessing health indices(89, 154) for discriminative instruments; and a content validation framework(172) 
was also employed to maximise content validity.  
 
9.7.1.2 Collaborations 
A considerable strength of this work has been the multi-professional collaboration and input 
obtained at various stages of the process, which is recommended when adopting the clinimetric 
approach to serve the needs of both clinical research and clinical practice(12). The PDG 
(membership detailed in chapter 2 section 2.4.2) has met 4 times to review and comment on the 
development, progress and evaluation while the expert panel (membership detailed in chapter 6 
section 6.3.3.3.2) was formed for the item reduction strategy and content validity processes. 
Furthermore, methodological and statistical advice for the model development and validation was 
sought from experts in the field of health outcome measurement and clinimetrics. 
 
9.7.1.3 Data quality 
The validity of the conclusions reached does depend partly on the accuracy of the data(96). A 
particular strength of this study is that despite a lack of guidance in the literature regarding 
development and implementation(98) and the minimal acceptable data quality levels for clinical 
data(104), a comprehensive and systematic data quality framework was devised and implemented. 
This process identified >99% completeness in >92% variables, with only 1.4% incompleteness 
overall, that 98.6% of erroneous inliers identified were rectified, there was <1% consistency error 
and there representativeness with those patients who didn’t participate in the study, following 
consideration of the study’s exclusion criteria. Thus, although it is not possible to ensure 100% 
quality data(99), there is considerable confidence in the quality of the data used in this study. 
Furthermore, consistent with the American Statistical Association guidelines(106), these processes 
and results have been reported, for complete transparency. 
 
9.7.2 Multi-dimensional nature of C-POMS 
C-POMS is multi-dimensional in that it measures multiple constructs within a single index, which is 
a key feature of the clinimetric approach(137). The advantage of this is that the summary score does 
then reflect the total morbidity burden as defined by C-POMS. One of the most useful aspects of C-
POMS is the ability to use as a summary score on D3, D5, D8 and D15. Although multifactorial 
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indexes are generally poorly integrated into clinical practice(72), summary scales provide an easy 
method of scoring are readily interpretable(173), and are commonly used in clinical practice. 
 
9.7.3 Clinical utility 
Thus far, C-POMS has been evaluated favourably from a clinical perspective. As highlighted in 
sections chapter 8 section 8.5.3 and section 9.2.4 of this chapter, both the Heart and London Chest 
Hospitals agree that C-POMS is fundamentally useful and have agreed to use C-POMS as a routine 
data collection tool. Further review will occur through the implementation processes at each site. 
 
 
9.8 FUTURE WORK 
9.8.1 Validate in other cardiac centres 
As highlighted in section 9.6.1, an important element of future work is the determination of the 
validity of C-POMS in other cardiac surgical centres. Since the quality of the performance of the 
instrument depends on the expertise of those using the tool(12), training, inter-reliability testing and 
ongoing support would need to be provided. As stated previously, this is currently in progress at the 
Heart Hospital and The London Chest Hospital. Ultimately, if C-POMS does exhibit sufficient validity 
in other institutions, a subsequent aim would be the incorporation of C-POMS domains into the 
national SCTS dataset for collection at all 55 cardiac surgical centres in the UK.  
 
9.8.2 Prognostic studies 
Since in-hospital audit underestimates morbidity in the post-operative period(252), and 3-year 
mortality is significantly higher in cardiac surgery patients with major morbidity after sugery(253), 
extension of follow-up beyond the initial hospitalization is indicated. Ethics committee approval has 
been received to obtain hospital episode statistics (HES) data for readmission (diagnosis and 
procedures) to any hospital within England and Wales and to National Statistics for mortality data, 
within the first year following surgery.  Additionally, work to identify pre-operative risk factors for 
post-operative morbidity (see section 9.8.3) could also include the determination of risk factors for 
the presence of morbidity in the year following surgery. 
 
Morbidities are indicators not only of quality of care but of quality of life(57). When considering 
longer-term morbidity rehabilitation, absence from symptoms(84) and patient reported outcome 
measures (PROMS)(193) could also be considered. 
 
9.8.3 Pre-operative risk assessment for total morbidity burden following cardiac surgery 
Unsurprisingly, the pre-operative risk assessment EuroSCORE, POSSUM and Magovern scores 
poorly predicted total morbidity burden as defined by C-POMS summary score. Thus, pre-operative 
variables that may predict post-operative total morbidity burden, as defined by C-POMS summary 
score, or those domains with greatest frequency/predictive ability for subsequent length of stay 
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should be explored. As stated in section 9.5.2, such prediction of post-operative complications has 
use in patient group and individual risk stratification , optimising available resources(64) and 
identifying those patients that could be fast-tracked for early discharge(71). However, subsequent 
risk prediction assessed at time of arrival on ICU should also be examined since morbidity 
prognosis at this time may differ from the pre-operative assessment(67) due to anaesthetic and intra-
operative factors. Such analysis might also identify targets for therapeutic intervention such that 
post-operative morbidity is also mitigated. 
 
9.8.4 Comparison of POMS components with other patient populations 
One of the most promising uses of discriminative instruments is to quantify the burden of illness 
across different populations(89). As stated previously, the inclusion of POMS domains and criteria 
within C-POMS does permit comparison with other patient populations where POMS has been 
validated. Thus, a collaboration is currently underway to directly compare the results of this study in 
cardiac patients within the urological, general and orthopaedic surgery patients in the Grocott et al 
study(93). Further comparison may also be occur when the paediatric version of POMS has been 
completed at Great Ormond Street Hospital, London and if possible, assessment of the applicability 
of C-POMS within a grown up congenital heart surgery (GUCH) population would also be of interest. 
 
9.8.5 Update C-POMS 
As stated in chapter 7 section 7.6.7, due to the dynamic nature of construct definitions and content 
validity(172),  revisions to C-POMS may become necessary in order for it to remain an appropriate 
measure of post-operative morbidity. Thus, future research has to include re-assessment of the 
validity of C-POMS to describe and quantify post-operative morbidity following cardiac surgery. 
 
 
9.9 CONCLUSIONS 
C-POMS is the first validated tool for identifying total morbidity burden post cardiac surgery. In 
clinical practice C-POMS can primarily be used as a standard outcome measure to describe and 
quantify post-operative morbidity and total morbidity burden. In this study, considerable C-POMS-
defined morbidity was observed in these patients which lends C-POMS to potentially useful in 
identifying those at greatest risk of post-operative morbidity, in guiding clinical decision making, as a 
prognostic indicator, in quality assurance (audit and performance/quality of care indicator) 
processes, in the optimising the utilisation of health services and in cost analysis.   
 
Historically, the diversity associated with attempting to measure morbidity, lead to imprecise 
measurement and monitoring of events. C-POMS provides a standardised definition and 
measurement tool for total morbidity burden after cardiac surgery. The use of C-POMS would 
permit morbidity to be considered independently of mortality in quality of care assessment in cardiac 
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surgical patients. Since clarity, measurement and the publication of quality performance is a key 
perspective of the NHS currently, such potential usage of C-POMS in this way is very timely. 
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APPENDICES 
Appendix 1: Pre-operative risk prediction scores for morbidity outcome patients undergoing cardiac surgery.  
Study/Score Sample/Method Outcome measure/Follow-
up 
Pre-operative variables in model 
(with scores in bold)  
Results/Comments 
Parsonnet Score 
Parsonnet V et al 
(1989).  A method of 
uniform stratification of 
risk for evaluating the 
results of surgery in 
aqcuried heart disease 
 
 
 
USA 
Univariate and multivariate logistic 
regression analyses were 
performed on data from 3,500 
consecutive open-heart surgery 
procedures selected retrospectively 
from an existing database (1982-
1987).  The odds ratio of each 
variable on outcome was calculated 
with those significant entering the 
additive model.  17 factors met the 
criteria and were analysed for an 
association with operative mortality 
and a second model was 
constructed.  The 2 models were 
compared by regression analysis to 
test the validity of the additive 
univariate model.  300 earlier cases 
from the same database were then 
tested retrospectively by summation 
of all the risk-scores applicable to 
each case.  The total score was 
compared with the actual outcome.  
The scores were tabulated by 
people not concerned directly with 
the outcome.  Scores tested 
Operative mortality: defined 
as any death occuring within 
30days of surgery 
Mean predicted operative 
mortality was 10.4%. 
Mean observed operative 
mortality was 8.9% 
 
Post-operative 
complications: 
824 (23.5%) had post-
operative complicatioin 
 
Length of hospital stay: 
Not stated 
 
Variable                                         Score 
Female                                               1 
Morbid obesity (>1.5x ideal weight)   3 
Diabetes (unspecified type)               3 
Hypertension (SBP >140mmHg)        3 
EF Good (>50)                                   0 
      Fair (30-49)                                  2 
      Poor (<30)                                    4 
Age (yr)    70-74                                 7 
75-79  12 
>80                                   20 
Reoperation - first                              5 
                    - second                       10 
Preoperative IABP                             2 
Left ventricular aneurysm                  5 
Emergency surgery following PTCA 10 
Or catheterisation complications  
Dialysis dependency (PD or Haemo)10 
Catastrophic states                      10-50 
Other rare circumstances              2-10 
Valve surgery   -mitral                        5 
                -PA pressure >60mmHg     8 
                -Aortic                                 5 
               - Pressure gradient                
                  >120mmHg                       7  
The mean predictive operative mortality was 
10.4%.  The mean observed operative 
mortality was 8.9%.  Correlation of univariate 
and multivariate models was 0.85.  Operative 
mortality in surgery subgroups resembled 
that of all groups combined.  The differences 
were not statistically different.  Correlation 
also between pre-operative score and length 
of stay and non-fatal complications. 
Excluded many variables that were too 
subjective, for example, NYHA classification, 
CPB time, use of LIMA etc. 
Roques et al (1995): Assessed predictive 
value of score on French population.  Seven 
risk factors were not predictive according to 
multivariate analysis and thus does not 
recommend it’s use in France 
Gabrielle et al (1997): Assessed the 
parsonnet and SUMMIT (modified parsonnet) 
in french surgical population.  Showed that 
parsonnet had moderate predictive value and 
the modified version was too complex. 
Lawrence et al (2000): Parsonnet score was 
a good predictor of ICU stay<24hrs, post-
operative complications and in-hospital 
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prospectively in 4 institutions. CABG at time of valve surgery           2      death. 
Wynne-Jones et al (2000): Found 
Parsonnet score overpredicted mortality and 
included variables not associated with 
mortality. 
Dupuis et al (2001):  Parsonnet score failed 
to calibrate for morbidity. 
Vanagas et al (2003): Parsonnet score over-
predicted mortality in lithuanian population 
Cleveland Clinical 
Severity Score 
Higgins et al (1992).  
Stratification of 
morbidity and mortality 
outcome by pre-
operative risk factors in 
coronary artery bypass 
patients.  A clinical 
severity score. 
 
 
USA 
Retrospective analysis of 5051 
patients to identify risk factors (out 
of 29 variables) associated with 
perioperative morbidity and 
mortality.  Model validation 
consisted of 4069 prospectively 
recruited patients undergoing 
CABG between July 1st 1986 to 
June 30th 1988 in Cleveland Clinic 
Foundation. 
ORs were calculated to measure 
the degree of association.  Factors 
significant to at least p<0.10 were 
used in logistic regression analysis.  
Potential interactions were 
evaluated. Forward step-wise 
regression models were developed 
to determine effects of pre-op 
factors on outcome and included 
only factors that were significant 
p<0.05.  The goodness of fit of the 
model was evaluated using 
Mortality 
No definition given 
126 (2.5%) died 
 
Morbidity defined as  
MI,  
IABP 
mechanical ventilation >3 
days, neurological deficit 
oliguric or anuric renal failure 
Serious infection. 
 
680 (13.5%) morbidity 
Variable                                         Score 
Emergency case                                6 
Serum creatinine    >141 and <167   1 
                               >168                   4 
Severe LV Dysfunction                      3 
Re-operation                                      3 
Operative mitral valve insufficiency   3 
Age >65 and <74yrs                          1 
       >75yrs                                         2 
Prior vascular surgery                        2 
COPD                                                 2 
Anaemia (haematocrit <0.34)             2 
Operative aortic valve stenosis           1 
Weight <65kg                                      1 
Diabetes, on oral or insulin therapy    1 
Cerebrovascular disease                    1 
  
                                
Mortality and distribution of severity score 
differ significantly between the 2 groups, with 
increased numbers of higher-risk patients 
(>5) in the validation group. 
The morbidity rate was lower than the CI of 
the predicted rate in 4 of the 9 severity score 
categories.  The Homer-Lemeshow 
goodness-of-fit test comparing observed and 
expected events by deciles of risk also 
showed lack of fit (p<0.001).  There was 
good agreement between the predicted and 
observed mortality rates in each severity 
score category.  The Hosmer-Lemeshow test 
showed overall agreement (p=0.3) between 
observed and expected events.  The cut-off 
point that yielded the largest combined 
sensitivity and specificity was a clinical score 
of 6 for mortality (Sensitivity 67.5%, 
specificity 86.2%, positive predictive value 
11.1%, negative predictive value 99.0%) and 
4 for morbidity (Sensitivity 62.5%, specificity 
73.2%, positive predictive value 26.7%, 
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Hosmer-Lemeshow x2 statistic. negative predictive value 92.6%). 
Kurki et al (2002): CABDEAL has the 
highest predictive value for morbidity 
compared with EUROScore and Cleveland 
models., while EuroSCORE and Cleveland 
better for mortality. 
Canadian Model 
Tuman et al (1992).  
Morbidity and duration 
of ICU stay after cardiac 
surgery.  A model for 
pre-operative risk 
assessment 
 
Prospective study on 3,156 patients 
undergoing cardiac surgery in 
Chicago. Univariate analysis 
determined factors predictive of 
morbidity and used to construct 
model. 17 variables included and 
15 were significant and 11 
independently predictive. 
The validation group consisted of 
394 prospective patients. 
Morbidity was defined as the 
presence of one or more of 
the following categories of 
complications: 
Cardiac 
Pulmonary 
Renal 
Infectious 
Neurologic 
 
700 (22.2%) morbidity 
 
Operative mortality was 
defined as intra-operative 
death or death within 24hrs of 
surgery.  Death after this 
period was defined as post-
operative mortality. 
 
197 (6.2%) died 
Variable                                        Score 
Emergency surgery                          4 
Age 65-74yrs                                    1 
       >75yrs                                       2 
Renal dysfunction                             2 
Age of previous MI 3-6mo                 1 
                                <3mo                 2 
Female                                              2 
Reoperation                                       2 
Pulmonary hypertension                    2 
Cerebrovascular disease                   2 
Multivalve or CABG/valve                  1 
CHF                                                   1 
LV dysfunction                                   1 
Low risk (0-5): Predicted probability (95%CI) 
14.6 (14.3-14.8); observed morbidity 14.7%, 
p=0.99 
Increased (6-9): Predicted 34.4 (33.8-35.0), 
observed 30.6%, p=0.49 
High (>10): Predicted 61.0 (59.4-62.5), 
Observed 52.9%, p=0.62. 
Geraci et al (1993) 
Predicting the 
occurrence of adverse 
events after coronary 
artery bypass surgery 
Retrospective data on 2213 
Medicare patients >65yrs 
undergoing bypass surgery 
between January 1985 and June 
1986 in Alabama, Arizona, Indiana, 
Mortality was defined as 
death within 30days of 
admission.  
 
145 (6.6%) died. 
Variable                              OR(95%CI) 
Intercept                                        0.31 
History of CABG               2.8 (2.0-4.0) 
Emergent CABG                2.3(1.6-3.3) 
History of COPD                2.0(1.3-2.8) 
The C statistic of the model is 0.64 and the 
Hosmer-Lemeshow statistic was 9.15 (NS) 
indicating acceptable fit of the model to the 
data.  Approximately 25% of patients in 
lowest 4 deciles experienced adverse events 
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USA 
 
 
New York, Pennsylvania, Utah and 
Wisconsin were extracted from 
MedisGroups software by trained 
chart extractors. Data included 250 
key clinical findings representing 
patient history, physical 
examination, laboratory tests, 
pathologic examination, radiologic 
examination from admission.  
Entrance required presence of one 
of following ICD-9 codes: 36.10 – 
36.16, 36.19, 36.20 and 36.30.  
Adverse events defined as serious 
post-operative complications 
potentially related to quality of care, 
resulting in a high likelihood of 
increased morbidity, subsequent 
intensive therapy or prolonged 
hospital stay (defined by literature 
review and expert opinion).  
Statistical analysis included 
descriptive statistics, regression 
models (forward selection stepwise) 
the C statistic (measure of 
explanatory power of logistic model) 
and Hosmer-Lemeshow statistic 
(goodness-of-fit).  Database split in 
half and model developed for each 
and tested with other half using 
R(2).  All variables from either 
model were used as candidates in 
 
Non-fatal adverse event was 
defined as: 
New MI by ECG (3.0%) 
Cardiorespiratory arrest 
(5.3%) 
New CHF by cxr  (15.0%) 
Acute graft failure (0.3%) 
New onset thromboembolism 
(0.4%) 
New onset stroke (1.8%) 
Coma (2.6%) 
Mechanical ventilation >48hrs 
(3.9%) 
Wound infection (0.8%) 
Bacteraemia (0.6%) 
Acute renal failure (1st time 
dialysis or rise in creatinine to 
442mmol/l) (1.7%) 
More than 6 units of blood or 
packed red blood cells (9.6%) 
Unplanned return to surgery 
(4.9%) 
 
Rate of one or more adverse 
events was 33.0% (n=730). 
Infiltrate on xray                 1.8(1.1-3.1) 
Pulse>110bpm                  1.8(1.1-3.0) 
Age (10yr incr >65)            1.6(1.3-2.0) 
Urea nitrogen >10.7mmol  1.5(1.1-2.1)    
AMI at admission               1.4(1.0-1.8) 
History of MI                      1.3(1.1-1.5) 
Male                                  0.9(0.7-1.1) 
1 or 2 vessel disease        0.8(0.6-1.0)       
compared with just over 50% in the highest 2 
deciles.  Post-operative occurrence of 
adverse events was modestly associated 
with severity of illness at admission thus 
suggest could be marker of sub-optimal care. 
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stepwise logistic regression model 
applied to whole database.   
The Montreal Heart 
Institute Risk 
Assessment 
Classification 
Tremblay et al (1993).  
A simple classification 
of the risk in cardiac 
surgery: the first 
decade. 
 
 
 
Canada 
500 patients from 1980 study were 
included to define and establish risk 
classification.  A further 2029 
consecutive patients undergoing 
cardiac surgery (range of surgery) 
were prospectively studied 
(November 1988 to November 
1990).  Risk factor data were 
collected (LV function, unstable 
angina, recent MI, age, BMI, 
emergent surgery, systemic 
disturbances.)  Full definitions of 
each were given.  All patients were 
prospectively classified as normal, 
increased or high risk of early death 
during hospitalisation according to 
the number of risk factors present.  
Statistical analysis included: 
ANOVA, Chi Squared, Z proportion. 
Mortality was defined as 
postoperative mortality during 
hospitalisation (1980 and 
1990 populations) 
 
17 (3.4%) died in 1980 set 
100 (4.9%) died in 1990 set 
 
Length of stay in post-
operative ICU (1990 
population) 
 
Not stated 
 
Length of postoperative 
hospitalisation (1990 
population) 
 
Not stated 
Risk factors 
Poor left ventricular function 
Unstable angina or recent MI 
Evidence of heart failure 
Advanced age 
Obesity 
Emergent surgery 
Reoperation 
Other severe and uncontrolled systemic 
disturbances 
 
Patient classification 
Normal risk = no risk factor 
Increased risk = 1 risk factor 
High risk = >2 risk factors 
Mortality, number of days in ICU and number 
of days in hospital all increased with 
increasing number of risk factors (p=0.0001 
in all).  Changes in surgery and practice 
between datasets which may have 
influenced results. 
STS Model 2 
Hattler et al (1994).  
Risk stratification using 
The Society of Thoracic 
Surgeons Program 
 
 
 
 
USA 
728 patients undergoing CABG only 
within 2 year period ending in 
October 1993.  Data collection as 
per STS database on standardised 
forms and discharge charts 
reviewed by 2 nurse practitioners.  
Morbidity and length of stay were 
extracted from the STS database.  
Short-term follow-up attained 
through clinic visits or telephone 
Mortality 
Definition not given. 
 
Predicted mortality was 
6.94% 
Observed mortality was 
3.98% (n=29) 
 
Morbidity 
Included: 
Mortality                                  Risk ratio 
Morbid obesity                                 4.6 
Time from failed PTCA to                6.6  
CABG <6hrs 
Prior MI<21days                             3.4 
Cardiogenic shock                          8.9 
Preop IV nitrates                             3.1 
Preop inotropic agents                    5.1 
NYHA class IV                                3.0 
Non-elective procedure                  5.0 
Significant difference between the predicted 
and observed mortality (p<0.005). 
Number of complications and length of 
hospital stay was linear with increasing 
predicted risk. 
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contact with patient or GP.  A 
questionnaire was used to 
determine NYHA class and 
patient’s subjective assessment of 
own condition.Statistical methods 
included univariate analysis and 
multivariate step-wise logistic 
regression to determine 
independent risk factors, 
significance taken at p<0.05. The 
model was used to examine the 
effect of multiple risk factors to 
patient survival.  The model uses a 
modification of the Bayesian 
algorithm and was validated using 
set/test approach.   
Re-operative bleeding, 
Perioperative MI 
Infection (mediastinal, 
septicaemia) 
Stroke (permanent/transient) 
Ventilator >5days 
Renal failure (no dialysis) 
Dialysis required 
Heart block (permanent) 
Cardiac arrest 
Anticoagulant complication 
Tamponade 
Gatrointestinal complication 
Multisystem failure 
In-hospital mortality 
 
Morbidity rate not stated 
Preop IABP                                     5.8 
Ejection fraction <0.30                    3.6 
 
Morbidity 
Morbidity was assessed according to 
the STS predicted risk intervals (0-5%, 
5-10%, 10-20%, 20-30%, >30%) 
Mean no of complications per 
patient: 0.27, 0.71, 1.07, 2.12, 3.00, 
respectively. 
%patients having complications: 
16.78, 34.92, 42.71, 76.47, 66.67, 
respectively. 
Length of hospital stay: 10.48, 12.94, 
13.85, 23.60, 25.54, respectively 
Ontario Province Risk 
Score (French Score) 
Roques et al (1995) 
Quality of care in adult 
heart surgery: proposal 
for a self-assessment 
approach based on a 
French multicentre 
study. 
 
 
 
France 
 
Prospective study of 7,181 
consecutive patients undergoing 
adult cardiac surgery (type not 
stated) between January and April 
1993 from 42 French centres.  108 
parameters were collected 
regarding pre-operative risk factors, 
surgical procedure and post-
operative course (mortality, post-
operative events, ICU length of 
stay, overall post-operative stay 
and transfer to another hospital).  
Statistical methods included 
univariate analysis, 2 multivaraiate 
Mortality  
Not specifically defined. 
 
Overall mortality rate  was 6% 
but in 2 sub-centres was 4.1% 
Mortality/severe morbidity 
was defined as: 
Reoperation for thoracic 
wound infection 
Perioperative MI 
Duration of intubation >48hrs 
Severe infection 
Reoperation with CPB 
Low cardiac output 
Variable                       Weighting index 
Age 70-74                                            3 
Age 75-79                                            4 
Age >80                                                5 
Acute renal failure (creat >200umol/l)   5 
Renal failure (on dialysis)                     6 
Ejection fraction (30-50%)                    2  
Ejection fraction (<30%)                       5 
Saphenous vein graft only                    2 
Reoperation                                          2 
Tricuspid surgery                                  4 
Valve + CABG                                       2 
Critical situations: 
MI<48hrs                                               4 
Predictive accuracy of score appeared better 
than Parsonnet score for mortality alone 
(ROC 0.75 v 0.65, p=<0.0001).  The ROC 
was 0.74 for the French score on 
mortality/severe morbidity. 
For mortality the predictive value of French 
score was better in CABG group than valve 
group (ROC 0.72 v 0.69). 
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logistic regression analyses 
(mortality and mortality/severe 
morbidity), ROC curves (Hanley’s 
method) for the accuracy and 
predictive value of scoring systems 
overall and in 2 subsets (CABG and 
valve) (between 0.5-0.7 is low 
accuracy, 0.7-0.9 is a useful test) 
Cardiac massage 
Low limb ischaemia 
Ventricular arrhythmia 
Renal failure 
Stroke 
Gastro-duodenal hemorrhage 
Insertion of IABP 
 
Severe morbidity rate not 
stated 
Ventricular tachy/fibrillation                   4 
Preoperative intubation                       10 
Transplantation                                     9 
Post MI VSD                                         8 
Acute aortic dissection                        13 
Pulmonary embolectomy                    15 
 
Risk groups divided into: 
Score <2 
Score 2-3 
Score 4-6 
Score >6 
Tu Score 
Tu et al (1995).  
Multicentre validation of 
a risk index for mortality, 
intensive care unit stay 
and overall hospital 
length of stay after 
cardiac surgery. 
 
 
Canada 
13,098 patients undergoing cardiac 
surgery from 9 institutions from 
April 1st 1991 to March 31st 1992 
(derivation group: 6213 patients) 
and April st 1992 to March 31st 
1993 (validation group: 6885 
patients).  All information obtained 
from the PACCN database of all 
patients undergoing cardiac surgery 
in Ontario. 
In-hospital mortality 
Overall 3.7% mortality rate 
 
ICU LOS 
Overall mean LOS was 3.2 
days 
 
Post-op LOS 
Overall mean LOS was 10.6 
days 
 
Very long ICU LOS was 
>6days 
Patient numbers not stated 
 
Very long post-op LOS was 
defined as >17days. 
Patient numbers not stated 
Variable                                        Score 
Age <65                                                 0 
65-74                    2 
>75                                                  3 
Female                                                  1 
LVEF Grade 1                                       0 
           Grade 2                                      1 
           Grade 3                                      2 
           Grade 4                                      3 
Type of surgery  
           CABG only                                 0 
           Single valve                                2 
          Complex                                      3 
Urgency of surgery 
          Elective                                       0 
          Urgent                                         1 
          Emergency                                  4 
Repeat operation (yes)                         2 
Areas under the ROC curve for the risk index 
were 0.75, 0.67 and 0.71 for mortality, very 
long ICU LOS and very long post-op LOS 
predictions in the derivation set and 0.75, 
0.66 and 0.69 for the validation group.  The 
index predicted mortality significantly better 
that the very long post-op LOS (P<0.05) in 
both groups. 
CABDEAL Score Retrospective study. Prolonged hospital stay Variable                                         Score The sensitivity of the model was 56% and the 
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Kurki and Kataja (1996) 
Preoperative prediction 
of postoperative 
morbidity in CABG 
 
Finland 
386 consecutive CABG patients in 
1990 and 1991 in Helsinki.  
Preoperative data were collected: 
demographic, NHYA class, ECG, 
past medical history, priority of 
operation, cardiac catheterisation 
data, co-morbidity factors. In total 
21 pre-operative variables were 
collected. 
defined as >12 days because 
of adverse events, transfer to 
another hospital for treatment 
of complications or death 
during hospital stay. 
 
Morbidity or mortality rate not 
stated 
Creatinine (> 111)                                 2 
Age (>70)                                              1 
BMI  (>28)                                             1 
Diabetes                                                2 
Emergency operation                            2 
Abnormal ECG                                      1 
Lung disease                                         1 
specificity 77%.  The model gave 69 false-
positive and 39 false-negative results at the 
score.  The higher the risk score the greater 
the risk of increased morbidity and the better 
the specificity. 
Kurki et al (2002): CABDEAL has the 
highest predictive value for morbidity 
compared with EUROScore and Cleveland 
models., while EuroSCORE and Cleveland 
better for mortality. 
Magovern 
 Model 
Magovern et al (1996).  
A model that predicts 
morbidity and mortality 
after coronary artery 
bypass graft surgery 
 
 
 
USA 
All patients undergoing 
cardiothoracic surgery from July 
1991 have data (including 170 
preoperative, 50 procedural and 
100 post-operative variables) 
collected prospectively for the 
Allegheny General Hospital’s 
cardiothoracic database (standard 
definitions included).  1567 
consecutive patients undergoing 
CABG only between July 1st 1991 
and December 31st 1992 (test 
group) and 1235 between January 
1st 1993 and April 30th 1994 
(validation group) were analysed.  
The association of 125 preoperative 
variables were analysed.  Statistics 
included univariate and forward 
step-wise regression, chi-squared, 
Fisher Exact Test, Students t test, 
Hosmer-Lemeshow statistic, ROC, 
Outcome was defined as 
mortality or morbidity during 
the hospitalisation only. 
 
Mortality  
Death at any time during the 
hospital stay 
 
Mortality was 3.8% and 3.0%  
in the test and validation 
group, respectively. 
 
Morbidity 
An unexpected post-operative 
complication, major or minor, 
which resulted in the increase 
consumption of hospital 
resources owing to the 
required treatment.  Full 
definitions of each major and 
minor complication stated. 
Variable                      Clinical risk score 
Cardiogenic shock                                7 
Emergency operation                            5 
Urgent operation                                   4 
Catheterisation induced coronary 
closure                                                  4 
Severe LV dysfunction (LVEF <30%)   4 
Age >75yrs                                            3 
Cardiomegaly                                        2 
PVD                                                       2 
Chronic renal insufficiency (creat >1.9) 2 
Age 70-74yrs                                         2 
IDDM                                                     2   
NIDDM                                                  1 
Low BMI                                                1 
Female gender                                      1 
Reoperation                                          1 
Age 65-69yrs                                         1 
Anaemia                                                1 
Cerebrovascular disease                      1 
COPD                                                    1 
The predicted versus observed morbidity and 
mortality fell within the 95%CI.  The 
predictive power of the model for morbidity 
was 0.82 and 0.86 for mortality (area under 
ROC). 
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Odds ratio.  The clinical risk score 
was devised using the independent 
predictors of morbidity and mortality 
from the logistic regression model 
and assigned points.  ROC 
characteristics were used to verify 
the predictive accuracy of the 
model in the validation group. 
Major: 
cardiovascular failure, 
respiratory failure, acute renal 
failure, permanent cerebral 
deficit, major wound infection, 
pulmonary embolus, surgical 
intervention after CABG 
Minor: 
Temporary central nervous 
system deficit, acute renal 
insufficiency, atrial 
arrhythmias, ventricular 
arrhythmias, superficial 
wound infection, respiratory 
insufficiency, pleural effusion, 
pneumothorax, systemic 
sepsis, gastrointestinal 
bleeding, post-operative 
mediastinal bleeding. 
 
Major and minor complication 
was 16% and 36% in the test 
group and 12% and 40% in 
validation group. 
Albumin <4.0mg/dl                                1 
Renal dysfunction (creatinine 1.5-1.9)  1 
Elevated blood urea nitrogen (>29mg/dl)   
                                                              1 
Congestive heart failure                        1 
Atrial arrhythmia                                    1 
 
Total number of points is 50 but 
maximum score is 37. 
 
Mortality             Points         
%Predicted 
Low                       0-4               0.2 
Average                5-8                  2 
Moderate             9-11                 6 
High                   12-18               30 
Extremely High      19+              95 
 
Morbidity            Points           
%Predicted 
Low                        0-2                 20 
Moderate               3-5                 50 
High                       6-8                 74 
Extremely High        9+                 93   
Higgins et al (1997) 
Higgins et al (1997).  
ICU admission score for 
predicting morbidity and 
mortality risk after 
coronary artery bypass 
grafting. 
Prospectively collected data on 
4,918 consecutive patients 
undergoing CABG (alone or 
combined)  between January 1st 
1993 and March 31st 1995.  Data 
from the first 15 months (n=2,793) 
was used to develop the model and 
Morbidity was defined as the 
presence of one or more of 
the following during 
hospitalisation: Cardiac 
complication, prolonged 
ventilatory support, CNS 
complication, renal failure, 
Pre-operative factors 
Small body size (BSA <1.72m2)           1 
Prior heart operation - one                    1 
                                  - two or more       2 
History of op or angioplasty for PVD     3 
Age >70yrs                                            3 
Pre-operative creatinine >1.9mg/dl       4 
The ROC C-statistic reflecting mortality for  
the logistic regression mortality and clinical 
models were 0.86 and 0.87, respectively, 
which were not statistically different.  For 
morbidity it was 0.82, 0.80, respectively 
(p=0.02).  For isolated CABG a C-statistic for 
mortality and morbidity was 0.87 and 0.82, 
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USA 
data from the next 12 months 
(n=2,125) was used to validate the 
mode.  Separate analysis was also 
conducted on CABG only patients 
(n=2,035; 73% of the developement 
group).  Data collection reliability 
was tested by comparing the data 
with chart review of a random 
subset.  For each variable 98-100% 
agreement was found. 
Over 100 risk factors identified from 
literature, clinical experience and 
own work were collected.  The 
association of each factor with 
morbidity and mortality was 
evaluated.  Factors significant 
(p<0.05) and had at least 2% 
prevalence were entered into 
multiple logistic regression model 
(58 variables).  Two models were 
developed; one each for mortality 
and morbidity.  The number of 
terms allowed in the models was 
limited to 10% of the number of 
outcome events.  The goodness-of-
fit of each final logistic model was 
tested using Hosmer-Lemeshow X2 
statistic.   ROC curves were 
generated to measure and compare 
the accuracy of the models.  C-
statistic values closer to 1.0 indicate 
serious infection, death. 
 
In total population morbidity 
rate was 10.4% 
 
Mortality included all deaths 
during hospitalisation for the 
operation, regardless of 
length of stay. 
 
Total population mortality rate 
was 3.1%. 
Pre-operative albumin <3.5mg/dl          5 
 
Intra-operative factors 
CPB time >160mins                              3 
Use of IABP after CPB                          7 
 
ICU admission physiology 
A-a gradient >250mmHg                       2 
Heart rate > 100 beats per min             3 
Cardiac index <2.1.min-1.m-2                 3 
CVP >17mmHg                                     4 
Arterial bicarbonate <21mmol/l             4 
 
                 
respectively.  Using the clinical model, the 
observed outcomes fell within the 95%CI 
predicted by the developmental set.  
Applying the clinical model to patients in the 
validation set produced C-statistics of 0.85 
for mortality and 0.82 for morbidity.  Hosmer-
Lemeshow goodness-of-fit determined all 
logistic and clinical models calibrate well. 
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better discrimination by the model. 
ACC/AHA Practice 
Guidelines 
Eagle et al (1999).  
ACC/AHA guidelines for 
coronary artery bypass 
graft surgery: Executive 
summary and 
recommendations. 
 
 
USA 
Based on 7,290 patients 
undergoing isolated CABG surgery 
between 1996 and 1998 
Mortality defined as in-
hospital mortality 
 
Mortality rate was 2.93% 
 
CVA defined as new focal 
neurological event persisting 
at least 24hrs. 
 
CVA rate was 1.58% 
 
Mediastinitis during index 
admission defined as a 
positive deep culture and/or 
Gram stain and/or 
radiographic findings 
indicating infection and 
requiring re-operation. 
 
Mediastinitis rate was 1.19% 
                     Mortality score         CVA 
score 
Age 60-69                   2                  3.5 
Age 70-79                   3                  5 
Age >80                      5                  6 
Female sex                  1.5                 
EF <40%                     1.5               1.5 
Urgent surgery            2                  1.5 
Emergency surgery     5                 2 
Prior CABG                 5                 1.5 
PVD                             2                  2 
Dialysis or creat >2     4                  2 
COPD                        1.5 
Peri-operative risk 
Total score       Mortality%        CVA% 
0                        0.4                    0.3 
1                        0.5                    0.4 
2                        0.7                    0.7 
3                        0.9                    0.9 
4                        1.3                    1.1 
5                        1.7                    1.5 
6                        2.2                    1.9 
7                        3.3                    2.8 
8                        3.9                    3.5 
9                        6.1                    4.5 
10                      7.7                   >6.5 
11                      10.6 
12                      13.7 
13                      17.7 
14                       >28.3 
Staat et al (1999) 
Severe morbidity after 
coronary artery surgery: 
development and 
validation of a simple 
predictive clinical score. 
 
France 
Retrospectively collected 43 pre-
operative and 4 intra-operative 
clinical variables for 679 
consecutive patients undergoing 
CABG between 1st January and 3rd 
Decemeber 1996 in one French 
institution.  Variables were decided 
on literature review, discussion with 
participating physicians and 
available data. 
Severe morbidity was 
defined as mortality or one of 
the following 10 non-fatal 
adverse events: 
Low cardiac output 
IABP 
MI 
Mechanical ventilation >48hrs 
Serious pneumonia 
Other serious infections 
Variable                                         Score 
Symptomatic right heart failure             7 
Ventricular arrhythmias                         4 
Reoperation (CABG)                             4 
COPD                                                    3 
BMI <24                                                 2 
ST changes on pre-op ECG                  2 
For the validation group, the area under the 
ROC curve was 0.65.  With a threshold score 
of 2 the sensitivity was 63% and specificity 
75%.  The positive predictive value was low 
at 23.8% and the negative predictive value 
was high (88.0%). 
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Acute renal failure 
Excessive bleeding 
Unplanned return to surgery 
CNS complication 
 
17 (2.5%) operative mortality  
156 (23.0%) severe morbidity 
Mean ICU LOS 2.8 days 
Mean hospital LOS 13.5 days 
A New Cardiac Risk 
Score 
Wong et al (1999).  Risk 
factors of delayed 
extubation, prolonged 
length of stay in the 
intensive care unit and 
mortality in patients 
undergoing coronary 
artery bypass graft with 
fast-track cardiac 
anaesthesia 
 
 
Canada 
 
Prospective study of 885 
consecutive patients undergoing 
CABG (following the fast-track 
anaesthesia protocol and standard 
surgical procedure) between April 
to November 1995 in 1 hospital.  
Data collection included pre-
operative, intra-operative, post-
operative and outcome variables 
(all stated) collected by 
anaesthetists and research nurses.  
Statistical methods included 
univariate analysis, multiple 
stepwise logistic regression models.  
A model was developed for each 
outcome measures.  An integer 
score between 1 and 6 was given 
based on the odds ratio and clinical 
considerations for each risk factor 
identified from logistic regression 
model.  The models and scores 
were validated using bootstrap 
Delayed extubation (>10hrs) 
Medium time 7hrs 
25% >10hrs 
 
Prolonged ICU LOS (>48hrs) 
Median time 1 day 
16.7% >48hrs 
 
Mortality (death occurring 
within 30 days of hospital or 
during hospital stay).   
23 (2.6%) died. 
Variable                                         Score 
Delayed extubation 
Age>75yrs                                             3 
Age 61-75yrs                                         2 
Female gender                                      2 
Excessive bleeding  (post)                    6 
IABP  (post)                                           6 
Inotropes (post)                                     2 
Atrial arrhythmia (post)                          2 
Prolonged ICU LOS 
Age >75yrs                                            4 
Age 61-75yrs                                         2 
MI                                                          3 
Female gender                                      3 
Renal insufficiency (post)                      6 
IABP  (post)                                           6 
Inotropes (post)                                     4 
Atrial arrhythmia (post)                          4 
Excessive bleeding (post)                     3 
 
Mortality 
Left ventricle grade 4                            5 
No significant differences between area 
under ROC curve between the logistic 
regression and clinical risk scores.  No 
significant differences between the observed 
and predicted outcomes at various clinical 
risk score ranges. 
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techniques.  Area under ROC curve 
was used to assess the predictive 
performance of the models and 
scoring. 
Emergency surgery                               4 
Female gender                                      3 
Pitkanen Model 
Pitkanen et al (2000).  
Intra-institutional 
prediction of outcome 
after cardiac surgery: 
comparison between a 
locally derived model 
and the EuroSCORE. 
 
 
 
 
Finland 
 
Retrospective analysis of 4592 
patients who underwent cardiac 
surgery (excluding those done off-
CPB) between January 1st 1992 
and December 31st 1996 and 
prospectively on 821 consecutive 
patients between September 1st 
1998 and May 31st 1999.  Data 
were collected by 2 investigators.  
Mortality data were obtained from 
Statistics Finland.  Compared with 
EuroSCORE.  Predictive models 
were developed by logistic 
regression.  3061 patients from 
retrospective sample were 
randomised to a derivation 
database and validated on the 
remaining sample and in the 
prospective sample.  A model for 
each outcome was developed using 
univariate analysis, backward 
stepwise logistic regression 
analysis. P<0.005 formed the final 
predictive model.  Model calibration 
was determined using Hosmer-
Lemeshow goodness-of-fit statistic.  
The discrimination abilities 
Morbidity (overall) was 
defined as 1 or more of the 
following: 
Haemodynamic problems 
(inotropic support, IABP), 
mechanical ventilation 
>24hrs, serious 
gastrointestinal complications, 
anuria, stroke multi-organ 
failure, resternotomy due to 
other cause than excessive 
bleeding, sepsis, pneumonia, 
mediastinitis, psychosis or 
remarkable confusion, 
readmission to the ICU or 
complicated clinical situation 
at discharge to another 
hospital. 
 
Overall morbidity was 22.0% 
and 18.4% in the 
retrospective and prospective 
databases, respectively. 
 
Morbidity: Length of ICU stay 
>2days. 
 
Variable                                OR(95%CI) 
Morbidity 
Age yrs                           1.04(1.03-1.06) 
Female gender               1.32(1.05-1.65) 
NYHA class                    1.29(1.10-1.51) 
Previous stroke               1.90(1.09-3.29) 
Number of previous MIs 1.32(1.16-1.51) 
Diuretic use                    1.35(1.04-1.74) 
Renal failure (creat>120)2.42(1.09-5.38) 
LVEF                              0.99(0.98-0.99) 
Pulmonary rales             1.68(1.02-2.76) 
CABG only                      0.52(0.36-0.75) 
UAP and ongoing MI      8.09(1.56-42.1) 
Combined CABG and valve 1.73(1.16- 
                                                        2.60) 
Combined AVR and MVR 4.57(1.47- 
                                                        14.2) 
Emergency operation     2.08(1.14-3.80) 
 
ICU LOS>2days 
Age yrs                          1.04(1.02-1.06) 
Female gender               1.62(1.18-2.21) 
NHYA class                    1.49(1.18-1.87) 
Diabetes                         1.57(1.11-2.24) 
Previous stroke               3.61(1.95-6.70) 
ASO in lower limbs         1.67(1.05-2.65) 
Previous inferior MI        1.84(1.27-2.66) 
There was a difference in the calculated risk 
between the retrospective and prospective 
databases.  The validation databases were 
not different with regard to expected risk of 
ICU LOS>2days.  All 3 predictive models 
calibrated well, with the exception of the 
morbidity model (Hosmer-Lemeshow p value 
for retrospective data p=0.002, the others in 
the region of p=0.4).  Discriminate abilities of 
the model compared with EuroSCORE with 
similar, except for morbidity.  In the 
prospective database EuroSCORE was 
higher among non-survivors than survivors, 
with morbidity than without and among those 
with ICU LOS>2days compared with <2days.  
This model and EuroSCORE appeared 
equally accurate in predicting adverse 
outcome, but not morbidity. 
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assessed by area under ROC 
curve.  Comparison with 
EuroSCORE in outcome states 
used non-parametric tests.   
Mean ICU LOS was 1.9 and 
1.4 days for the retrospective 
and prospective databases, 
respectively. 
 
Mortality was defined as 
death occurring within 30 
days from the operation. 
 
Mortality was 2.0% and 1.1% 
in the retrospective and 
prospective databases, 
respectively. 
 
Diuretic use                    1.51(1.08-2.12) 
LVEF                              0.98(0.97-0.99) 
CABG only                     0.32(0.23-0.45) 
UAP and ongoing MI      4.06(1.09-15.1) 
Emergency operation     2.61(1.35-5.03) 
 
Mortality 
Age yrs                           1.09(1.04-1.13) 
NYHA class                    1.37(1.17-1.59) 
Diabetes                         2.14(1.12-4.12) 
Number of previous MIs 1.54(1.14-2.07) 
LVEF                              0.98(0.96-0.99) 
CABG only                      0.30(0.16-0.57) 
AVR, MVR and CABG    4.98(1.19-20.7) 
Emergency operation     4.33(1.78-10.5) 
Cardiac Anaesthesia 
Risk Evaluation Score 
(CARE) 
Dupuis et al (2001).  A 
clinically useful predictor 
of mortality and 
morbidity after cardiac 
surgery 
 
 
 
Canada 
Prospective observational study of 
3,548 consecutive patients 
undergoing a cardiac surgical 
procedure at Ottawa Heart Institute.  
Split into reference group (2000 
patients between November 12 
1996 and March 18th 1998) and 
validation group (1,548 patients 
between March 19th 1998 and April 
2nd 1999). 
CARE score was designed to 
resemble the ASA physical staus 
classification. 
Mortality defined as in-
hospital death 
 
Reference and validation 
group mortality rate both 3.4% 
 
Morbidity defined as 
complications in one or more 
of the following categories: 
cardiovascular, respiratory, 
neurological, renal, infectious, 
any other. 
-If no morbidity data, 
prolonged post-operative LOS 
used as a surrogate. 
 
1. patient with a stable cardiac 
disease and no other medical 
problem.  A non-complex surgery 
is undertaken 
2. Patient with stable cardiac disease 
and one or more uncontrolled 
medical problems.  A non-complex 
surgery is undertaken 
3. Patient with any uncontrolled 
medical problem and in whom a 
complex surgery is undertaken 
4. Patient with any uncontrolled 
medical problem and in whom a 
complex surgery is taken 
5. Patient with chronic or advanced 
cardiac disease for whom cardiac 
surgery is undertaken as a last 
hope to save or improve life 
E. Emergency: surgery as soon as 
diagnosis is made and operating 
room is available 
Can have scores 1-5 or 3E, 4E, 5E 
Areas under ROC curve were 0.791 +/- 
0.067 and 0.740 +/- 0.024 for the prediction 
of morbidity and mortality, respectively. 
Compared all analyses with the Parsonnet 
score and Tuman classification.  All risk 
models had acceptable calibration in 
predicting mortality and morbidity, except 
Parsonnet which failed to calibrate for 
morbidity. 
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Ref grp morbidity rate 20.7% 
Validation grp morbidity rate 
22.2% 
Ref grp prolonged LOS 10.2% 
Validation grp prolonged LOS 
12.3% 
Ref grp mean post-op LOS 
8.8 days 
Validation group mean post-
op LOS 9 days. 
QMMI Score 
Fortescue et al (2001).  
Development and 
validation of a clinical 
prediction rule for major 
adverse outcomes in 
coronary bypass 
grafting. 
 
 
USA 
 
All patients undergoing CABG only  
without additional procedure 
between August 1993 to October 
1995 in 12 large tertiary care 
centres.  The 9,498 patients were 
divided randomly into 2 mutually 
exclusive subsets of episodes: the 
derivation set (6,237) and validation 
set (3,261). 
Considered 27 pre-operative 
factors.  Data obtained 
prospectively through patient 
interviews and retrospectively 
through the medical notes.  Data 
collection benchmarking was 
performed by comparing with the  
Uniform Hospital Discharge Data 
Set.  Factors considered potential 
predictors of major adverse 
outcomes included correlates of 
morbidity and mortality published in 
Major adverse outcome 
defined as any of the 
following: 
Death 
Renal failure, 
MI 
Cardiac arrest 
Stroke 
Coma 
Death 
Each patient counted only 
once in the analyses 
regardless of total number of 
adverse outcomes. 
 
Mortality rate 2.5% 
 
In total 408 (4.3%) morbidity 
rate 
In derivation set 6.5% had 
one or more adverse 
Variable                                                
Score 
Pre-CABG creatinine >3.0mg/dl          12   
Age >80yrs                                          11   
Cardiogenic shock                              10    
Emergent operation                              9    
Age 70-79 yrs                                        8   
Prior CABG                                           7    
EF <30%                                               6    
History of liver disease                          6   
Age 60-69yrs                                         5   
Pre-op creatinine 1.5-3.0mg/dl              5   
Stroke or TIA                                         4   
EF 30-49%                                            3    
History of COPD                                   3    
Female gender                                      3   
History of hypertension                         2    
Urgent operation                                   2    
The mean total risk score of those with and 
without a major adverse outcome was 18.0 
+/- 8.5 and 11.3 +/- 6.6 points, respectively.  
Calibration of the model using Hosmer-
Lemeshow goodness-of-fit test was good.  
ROC curve areas were 0.77 for death, 0.71 
for renal failure, 0.75 for coma, 0.68 for 
stroke, 0.72 for cardiac arrest and 0.67 for 
MI.  In the validation set the ROC curve 
areas were 0.74, 0.75, 0.74, 0.70, 0.68 and 
0.64 in above categories, respectively. 
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previous analyses and other 
variables suggested by members of 
the Consortium.  Variables studied 
included ischaemic heart disease 
stage, cardiac anatomy and 
function, other conditions and risks 
prior to surgery, and therapy 
received before surgery.  Variables 
that showed significant correlation 
(p<0.05) were then entered into a 
step-wise regression analysis.  
Factors with p<0.05 were retained.  
The resulting independent 
correlates were used to develop the 
clinical prediction rule.  After 
assigning a value to each variables 
each patient was given a total 
score.  Discriminatory performance 
of the model was internally 
validated between the 2 groups 
using area under ROC 
outcomes. 
CORRAD Score 
Wouters et al (2002) 
Preoperative prediction 
of early mortality and 
morbidity in coronary 
bypass surgery 
 
The Netherlands 
 
?retrospective study 
The development set was the first 
653 patients undergoing CABG in 
1998.  Validation set 1 contained 
503 patients undergoing CABG in 
1999.  Validation set 2 contained 
466 patients undergoing CABG in 
2000.  Pre-, per- and post-operative 
data obtained from CORRAD 
database (variables stated).  All 
Follow-up was 180 days (6 
months post-surgery) 
 
Early mortality defined as 
hospital mortality and cardiac-
related mortality within the 6 
month follow-up period. 
 
Development set: 5.6% 
(n=32) 
Early mortality                B-coefficient 
Sex                                                   0.71 
Age                                                   0.67 
Hypertension                                    0.62 
Lung disease                                      1.0 
Reoperation                                       0.9 
Operative status                                 0.7 
Ventricular function                          0.67 
 
Morbidity 
Area under ROC for early mortality was 0.81 
(development) 0.77 (validation 1), 0.73 
(validation 2), 0.67 (Parsonnet in validation 
1), 0.67 (Parsonnet in validation 2), 0.70 
(EuroSCORE in validation 1) and 0.68 
(EuroSCORE in validation 2). 
Area under ROC for morbidity was 0.73 
(development) 0.62 (validation 1) and 0.69 
(validation 2).  
Score sensitivity  and specificity was 0.46 
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follow-up was 6 months post-
surgery.  Statistical methods 
included univariate analysis (odds 
ratios and chi-squared) to identify 
risk factors, multiple logistic 
regression analysis for independent 
risk factors.  Non-significant 
variables eliminated from the model 
one at a time.  The weight attributed 
to each variable was obtained from 
the logistic regression B-
coefficients.  The area under ROC 
was used to assess discrimination 
between mortality and morbidity for 
all datasets.  Low and high risk 
groups were then defined.  Score 
was compared with parsonnet and 
EuroSCORE for the validation sets. 
 
Validation 1: 5.7% (n=29) 
Validation 2: 4.8% (n=21) 
 
Morbidity was registered in 
the case of hospital mortality 
and also the following 
complications resulting in a 
prolonged hospital stay: 
ventilatory support > 3days, 
sternal wound 
nephrological 
neurological 
pulmonary 
gastrointestinal 
vascular problems  
 
Development set: 19.1% 
(n=108) 
Validation 1: 26% (n=131) 
Validation 2: 16% (n=75) 
Age                                                   0.45 
Diabetes                                           0.62 
Hypertension                                    0.80 
Kidney disease                                 1.06 
Lung disease                                    0.60 
Reoperation                                     0.84 
Operative status                               1.13 
Ventricular function                          0.54 
 
 
Hospital stay for the 1999 and 2000 sets 
was 7.1 and 7.3 days respectively for 
low risk  (<2) patients and 13 and 12 
days for high risk patients (>2). 
 
 
 
 
 
 
 
(82/186) and 0.86 (673/783), respectively.  
The predictive value for morbidity was 0.42 
(82/195) and for no-morbidity 0.87 (673/777).  
Rates of mortality and morbidity between low 
risk (<2) and high risk (>2) patients was 
statistically significant (p,0.05).   
The hospital stay between predicted high 
and low risk groups is statistically significant 
(p<0.05). 
Amphia Score 
Huijskes et al (2003).  
Outcome prediction in 
CABG and valve 
surgery in the 
Netherlands: 
development of the 
Amphiascore and it's 
comparison with the 
EUROScore 
7282 patients undergoing CABG 
and /or valve surgery between 
January 1997 and December 2001. 
Collected demographic, morbidity, 
cardiac status and 
indication/intervention variables 
pre-operatively. 
1. in-hospital death.         
171 (2.3%) died 
 
2. Major adverse cardiac 
event (MACE) defined 
as in-hospital death or 
peri-operative MI or 
VT/VF 1224 (17%) 
MACE 
 
3. Extended length of 
stay (ELOS) defined as 
intensive care length of 
stay of at least 3 days or 
in-hospital death.              
In hospital death 
Age, per 5 yrs over 60,                          1 
Female                                                  1 
Creatinine level (150-200)                     3 
Poor LVEF                                            2 
Prior cardiac surgery                             4 
MI within last 24hrs                               5 
Emergency procedure                           3 
Combined CABG/Mitral valve               4 
 
The MACE and ELOS models was less 
predictive than the in-hospital death model. 
Good correlation with the EUROScore - 
complete agreement in 72%, partial 
agreement in 93%, Kappa=0.37, weighted 
Kappa 0.51. 
Only included pre-operative factors and 
increased cross-clamping time, increased 
operative use of blood products, lower 
intraoperative diastolic blood pressure and 
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The Netherlands 
1001 (14%) ELOS MACE 
Age                                                        1 
Extracardiac arteriopathy                      2 
Pulmonary hypertension                       2 
MI>30days                                            2 
Prior cardiac surgery                             6 
MI within last 24hrs                               9 
Emergency procedure                           3 
Cobmined CABG/AVR                          5 
Combined CABG/MVR                         6 
 
ELOS 
Age                                                        1 
Female                                                  2 
Neurological dysfunction disease         2 
Creatinine level (150-200)                     4 
Haemoglobin (80-90%)                         1 
Poor LVEF                                            4 
Pulmonary hypertension                       3 
Prior cardiac surgery                             4 
MI within last 24hrs                               4 
Failed PCI                                             3 
Emergency procedure                           3 
Critical pre-operative state                    3 
Combine CABG/AVR                            2 
Combined CABG/MVR                         6 
intraoperative electrocardiographic ST-T 
chages are factors influencing post-op MI. 
Janssen et al (2004) 
Preoperative prediction 
of prolonged stay in the 
intensive care unit for 
coronary bypass 
888 patients undergoing CABG only 
between January 2000 and 
December 2001 in the University 
Medical Centre.  Pre-, per- and 
post-operative data extracted from 
Prolonged length of stay in 
ICU was defined as longer 
than 3 days.   
Indications for prolonged 
length of ICU stay were: 
Variables                            Odds Ratio      
Lung disease (Y/N)                          2.46 
No sinus rhythm (Y/N)                      4.60 
Mild valve pathology (Y/N)               0.30 
Reoperation (Y/N)                            4.00 
Area under ROC was 0.68 for prolonged 
length of ICU stay.  The observed risk 
compared well with predicted risk.  The 
specificity and sensitivity of the prognostic 
test was 99% (95%CI 98.4-99.6) and 9% 
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surgery 
 
The Netherlands 
CORRAD database (stated).  
Statistical methods included 
univariate analysis, Fisher’s exact 
test (which variables contributed to 
prolonged ICU length of stay), odds 
ratios, multiple logistic regression 
analysis (independent risk factors), 
odds ratios (used as estimates of 
risk) and step-wise logistic 
regression (prognostic value of 
variables).  P<0.05 was taken as 
statistically significant for entry into 
prognostic model.  ROC curve was 
calculated was used to measure the 
prognostic value of these variables.  
A score was then calculated as a 
linear function of the variables 
included and the predicted 
probability of prolonged length of 
stay determined. 
Probability of >40% was the cut-off 
for constructing a prognostic test. 
Prolonged ventilation 
Low cardiac output defined as 
need for inotropic support and 
a cardiac index <2.2l/min per 
m2 
Need for Swan ganz-catheter. 
 
104 (12%) had a prolonged 
length of stay.  Mean ICU stay 
was 2.2±5.1 days with a 
median of 1 day (range 0-
79days). 
 
Hospital mortality was 2.8%. 
No elective operation (Y/N)              4.01 
Off-pump procedure (Y/N)               0.20 
 
The S-Score was calculated for each 
patient using the logistic regression 
coefficients and the distribution and 
predicted probabilities for those with and 
without prolonged ICU length of stay 
were calculated. 
 
Low risk: 5% 
Intermediate risk: 15% 
High risk: 30% 
Very high risk: >40% 
 
 
(95%CI 4-14), respectively.  The positive 
predictive value was 60% (95%CI 36-84) and 
the negative predictive value was 89% 
(95%CI 87-91). 
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Appendix 2: Data Definition Tables. 
• All the tables are below are constructed in the order in which the variables appear on the CRF and in the data entry tables. 
• An indicator field is where completion of subsequent fields are dependent on answering ‘yes’ in the indicator field.  In all instances, subsequent 
fields follow directly after the indicator field. 
• In the field name/variable column prefixes are used to identify variables that are repeated at different time-points.  Pre- is pre-operative, IO is 
intra-operative, PO is within the first 12 hours post-op and D1, D3, D5, D8 and D15 are post-operative days 1, 3, 5, 8 and 15, respectively. 
• In the code in database column the code 3 for ‘not stated’ means variable not found from source by the data collector.  A code of -1 for ‘missing’ 
indicates the variable has been missed by the data collector. 
• Consistency in coding:  1=yes, 2=no, 3=not stated, -2=not done or not stated and -1=missing/NA.  Mainly numerical fields where possible.  
Consistency in text fields due to one data collector/enterer. 
 
Admin table  
Field name/Variable Definition Type of field Code in database 
Study number Unique identifier Text As stated 
Hosp no Participant hospital number Text As stated 
NHS no Participant unique NHS number Text As stated, -1=missing 
Incl in Pilot II Included in pilot study Number  1=yes, 2=no,  -1=missing 
Consultant Consultant surgeon Text Initials stated 
DoRecruit Date of recruitment into study Date  As stated, 01/01/2001 if missing 
Incl criteria met? Were all inclusion criteria met? Number 1=yes, 2=no,  -1=missing 
DOB Participant date of birth Date As stated, 01/01/2001 if missing 
Age Participant age (yrs) Number As stated, -1=missing 
Gender  Participant gender Number 1=male, 2=female, -1=missing 
Ethnicity Participant ethnicity, participant defined  Text As stated, blank if missing 
Ethnicity code Recode of participant ethinicity Number 1= Causasian, 2=Asian, 3=Black, 4=Other, -2=not 
stated 
Postcode Participant’s home postcode Text As stated, in AA1 1BB format 
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DoAdm Date of admission to Heart Hospital Date As stated, 01/01/2001 if missing 
Home or transfer Indicator code: Source of admission Number 1=home, 2=transfer, 3=other, -1=missing 
State other adm method State other admission method if 3 in indicator code Text As stated, blank if missing 
Tranferring hospital State transferring hospital, if 2  in indicator code Text As stated, blank if missing 
DoAdm Transfer hosp Date of admission to transferring hospital, if 2 in indicator code Date As stated, 01/01/2001 if missing 
Private patient? Was the participant a private patient? Number 1=yes, 2=no, -1=missing 
Compl study? Indicator field: Did the participant complete the study? Number 1=yes, 2=no, -1=missing 
DODiscont Date of discontinuation in study, if no in indicator field Date As stated, 01/01/2001 if missing 
Reason for discont Reason for discontinuation, if no in indicator field Number 1= not fulfill incl crit, 2=pt request to withdraw, 3= 
invest judgement, 4=pt death, 5=non-compliance, 
6=lost to f-up, 7=other 
Explanation Further explanation for discontinuation in study, if no in indicator field Text As stated, blank if missing/NA 
Genetics sample received? Was a DNA sample received from the retrospective sampling? Number 1=yes, 2=no, -1=missing. 
Genetics consent (prospective) Was consent for prospective genetics study given? Number 1=yes, 2=no, -1=missing. 
Fit for discharge validation Was the participant included in the ‘fit for discharge’ validation? Number 1=yes, 2=no, -1=missing. 
Other trial participation Indicator field: Did the participant take part in another trial? Number 1=yes, 2=no, -1=missing 
State trial State the trial, if yes in indicator field Text As stated, blank if missing/NA 
Trial control or treat State whether the participant was a control or treatment subject, if yes in 
indicator field 
Text As stated, blank if missing/NA 
Admin comments Any other admin comments Text As stated, blank if no other comments 
 
 
Pre-operative table 
Field name/Variable Definition Type of field Code in database 
Study number Unique identifier Text As stated 
Hosp number Participant hospital number Text As stated 
Cardiogenic shock Magovern indicator field: Cardiogenic shock present. Defined as systolic 
blood pressure <50mmHg and a cardiac index <2.0l/min/m2 and evidence 
of peripheral hypoperfusion. 
Number 1=yes, 2=no,  -1=missing 
Catheter coronary closure Magovern indicator field: Catheter induced coronary closure. Defined as 
iatrogenic coronary occlusion or dissection secondary to a diagnostic 
Number 1=yes, 2=no,  -1=missing 
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catheterisation or angioplasty, or both, that requires heart surgery within 
24 hrs. 
DOpreopCXR Date of pre-op chest x-ray Date As stated, 01/01/2001 if missing 
Cardiomegaly Magovern indicator field: Cardiomegaly present. Defined as enlarged 
heart as determined by chest radiography or echocardiography 
Number 1=yes, 2=no, 3=not stated, -1=missing/report 
missing 
Cardiomegaly state on CXR 
report 
Definition of cardiomegaly on chest-x-ray report, if yes in indicator field Text As stated, blank if missing 
Reoperation Magovern indicator field: Has the participant had any previous cardiac 
surgery? 
Number 1=yes, 2=no,  -1=missing 
No prev op Number of previous cardiac surgeries, if yes in indicator field Number As stated, -1=missing 
Doprevop Date of previous surgery, if yes in indicator field Date As stated, 01/01/2001 if missing 
Prev op state State the previous operation, if yes in indicator field Number 1= CABG, 2=AVR, 3=MVR, 4=CABG+AVR, 
5=CABG+MVR, 6=AVR+MVR, 
7=CABG+MVR+AVR,8=other, -1=missing/not 
stated 
Cerebrovasc disease Magovern indicator field: Cerebrovascular disease present. Defined as 
history of transient ischaemic attack, embolic stroke or non-embolic stroke 
and/or angiographic evidence of internal carotid stenosis >50%. 
Number 1=yes, 2=no,  -1=missing 
COPD Magovern indicator field: Chronic obstructive pulmonary disease 
present.  Defined as pulmonary disease that results in functional disability 
or requires bronchodilator therapy and/or results in abnormal spirometry 
as defined by a forced expiratory volume in 1s <75% of that predicted. 
Number 1=yes, 2=no,  -1=missing 
Atrial arrhyth Magovern indicator field: History of atrial arrhythmia, defined as atrial 
fibrillation, flutter or tachycardia. 
Number 1=yes, 2=no,  -1=missing 
State arrhyth State atrial arrhythmia, if yes in indicator field Text As stated, blank if missing 
CVA Has the participant ever had a stroke? Number 1=yes, 2=no,  -1=missing 
TIA Has the participant ever had a transient ischaemic attack Number 1=yes, 2=no,  -1=missing 
State CVA/TIA State any additional information related to CVA/TIA Text As stated, blank if no further details/missing 
Pre Albumin Magovern indicator field: Pre-operative albumin level (mg/dl). Low 
serum albumin defined as <4.0 mg/dl. 
Number As stated, -2, not done, -1=missing 
Hypertension SCTS definition: Identifies if the patient has hypertension defined as Number 1=yes, 2=no,  -1=missing 
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receiving treatment or dietary advice or if blood pressure has been 
recorded greater than 140/90mmHg on two occasions, or lower if on 
medication. 
State hypertension State any additional information related to hypertension Text  
Liver disease Has the participant ever had or currently has liver disease? Number 1=yes, 2=no,  -1=missing 
GI bleeding Has the participant ever had or currently have GI bleeding? Number 1=yes, 2=no,  -1=missing 
State GI bleeding If yes above, state type of bleeding Text  
Dialysis Does the participant have a current requirement for dialysis? Number 1=yes, 2=no,  -1=missing 
Immunosuppressants Is the participant currently taking immunosuppressant medication? Number 1=yes, 2=no,  -1=missing 
NYHA class Class I: patients with no limitation of activities; they suffer no symptoms 
from ordinary activities. Class II: patients with slight, mild limitation of 
activity; they are comfortable with rest or with mild exertion. Class III: 
patients with marked limitation of activity; they are comfortable only at 
rest.  Class IV: patients who should be at complete rest, confined to bed 
or chair; any physical activity brings on discomfort and symptoms occur at 
rest.  
Number Class as stated, -1=missing 
ACEI Indicator field: Is the participant currently taking ACE Inhibitor medication? Number 1=yes, 2=no,  -1=missing 
ACEI state drug State the ACE inhibitor taking, if yes in indicator field Text As stated, blank if missing 
ACEI state dose State the dose (mg) of the ACE inhibitor taking, if yes in indicator field  Number As stated, -2=not documented, -1=missing 
AntiArrh Indicator field: Is the participant currently taking anti-arrhythmia 
medication? 
Number 1=yes, 2=no,  -1=missing 
AntiArrh state drug State the anti-arrhythmic taking, if yes in indicator field Text As stated, blank if missing 
AntiArrhy state dose State the dose (mg) of the anti-arrhythmic taking, if yes in indicator field  Number As stated, -2=not documented, -1=missing 
Anticoag Indicator field: Is the participant currently taking anticoagulation 
medication? 
Number 1=yes, 2=no,  -1=missing 
Anticoag state drug State the anticoagulant taking, if yes in indicator field Text As stated, blank if missing 
Anticoag state dose State the dose of the anticoagulant taking, if yes in indicator field  Number As stated, -2=not documented, -1=missing 
Antiplatelets Indicator field: Is the participant currently taking anti-platelet medication? Number 1=yes, 2=no,  -1=missing 
Antiplatelets state drug State the anti-platelet  taking, if yes in indicator field Text As stated, blank if missing 
Antiplatelets state dose State the dose (mg) of the anti-platelet taking, if yes in indicator field  Number As stated, -2=not documented, -1=missing 
BBlock Indicator field: Is the participant currently taking beta blocker medication? Number 1=yes, 2=no,  -1=missing 
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BBlock state drug State the beta blocker taking, if yes in indicator field Text As stated, blank if missing 
Bblock state dose State the dose (mg) of the beta blocker taking, if yes in indicator field  Number As stated, -2=not documented, -1=missing 
CCB Indicator field: Is the participant currently taking calcium channel blocker 
medication? 
Number 1=yes, 2=no,  -1=missing 
CCB state drug State the calcium channel blocker taking, if yes in indicator field Text As stated, blank if missing 
CCB state dose State the dose (mg) of the calcium channel blocker taking, if yes in 
indicator field  
Number As stated, -2=not documented, -1=missing 
Diuretic Indicator field: Is the participant currently taking diuretic medication? Number 1=yes, 2=no,  -1=missing 
Diuretic state drug State the diuretic taking, if yes in indicator field Text As stated, blank if missing 
Diuretic state dose State the dose (mg) of the diuretic taking, if yes in indicator field  Number As stated, -2=not documented, -1=missing 
Nitrate Indicator field: Is the participant currently taking nitrate medication? Number 1=yes, 2=no,  -1=missing 
Nitrate state drug State the nitrate taking, if yes in indicator field Text As stated, blank if missing 
Nitrate state dose State the dose (mg) of the nitrate taking, if yes in indicator field  Number As stated, -2=not documented, -1=missing 
PCA Indicator field: Is the participant currently taking potassium channel 
activator medication? 
Number 1=yes, 2=no,  -1=missing 
PCA state drug State the potassium channel activator taking, if yes in indicator field Text As stated, blank if missing 
PCA state dose State the dose (mg) of the potassium channel activator taking, if yes in 
indicator field  
Number As stated, -2=not documented, -1=missing 
Statin Indicator field: Is the participant currently taking statin medication? Number 1=yes, 2=no,  -1=missing 
Statin state drug State the statin taking, if yes in indicator field Text As stated, blank if missing 
Statin state dose State the dose (mg) of the statin taking, if yes in indicator field  Number As stated, -2=not documented, -1=missing 
H2agonists Indicator field: Is the participant currently taking H2 agonist medication? Number 1=yes, 2=no,  -1=missing 
H2agonists state drug State the H2 agonist taking, if yes in indicator field Text As stated, blank if missing 
H2agonists state dose State the dose (mg) of the H2 agonist taking, if yes in indicator field  Number As stated, -2=not documented, -1=missing 
PPI Indicator field: Is the participant currently taking proton pump Inhibitor 
medication? 
Number 1=yes, 2=no,  -1=missing 
PPI state drug State the proton pump inhibitor taking, if yes in indicator field Text As stated, blank if missing 
PPI state dose State the dose (mg) of the proton pump inhibitor taking, if yes in indicator 
field  
Number As stated, -2=not documented, -1=missing 
AngioII Indicator field: Is the participant currently taking angiotensin II receptor 
agonist medication? 
Number 1=yes, 2=no,  -1=missing 
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AngioII state drug State the angiotensin II receptor agonist taking, if yes in indicator field Text As stated, blank if missing 
AngioII state dose State the dose (mg) of the angiotensin II receptor agonist taking, if yes in 
indicator field  
Number As stated, -2=not documented, -1=missing 
Thyroid Indicator field: Is the participant currently taking thyroid medication? Number 1=yes, 2=no,  -1=missing 
Thyroid state drug State the thyroid taking, if yes in indicator field Text As stated, blank if missing 
Thyroid state dose State the dose of the thyroid taking, if yes in indicator field  Number As stated, -2=not documented, -1=missing 
Asthma Indicator field: Is the participant currently taking asthma medication? Number 1=yes, 2=no,  -1=missing 
Asthma state drug State the asthma medication taking, if yes in indicator field Text As stated, blank if missing 
Asthma state dose State the dose of the asthma medication taking, if yes in indicator field  Number As stated, -2=not documented, -1=missing 
Pain meds Indicator field: Is the participant currently taking analgesic medication? Number 1=yes, 2=no,  -1=missing 
Pain state drug State the analgesic taking, if yes in indicator field Text As stated, blank if missing 
Pain state dose State the dose (mg) of the analgesic taking, if yes in indicator field  Number As stated, -2=not documented, -1=missing 
Diabetic Indicator field: Is the participant currently taking diabetic medication? Number 1=yes, 2=no,  -1=missing 
Diabetic state drug State the diabetic medication taking, if yes in indicator field Text As stated, blank if missing 
Diabetic state dose State the dose of the diabetic medication taking, if yes in indicator field  Number As stated, -2=not documented, -1=missing 
Alpha adreno block Indicator field: Is the participant currently taking alpha-adrenoceptor 
blocking medication? 
Number 1=yes, 2=no,  -1=missing 
Alpha adreno state drug State the alpha-adrenoceptor blocker taking, if yes in indicator field Text As stated, blank if missing 
Alpha adreno state dose State the dose (mg) of the alpha-adrenoceptor blocker taking, if yes in 
indicator field  
Number As stated, -2=not documented, -1=missing 
Other lipids Indicator field: Is the participant currently taking other lipid medication? Number 1=yes, 2=no,  -1=missing 
Other lipids state drug State the other lipid taking, if yes in indicator field Text As stated, blank if missing 
Other lipids state dose State the dose (mg) of the ACE other lipid taking, if yes in indicator field  Number As stated, -2=not documented, -1=missing 
Other HBP drugs Indicator field: Is the participant currently taking other anti-hypertensive 
medication? 
Number 1=yes, 2=no,  -1=missing 
Other HBP state drug State the other anti-hypertensive taking, if yes in indicator field Text As stated, blank if missing 
Other HBP state dose State the dose (ug) of the other anti-hypertensive taking, if yes in indicator 
field  
Number As stated, -2=not documented, -1=missing 
Other1 (1-6) Indicator field: Is the participant currently taking any other medication? Number 1=yes, 2=no,  -1=missing 
Other1 state drug (1-6) State the other medication taking, if yes in indicator field Text As stated, blank if missing 
Other1 state dose (1-6) State the dose of the other medication taking, if yes in indicator field Number As stated, -2=not documented, -1=missing 
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DOpre-op values Date pre-op data collected from Date As stated, 01/01/2001 if missing 
DOpre-op bloods Date of pre-op blood results Date As stated, 01/01/2001 if missing 
Age value Participant age Number As stated, -1=missing 
Age score POSSUM indicator field: Age score according to POSSUM criteria Number 1=<=60, 2=61-70, 4=>71, -1=missing 
Pre-op SBP value Systolic blood pressure (mmHg) Number As stated, -1=missing 
Pre-op SBP score POSSUM indicator field: Systolic blood pressure score according to 
POSSUM criteria 
Number 8=<=89, 4=90-99, 2=100-109, 1=110-130, 2=131-
170, 4=>171, -1=missing 
Pre-op HR value  Pre-op heart rate (bpm) Number As stated, -1=missing 
Pre-op HR score POSSUM indicator field: Heart rate score according to POSSUM criteria Number 8=<=39, 2=40-49, 1=50-80, 2=81-100, 4=101-120, 
8=>121, -1=missing 
Pre-op GCS value Pre-op Glasgow coma score  Number  
Pre-op GCS score POSSUM indicator field: GCS score according to POSSUM criteria Number 1=15, 2=12-14, 4=9-11, 8=<=8, -1=missing 
Pre-op urea value  Pre-op urea (mmol/l) Number As stated, -1=missing, 2=haemolysed 
Pre-op urea score POSSUM indicator field: Urea score according to POSSUM criteria Number 1=<=7.5, 2=6-10, 4=10.1-15, 8=>=15.1, -1=missing, 
2=haemolysed/Not done 
Pre-op K value  Pre-op serum potassium (mmol/l) Number As stated, -1=missing, -2=haemolysed 
Pre-op K score POSSUM indicator field: Potassium score according to POSSUM criteria Number 8=<=2.8, 4=2.9-3.1, 2=3.2-3.4, 1=3.5-5.0, 2=5.1-
5.3, 4=5.4-5.9, 8=>=6.0, -1=missing, -
2=haemolysed/not done 
Pre-op Na value  Pre-op serum sodium (mmol/l) Number As stated, -1=missing, -2=not done 
Pre-op Na score POSSUM indicator field: Sodium score according to POSSUM criteria Number 8=<=125, 4=126-130, 2=131-135, 1=>=136, -
1=missing, -2=not done 
Pre-op Hb value  Magovern indicator field: Pre-op haemoglobin (g/dl) Number As stated, -1=missing, -2=not done (sample 
underfilled) 
Pre-op Hb score POSSUM indicator field: Haemaglobin score according to POSSUM 
criteria 
Number 8=<=9.9, 4=10-11.4, 2=11.5-12.9, 1=13-16, 2=16.1-
17, 4=17.1-18, 8=>=18.1, -1=missing, -2=not done 
(sample underfilled) 
Pre-op WCC value Pre-op white cell count   (x109/l)) Number As stated, -1=missing, -2=not done (sample 
underfilled) 
Pre-op WCC score POSSUM indicator field: White cell count score according to POSSUM 
criteria 
Number 4=<or=3000, 2=3100-3999, 1=4000-10000, 
2=10100-20000, 4=>=20100, -1=missing, -2=not 
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done (sample underfilled) 
Pre-op ECG score POSSUM indicator field: ECG score according to POSSUM criteria Number 1=Normal, 4=AF and rate 60-90/min, 8=Any other 
abnormal rhythm or >5 ectopics/min, Q wave or 
ST/T wave changes, -1=missing 
Pre-op cardiac status POSSUM indicator field: Cardiac status score according to POSSUM 
criteria 
Number 1=No failure, 2=Diuretic, digoxin, anti-anginal or 
antihypertensive therapy, 4=Peripheral oedema, 
warfarin therapy, borderline cardiomegaly, 
8=Raised JVP or cardiomegaly on CXR, -1=missing 
Pre-op respiratory status POSSUM indicator field: Respiratory score according to POSSUM 
criteria 
Number 1=No dyspnoea, 2=Dyspnoea on exertion or mild 
obstructive changes, 4=dyspnoea limiting patient to 
one flight of stairs or moderate chronic obstructive 
changes on CXR, 8=dyspnoea at rest or fibrosis or 
consolidation on CXR, -1=missing 
POSSUM score Total POSSUM score Number Calculated total of all POSSUM score, -
1=missing/incomplete variables 
 
The pre-op C-POMS variables are also collected and entered within this table.  The details of these variables are found within the C-POMS tables. 
 
Intra-operative data table 
All data items with the D1 prefix are considered within the full 24 hours of post-operative day 1. 
Field name/Variable Definition Type of field Code in database 
Study number Unique identifier Text As stated 
Hosp No Hospital number Text As stated 
DOOP Date of operation Date As stated, 01/01/2001 if missing 
DOOpDay of Wk Day of the week of the operation Text As stated, blank if missing 
Op performed Indicator field: Identifies the operation performed Number 1= CABG, 2=AVR, 3=MVR, 4=CABG+AVR, 
5=CABG+MVR, 6=AVR+MVR, 
7=CABG+MVR+AVR, 8=other, -1=missing 
State other op State other type of operation if 8 in the indicator field Text As stated, blank if missing/NA 
Total no of grafts State total number of grafts if indicator field includes CABG Number As stated, -1=missing 
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No of SVG Include total number of saphenous veins used, if indicator field includes 
CABG 
Number As stated, -1=missing 
No arterial grafts Include total number of arterial grafts used, if indicator field includes 
CABG 
Number As stated, -1=missing 
Tiss or mech valve State whether a tissue or mechanical valve is used, if the indicator field 
includes any valve surgery 
Number 1=Tissue, 2=mechanical, 3=not stated, -1=missing 
ASA Class 1: Healthy patient, no medical problems; Class 2: Mild systemic 
disease; Class 3: Severe systemic disease, but not incapacitating; Class 
4: Severe systemic disease that is a constant threat to life; Class 5: 
Moribund, not expected to live 24 hours irrespective of operation 
Number As stated, -2=not stated,  -1=missing 
Anaes room time Time arrived in anaesthetic room Time As stated, 00:00:00 if missing 
Anaes start Time anaesthetic started Time As stated, 00:00:00 if missing 
Enter theatre Time entered theatre Time As stated, 00:00:00 if missing 
Skin prep Time skin preparation started Time As stated, 00:00:00 if missing 
Op end Time operation ended Time As stated, 00:00:00 if missing 
Leave theatre Time left theatre Time As stated, 00:00:00 if missing 
Op duration Total duration of operation (mins) Time As stated, 00:00:00 if missing 
Anaes agents Identify type of administration of anaesthesia Number 1=IV, 2=Gaseous, -1=missing 
IO RBC Indicator field: Received red cells Number 1=yes, 2=no, 3=not stated, -1=missing 
IO RBC units State number of units, if yes in indicator field Number As stated, -1=missing/NA 
IO Platelets Indicator field: Received platelets Number 1=yes, 2=no,  3=not stated, -1=missing 
IO Platelets units State number of units, if yes in indicator field Number As stated, -1=missing/NA 
IO FFP Indicator field: Received fresh frozen plasma Number 1=yes, 2=no,  3=not stated, -1=missing 
IO FFP units State number of units, if yes in indicator field Number As stated, -1=missing/NA 
IO cryo Indicator field: Received cryoprecipitates Number 1=yes, 2=no,  3=not stated, -1=missing 
IO cryo units State number of units, if yes in indicator field Number As stated, -1=missing/NA 
IO Aprotinin Indicator field: Received aprotinin  Number 1=yes, 2=no,  3=not stated, -1=missing 
IO Aprotinin dose State dose (mu), if yes in indicator field Number As stated, -2=not stated, -1=missing/NA 
IO Enoximone Indicator field: Received enoximone  Number 1=yes, 2=no,  3=not stated, -1=missing 
IO Enoximone dose State dose (ug/kg/min), if yes in indicator field Number As stated, -2=not stated, -1=missing/NA 
IO Inotropes used Indicator field: Received inotropes Number 1=yes, 2=no,  3=not stated, -1=missing 
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IO Inotrope state State inotrope, if yes in indicator field Number 1=dopamine, 2=dobutamine, 3=isoprenaline, 
4=dopexanine, -1=missing 
IO Inotrope highest dose State highest dose (ug/kg/min), if yes in indicator field  Number As stated, -2=not stated, -1=missing/NA 
IO Vasocon Indicator field: Received vasoconstrictors Number 1=yes, 2=no,  3=not stated, -1=missing 
IO Vasocon state State vasoconstrictor, if yes in indicator field Number 1=nor adrenaline, 2=phenylephrine, 3=metaraminol, 
-1=missing/NA 
IO Vasocon highest dose State highest dose (ug/ml/min), if yes in indicator field  Number As stated, -2=not stated, -1=missing/NA 
IO IABP Identify whether the patient required intra-operative aortic balloon pump Number 1=yes, 2=no,  3=not stated, -1=missing 
IO Tranexamic acid Indicator field: Received tranexamic acid Number 1=yes, 2=no,  3=not stated, -1=missing 
IO Tran acid dose State dose (g), if yes in indicator field  Number As stated, -2=not stated, -1=missing/NA 
IO ABs Indicator field: Received antibiotics Number 1=yes, 2=no,  3=not stated, -1=missing 
IO ABs state State antibiotics and dose, if yes in indicator field Text As stated, blank if missing/NA 
IO Others State any other medications given intra-operatively, and dose Text As stated, blank if NA. If more than one separated 
by a comma. 
IO Comments State any other intra-operative comments Text As stated, blank if NA. If more than one separated 
by a comma. 
FiO2 First value on ICU: FiO2 (l) Number As stated, -2=not stated, -1=missing 
pH First value on ICU: pH level  Number As stated, -2=not stated, -1=missing 
pCO2 First value on ICU: : partial pressure carbon dioxide (kPa) Number As stated, -2=not stated, -1=missing 
pO2 First value on ICU: partial pressure oxygen (kPa) Number As stated, -2=not stated, -1=missing 
SBCc First value on ICU: SBCc (mmol/l) Number As stated, -2=not stated, -1=missing 
SBEc First value on ICU: base deficit level (mmol/l) Number As stated, -2=not stated, -1=missing 
K First value on ICU: potassium level (mmol/l) Number As stated, -2=not stated, -1=missing 
Na First value on ICU: sodium level (mmol/l) Number As stated, -2=not stated, -1=missing 
Glu First value on ICU: glucose level (mmol/l) Number As stated, -2=not stated, -1=missing 
Hb First value on ICU: haemaglobin (g/dl) Number As stated, -2=not stated, -1=missing 
PO RBC Indicator field: Received red cells  Number 1=yes, 2=no,  3=not stated, -1=missing 
PO RBC units State number of units, if yes in indicator field Number As stated, -1=missing/NA 
PO Platelets Indicator field: Received platelets Number 1=yes, 2=no,  3=not stated, -1=missing 
PO Platelets units State number of units, if yes in indicator field Number As stated, -1=missing/NA 
PO FFP Indicator field: Received fresh frozen plasma Number 1=yes, 2=no,  3=not stated, -1=missing 
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PO FFP units State number of units, if yes in indicator field Number As stated, -1=missing/NA 
PO cryo Indicator field: Received cryoprecipitates Number 1=yes, 2=no,  3=not stated, -1=missing 
PO cryo units State number of units, if yes in indicator field Number As stated, -1=missing/NA 
PO Aprotinin Indicator field: Received aprotinin  Number 1=yes, 2=no,  3=not stated, -1=missing 
PO Aprotinin dose State dose (mu), if yes in indicator field Number As stated, -2=not stated, -1=missing/NA 
PO Aprotinin end State time aprotinin was discontinued, if yes in indicator field Time As stated, 00:00:00 if missing/NA 
PO Enoximone Indicator field: Received enoximone  Number 1=yes, 2=no,  3=not stated, -1=missing 
PO Enoximone dose State dose (ug/kg/min), if yes in indicator field Number As stated, -2=not stated, -1=missing/NA 
PO Enoximone end State time enoximone was discontinued, if yes in indicator field Time As stated, 00:00:00 if missing/NA 
PO Inotropes used Indicator field: Received inotropes Number 1=yes, 2=no,  3=not stated, -1=missing 
PO Inotropes state State inotrope, if yes in indicator field Number 1=dopamine, 2=dobutamine, 3=isoprenaline, 
4=dopexanine, -1=missing/NA 
PO Inotrope highest dose State highest dose (ug/kg/min), if yes in indicator field  Number As stated, -2=not stated, -1=missing/NA 
PO Inotrope end State time inotrope was discontinued, if yes in indicator field Time As stated, 00:00:00 if missing/NA 
PO Vasocon Indicator field: Received vasoconstrictors Number 1=yes, 2=no,  3=not stated, -1=missing 
PO Vasocon state State vasoconstrictor, if yes in indicator field Number 1=nor adrenaline, 2=phenylephrine, 3=metaraminol, 
-1=missing 
PO Vasocon highest dose State highest dose (ug/ml/min), if yes in indicator field  Number As stated, -2=not stated, -1=missing/NA 
PO Vasocon end State time vasoconstrictor was discontinued, if yes in indicator field Time As stated, 00:00:00 if missing/NA 
PO Frusemide Indicator field: Received frusemide infusion Number 1=yes, 2=no,  3=not stated, -1=missing 
PO Frusemide dose State dose (mg/hr), if yes in indicator field  Number As stated, -2=not stated, -1=missing/NA 
PO Frusemide end State time frusemide was discontinued, if yes in indicator field Time As stated, 00:00:00 if missing/NA 
PO Morphine Indicator field: Received morphine Number 1=yes, 2=no,  3=not stated, -1=missing 
PO Morphine dose State dose (mg/hr), if yes in indicator field  Number As stated, -2=not stated, -1=missing/NA 
PO Morphine end State time morphine was discontinued, if yes in indicator field Time As stated, 00:00:00 if missing/NA 
PO Propofol Indicator field: Received propofol Number 1=yes, 2=no,  3=not stated, -1=missing 
PO Propofol dose State dose (mg/hr), if yes in indicator field  Number As stated, -2=not stated, -1=missing/NA 
PO Propofol end State time propofol was discontinued, if yes in indicator field Time As stated, 00:00:00 if missing/NA 
PO GTN Indicator field: Received GTN Number 1=yes, 2=no,  3=not stated, -1=missing 
PO GTN dose State dose (mg/hr), if yes in indicator field  Number As stated, -2=not stated, -1=missing/NA 
PO GTN end State time GTN was discontinued, if yes in indicator field Time As stated, 00:00:00 if missing/NA 
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PO Actrapid Indicator field: Received actrapid Number 1=yes, 2=no,  3=not stated, -1=missing 
PO Actrapid dose State dose (iu/hr), if yes in indicator field  Number As stated, -2=not stated, -1=missing/NA 
PO Actrapid end State time actrapid was discontinued, if yes in indicator field Time As stated, 00:00:00 if missing/NA 
PO SNP Indicator field: Received SNP Number 1=yes, 2=no,  3=not stated, -1=missing 
PO SNP dose State dose (mg/hr), if yes in indicator field  Number As stated, -2=not stated, -1=missing/NA 
PO SNP end State time SNP was discontinued, if yes in indicator field Time As stated, 00:00:00 if missing/NA 
PO other infusions State any other infusion, dose and time commenced and discontinued. Text As stated, blank if NA. If more than one separated 
by a comma. 
12hr Gelo Total gelofusin given in first 12 hrs post surgery (mls) Number As stated, -1=missing 
12hr IVI Total intravenous fluid given in first 12 hrs post surgery (mls) Number As stated, -1=missing 
12hr input Total fluid input given in first 12 hrs post surgery (mls) Number As stated, -1=missing 
12hr urine Total urine output in first 12 hrs post surgery (mls) Number As stated, -1=missing 
12hr drainage Total chest drain drainage in first 12 hrs post surgery (mls) Number As stated, -1=missing 
Highest sedation score Highest sedation score (Bloomsbury) in first 12 hrs post surgery Text As stated, blank if missing 
Lowest sedation score Lowest sedation score (Bloomsbury) in first 12 hrs post surgery Number As stated, -1=missing 
Total K+ Total potassium supplements given in first 12 hrs post surgery (mmol) Number As stated, -1=missing 
Total MgSO4 Total magnesium supplements given in first 12 hrs post surgery (mmol) Number As stated, -1=missing 
PO Heart Rhythm Indicator code: Worst heart rhythm in first 12 hrs post surgery Number 1=SR, 2=ST, 3=SB, 4=AF, 5=other, -1=missing 
PO Heart rhythm other State any other heart rhythm if answer 5 in indicator field Text As stated, blank if missing/NA 
PO Paced Identify whether receiving pacing (temporary or permanent) Number 1=yes, 2=no,  3=not stated, -1=missing 
PO HR Highest heart rate in first 12 hrs post surgery (bpm) Number As stated, -1=missing 
PO SBP Highest systolic blood pressure in first 12 hrs post surgery (mmHg) Number As stated, -1=missing 
PO DBP Diastolic blood pressure corresponding to highest systolic blood pressure 
in first 12 hrs post surgery (mmHg) 
Number As stated, -1=missing 
PO RR Indicator field: Highest respiratory rate if ventilated.  If not ventilated 
highest respiratory rate in first 12 hrs post surgery (bpm) 
Number As stated, -1=missing 
PO RR vent or ext Identify whether respiratory rate in indicator field is ventilated or extubated Number 1=ventilated, 2=extubated, -1=missing 
Temp (first) Temperature on arrival to ICU (oC) Number As stated, -1=missing, -2=Not done 
Temp (highest) Highest temperature in first 12 hrs post surgery (oC) Number As stated, -1=missing 
Intubation grade State the intubation grade Class I: the vocal cords are visible; Class II: the 
vocals cords are only partly visible; Class III: only the epiglottis is seen; 
Number As stated, -2=not done/documented, -1=missing 
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Class IV: the epiglottis cannot be seen. 
CVP Highest CVP in first 12 hrs post surgery (mmHg) Number As stated, -1=missing 
MAP Highest mean arterial pressure in first 12 hrs post surgery (mmHg) Number As stated, -1=missing 
Additional DOOP comments State any additional comments relating to first 12 hrs post surgery Text As stated, blank if NA. If more than one separated 
by a comma. 
DODay1 Date of post-operative day 1 Date As stated, 01/01/2001 if missing 
D1 Heart Rhythm Indicator code: Worst heart rhythm  Number 1=SR, 2=ST, 3=SB, 4=AF, 5=other, -1=missing 
D1 Heart rhythm other State any other heart rhythm if answer 5 in indicator field Text As stated, blank if missing/NA 
D1 Paced Identify whether receiving pacing (temporary or permanent)  Number 1=yes, 2=no,  3=not stated, -1=missing 
D1 HR Highest heart rate (bpm) Number As stated, -1=missing 
D1 SBP Highest systolic blood pressure (mmHg) Number As stated, -1=missing 
D1 DBP Diastolic blood pressure corresponding to the highest systolic blood 
pressure (mmHg) 
Number As stated, -1=missing 
D1 RR Highest respiratory rate (bpm) Number As stated, -1=missing 
D1 Temp Highest temperature (oC) Number As stated, -1=missing 
D1 CVP Highest CVP (mmHg) Number As stated, -1=missing, -2=Not stated 
D1 RBC Indicator field: Received red cells Number 1=yes, 2=no,  3=not stated, -1=missing 
D1 RBC units State number of units, if yes in indicator field Number As stated, -1=missing/NA 
D1 Platelets Indicator field: Received red cells Number 1=yes, 2=no,  3=not stated, -1=missing 
D1 Platelet units State number of units, if yes in indicator field Number As stated, -1=missing/NA 
D1 FFP Indicator field: Received red cells Number 1=yes, 2=no,  3=not stated, -1=missing 
D1 FFP units State number of units, if yes in indicator field Number As stated, -1=missing/NA 
D1 cryo Indicator field: Received red cells Number 1=yes, 2=no,  3=not stated, -1=missing 
D1 cryo units State number of units, if yes in indicator field Number As stated, -1=missing/NA 
Drains out 1 Indicator field: identify whether chest drains were removed on post-
operative day 1 
Number 1=yes, 2=no,  3=not stated, -1=missing 
TODR Time of chest drain removal, if yes in indicator field Time As stated, 00:00:00 if missing/NA 
D1 Aprotinin Indicator field: Received aprotinin Number 1=yes, 2=no,  3=not stated, -1=missing 
D1 Aprotinin dose State dose (mu), if yes in indicator field  Number As stated, -2=not stated, -1=missing/NA 
D1 Aprotinin end  State time aprotinin was discontinued, if yes in indicator field Time As stated, 00:00:00 if missing/NA 
D1 Enoximone Indicator field: Received enoximone  Number 1=yes, 2=no,  3=not stated, -1=missing 
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D1 Enoximone dose State dose (ug/kg/min), if yes in indicator field  Number As stated, -2=not stated, -1=missing/NA 
D1 Enoximone end State time enoximone was discontinued, if yes in indicator field Time As stated, 00:00:00 if missing/NA 
D1 Inotropes used Indicator field: Received inotropes Number 1=yes, 2=no,  3=not stated, -1=missing 
D1 Inotropes state State inotrope, if yes in indicator field Number 1=dopamine, 2=dobutamine, 3=isoprenaline, 
4=dopexanine, -1=missing/NA 
D1 Inotrope highest dose State highest dose (ug/kg/min), if yes in indicator field  Number As stated, -2=not stated, -1=missing/NA 
D1 Inotrope end State time inotrope was discontinued, if yes in indicator field Time As stated, 00:00:00 if missing/NA 
D1 Vasocon Indicator field: Received vasoconstrictors Number 1=yes, 2=no,  3=not stated, -1=missing 
D1 Vasocon state State vasoconstrictor, if yes in indicator field Number 1=nor adrenaline, 2=phenylephrine, 3=metaraminol, 
-1=missing/NA 
D1 Vasocon highest dose State highest dose (ug/ml/min), if yes in indicator field  Number As stated, -2=not stated, -1=missing/NA 
D1 Vasocon end State time vasoconstrictor was discontinued, if yes in indicator field Time As stated, 00:00:00 if missing/NA 
D1 Frusemide Indicator field: Received frusemide infusion Number 1=yes, 2=no,  3=not stated, -1=missing 
D1 Frusemide dose State dose (mg/hr), if yes in indicator field  Number As stated, -2=not stated, -1=missing/NA 
D1 Frusemide end State time frusemide was discontinued, if yes in indicator field Time As stated, 00:00:00 if missing/NA 
D1 Morphine Indicator field: Received morphine Number 1=yes, 2=no,  3=not stated, -1=missing 
D1 Morphine dose State dose (mg/hr), if yes in indicator field  Number As stated, -2=not stated, -1=missing/NA 
D1 Morphine end State time morphine was discontinued, if yes in indicator field Time As stated, 00:00:00 if missing/NA 
D1 Propofol Indicator field: Received propofol Number 1=yes, 2=no,  3=not stated, -1=missing 
D1 Propofol dose State dose (mg/hr), if yes in indicator field  Number As stated, -2=not stated, -1=missing/NA 
D1 Propofol end State time propofol was discontinued, if yes in indicator field Time As stated, 00:00:00 if missing/NA 
D1 GTN Indicator field: Received GTN Number 1=yes, 2=no,  3=not stated, -1=missing 
D1 GTN dose State dose (mg/hr), if yes in indicator field  Number As stated, -2=not stated, -1=missing/NA 
D1 GTN end State time GTN was discontinued, if yes in indicator field Time As stated, 00:00:00 if missing/NA 
D1 Actrapid Indicator field: Received actrapid Number 1=yes, 2=no,  3=not stated, -1=missing 
D1 Actrapid dose State dose (iu/hr), if yes in indicator field  Number As stated, -2=not stated, -1=missing/NA 
D1 Actrapid end State time actrapid was discontinued, if yes in indicator field Time As stated, 00:00:00 if missing/NA 
D1 SNP Indicator field: Received SNP Number 1=yes, 2=no,  3=not stated, -1=missing 
D1 SNP dose State dose (mg/hr), if yes in indicator field  Number As stated, -2=not stated, -1=missing/NA 
D1 SNP end State time SNP was discontinued, if yes in indicator field Time As stated, 00:00:00 if missing/NA 
D1 other infusions State any other infusions received during post-operative day 1, the dose Text As stated, blank if NA. If more than one separated 
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and the time commenced and discontinued. by a comma. 
D1 comments State any other comments relating to post-operative day 1 Text As stated, blank if NA. If more than one separated 
by a comma. 
 
C-POMS data table 
These variables are collected pre-operatively and post-operatively on days 1, 3, 5, 8 and 15 where the participant is still an in-patient.  The data from 
each post-operative day is stored in different tables.  D1 Chair (whether the participant sat in a chair on post-operative day 1) is the only variable included 
on day 1 only.  All data items are considered within the full 24 hours of that day. 
In code in database column, ‘not applicable’ is abbreviated to NA. 
Field name/variable Definition Type of field Code in database 
Study number Unique identifier Text As stated 
Hospital number Hospital number Text As stated 
D1 inpt? Is the participant an in-patient  Number 1=yes, 2=no, 3= not stated, -1=missing 
DODay1 Date of post-op D1 Date As stated, 00/00/2001 =missing 
D1 Ward Indicator field: Highest dependency ward on this day Number 1=ITU, 2=HDU, 3=ACW, 4=3rd fl monitoring bay, 
5=3rd floor, 6=4th floor, 7=other 
D1 Ward other State other ward, if answered 7 in indicator field Text As stated, blank if missing/NA 
D1 ward transfer Indicator field: Was the participant transferred to another ward? Number 1=yes, 2=no, 3= not stated, -1=missing 
D1 transfer to Which ward was the participant transferred to, if yes to above. Number 1=ITU, 2=HDU, 3=ACW, 4=3rd fl monitoring bay, 
5=3rd floor, 6=4th floor, 7=other 
D1 How much oxy? Highest number of litres of oxygen received Number As stated, -1=missing 
D1 RR Highest respiratory rate (bpm) Number As stated, -1=missing, -2=not done 
D1 FiO2 Highest FiO2 (%) Number As stated, -1=missing, -2=not stated 
D1 SaO2 Lowest SaO2 (%) Number As stated, -1=missing, -2=not done 
D1 temperature Highest temperature (oC) Number As stated, -1=missing, -2=not done 
D1 wound complication Iindicator field: Is a wound complication present? Number 1=yes, 2=no, 3= not stated, -1=missing 
D1 wound site 1 State the wound site with the complication, if yes in indicator field. Number 1=sternum, 2=left leg, 3=right leg, 4=left arm, 
5=right arm, 6=sacrum, 8=other/combination, -
1=missing 
D1 wound site 2 State the wound site with the complication, if yes in indicator field and more Number 1=sternum, 2=left leg, 3=right leg, 4=left arm, 
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than 1 wound complication 5=right arm, 6=sacrum, 8=other/combination, -
1=missing 
D1 wound site other State other wound site with complication, if not covered by coding Text As stated, blank if missing/NA 
D1 wound site compl State the type of complication of the wounds, if yes to above. Text State type and details of wound complication 
D1 Abs Indicator field: Received antibiotics Number 1=yes, 2=no, 3= not stated, -1=missing 
D1 Abs new? Is this a new requirement (compared to pre-op), if yes in indicator field? Number 1=yes, 2=no,  -1=missing/NA 
D1 state Abs State the antibiotic(s) and dose(s) received, if yes in indicator field Text As stated, blank if missing/NA 
D1 antiemetic Indicator field: Received antiemetic(s) Number 1=yes, 2=no, 3= not stated, -1=missing 
D1 antiemetic new Is this a new requirement (compared to pre-op) if yes in indicator field? Number 1=yes, 2=no,  -1=missing/NA 
D1 state antiemetic State the antiemetic(s) and dose(s) received, if yes in indicator field Text As stated, blank if missing/NA 
D1 Inotropes Indicator field: Received inotropes Number 1=yes, 2=no, 3= not stated, -1=missing 
D1 state inotropes State the inotrope(s) and dose(s) received, if yes in indicator field Text As stated, blank if missing/NA 
D1 RBC Indicator field: Received red cells Number 1=yes, 2=no, 3= not stated, -1=missing 
D1 RBC units State number of units, if yes in indicator field Number As stated,  -1=missing/NA 
D1 Platelets Indicator field: Received platelets Number 1=yes, 2=no, 3= not stated, -1=missing 
D1 Platelets units State number of units, if yes in indicator field Number As stated, -1=missing/NA 
D1 FFP Indicator field: Received fresh frozen plasma Number 1=yes, 2=no, 3= not stated, -1=missing 
D1 FFP units State number of units, if yes in indicator field Number As stated, -1=missing/NA 
D1 cryo Indicator field: Received cryoprecipitates Number 1=yes, 2=no, 3= not stated, -1=missing 
D1 Cryo units State number of units, if yes in indicator field Number As stated, -1=missing/NA 
D1 Aprotinin Indicator field: Received aprotinin Number 1=yes, 2=no, 3= not stated, -1=missing 
D1 Aprotinin dose State dose, if yes in indicator field Text As stated, 3= not stated, -1=missing/NA 
D1 Pain POMS indicator field: New postoperative pain significant enough to 
received parenteral opioids or regional analgesia 
Number 1=yes, 2=no, 3= not stated, -1=missing 
D1 Pain new? Is this a new requirement (compared to pre-op), if yes in indicator field? Number 1=yes, 2=no, 3= not stated, -1=missing/NA 
D1 Analgesia type Identify which form of administration the analgesia was given, if yes in 
indicator field 
Number 1=PCA, 2=epidural, 3= IV, 4=IM, 5=PO, -
1=missing/NA 
D1 Analgesia state State the analgesia and dose given, if yes in indicator field Text As stated, blank if missing/NA 
D1 Fragmin Indicator field: Received fragmin Number 1=yes, 2=no, 3= not stated, -1=missing 
D1 Fragmin dose State fragmin dose, if yes in indicator field Number As stated, 3= not stated, -1=missing/NA 
D1 Creat Serum creatinine level (mmol/l) Number As stated, -2= not done, -1=missing 
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D1 Wound culture Indicator field: Was a wound culture taken? Number 1=yes, 2=no, 3=not stated, -1=missing 
D1 wound culture results Wound culture results, if yes in indicator field Text As stated, blank if missing/NA 
D1 wound culture rx State treatment given in light of wound culture results, if yes in indicator 
field and positive culture obtained. 
Text As stated, blank if missing/NA 
D1 Pulmonary POMS indicator field: Has the participant developed a new requirement 
for oxygen or respiratory support 
Number 1=yes, 2=no, 3=not stated, -1=missing 
D1 Pulmonary new? Is this a new requirement (compared to pre-op), if yes in indicator field? Number 1=yes, 2=no, 3=not stated, -1=missing/NA 
D1 intub and vent? Is the participant intubated and ventilated, if yes in indicator field? Number 1=yes, 2=no, 3=not stated, -1=missing/NA 
D1 oxygen suppl? Identify type of supplementary oxygen received, if yes in indicator field Number 1=cpap, 2=bipap, 3=bird, 4=mask, 5=nasal specs, 
6=none, 7=AQP, -1=missing/NA 
D1 Infectious POMS indicator field: Received antibiotics and/or has had a temperature 
of >38°C in the last 24 hours 
Number 1=yes, 2=no, 3=not stated, -1=missing 
D1 Infectious new? Is this a new requirement (compared to pre-op), if yes in indicator field? Number 1=yes, 2=no, 3=not stated, -1=missing/NA 
D1 Renal POMS indicator field: Presence of oliguria < 500ml/24hours, increased 
serum creatinine (>30% from pre operative level); urinary catheter in situ 
for non surgical reason 
Number 1=yes, 2=no, -2=creatinine not done, -1=missing 
D1 renal new? Is this a new requirement (compared to pre-op), if yes in indicator field? Number 1=yes, 2=no, 3=not stated, -1=missing/NA 
D1 Oliguria Indicator field: Presence of oliguria < 500ml/24hours Number 1=yes, 2=no, 3=not stated, -1=missing 
D1 oliguria new? Is this a new requirement (compared to pre-op), if answered yes to 
indicator field? 
Number 1=yes, 2=no, 3=not stated, -1=missing/NA 
D1 creat >30% Increased serum creatinine (>30% from pre operative level) Number 1=yes, 2=no, -2=not done, -1=missing 
D1 urine cath Indicator field: Urinary catheter in situ for non surgical reason Number 1=yes, 2=no, 3=not stated, -1=missing 
D1 urine cath new? Is this a new requirement (compared to pre-op), if yes to indicator field? Number 1=yes, 2=no, 3=not stated, -1=missing/NA 
D1 RRT Indicator field: Received renal replacement therapy Number 1=yes, 2=no, 3=not stated, -1=missing 
D1 RRT state State the type of renal replacement therapy received, if yes in indicator field Text As stated, blank if missing/NA 
D1 nutrition support Indicator field: Received nutritional support Number 1=yes, 2=no, 3=not stated, -1=missing 
D1 nutrition support state Identify the type of nutritional support received, if yes in indicator field Number 1= NG feed, 2=TPN, 3=not stated, -1=missing/NA 
D1 nutrition support new? Is this a new requirement (compared to pre-op), if yes in indicator field? Number 1=yes, 2=no, 3=not stated, -1=missing/NA 
D1 GI dist Is nutritional support given due to gastrointestinal disturbance, if yes in 
indicator field? 
Number 1=yes, 2=no, 3=not stated, -1=missing/NA 
D1 intol ent diet POMS indicator field: Unable to tolerate an enteral diet for any reason Number 1=yes, 2=no, 3=not stated, -1=missing 
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including nausea, vomiting and abdominal distension 
D1 intol type ent diet Identify the type of enteral diet intolerant of, if yes to indicator field Number 1=oral, 2=NG feed, 3=TPN, 4=not stated, -
1=missing/NA 
D1 nausea Indicator field: Unable to tolerate an enteral diet due to nausea Number 1=yes, 2=no, 3=not stated, -1=missing 
D1 nausea new? Is this a new symptom (compared to pre-op), if yes to indicator field? Number 1=yes, 2=no, 3=not stated, -1=missing/NA 
D1 vomiting Indicator code: Unable to tolerate an enteral diet due to vomiting Number 1=yes, 2=no, 3=not stated, -1=missing 
D1 vomiting new? Is this a new symptom (compared to pre-op), if yes in indicator field? Number 1=yes, 2=no, 3=not stated, -1=missing/NA 
D1 abdo dist Indicator field: Unable to tolerate an enteral diet due to abdominal 
distension 
Number 1=yes, 2=no, 3=not stated, -1=missing 
D1 abdo dist new? Is this a new symptom (compared to pre-op), if yes in indicator field? Number 1=yes, 2=no, 3=not stated, -1=missing/NA 
D1 CV POMS indicator field: Diagnostic tests or therapy within the last 24 hours 
for any of the following: 1) new MI or ischaemia, 2)hypotension (requiring 
fluid therapy >200ml/hr or pharmacological therapy, 3) atrial or ventricular  
arrhythmias, 4) cardiogenic pulmonary oedema, thrombotic event (requiring 
anticoagulation). 
Number 1=yes, 2=no, 3=not stated, -1=missing 
D1 CV new? Is this a new symptom (compared to pre-op), if yes in indicator field? Number 1=yes, 2=no, 3=not stated, -1=missing/NA 
D1 new MI Indicator field: Diagnostic tests or therapy within the last 24 hours for new 
MI or ischaemia,  
Number 1=yes, 2=no, 3=not stated, -1=missing 
D1 MI test State MI  or ischaemia test, if yes indicator field Text As stated, blank if missing/NA 
D1 MI diagnosis State MI or ischaemia diagnosis, if yes in indicator field Text As stated, blank if missing/NA 
D1 MI treated Indicator field: Identify whether MI or ischaemia was treated, if yes in 
indicator field 
Number 1=yes, 2=no, 3=not stated, -1=missing 
D1 MI rx State treatment for MI or ischaemia, if yes in indicator field Text As stated, blank if missing/NA 
D1 Hypotension Indicator field: Diagnostic tests or therapy within the last 24 hours for 
hypotension (requiring fluid therapy >200ml/hr or pharmacological therapy 
Number 1=yes, 2=no, 3=not stated, -1=missing 
D1 Hypo new? Is this a new symptom (compared to pre-op), if yes in indicator field? Number 1=yes, 2=no, 3=not stated, -1=missing/NA 
D1 Hypo test State hypotension test, if yes in indicator field Text As stated, blank if missing/NA 
D1 Hypo diagnosis State hypotension diagnosis, if yes in indicator field Text As stated, blank if missing/NA 
D1 Hypo treated Indicator field: Identify whether  hypotension was treated, if yes in indicator 
field 
Number 1=yes, 2=no, 3=not stated, -1=missing/NA 
D1 Hypo Rx State treatment for hypotension, if yes in indicator field Text As stated, blank if missing/NA 
 259
D1 Arrhythmias Indicator field: Diagnostic tests or therapy within the last 24 hours for atrial 
or ventricular  arrhythmias 
Number 1=yes, 2=no, 3=not stated, -1=missing/NA 
D1 Arrhythmias new? Is this a new symptom (compared to pre-op), if yes in indicator field? Number 1=yes, 2=no, 3=not stated, -1=missing/NA 
D1 Arrhy test State arrhythmia  test, if yes in indicator field Text As stated, blank if missing/NA 
D1 Arrhy diagnosis State arrhythmia diagnosis, if yes in indicator field Text As stated, blank if missing/NA 
D1 Arrhy treated Indicator field: Identify whether arrhythmia was treated, if yes in indicator 
field 
Number 1=yes, 2=no, 3=not stated, -1=missing/NA 
D1 Arrhy rx State arrhythmia treatment, if yes in indicator field Text As stated, blank if missing/NA 
D1 Pul oed/anticoag Indicator field: Diagnostic tests or therapy within the last 24 hours for 
cardiogenic pulmonary oedema, thrombotic event (requiring 
anticoagulation). 
Number 1=yes, 2=no, 3=not stated, -1=missing 
D1 Pul oed/anticoag new? Is this a new symptom (compared to pre-op), if yes in indicator field? Number 1=yes, 2=no, 3=not stated, -1=missing/NA 
D1 Pul oed/anticoag test State pulmonary oedema/thrombotic event test, if yes in indicator field Text As stated, blank if missing/NA 
D1 Pul oed/anticoag diag State pulmonary oedema/thrombotic event diagnosis, if yes in indicator 
field 
Text As stated, blank if missing/NA 
D1 Pul oed/anticoag treated Indicator field: Identify whether pulmonary oedema/thrombotic event was 
treated, if yes in indicator field 
Number 1=yes, 2=no, 3=not stated, -1=missing/NA 
D1 Pul oed/anticoag Rx State pulmonary oedema/thrombotic event treatment, if yes in indicator 
field 
Text As stated, blank if missing/NA 
D1 Dysrhythm Indicator field: Identify whether a dysrhythmia was present Number 1=yes, 2=no, 3=not stated, -1=missing 
D1 paced Iindicator field: Identify whether pacing was required (internal or external) Number 1=yes, 2=no, 3=not stated, -1=missing 
D1 Dysrhythm/underlying State dysrhythmia and/or underlying rhythm if yes in either above indicator 
fields 
Text As stated, blank if missing/NA 
D1 Dysrhythm treated Indicator field: Identify if treatment received,  if yes to dysrhythm indicator 
field 
Number 1=yes, 2=no, 3=not stated, -1=missing/NA 
D1 Dysrhythm Rx State treatment received if yes in indicator field Text As stated, blank if missing/NA 
D1 Neuro POMS indicator field: New focal neurological deficit, confusion, delirium 
or coma within the last 24 hrs? 
Number 1=yes, 2=no, 3=not stated, -1=missing 
D1 Neuro new? Is this a new symptom (compared to pre-op), if yes in indicator field? Number 1=yes, 2=no, 3=not stated, -1=missing/NA 
D1 Neuro state Identify type of neurological deficit, if yes in indicator field Number 1=confusion, 2=delirium, 3=focal deficit, 4=coma, 
5=agitated/violent, -1=missing/NA 
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D1 Neuro comments State additional comments relating to neurological deficit, if yes in indicator 
field 
Text As stated, blank if missing/NA 
D1 Wound compl POMS indicator field: Wound complication present: Wound dehiscence 
requiring surgical exploration or drainage of pus from the operation wound 
with or without isolation of organisms 
Number 1=yes, 2=no, 3=not stated, -1=missing 
D1 Wound surg Wound dehiscence requiring surgical exploration with or without isolation of 
organisms 
Number 1=yes, 2=no, 3=not stated, -1=missing/NA 
D1 Wound drain Wound dehiscence requiring drainage of pus from the operation wound 
with or without isolation of organisms 
Number  1=yes, 2=no, 3=not stated, -1=missing/NA 
D1 Haematol POMS indicator field: Requirement for any of the following within the last 
24 hrs: packed erythrocytes, platelets, fresh-frozen plasma, or 
cryoprecipitate 
Number 1=yes, 2=no, 3=not stated, -1=missing 
D1 Assisted ambulation Requirement for any assistance with ambulation? Number 1=yes, 2=no, 3=not stated, -1=missing 
D1 Assisted ambul new? Is this a new symptom (compared to pre-op)? Number 1=yes, 2=no, 3=not stated, -1=missing/NA 
D1 Assisted ambul type State the type of ambulation assistance required, if yes to above. Number 1=wheelchair, 2=unaided, 3= crutches, 4=zimmer, 
5=not stated, 6=walking sticks, 7=bedbound,  
8=with assistance, 9=attached to equip, -
1=missing/NA 
D1 In chair Identify whether the participant sat in the chair day 1 after surgery Number 1=yes, 2=no, 3=not stated, -1=missing 
D1 DVT diag or test Indicator field: Diagnostic tests or therapy within the last 24 hours for a 
deep vein thrombosis 
Number 1=yes, 2=no, 3=not stated, -1=missing 
D1 DVT rx Identify whether any treatment was administered for deep vein thrombosis, 
if yes in indicator field 
Number 1=yes, 2=no, 3=not stated, -1=missing/NA 
D1 Blood sugar control Received treatment for blood sugar control (additional to regular 
requirements) 
Number 1=yes, 2=no, 3=not stated, -1=missing 
D1 Blood sugar control 
comment 
State the type and dose of treatment, if yes to above Text As stated, blank if missing/NA 
D1 IV Frusemide given Received IV Frusemide Number 1=yes, 2=no, 3=not stated, -1=missing 
D1 IV frusemide comment State the type and dose of treatment, if yes to above Text As stated, blank if missing/NA 
D1 Hypertension Rx Received treatment for hypertension (additional to regular requirements) Number 1=yes, 2=no, 3=not stated, -1=missing 
D1 Hypertension Rx comments State the type and dose of treatment, if yes to above Text As stated, blank if missing/NA 
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D1 Chest drains Chest drains in situ Number 1=yes, 2=no, 3=not stated, -1=missing 
D1 Chest drains comments State any additional information, if yes to above Text As stated, blank if missing/NA 
D1 Inotrope support Received  inotrope support Number 1=yes, 2=no, 3=not stated, -1=missing 
D1 Inotrope comments State the type and dose of treatment, if yes to above Text As stated, blank if missing/NA 
D1 Hypotension (fluid) Received treatment for hypotension (fluid <200mls/hr or medications 
omitted)  
Number 1=yes, 2=no, 3=not stated, -1=missing 
D1 Hypotension comments State the type and dose of treatment, if yes to above Text As stated, blank if missing/NA 
D1 Pleural eff Drains insitu for pleural effusion Number 1=yes, 2=no, 3=not stated, -1=missing 
D1 Pleural eff comments State details on drain site, drainage, time of removal Text As stated, blank if missing/NA 
D1 INR Received treatment for untherapeutic INR Number 1=yes, 2=no, 3=not stated, -1=missing 
D1 INR comments State the type and dose of treatment and INR level, if yes to above Text As stated, blank if missing/NA 
D1 Periph oed Presence of peripheral oedema Number 1=yes, 2=no, 3=not stated, -1=missing 
D1 Periph oed comments State the site and type and dose of treatment (if any), if yes to above Text As stated, blank if missing/NA 
D1 Blurred vision Presence of blurred vision Number 1=yes, 2=no, 3=not stated, -1=missing 
D1 Blurred vision comments State any details relating to above Text As stated, blank if missing/NA 
D1 Incr wt Received treatment for increased weight Number 1=yes, 2=no, 3=not stated, -1=missing 
D1 Incr wt comments State the type and dose of treatment, if yes to above Text As stated, blank if missing/NA 
D1 Pneumothorax Presence and/or treatment of pneumothorax Number 1=yes, 2=no, 3=not stated, -1=missing 
D1 Pneumothorax comments State details of pneumothorax and treatment, if yes to above. Text As stated, blank if missing/NA 
D1 Other morbidity 1 (1-7) Indicator field for whether any other morbidities experienced not covered 
within these fields 
Number 1=yes, 2=no, 3=not stated, -1=missing 
D1 Other comments (1-7) State any other morbidity Text As stated, blank if NA. If more than one separated 
by a comma. 
 
For post-operative days 5, 8 and 15 the following fields are also collected in relation to delayed discharge at the end of the C-POMS data table. 
Field name/variable Definition Type of field Code in database 
D5 POMS=0 Indicator field: All POMS indicator fields entered as no (to define other 
reasons for delayed discharge) 
Number 1=yes, 2=no, 3= not stated, -1=missing/NA 
D5 Social reasons Delayed discharge due to social reasons Number 1=yes, 2=no, 3= not stated, -1=missing/NA 
D5 Equipment Delayed discharge due to equipment needed at home Number 1=yes, 2=no, 3= not stated, -1=missing/NA 
D5 Mobility Delayed discharge due to mobility (ongoing physiotherapy or occupational Number 1=yes, 2=no, 3= not stated, -1=missing/NA 
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therapy needs) 
D5 Institution Delayed discharge due to institutional failure (transport not booked, no 
out-patient appointment or follow-up arranged) 
Number 1=yes, 2=no, 3= not stated, -1=missing/NA 
D5 Delayed dc Delayed discharge due to lack of rehab or other bed Number 1=yes, 2=no, 3= not stated, -1=missing/NA 
D5 DC today Discharged today Number 1=yes, 2=no, 3= not stated, -1=missing/NA 
D5 Other medical Delayed discharge due to any other medical reason (not covered in C-
POMS criteria) 
Number 1=yes, 2=no, 3= not stated, -1=missing/NA 
D5 Other medical state State medical reason for delayed discharge Text As stated, blank if missing/NA 
D5 Other comments State any other comments relating to delayed discharge Text As stated, blank if NA. If more than one separated 
by a comma. 
 
Outcome data table 
Field name/Variable Definition Type of field Code in database 
Study number Unique identifier Text As stated 
Hosp No Hospital number Text As stated 
DOAdmICU Date of admission to ICU Date As stated, 01/01/2001 if missing 
DODcICU Date of discharge from ICU Date As stated, 01/01/2001 if missing 
Dcicu post-op day Post-operative day discharged from ICU Number As stated, -1=missing 
Dest from ICU Indicator code: Ward destination following discharge from ICU Number 1=ITU, 2=HDU, 3=ACW, 4=3rd floor monitoring 
bay, 5=3rd floor, 6=4th floor, 7=other 
Dest ICU other State other destination if 7in indicator code Text As stated, blank if missing/NA 
DODCphysio Post-operative day of discharge from physiotherapist Number As stated, -2=not known, -1=missing 
DOHospDC Date of discharge from Heart Hospital Date As stated, 01/01/2001 if missing 
DCPost-op day Post-operative day on day of discharge Number As stated, -1=missing/NA 
Dcday of wk Day of the week discharged on Text As stated, NA if not applicable 
DC destination Indicator field: Destination of discharge (home, other NHS hospital (state 
NHS gen (state hospital), convalescence, RIP if died) 
Text As stated, blank if missing 
DODC Tr Hosp Date of discharge from transferred to hospital, if transfer indicated in 
indicator field 
Date As stated, 01/01/2001 if missing/NA 
DOD Needs indicator field Date of death Needs indicator field Date As stated, 01/01/2001 if missing/NA  Needs 
indicator field 
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In-hosp death Indicator field: Identify whether participant died during course of overall 
admission for surgery 
Number 1=yes, 2=no, -1=missing/NA 
Cause of death State course of death as documented in medical notes, if yes to indicator 
field 
Text As stated, blank if missing/NA 
DC services Indicator field: Required services were required on discharge Number 1=yes, 2=no, 3=not stated, -1=missing 
DC DN Required district nurse on discharge, if yes in indicator field Number 1=yes, 2=no, 3=not stated, -1=missing 
DC SS Required social services on discharge, if yes in indicator field Number 1=yes, 2=no, 3=not stated, -1=missing 
DC services other State if required other services on discharge Text As stated, blank if missing/NA 
DC services comments State any additional comments regarding discharge services Text As stated, blank if no other comments 
Outcome comments State any additional outcome comments Text As stated, blank if NA. If more than one separated 
by a comma. 
Total post-op LOS Total post-operative length of stay.  Includes length of stay in local hospital 
if transferred from Heart Hospital 
  
 
SCTS data table 
Magovern variables highlighted as such where they are included in the dataset purely for the Magovern model. 
Variables from SCTS database are collected according to SCTS definitions 
Field name/Variable Definition Type of field Code in database 
Study number Unique identifier Text As stated 
Hosp no Hospital number Text As stated 
Diabetes (rx) Identified the type of management, if any, for diabetes Text As stated, blank if missing 
Diabetes Recode of diabetes management Number 1=yes (all types of treatment), 2=no (non-diabetic), -
1=not stated/missing 
Smoking Cigarette smoking history.  Never: has never smoked cigarettes; Ex: has 
smoked one or more cigarettes per day in the past but not within the last 
month; Current: regularly smokes one or more cigarette per day or has 
smoked in the last month 
Text As stated, blank if missing 
Smoking code Recode of smoking Number 1=current, 2=ex, 3=never, -1=not stated/missing 
History of pulmonary disease Pulmonary medical history.  No: no history of pulmonary disease; 
COAD/Emphysema: participant requires medication for chronic pulmonary 
Text As stated, blank if missing 
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disease or FEV1 less that 75% predicted value.  Venous pO2 <600mgHg, 
pCO2 >50mmHg; Asthma: intermittent or allergic reversible airway disease 
treated with bronchodilators or steroids 
Hx Pul Dis code Recode of pulmonary Number 1=yes, 2=no, -1=not stated/missing 
Renal (e/p) Renal medical history.  No: No history of renal disease and creatinine 
<200umol/l on admission; Functioning  transplant: functioning renal 
transplant irrespective of creatinine; Creatinine >200umol/l: creatinine 
>200umol/l at the time of surgery; Acute renal failure: acute renal failure 
within 6 weeks of surgery necessitating any form of dialysis up to the time 
of surgery; Chronic renal failure: chronic renal failure on regular dialysis 
Text As stated, blank is missing 
Renal Recode of renal Number 1=yes, 2=no, -1=not stated/missing 
Neurological dysfunction (e/p) Indicator code: History of neurological disease affecting ambulation or 
day-to-day functioning.  
Text As stated, blank if missing 
Neuro hx Recode of neurological dysfunction Number 1=yes, 2=no, -1=not stated/missing 
History of neurological disease CVA with full recovery, No history of neurological disease, TIA or RIND. Text As stated, blank if missing 
GI tract Gastrointestinal medical history. No: no history of GI problems; Peptic 
ulcer: previous surgery, medical treatment or current treatment for known 
peptic ulceration. 
Text As stated, blank if missing 
GI Hx Recode of GI tract Number 1=yes, 2=no, -1=not stated/missing 
Hypercholesteraemia A history of serum cholesterol of greater than 5.0mmol or lower if on 
treatment 
Number 1=yes, 2=no, -1=not stated/missing 
Family history of IHD Does the patient have a family history of ischaemic heart disease? Number 1=yes, 2=no, -1=not stated/missing 
Hypertension Identifies if the patient has hypertension defined as receiving treatment or 
dietary advice or if blood pressure has been recorded greater than 
140/90mmHg on two occasions, or lower if on medication. 
Number 1=yes, 2=no, -1=not stated/missing 
Extracardiac arteriopathy Indicates if the patient has a history of peripheral vascular disease (PVD).  
Defined as history or evidence of aneurysm or occlusive peripheral 
vascular disease or carotid disease, including aortic aneurysm, previous 
aorto-iliac or peripheral vascular surgery, or reduced or absent peripheral 
pulses and/or angiographic stenosis of more than 50%.  Includes femoral 
or carotid bruits as evidence of PVD. 
Number 1=yes, 2=no, -1=not stated/missing 
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Parsonnet score (PATS) Total parsonnet score Number 1=yes, 2=no, -1=not stated/missing 
EuroSCORE (additive) Total additive EuroSCORE Number 1=yes, 2=no, -1=not stated/missing 
Operative priority Operative status.  Elective: routine admission from the waiting list. The 
procedure can be deferred without risk; Urgent: patients who have not 
been scheduled for routine admission from the waiting list but who require 
surgery on the current admission for medical reasons.  They cannot be 
sent home without surgery; Emergency: unscheduled patients with 
ongoing refractory cardiac compromise. There should be no delay in 
surgical intervention irrespective of the time of day; Salvage: patients 
requiring CPR en-route to the operating theatre or prior to anaesthetic 
induction.  
Number 1=Elective, 2=urgent, 3=emergency, 4=salvage, -
1=missing 
Ejection fraction category Left ventricular function (EF).  Good: EF of 50%; Fair: EF 30-49%; Poor: 
EF <30% 
Text As stated, blank if missing 
EF code Recode of ejection fraction category Number 1=good, 2=fair, 3= poor, -1=missing 
PPM The patient has any type of pacemaker (temporary or permanent) Number 1=yes, 2=no, -1=not stated/missing 
CCSC Canadian Cardiovascular Society score for angina.  CCS Class I - ordinary 
physical activity such as walking, climbing stairs does not cause angina. 
Angina occurs with strenuous, rapid or prolonged exertion at work or 
recreation.  CCS Class II - Slight limitation of ordinary activity. Angina 
occurs on walking or climbing stairs rapidly, walking uphill, walking or stair-
climbing after meals, or in cold, or in wind, or under emotional stress, or 
only during the few hours after awakening. Walking more than two blocks 
on the level and climbing more than one flight of ordinary stairs at a 
normal pace and in normal conditions.  CCS Class III - Marked limitations 
of ordinary physical activity. Angina occurs on walking one to two blocks 
on the level and climbing one flight of stairs in normal conditions and at a 
normal pace. CCS Class IV - Inability to carry on any physical activity 
without discomfort - anginal symptoms may be present at rest. 
Number 0=none, 1= Class 1, 2=Class 2, 3=Class 3, 4=Class 
4, -1=not stated/missing 
NYHA New York Heart Association dyspnoea status (see pre-op table for 
definitions) 
Number 1=Class 1, 2= Class 2, 3= Class3, 4=Class 4, -
1=not stated/missing 
Extent of coronary disease The number of major vessels (LAD, Cx, RCA system) with >50% Text As stated, blank if missing 
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narrowing in any angiographic view (excludes left main stem) 
No Dis Vessels Recode of extent of coronary disease Number 0=normal, 1=single vessel disease, 2=double 
vessel disease, 3=triple vessel disease, -1=not 
stated/missing 
LMS>50% Left main stem stenosis of >50% diameter is present observed in any 
angiographic view 
Number 1=yes, 2=no, -1=not stated/missing 
Height (cm) Participant height (cms) Number As stated, -1=not stated/missing 
Weight (kg) Participant weight (kg) Number As stated, -1=not stated/missing 
BMI Magovern indicator field:  kg/m2.   
Body mass index calculated from height and weight. 
Number As stated, -1=not stated/missing 
CCF Magovern indicator field:  Documented history of or treatment for heart 
failure and/or clinical evidence of heart failure (S3 gallop, jugular venous 
distention, pleural effusion, pulmonary oedema, peripheral oedema or 
radiographic evidence of interstitial oedema) 
Number 1=yes (current), 2=no (never), 3=In past, -1=not 
stated/missing 
Cardiogenic shock Patient in shock prior to operation.  BP<100mmHg, pulse >100bpm, 
patient cool, clammy, or requiring inotropes, intra-aortic balloon pump or 
CPS to support circulation. 
Number 1=yes, 2=no, -1=not stated/missing 
Heart rhythm Pre-op arrhythmia within two weeks prior to surgery.  Normal: patient in 
sinus rhythm; Atrial fibrillation/flutter: Demonstrable, chronic or paroxysmal 
atrial fibrillation or flutter; Complete Heart Block: no association of p waves 
to QRS complexes or pacing system in place; VF/VT: sustained VF/VT 
requiring cardioversion or IV medication (i.e. amiodarone infusion).  
Recoded from SCTS text field. 
Number 1=normal sr, 2=atrial arrhythmia, 3=ventricular 
arrhythmia, 4=CHB/pacing, -1=not stated/missing 
No of Prev MI’s Number of previous Q-wave myocardial infarctions Number 0=none, 1=one, 2=two or more, -1=not 
stated/missing 
Previous PCI Identifies whether the patient has undergone percutaneous coronary 
intervention in any hospital on this hospital admission 
Number 1=PCI >24hrs before op, previous admission, 2=no, 
3=failed, -1=not stated/missing 
Cardioplegia method Method of cardioplegia used stating solution (blood/crystalloid), 
temperature (cold/warm), infusion mode (antegrade, retrograde), timing 
(intermittent/continuous) 
Text As stated, blank if missing 
1=antegrade, 2=antegrade, intermittent, warm 
blood, 3=antegrade, intermittent, cold blood, 4= 
antegrade cold blood, 5= antegrade, retrograde, 
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intermittent cold blood, 6=antegrade, intermittent 
blood, -1=missing 
Circulatory arrest time Circulatory arrest time (mins) Number As stated, -1=not stated/missing 
XC time Cumulative aortic cross clamp time (mins) Number As stated, -1=not stated/missing 
CPB? Cardiopulmonary bypass used for part or all of the procedure Number 1=yes, 2=no, -1=not stated/missing 
CPB time Cumulative cardiopulmonary bypass time (mins) Number As stated, -1=not stated/missing 
Extubation time Time of extubation Text Date and time as stated, blank if missing 
Hours ventilated Total number of whole hours ventilated, if less than 24 hours Number As stated, blank if missing 
Days ventilated Total number of whole days ventilated, if more than 24 hours Number As stated, blank if missing 
Rtn theatre? Indicator code: Did the patient have to return to theatre Number 1=yes, 2=no, -1=not stated/missing 
Rtn theatre reason If yes above, the reason for return to theatre Text As stated, blank if missing 
Stay on ICU (nights) Total length of stay on the intensive care unit, whole number of nights Number As stated, -1=not stated/missing 
Readmitted ICU Was the patient readmitted to ICU Number 1=yes, 2=no, -1=not stated/missing 
Post-op stay (days) Total length of post-operative stay in the Heart Hospital, whole number of 
days 
Number As stated, -1=not stated/missing 
Total hospital stay (days) Total length of hospital stay from admission to discharge Number As stated, -1=not stated/missing 
Patient status Indicator field, Patient status at discharge (alive or dead) Text As stated, blank if missing 
Cause of death If indicated dead above, the cause of death as stated in the medical notes. Text As stated, blank if missing/NA 
 
New variables 
Field name/Variable Definition Type of 
field 
Code in database Details 
Pulmonary C-POMS indicator field: New requirement for oxygen or respiratory support (including 
nebuliser therapy, or request for chest physiotherapy on or after D5); pleural effusion 
requiring drainage 
Number 1=yes, 0=no, -1=missing 
SupplO2 New requirement for oxygen or respiratory support (including nebuliser therapy, or 
request for chest physiotherapy on or after D5) 
Number 1=yes, 2=no, 3= not stated, 
-1=missing 
Nebs New requirement for nebuliser therapy Number 1=yes, 2=no, 3= not stated, 
-1=missing 
Chest physio New request for chest physiotherapy on or after D5 Number 1=yes, 2=no, 3= not stated, 
-1=missing 
New C-POMS definitions 
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Pleuraleff pleural effusion requiring drainage Number 1=yes, 2=no, 3= not stated, 
-1=missing 
Infectious C-POMS indicator field: Currently on antibiotics and/or has had a temperature of 
>38°C in the last 24 hours and/or has a white cell count/CRP level requiring in-hospital 
review or treatment 
Number 1=yes, 0=no, -1=missing 
Temp38 a temperature of >38°C in the last 24 hours Number 1=yes, 2=no, 3= not stated, 
-1=missing 
WCCorCRP white cell count/CRP level requiring in-hospital review or treatment Number 1=yes, 2=no, 3= not stated, 
-1=missing 
Renal C-POMS indicator field: Presence of decreased urine output requiring intervention 
(including IV frusemide), increased serum creatinine (>30% from pre operative level); 
urinary catheter in situ; new urinary incontinence; serum potassium abnormalities* 
requiring treatment 
Number 1=yes, 0=no, -1=missing, -
2=creatinine not done and 
no other renal morbidity 
present 
DecrUO Presence of decreased urine output requiring intervention (including IV frusemide) Number 1=yes, 2=no, 3= not stated, 
-1=missing 
Urineincontinence New urinary incontinence Number 1=yes, 2=no, 3= not stated, 
-1=missing 
Kabnorm Serum potassium abnormalities* requiring treatment Number 1=yes, 2=no, 3= not stated, 
-1=missing 
GI C-POMS indicator field: Unable to tolerate an enteral diet for any reason including 
nausea, vomiting and abdominal distension; the presence of a nasogastric tube; 
diagnosis of a gastrointestinal bleed; presence of diarrhoea 
Number 1=yes, 0=no, -1=missing 
NGtube The presence of a nasogastric tube Number 1=yes, 2=no, 3= not stated, 
-1=missing 
GIbleed Diagnosis of a gastrointestinal bleed Number 1=yes, 2=no, 3= not stated, 
-1=missing 
Diarrhoea Presence of diarrhoea Number 1=yes, 2=no, 3= not stated, 
-1=missing 
CV C-POMS indicator field: The use of inotropic therapy for any cardiovascular cause; the 
presence of pacing wires (on or after D5) and/or requiring temporary or new permanent 
pacing**; diagnostic tests or therapy within the last 24 hours for any of the following: 1) 
Number 1=yes, 0=no, -1=missing 
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new MI or ischaemia, 2) hypotension (requiring fluid therapy, pharmacological therapy or 
omission of pharmacological therapy 3) atrial or ventricular  arrhythmias, 4) cardiogenic 
pulmonary oedema, thrombotic event (requiring anticoagulation), 5) hypertension 
(pharmacological therapy or omission of pharmacological therapy) 
Inotropes The use of inotropic therapy for any cardiovascular cause Number 1=yes, 2=no, 3= not stated, 
-1=missing 
Pacingwires The presence of pacing wires (on or after D5)  Number 1=yes, 2=no, 3= not stated, 
-1=missing 
Hypotension hypotension (requiring fluid therapy, pharmacological therapy or omission of 
pharmacological therapy 
Number 1=yes, 2=no, 3= not stated, 
-1=missing 
Wound C-POMS indicator field: Wound dehiscence requiring surgical exploration or drainage 
of pus from the operation wound with or without isolation of organisms; presence of 
chest drains; wound pain significant enough to require continuing or escalating 
analgesic intervention 
Number 1=yes, 0=no, -1=missing 
Woundpain  Wound pain significant enough to require continuing or escalating analgesic intervention Number 1=yes, 2=no, 3= not stated, 
-1=missing 
Neuro C-POMS indicator field: New neurological deficit (including confusion, delirium, coma, 
lack of coordination, drowsy/slow to wake, poor swallow, blurred vision, sedated, 
changing loss of consciousness) 
Number 1=yes, 2=no, 3= not stated, 
-1=missing 
Confusion The presence of confusion Number 1=yes, 2=no, 3= not stated, 
-1=missing 
Delirium The presence of delirium Number 1=yes, 2=no, 3= not stated, 
-1=missing 
Focal deficit The presence of focal deficit Number 1=yes, 2=no, 3= not stated, 
-1=missing 
Coma The presence of coma Number 1=yes, 2=no, 3= not stated, 
-1=missing 
Agitated The presence of agitation Number 1=yes, 2=no, 3= not stated, 
-1=missing 
Lackofcoord The presence of lack of coordination Number 1=yes, 2=no, 3= not stated, 
-1=missing 
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Drowsy The presence of drowsiness Number 1=yes, 2=no, 3= not stated, 
-1=missing 
Poorswallow The presence of poor swallow Number 1=yes, 2=no, 3= not stated, 
-1=missing 
Blurredvision The presence of blurred vision Number 1=yes, 2=no, 3= not stated, 
-1=missing 
Sedated The patient has received sedation  Number 1=yes, 2=no, 3= not stated, 
-1=missing 
ChangingLOC The presence of changing loss of consciousness Number 1=yes, 2=no, 3= not stated, 
-1=missing 
Haematol C-POMS indicator field: Untherapeutic INR requiring pharmacological therapy or 
omission of pharmacological therapy; Requirement for any of the following within the last 
24 hrs: packed erythrocytes, platelets, fresh-frozen plasma, or cryoprecipitate 
Number 1=yes, 0=no, -1=missing 
Electrolyte C-POMS indicator field: Electrolyte (including sodium, urea, phosphate) imbalance 
requiring oral or intravenous intervention (NB not including potassium as included in 
Renal category) 
Number 1=yes, 2=no, 3= not stated, 
-1=missing 
Sodium Sodium imbalance requiring oral or intravenous intervention Number 1=yes, 2=no, 3= not stated, 
-1=missing 
Urea Urea imbalance requiring oral or intravenous intervention Number 1=yes, 2=no, 3= not stated, 
-1=missing 
Phosphate Phosphate imbalance requiring oral or intravenous intervention Number 1=yes, 2=no, 3= not stated, 
-1=missing 
Review C-POMS indicator field: Remaining in hospital for further review, investigation and/or 
procedure 
Number 1=yes, 2=no, 3= not stated, 
-1=missing 
Further review Remaining in hopital for further review Number 1=yes, 2=no, 3= not stated, 
-1=missing 
Investigation/procedure Remaining in hospital for an investigation or procedure Number 1=yes, 2=no, 3= not stated, 
-1=missing 
 
All these new variables will 
be prefixed with D1, D3, D5, 
D8 and D15 for the 
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corresponding post-
operative day 
CPOMS0 Indicator field: All C-POMS indicator fields entered as no (to define other reasons for 
delayed discharge) 
Number   
All POMS indicator fields 
became prefixed with 
D1POMS, D3POMS, 
D5POMS, D8POMS and 
D15POMS for the 
corresponding post-
operative day 
    
D3Score C-POMS summary score on postoperative D3 of all C-POMS domains whereby each 
domain is coded 1 for present and 0 for absent 
Number As stated (between 0-13), -
1=missing 
C-POMS summary score 
also calculated for D5, D8 
and D15 
D3Renal2 Recode of C-POMS Renal domain for post-operative D3: whereby -2=creatinine not 
done and no other renal morbidity present recoded to ‘no morbidity' 
Number 1=yes, 0=no, -1=missing New C-POMS Renal 
definition also recoded  for 
D5, D8 and D15 
D3Score2 Revised C-POMS summary score on postoperative D3 following recoding of the Renal 
domain 
Number As stated (between 0-13), -
1=missing 
Version 2 of the C-POMS 
summary score also 
calculated for D5, D8 and 
D15 
D3LOS Subsequent post-operative length of stay (in days) from post-operative D3  As stated, -1=missing Also calculated for D5, D8 
and D15 
D3noCPOMS Where no C-POMS domains are present at all.  1=no CPOMS, 0=C-POMS 
present 
Also calculated for D5, D8 
and D15 
Euroscoregrps Euroscore categorised into groups whereby a score of 0-2 is a low risk, 3-5 is a medium 
risk and 6+ is a high risk. 
 1= low risk, 2=medium risk, 
3=high risk 
 
Euroscore2grps EuroSCORE categorised into high (5-14) and low (0-4) risk groups Number 1=high risk, 0=low risk, -
1=missing 
 
POSSUM2grps POSSUM score categorised into high (19-40) and low (12-18) risk groups Number 1=high risk, 0=low risk, -
1=missing 
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MagCardiogenicscore Magovern score for cardiogenic shock: systolic blood pressure <90mmHg or mean 
systemic blood pressure <50mmHg and a cardiac index <2.0 L/min per m2 and evidence 
of peripheral hypoperfusion.  
Number If present, score 7  
MagOPpriorityscore Magovern score for operative priority: a) Emergency: operation performed immediately 
to prevent death. The patient is having an acute event that is refractory to all other 
appropriate forms of therapy and is haemodynamically unstable, b) Urgent: operation 
performed to reverse or stabilise a deteriorating clinical condition. These patients are 
already receiving support with an IABP, inotropic medications, nitroglycerine or heparin, 
or a combination of these. These operations are done 24 to 48hrs from the onset of the 
acute event precipitating the symptoms. 
Number Emergency: If present, 
score 5 
Urgent: If present, score 4 
 
MagCathClosurescore Magovern score for catheter coronary closure: Iatrogenic coronary occlusion or 
dissection secondary to a diagnostic catheterisation or angioplasty, or both, that requires 
heart surgery within 24hrs. 
Number If present, score 4  
MagEFscore Magovern score for ejection fraction: LVEF <30% Number If present, score 4  
MagAgescore Magovern score for age Number ≥75yrs  score 3, 70-74yrs 
score 2, 65-69yrs score 1 
 
MagCardiomegalyscore Magovern score for cardiomegaly: Enlarged heart as determined by chest radiography 
or echocardiography 
Number If present, score 2  
MagPVDscore Magovern score for peripheral vascular disease: Claudication, ischaemic rest pain, prior 
peripheral vascular surgery, absent lower extremity pulses, inability to insert an IABP 
from the groin and/or a non-invasive vascular test showing >50% obstruction of the 
lower extremity vasculature. 
Number If present, score 2  
MagCreatininescore Magovern score for renal dysfunction: a) renal insufficiency: History of chronic renal 
disease or serum creatinine ≥1.9mg/dl, or both, b) renal dysfunction: serum creatinine 
1.5-1.9mg/dl. 
Number a) present, score2 
b) present, score1 
 
MagDiabetesscore Magovern score for diabetes: a) insulin-dependent diabetes mellitus: Diabetes that has 
been treated with insulin before the surgical procedure, b) non-insulin-dependent 
diabetes: Diabetes that has been treated with oral hypoglycaemic agents before the 
surgical procedure. 
Number a) present, score 2 
b) present, score 1 
 
MagBMIscore Magovern score for body mass index: Low body mass index ≤24kg/m2. Number If present, score 1  
MagGenderscore Magovern score for gender Number Female score 1  
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MagReopscore Magovern score for re-operation: Any prior cardiac surgery Number If present, score 1  
MagAnaemiascore Magovern score for anaemia: Haemoglobin ≤12.5g/dl and ≤11g/dl for males and 
females, respectively, or the need for pre-operative blood transfusion. 
Number If present, score 1  
MagCOPDscore Magovern score for chronic obstructive pulmonary disease: Pulmonary disease that 
results in functional disability or requires bronchodilator therapy and/or results in 
abnormal spirometry, as defined by a forced expiratory volume in 1 second, <75% of 
that predicted. 
Number If present, score 1  
MagCVDscore Magovern score for cerebrovascular disease: History of TIA, embolic stroke or non-
embolic stroke, and/or angiographic evidence of internal carotid stenosis >50%. 
Number If present, score 1  
MagAlbuminscore Magovern score for albumin: Low serum albumin <4.0mg/dl Number If present, score 1  
MagUreaN2score Magovern score for blood urea nitrogen: Blood urea nitrogen >29mg/dl. Number If present, score 1  
MagCCFscore Magovern score for congestive cardiac failure: Documented history of or treatment for 
heart failure and/or clinical evidence of heart failure, as defined by an S3 gallop, jugular 
venous distention, pleural effusion, pulmonary oedema, peripheral oedema or 
radiographic evidence of interstitial oedema (flash pulmonary oedema excluded). 
Number If present, score 1  
MagAtrialarrhyscore Magovern score for atrial arrhythmia: Prior admission or out-patient treatment for atrial 
fibrillation, flutter or tachycardia. 
Number If present, score 1  
Magovernscore Magovern total score (maximum 37) Number As stated, -1=missing  
Magovernscore2 Magovern score divided into high (6-18 (max score in study)) and low (0-5) risk groups Number 1=high risk, 0=low risk, -
1=missing 
 
NoPOMSD3 Where no POMS domains are present at all.  1=no POMS, 0=POMS 
present 
Also calculated for D5, D8 
and D15 
D15POMSscore POMS summary score on postoperative D15 of all POMS domains whereby each 
domain is coded 1 for present and 0 for absent 
Number As stated (between 0-9), -
1=missing 
POMS summary score 
also calculated for D5, D8 
and D15 
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Normal clinical ranges at study site 
 Units Normal range 
Albumin g/L 34-50 
Creatinine umol/L 49-92 
Haemaglobin g/dl 11.5-15.5 
Internationalised Normal Ratio (INR) NA 1.0-2.0 
Potassium mmol/l 3.5-5.1 
Sodium mmol/l 135-145 
Urea mmol/l 1.7-8.3 
White cell count X109/L 3.0-10.0 
 
MAP: 70-100mmHg 
CVP 2-6mmHg 
 
Arterial Blood gas values 
pH    7.35-7.45 
pCO2    4.7-5.9kPa 
pO2    11-13 kPa 
cBase    +3 - -3 mmolL 
HCO3    21-28 mmol/L 
Hb    11.5-15.5 g/dl 
K+    3.5-5.1 mmol/L 
Chloride   98-107 mmol/L 
Na+    135-145 mmol/L 
Glu    5-7 mmol/L 
Lactacte   0.2-0.8 mmol/L 
 
Venous Blood Gas Values 
pH    7.35-7.45  
pCO2    5.6-6.7 KPa 
pO2    5.0-5.6 KPa 
others as for ABG above 
 
Venous blood  
Urea    1.7-8.3 mmol/L 
Potassium   3.5-5.1 mmol/L 
Sodium    135-145 mmol/L 
Creatinine   49-92 umol/L (Female); 66-112 umol/L (Male) 
Albumin   34-50 g/L 
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Haemoglobin   11.5-15.5 g/dl (Female); 13.0-17.0 g/dl (Male)  
White cell count   3.0-10.0 x109/L 
 
Haemodynamic variables 
SBP    <140 mmHg (pre-surgery), <120mmHg (post surgery) 
DBP    <85 mmHg (pre-surgery), <70 mmHg (post surgery) 
HR    60-100 bpm 
Respiratory rate  12-20 bpm 
SaO2    96-100% 
CVP 
MAP    80-100  
Actual body temperature 36.5-37.2 oC 
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Appendix 3: Additional morbidities not captured within POMS in the pilot study. 
Morbidity All 
patients 
(n=100) 
Frequency 
at post-op 
day 1 
(n=100) 
Frequency 
at post-op 
day 3 
(n=100) 
Frequency 
at post-op 
day 5 
(n=95) 
Frequency 
at post-op 
day 8 
(n=33) 
Frequency 
at post-op 
day 15 
(n=10) 
Blood sugar control 
(actrapid 
infusion/uncontrolled 
diabetes) 
97 88 26 11 4 3 
Potassium supplements 83 73 22 13 3 1 
IV Frusemide 
(stat/infusion) 
41 36 6 5 2 1 
Magnesium supplements 34 27 9 2 0 0 
Salbutamol or atrovent 
nebs 
29 18 15 7 3 1 
Hypertension 27 19 10 7 0 0 
Chest drains remain insitu 17 17 1 0 1 0 
Inotropic support 17 16 3 0 0 0 
Hypotension (fluid/omit 
medication/drink) 
15 10 9 3 0 0 
*Pleural effusion  15 1 7 10 0 0 
LLL collapse 13 11 0 1 0 0 
Constipation 11 0 5 6 2 0 
Untherapeutic INR 9 0 1 6 5 1 
Diarrhoea 8 0 3 3 2 0 
Low Hb (ferrous sulphate) 7 0 2 4 2 1 
Peripheral oedema 6 1 1 2 2 2 
Blurred vision/visual 
disturbances (not 
delirium) 
5 0 3 1 1 0 
Increased weight (medical 
Rx) 
5 0 2 4 0 0 
Pneumothorax 5 4 2 1 0 0 
Sputum spec/productive 
cough 
5 3 3 2 0 0 
Miscellaneous – changes 
in medication ?reason 
4 0 1 4 0 0 
NG tube free drainage 4 4 1 0 1 0 
NBM for procedure 4 1 0 1 2 0 
Propofol infusion 4 3 1 0 0 0 
ATN 3 0 2 0 1 0 
Fall 3 0 2 1 0 0 
Fluid therapy (clinically 
dry) 
3 1 1 1 0 0 
MRSA +ve/eradication 3 3 3 3 1 1 
Poor nutrition 3 0 2 0 2 1 
Urinary 3 0 2 1 1 0 
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dribbling/incontinence/rete
ntion 
Reintubated 3 2 1 0 2 0 
Surgical emphysema 3 2 2 1 1 0 
Cellulitis 2 0 1 1 1 0 
Fluid overload 2 2 0 0 0 0 
Increased wound pain 2 0 1 1 0 0 
Low urine output (filling) 2 1 0 0 0 0 
Oral thrush 2 0 1 1 0 0 
Paracetamol for pyrexia 
(low) 
2 0 1 1 0 0 
Slow coordination 2 1 1 0 0 0 
Adrenaline infusion 1 0 1 0 0 0 
Anxiety attack 1 0 1 0 0 0 
Awaiting ICD insertion 1 0 0 0 1 0 
Behaviour out of character 1 0 0 1 0 0 
Blood cultures (+ve) 1 1 0 0 0 0 
Calcium resonin for 
resistant hyperkalaemia 
1 0 0 0 1 0 
Cerebral irritation 1 1 0 1 0 0 
Chest pain 1 1 0 0 0 0 
Cramps 1 0 1 0 0 0 
Depression 1 0 1 0 0 0 
Femoral line insitu 1 0 1 1 1 0 
Fluid restriction 1 1 1 0 0 0 
GI bleed 1 0 0 0 0 1 
Increased platelets 1 0 0 1 0 0 
Ischaemic injury to bowel 1 0 0 0 1 0 
Left arm weakness 1 1 0 0 0 0 
Low CVP (fluid) 1 1 0 0 0 0 
Mild cognitive impairment 1 0 0 0 1 0 
NaCl supplements 1 0 0 1 0 0 
Paracetamol IV 1 1 0 0 0 0 
Pericardial effusion 1 0 0 1 0 0 
Pericarditis 1 1 0 0 0 0 
Phosphate infusion 1 0 1 0 0 0 
Phrenic nerve palsy 1 0 0 0 1 0 
Polyuric 1 0 1 0 0 0 
Poor respiratory function 1 0 1 0 0 0 
Poor swallowing 1 1 0 0 0 0 
PPM insertion 1 0 0 0 0 1 
Previous diabetic ulcers 
oedematous 
1 0 0 1 0 0 
Rash 1 0 1 0 0 0 
Sedation and insertion of 
vascath 
1 0 1 0 0 0 
Sore throat (simple 
linctus) 
1 1 1 0 0 0 
Tremor 1 0 0 1 0 0 
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UTI 1 0 0 1 0 0 
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Appendix 4: Pre-operative baseline and immediate post-operative characteristics 
 
Pre-operative baseline characteristics (n=450). Values are n(%) or mean, range and standard 
deviation (SD) as appropriate. 
 Frequency/mean Range SD 
Medical history    
Non-cardiac history    
Cerebrovascular disease 
- CVA 
32  ( 7.1) 
17   (3.8) 
  
COPD 56 (12.4)   
Liver disease   1   (0.2)   
GI history 
   - Bleeding 
51 (11.3) 
18   (4.0) 
  
Renal 
     - Dialysis 
12   (2.7) 
 7   (1.6) 
  
Hypothyroidism 21   (4.7)   
Varicose veins 65 (14.4)   
Immunosuppressants   1   (0.2)   
    
Cardiac history    
History of previous MI 149 (33.1)   
Number of previous MIs – 1 
                                       -  2 
119 (79.9) 
  30 (20.1) 
  
Previous PCI   36   (8.0)   
Re-operation 
Number of previous operations -1 
                                                  -2 
  19   (4.2) 
  16   (3.6) 
    3   (0.7) 
  
Congestive heart failure 102 (22.7)   
Cardiogenic shock (current)     1   (0.2)   
Permanent pacemaker     8  (1.8)   
Atrial arrhythmia (current)   43   (9.6)   
    
Symptoms    
NYHA Class -I 
- II 
- III 
- IV 
116 (25.8) 
207 (46.0) 
102 (22.7) 
  23   (5.1) 
  
CCSC – 0   86 (19.1)   
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- I 
- II 
- III 
- IV 
  93 (20.7) 
114 (25.3) 
  85 (18.9) 
  44   (9.8) 
    
Cardiac risk factors    
Smoking – Current 
- Ex 
- Never 
  49 (10.9) 
250 (55.6) 
151 (33.6) 
  
Hypertension 306 (68.0)   
Hypercholesteraemia 347 (77.1)   
Diabetes 105 (23.3)   
Family history of IHD 239 (53.1)   
    
Current medication     
ACEI   24   (5.3)   
Antiarrhythmic   24   (5.3)   
Anticoagulant   52 (11.6)   
Antiplatelet 260 (57.8)   
Beta Blocker 219 (48.7)   
Calcium Channel Blocker 102 (22.7)   
Diuretic 112 (24.9)   
Nitrate 104 (23.1)   
Potassium channel activators   40   (8.9)   
Statin 277 (61.6)   
H2 agonist     8   (1.8)   
PPI   96 (21.3)   
Angiotensin II inhibitor   45 (10.0)   
Thyroid medication   26   (5.8)   
Asthma medication   32   (7.1)   
Pain medication   27   (6.0)   
Diabetic medication   72 (16.0)   
Alpha adreno blockers   23   (5.1)   
Other lipid medication   11   (2.4)   
Other hypertension medication     3   (0.7)   
    
Examination and Investigation    
Heart rhythm* – Sinus rhythm 
               - Atrial arrhythmia 
379 (84.2) 
  37   (8.2) 
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               - Ventricular arrhythmia 
               - Paced/CHB 
    2   (0.4) 
    6   (1.3) 
Number of diseased vessels -0 
- 1 
- 2 
- 3 
  80 (17.8) 
  36   (8.0) 
  80 (17.8) 
245 (54.4) 
  
LMS >50%   93 (20.7)   
Extracardiac arteriopathy   42   (9.3)   
Catheter coronary closure     0   (0.0)   
LVEF – Good 
- Fair 
- Poor 
327 (72.7) 
  90 (20.0) 
  24   (5.3) 
  
Cardiomegaly   57 (12.7)   
Albumin (g/L) 43.7 19.0-52.0 3.9 
Urea (mmol/L) 6.9 2.0-26.0 2.6 
Potassium (mmol/L) 4.4 3.3-6.3 0.4 
Sodium (mmol/L) 139.6 128.0-148.0 3.2 
Haemaglobin (g/dL) 13.3 7.9-17.3 1.6 
White cell count (x109L) 1.13 1.0-4.0 0.4 
Creatinine (mmol/L) 99.9 46.0-838.0 66.2 
Systolic blood pressure (mmHg) 133.3 90.0-212.0 19.0 
Heart rate (bpm) 69.5 44.0-150.0 13.9 
Glasgow Coma Score 15 15.0-15.0 0.0 
Respiratory rate (breaths/min) 19.2 10.0-30.0 2.1 
Temperature (oC) 36.5 36.0-38.0 0.4 
Height (cm) 168.9 131.0-197.0 9.6 
Weight (kg) 81.3 44.0-158.0 16.9 
BMI (kg/m2) 28.5 18.3-62.9 5.6 
    
Pre-operative risk assessment    
Parsonnet 11.3 0-37 8.1 
EuroSCORE 4.2 1-14 2.8 
POSSUM 19.5 12-40 5.0 
* *Heart rhythm was taken as that reported by medical staff on the patient’s integrated care pathway 
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Immediate ICU characteristics (n=450). Values are n(%) or mean, range and standard deviation 
(SD) as appropriate. 
 Frequency/mean Range SD 
First ABG on ICU    
FiO2 0.96  0.4-1.0  
pH  7.4 7.2-7.5 0.06 
pCO2 (kPa) 5.3 3.0-9.0 0.8 
pO2 (kPa) 18.0 2.9-47.8 7.2 
SBCc (mmol/L) 22.1 -4.2-93.7 4.9 
SBEc (mmol/L) -1.7 -10.3-99.8 7.7 
K (mmol/L) 4.1 3.0-6.9 0.4 
Na (mmol/L) 139.3 110.0-162.0 2.9 
Glucose (mmol/L) 6.1 1.0-13.1 1.7 
Hb (g/dl) 9.7 6.0-14.4 1.6 
    
Immediate post-operative medication     
RBC 
  - number of units (mean/patient) 
100 (22.2) 
1.9 
 
1.0-9.0 
 
1.6 
Platelets 
  - number of units (mean/patient) 
  35   (7.8) 
1.3 
 
1.0-5.0 
 
0.8 
FFP 
  - number of units (mean/patient) 
  38   (8.4) 
3.1 
 
1.0-11.0 
 
2.1 
Cryoprecipitate     0   (0.0)   
Aprotinin   52 (11.6)   
Enoximone   62 (13.8)   
Inotropes   71 (15.8)   
Vasoconstrictors 139 (30.9)   
Frusemide     6   (1.3)   
Morphine 437 (97.1)   
Propofol 441 (98.0)   
GTN 422 (93.8)   
Actrapid 444 (98.7)   
SNP   18   (4.0)   
    
Immediate post-operative measurements 
and examinations (12 hrs) 
   
Intubation grade – 1 
- 2 
330 (73.3) 
  69 (15.3) 
  
 283
- 3   30   (6.7) 
Heart rhythm*  - Sinus rhythm 
                   - Sinus tachycardia 
                   - Sinus bradycardia 
                   - Atrial fibrillation 
                   - Other 
321 (71.3) 
  54 (12.0) 
  21   (4.7) 
  19   (4.2) 
  34   (7.6) 
,  
Paced 131 (29.1)   
Total gelofusin (ml) 1318.9 0.0-3150.0 585.1 
Total IVI (ml) 846.5 50.0-2417.0 209.2 
Total input (ml) 2802.3 746.0-9766.0 827.7 
Total urine output (ml) 1339.15 0.0-3280.0 531.2 
Total drainage (ml) 485.64 70.0-3035.0 366.1 
Lowest sedation score -3 -5--2 0.7 
Total K supplements (mmol) 53.5 0.0-200.0 35.9 
Total MgSO4 supplements (mmol) 0.6 0.0-30.0 3.5 
Heart rate (bpm) 87.5 50.0-180.0 14.7 
Systolic blood pressure (mmHg) 138.7 70.0-188.0 19.3 
Diastolic blood pressure (mmHg) 61.8 35.0-100.0 9.9 
Respiratory rate (bpm) 12.2 8.0-26.0 1.7 
First temperature (oC) 35.8 32.0-38.0 0.9 
Highest temperature (oC) 36.9 36.0-38.0 0.4 
CVP (mmHg) 14.8 3.0-29.0 3.7 
MAP (mmHg) 85.0 60.0-130.0 10.3 
    
Day 1 medication    
RBC 
  - number of units (mean/patient) 
63 (14.0) 
1.4 
 
1.0-5.0 
 
0.7 
Platelets 
  - number of units (mean/patient) 
  3  (0.7) 
1.0 
 
1.0-1.0 
 
0.0 
FFP 
  - number of units (mean/patient) 
10 (2.2) 
2.3 
 
1.0-4.0 
 
1.1 
Cryoprecipitate 
  - number of units (mean/patient) 
  2 (0.4) 
10.0 
 
10.0-10.0 
 
0.0 
Aprotinin     6   (1.3)   
Enoximone   68 (15.1)   
Inotropes   53 (11.8)   
Vasoconstrictors   93 (20.7)   
Furosemide   25   (5.6)   
Morphine 423 (94.0)   
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Propofol   38   (8.4)   
GTN 400 (88.9)   
Actrapid 438 (97.3)   
SNP     7   (1.6)   
    
Day 1 examinations    
Drains out 381 (84.7)   
Heart rhythm* - Sinus rhythm 
                   - Sinus tachycardia  
                   - Sinus bradycardia  
                   - Atrial fibrillation 
                   - Other 
289 (64.2) 
  66 (14.7) 
  12   (2.7) 
  47 (10.4) 
  33   (7.3) 
  
Heart rate (bpm) 90.6 30.0-190.0 17.3 
Systolic blood pressure (mmHg) 142.2 90.0-215.0 19.2 
Diastolic blood pressure (mmHg) 63.5 42.0-100.0 9.9 
Respiratory rate (breathspm) 22.4 10.0-47.0 5.0 
Temperature (oC) 37.1 35.6-38.6 0.5 
CVP (mmHg) 16.1 0.0-30.0 4.6 
*Heart rhythm was taken as that reported by ICU nursing staff 
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Appendix 5: The McMaster Framework for discriminative, predictive and evaluative tools(89) 
 Discriminative  Predictive Evaluative 
Function  
 
to distinguish between 
individuals or groups on an 
underlying dimension when 
no external criterion or gold 
standard is available for 
validating these measures 
To classify individuals into a set 
of pre-defined measurement 
categories. When a gold 
standard is available, either 
concurrently or prospectively, to 
determine whether individuals 
have been classifed correctly. 
To measure the magnitude of 
longitudinal change in an 
individual or group on the 
dimension of interest 
Item selection  Tap important components 
of the domain 
 Universal applicability to 
respondents 
 Stability over time 
Statistical association with 
criterion measure 
 Tap areas related to change 
in health status 
 Responsiveness to clinically 
significant change 
Item scaling Short response sets which 
facilitate uniform 
interpretation 
Response sets which maximise 
correlations with the criterion 
measure 
Response sets with sufficent 
graduations to register change 
Item reduction  Internal scaling or 
consistency 
 Comprehensiveness and 
reduction of random error 
vs respondent burden 
Power to predict vs respondent 
burden 
Responsiveness vs respondent 
burden 
Reliability Large and stable intersubject 
variation: correlation 
between replicate measures 
Stable inter and intra-subject 
variation: chance corrected 
agreement between replicate 
measures 
Stable intersubject variation: 
insignificant variation between 
replicate measures 
Validity Cross-sectional construct 
validity: relationship between 
index and external measures 
at a single point in time 
Criterion validity: agreement 
with criterion measure 
Longitudinal construct validity: 
relationship between changes 
in index and external measures 
over time 
Responsiveness Not relevant Not relevant Power of the test to detect a 
clinically important difference 
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Appendix 6: Categorisation of additional morbidities/items into POMS and/or new domains 
POMS domains 
Pulmonary 
Pleural effusion 
Renal/ Metabolic 
IV furosemide 
Pneumothorax Polyuric 
Surgical emphysema Na abnormalities 
Saline/other nebs IDC bypassing  
DIB/pain from chest drains  UO decreased 
Reintubated K abnormalities 
Aspiration pneumonia Haematuria 
Respiratory acidosis U and E abnormalities 
Chest physiotherapy Prostate problems 
Ventilation difficulties Incontinence 
SOB after medication Kidney pain 
Bronchoscopy UTI 
Phrenic nerve palsy Cramps 
Hiccups Increased base excess 
Haemothorax Phosphate infusion - low phosphate 
Infectious Lactate abnormalities 
Infected venflon site Urinary retention 
Abscess Gastrointestinal 
MRSA +ve  NG tube 
WCC/CRP abnormalities GI bleed 
Eye infection (from CPAP) Constipated 
Pyrexia (<38oC) Stomach ache 
Fungal infection under breast  NBM for procedure 
Oral thrush Decreased appetite 
UTI Indigestion 
Pus from tooth Diarrhoea 
Shingles Incontinence 
Hot/sweaty Ischaemic bowel 
Shivery  Gastric reflux 
Haematological PR Bleed  
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Cardiovascular 
Hypertension 
Neurological 
Blurred vision 
Inotropes  Weird dreams 
Hypotension Cerebral irritation 
K abnormalities Lack of coordination 
PW remain insitu Panic attack 
Tamponade ?echo Depression 
Aortic dissection? Changing LOC 
Pericarditis? Dizzy   
HR decreased  Tinnitus 
Tamponade ?theatre Sedated  
Dizzy  Insomnia  
Vasovagal Poor swallow  
Large heart on CXR   Drowsy/slow to wake  
Pericardial effusion Pressure in head  
Lactate abnormalities Feels weak/tired 
Cold extremities Pain 
Wound complications Shoulder pain 
Chest drains Pain around ears 
Wound pain Headache 
Chest support in situ Pain from chest drains 
Wound tightness Back pain 
Sternal click   Wound pain 
Numbness of donor site Stomach ache 
Rtn to theatre (4 for bleeding, 1 rewire, I wire 
removal) 
General pain 
 Ileostomy pain 
 Wound tightness 
 Pain in foot 
 Kidney pain 
 R pleural chest pain 
 Swollen knee 
 Sore throat 
 Pericarditis 
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POTENTIAL NEW DOMAINS 
Blood sugar management  General pain 
Blood sugar  Shoulder pain 
Previous diabetic ulcers  Pain around ears 
Anticoagulation Headache 
Untherapeutic INR Back pain 
Platelet abnormalities Wound pain 
Clotting coagulopathy General pain 
Bleeding with treatment Ileostomy pain 
Hypo/hypervolaemia Wound tightness 
Thirsty Pain in foot 
Na abnormalities  Kidney pain 
UO decreased  Right pleural chest pain 
Positive fluid balance  Swollen knee 
Overfilled Sore throat 
U and E abnormalities  Pericarditis 
IV fluids/dehydration Liver function 
CVP/fluid challenge Decreased liver function 
Clinical review/intervention ALT increased 
D1 post-procedure Vitamin B  
NBM for procedure Fluid overload 
WCC/CRP abnormalities Peripheral oedema 
For investigation/procedure Increased weight 
D2/3 post procedure Whole body oedema 
For review Overfilled 
Tamponade ?echo Skin complaint 
Aortic dissection? Blisters 
Pericarditis? Rash 
Tamponade ?theatre Itchy 
Bronchoscopy Iodine burns 
Rtn to theatre Allergic reaction 
Mobility Severe bruising 
Mobility encouragement Miscellaneous 
Occupational therapy assistance Increased sense of smell 
Fall Nose bleed 
Death Collapse (no obvious cause) 
 Dexamethasone – reason for given not 
documented in medical notes 
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Potential to delete as not morbidities  
Nicotine patches  
Femoral line  
 
 290
Appendix 7: C-POMS domain level analysis. 
 
Euroscore 
C-POMS domain frequencies in those with high and low risk of post-operative mortality 
(EuroSCORE) on D3. Values shown are for the presence of the C-POMS morbidity and are n(%). 
Data available in 449/450 
D3: C-POMS 
domains 
EuroSCORE: low 
risk (n=267) 
EuroSCORE: high 
risk (n=182) 
p  
Pulmonary 171 (64.0) 147 (80.8) 0.000 
Infectious 75 (28.1) 46 (25.3) 0.291 
Renal 66 (24.7) 94 (51.6) 0.000 
Gastrointestinal 64 (24.0) 70 (38.5) 0.001 
Cardiovascular 123 (46.1) 110 (60.4) 0.002 
Neurological 63 (23.6) 45 (24.7) 0.434 
Haematological 29 (10.9) 30 (16.5) 0.057 
Wound complication 9 (3.4) 10 (5.5) 0.194 
Pain 4 (1.5) 5 (2.7) 0.278 
Endocrine 69 (25.8) 68 (37.2) 0.007 
Electrolyte 3 (1.1) 7 (3.8) 0.058 
Review 5 (1.9) 8 (4.4) 0.103 
Assisted ambulation 89 (33.5) 116 (63.7) 0.000 
 
C-POMS domain frequencies in those with high and low risk of post-operative mortality 
(EuroSCORE) on D5. Values shown are for the presence of the C-POMS morbidity and are n(%). 
D5: C-POMS 
domains 
EuroSCORE: low 
risk (n=244) 
EuroSCORE: high 
risk (n=182) 
p  
Pulmonary 74 (30.3) 85 (46.7%) 0.001 
Infectious 92 (37.7) 63 (34.6) 0.542 
Renal 31 (12.7) 44 (24.2) 0.003 
Gastrointestinal 59 (24.2) 57 (31.3) 0.123 
Cardiovascular 104 (42.6) 105 (57.7) 0.002 
Neurological 31 (12.7) 27 (14.8) 0.569 
Haematological 34 (13.9) 36 (19.8) 0.114 
Wound complication 10 (4.1) 7 (3.8) 1.000 
Pain 19 (7.8) 14 (7.7) 1.000 
Endocrine 22 (9.0) 26 (14.4) 0.090 
Electrolyte 3 (1.2) 6 (3.3) 0.180 
Review 15 (6.1) 13 (7.1) 0.679 
 291
Assisted ambulation 42 (17.2) 76 (41.8) 0.000 
 
C-POMS domain frequencies in those with high and low risk of post-operative mortality 
(EuroSCORE) on D8. Values shown are for the presence of the C-POMS morbidity and are n(%). 
D8: C-POMS 
domains 
EuroSCORE: low 
risk (n=80) 
EuroSCORE: high 
risk (n=100) 
p  
Pulmonary 24 (30.0) 44 (44.0) 0.064 
Infectious 49 (61.2) 53 (53.0) 0.292 
Renal 15 (18.8) 36 (35.6) 0.013 
Gastrointestinal 19 (23.8) 31 (31.0) 0.317 
Cardiovascular 40 (50.0) 73 (73.0) 0.002 
Neurological 13 (16.2) 24 (24.0) 0.265 
Haematological 18 (22.5) 30 (30.0) 0.310 
Wound complication 6 (7.5) 7 (7.0) 1.000 
Pain 6 (7.5) 8 (8.0) 1.000 
Endocrine 12 (15.0) 14 (14.0) 1.000 
Electrolyte 3 (3.8) 5 (5.0) 1.000 
Review 7 (8.8) 11 (10.9) 0.803 
Assisted ambulation 22 (27.5) 46 (46.0) 0.013 
 
C-POMS domain frequencies in those with high and low risk of post-operative mortality 
(EuroSCORE) on D15. Values shown are for the presence of the C-POMS morbidity and are n(%). 
D15: C-POMS 
domains 
EuroSCORE: low 
risk (n=16) 
EuroSCORE: high 
risk (n=32) 
p  
Pulmonary 4 (25.0) 15 (46.9) 0.213 
Infectious 12 (75.0) 16 (50.0) 0.127 
Renal 4 (25.0) 15 (46.9) 0.213 
Gastrointestinal 2 (12.5) 11 (34.4) 0.170 
Cardiovascular 10 (62.5) 21 (65.6) 1.000 
Neurological 3 (18.8) 7 (21.9) 1.000 
Haematological 5 (31.2) 4 (12.5) 0.138 
Wound complication 6 (37.5) 6 (18.8) 0.178 
Pain 1 (6.2) 2 (6.2) 1.000 
Endocrine 4 (25.0) 6 (18.8) 0.712 
Electrolyte 0 (0.0) 1 (3.1) 1.000 
Review 1 (6.2) 5 (15.6) 0.648 
Assisted ambulation 2 (12.5) 17 (53.1) 0.011 
 
 
 292
 
 
POSSUM Physiological Component 
C-POMS domain frequencies and post-operative mortality and morbidity risk on D3. Values shown 
are for the presence of the C-POMS morbidity and are n(%). Data available on n=435/450. 
D3: C-POMS 
domains 
POSSUM: low risk 
(n=227) 
POSSUM: high risk 
(n=208) 
p  
Pulmonary 142 (62.6) 165 (79.3) 0.000 
Infectious 60 (26.4) 56 (26.9) 0.914 
Renal 44 (19.4) 107 (51.4) 0.000 
Gastrointestinal 61 (26.9) 69 (33.2) 0.173 
Cardiovascular 100 (44.1) 124 (59.6) 0.002 
Neurological 52 (22.9) 52 (25.0) 0.653 
Haematological 24 (10.6) 31 (14.9) 0.195 
Wound complication 10 (4.4) 8 (3.8) 0.814 
Pain 4 (1.8) 4 (1.9) 1.000 
Endocrine 51 (22.5) 82 (39.2) 0.000 
Electrolyte 2 (0.9) 6 (2.9) 0.161 
Review 6 (2.6) 7 (3.3) 0.781 
Assisted ambulation 65 (28.8) 132 (63.5) 0.000 
 
C-POMS domain frequencies and post-operative mortality and morbidity risk on D5. Values shown 
are for the presence of the C-POMS morbidity and are n(%). Data available on n=412/426. 
D5: C-POMS 
domains 
POSSUM: low risk 
(n=210) 
POSSUM: high risk 
(n=202) 
p  
Pulmonary 56 (26.7) 98 (48.5) 0.000 
Infectious 74 (35.2) 76 (37.6) 0.682 
Renal 17 (8.1) 54 (26.7) 0.000 
Gastrointestinal 56 (26.7) 56 (27.7) 0.825 
Cardiovascular 82 (39.0) 117 (57.9) 0.000 
Neurological 25 (11.9) 30 (14.9) 0.389 
Haematological 30 (14.3) 35 (17.3) 0.420 
Wound complication 9 (4.3) 7 (3.5) 0.800 
Pain 14 (6.7) 17 (8.4) 0.577 
Endocrine 16 (7.6) 29 (14.4) 0.039 
Electrolyte 2 (1.0) 5 (2.5) 0.276 
Review 12 (5.7) 16 (7.9) 0.436 
Assisted ambulation 34 (16.2) 79 (39.1) 0.000 
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C-POMS domain frequencies and post-operative mortality and morbidity risk on D8. Values shown 
are for the presence of the C-POMS morbidity and are n(%). Data available on n=174/181 
D8: C-POMS 
domains 
POSSUM: low risk 
(n=60) 
POSSUM: high risk 
(n=114) 
p  
Pulmonary 20 (33.3) 44 (38.6) 0.513 
Infectious 41 (68.3) 57 (50.0) 0.025 
Renal 11 (18.3) 38 (33.0) 0.051 
Gastrointestinal 13 (21.7) 34 (29.8) 0.285 
Cardiovascular 35 (58.3) 73 (64.0) 0.512 
Neurological 10 (16.7) 26 (22.8) 0.432 
Haematological 18 (30.0) 30 (26.3) 0.598 
Wound complication 5 (8.3) 8 (7.0) 0.767 
Pain 4 (6.7) 10 (8.8) 0.774 
Endocrine 6 (10.0) 19 (16.7) 0.265 
Electrolyte 3 (5.0) 5 (4.3) 1.000 
Review 4 (6.7) 14 (12.2) 0.305 
Assisted ambulation 17 (28.3) 49 (43.0) 0.071 
 
C-POMS domain frequencies and post-operative mortality and morbidity risk. Values shown are for 
the presence of the C-POMS morbidity and are n(%). Data available on n= 45/48. 
D15: C-POMS 
domains 
POSSUM: low risk 
(n=15) 
POSSUM: high risk 
(n=30) 
p  
Pulmonary 3 (20.0) 14 (46.7) 0.110 
Infectious 11 (73.3) 15 (50.0) 0.203 
Renal 5 (33.3) 13 43.3) 0.748 
Gastrointestinal 3 (20.0) 9 (30.0) 0.722 
Cardiovascular 10 (66.7) 18 (60.0) 0.752 
Neurological 3 (20.0) 7 (23.3) 1.000 
Haematological 3 (20.0) 6 (20.0) 1.000 
Wound complication 5 (33.3) 7 (23.3) 0.496 
Pain 1 (6.7) 2 (6.7) 1.000 
Endocrine 2 (13.3) 7 (23.3) 0.695 
Electrolyte 0 (0.0) 1 (3.3) 1.000 
Review 1 (6.7) 5 (16.7) 0.647 
Assisted ambulation 2 (13.3) 15 (50.0) 0.023 
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Magovern score 
C-POMS domain frequencies and post-operative morbidity risk on D3. Values shown are for the 
presence of the C-POMS morbidity and are n(%). Data available on n=333/450. 
D3: C-POMS 
domains 
Magovern score: 
low risk 
(n=184) 
Magovern score: 
high risk 
(n=149) 
p  
Pulmonary 117 (63.6) 119 (79.9) 0.002 
Infectious 45 (24.5) 40 (26.8) 0.705 
Renal 41 (22.3) 70 (47.0) 0.000 
Gastrointestinal 43 (23.4) 48 (32.2) 0.084 
Cardiovascular 85 (46.2) 90 (60.4) 0.011 
Neurological 46 (25.0) 32 (21.5) 0.516 
Haematological 25 (13.6) 21 (14.1) 1.000 
Wound complication 7 (3.8) 3 (2.0) 0.521 
Pain 2 (1.1) 5 (3.4) 0.250 
Endocrine 36 (19.6) 59 (39.3) 0.000 
Electrolyte 3 (1.6) 5 (3.3) 0.475 
Review 5 (2.7) 4 (2.7) 1.000 
Assisted ambulation 60 (32.8) 87 (58.4) 0.000 
 
C-POMS domain frequencies and post-operative morbidity risk. Values shown are for the presence 
of the C-POMS morbidity and are n(%). Data available on 315/426 
D5: C-POMS 
domains 
Magovern score: 
low risk 
(n=168) 
Magovern score: 
high risk 
(n=147) 
p  
Pulmonary 47 (28.0) 67 (45.6) 0.001 
Infectious 58 (34.5) 51 (34.7) 1.000 
Renal 15 (8.9) 40 (27.2) 0.000 
Gastrointestinal 38 (22.6) 46 (31.3) 0.097 
Cardiovascular 76 (45.2) 84 (57.1) 0.042 
Neurological 18 (10.7) 21 (14.3) 0.392 
Haematological 30 (17.9) 23 (15.6) 0.652 
Wound complication 7 (4.2) 6 (4.1) 1.000 
Pain 9 (5.4) 15 (10.2) 0.136 
Endocrine 6 (3.6) 23 (15.6) 0.000 
Electrolyte 1 (0.6) 5 (3.4) 0.101 
Review 9 (5.4) 10 (6.8) 0.641 
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Assisted ambulation 22 (13.1) 62 (42.2) 0.000 
 
C-POMS domain frequencies and post-operative morbidity risk. Values shown are for the presence 
of the C-POMS morbidity and are n(%). Data available on 130/181 
D8: C-POMS 
domains 
Magovern score: 
low risk 
(n=52) 
Magovern score: 
high risk 
(n=78) 
p  
Pulmonary 14 (26.9) 33 (42.3) 0.094 
Infectious 30 (57.7) 43 (55.1) 0.857 
Renal 5 (9.4) 26 (33.3) 0.002 
Gastrointestinal 12 (23.1) 22 (28.2) 0.548 
Cardiovascular 29 (55.8) 56 (71.8) 0.090 
Neurological 7 (13.5) 19 (24.4) 0.179 
Haematological 15 (28.8) 22 (28.2) 1.000 
Wound complication 4 (7.7) 6 (7.7) 1.000 
Pain 2 (3.8) 7 (9.0) 0.314 
Endocrine 3 (5.8) 11 (14.1) 0.159 
Electrolyte 2 (3.8) 1 (1.3) 0.565 
Review 5 (9.4) 9 (11.5) 0.780 
Assisted ambulation 11 (21.2) 33 (42.3) 0.014 
 
C-POMS domain frequencies and post-operative morbidity risk. Values shown are for the presence 
of the C-POMS morbidity and are n(%). Data available on 30/48 
D15: C-POMS 
domains 
Magovern score: 
low risk 
(n=11) 
Magovern score: 
high risk 
(n=19) 
p 
Pulmonary 1 (9.1) 9 (47.4) 0.049 
Infectious 8 (72.7) 10 (52.6) 0.442 
Renal 2 (18.2) 8 (42.1) 0.246 
Gastrointestinal 2 (18.2) 4 (21.1) 1.000 
Cardiovascular 7 (63.6) 13 (68.4) 1.000 
Neurological 1 (9.1) 4 (21.1) 0.626 
Haematological 3 (27.3) 3 (15.8) 0.641 
Wound complication 5 (45.5) 4 (21.1) 0.225 
Pain 0 (0.0) 2 (10.5) 0.520 
Endocrine 1 (9.1) 5 (26.3) 0.372 
Electrolyte - - - 
Review 1 (9.1) 2 (10.5) 1.000 
Assisted ambulation 0 (0.0) 7 (36.8) 0.029 
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Appendix 8: POMS domain level analysis. 
 
EuroSCORE 
POMS domain frequencies in those with high and low risk of post-operative mortality (EuroSCORE) 
on D3. Values shown are for the presence of the POMS morbidity and are n(%). Data available in 
n=449/450. 
D3: POMS domains EuroSCORE: low 
risk (n=267) 
EuroSCORE: high 
risk (n=182) 
p  
Pulmonary 158 (59.2) 145 (79.7) 0.000 
Infectious 69 (25.8) 44 (24.2) 0.740 
Renal 63 (23.6) 91 (50.0) 0.000 
Gastrointestinal 53 (19.9) 59 (32.4) 0.003 
Cardiovascular 105 (53.6) 91 (50.0) 0.026 
Neurological 43 (16.1) 37 (20.3) 0.260 
Haematological 3 (1.1) 9 (4.9) 0.017 
Wound complication 3 (1.1) 8 (4.4) 0.057 
Pain 4 (1.5) 5 (2.7) 0.496 
 
POMS domain frequencies in those with high and low risk of post-operative mortality (EuroSCORE) 
on D5. Values shown are for the presence of the POMS morbidity and are n(%).  
D5: POMS domains EuroSCORE: low 
risk (n=244) 
EuroSCORE: high 
risk (n=182) 
p  
Pulmonary 47 (19.3) 66 (36.3) 0.000 
Infectious 92 (37.7) 62 (34.1) 0.476 
Renal 27 (11.1) 40 (22.0) 0.003 
Gastrointestinal 47 (19.3) 46 (25.3) 0.155 
Cardiovascular 90 (36.9) 94 (51.6) 0.003 
Neurological 22 (9.0) 23 (12.6) 0.265 
Haematological 1 (0.4) 5 (2.7) 0.088 
Wound complication 3 (1.2) 4 (2.2) 0.467 
Pain 5 (2.0) 6 (3.3) 0.540 
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POMS domain frequencies in those with high and low risk of post-operative mortality (EuroSCORE) 
on D8. Values shown are for the presence of the POMS morbidity and are n(%).  
D8: POMS domains EuroSCORE: low 
risk (n=80) 
EuroSCORE: high 
risk (n=100) 
p  
Pulmonary 17 (21.2) 33 (33.0) 0.095 
Infectious 49 (61.2) 51 (51.0) 0.178 
Renal 14 (17.5) 31 (30.7) 0.056 
Gastrointestinal 15 (18.8) 23 (23.0) 0.582 
Cardiovascular 39 (48.8) 65 (65.0) 0.034 
Neurological 9 (11.2) 18 (18.0) 0.294 
Haematological 1 (1.2) 7 (7.0) 0.078 
Wound complication 6 (7.5) 6 (6.0) 0.768 
Pain 3 (3.8) 6 (6.0) 0.733 
 
POMS domain frequencies in those with high and low risk of post-operative mortality (EuroSCORE) 
on D15. Values shown are for the presence of the POMS morbidity and are n(%).  
D15: POMS domains EuroSCORE: low 
risk (n=16) 
EuroSCORE: high 
risk (n=32) 
p  
Pulmonary 2 (12.5) 12 (37.5) 0.098 
Infectious 12 (42.9) 16 (50.0) 0.127 
Renal 3 (18.8) 15 (46.9) 0.068 
Gastrointestinal 1 (6.2) 7 (21.9) 0.240 
Cardiovascular 10 (62.5) 18 (56.2) 0.763 
Neurological 3 (18.8) 5 (15.6) 1.000 
Haematological 2 (12.5) 2 (6.2) 0.592 
Wound complication 6 (37.5) 5 (15.6) 0.144 
Pain 1 (2.1) 2 (4.2) 1.000 
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POSSUM (Physiological component) 
POMS domain frequencies and post-operative mortality and morbidity risk on D3. Values shown are 
for the presence of the POMS morbidity and are n(%). Data available in n=435/450 
D3: POMS domains POSSUM: low 
risk (n=227) 
POSSUM: high risk 
(n=208) 
p  
Pulmonary 131 (42.3) 162 (77.9) 0.000 
Infectious 55 (24.2) 53 (25.5) 0.824 
Renal 40 (17.6) 105 (50.5) 0.000 
Gastrointestinal 52 (22.9) 56 (26.9) 0.374 
Cardiovascular 82 (36.1) 105 (50.5) 0.003 
Neurological 32 (14.1) 46 (22.1) 0.033 
Haematological 5 (2.2) 6 (2.9) 0.764 
Wound complication 4 (1.8) 6 (2.9) 0.530 
Pain 4 (1.8) 4 (1.9) 1.000 
 
POMS domain frequencies and post-operative mortality and morbidity risk on D5. Values shown are 
for the presence of the POMS morbidity and are n(%). Data available on n=412/426. 
D5: POMS domains POSSUM: low 
risk (n=210) 
POSSUM: high risk 
(n=202) 
p  
Pulmonary 36 (17.1) 73 (36.1) 0.000 
Infectious 74 (35.2) 75 (37.1) 0.758 
Renal 13 (6.2) 50 (24.8) 0.000 
Gastrointestinal 48 (22.9) 41 (20.3) 0.551 
Cardiovascular 73 (34.8) 102 (50.5) 0.001 
Neurological 16 (7.6) 27 (13.4) 0.075 
Haematological 2 (1.0) 4 (2.0) 0.441 
Wound complication 2 (1.0) 4 (2.0) 0.441 
Pain 5 (2.4) 6 (3.0) 0.768 
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POMS domain frequencies and post-operative mortality and morbidity risk on D8. Values shown are 
for the presence of the POMS morbidity and are n(%). Data available on n=174/181. 
D8: POMS domains POSSUM: low 
risk (n=60) 
POSSUM: high risk 
(n=114) 
p  
Pulmonary 16 (26.7) 31 (27.2) 1.000 
Infectious 40 (66.7) 56 (49.1) 0.037 
Renal 11 (18.3) 32 (27.8) 0.198 
Gastrointestinal 11 (18.3) 25 (21.9) 0.695 
Cardiovascular 34 (56.7) 66 (57.9) 0.874 
Neurological 7 (11.7) 19 (16.7) 0.503 
Haematological 2 (3.3) 6 (5.3) 0.716 
Wound complication 5 (8.3) 7 (6.1) 0.754 
Pain 3 (5.0) 6 (5.3) 1.000 
 
POMS domain frequencies and post-operative mortality and morbidity risk on D15. Values shown 
are for the presence of the POMS morbidity and are n(%). Data are available on n=45/48. 
D15: POMS domains POSSUM: low risk 
(n=15) 
POSSUM: high risk 
(n=30) 
p  
Pulmonary 2 (13.3) 11 (36.7) 0.165 
Infectious 11 (73.3) 15 (50.0) 0.203 
Renal 4 (26.7) 13 (43.3) 0.341 
Gastrointestinal 2 (13.3) 5 (16.7) 1.000 
Cardiovascular 10 (66.7) 15 (50.0) 0.352 
Neurological 2 (13.3) 6 (20.0) 0.699 
Haematological 1 (6.7) 3 (10.0) 1.000 
Wound complication 5 (33.3) 6 (20.0) 0.464 
Pain 1 (6.7) 2 (6.7) 1.000 
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Magovern score 
POMS domain frequencies and post-operative morbidity risk on D3. Values shown are for the 
presence of the POMS morbidity and are n(%). Data available on n=333/450. 
D3: POMS domains Magovern score: 
low risk (n=184) 
Magovern score: 
high risk (n=149) 
p  
Pulmonary 108 (55.3) 149 (44.7) 0.000 
Infectious 40 (21.7) 40 (26.8) 0.303 
Renal 40 (21.7) 67 (45.0) 0.000 
Gastrointestinal 38 (20.7) 35 (23.5) 0.595 
Cardiovascular 74 (40.2) 74 (49.7) 0.096 
Neurological 34 (18.5) 25 (16.8) 0.773 
Haematological 3 (1.6) 5 (3.4) 0.475 
Wound complication 3 (1.6) 3 (2.0) 1.000 
Pain 2 (1.1) 5 (3.4) 0.250 
 
POMS domain frequencies and post-operative morbidity risk on D5. Values shown are for the 
presence of the POMS morbidity and are n(%). Data available on n=315/426. 
D5: POMS domains Magovern score: 
low risk (n=168) 
Magovern score: 
high risk (n=147) 
p  
Pulmonary 30 (17.9) 54 (36.7) 0.000 
Infectious 58 (34.5) 51 (34.7) 1.000 
Renal 12 (7.1) 37 (25.2) 0.000 
Gastrointestinal 31 (18.5) 37 (25.2) 0.170 
Cardiovascular 70 (41.7) 72 (49.0) 0.213 
Neurological 13 (7.7) 18 (12.2) 0.190 
Haematological 2 (1.2) 2 (1.4) 1.000 
Wound complication 1 (0.6) 2 (1.4) 0.600 
Pain 1 (0.6) 5 (3.4) 0.101 
 
 
 
 
 
 
 
 
 
 
 
 301
POMS domain frequencies and post-operative morbidity risk on D8. Values shown are for the 
presence of the POMS morbidity and are n(%). Data available in n=130/181. 
D8: POMS domains Magovern score: 
low risk (n=52) 
Magovern score: 
high risk (n=78) 
p  
Pulmonary 10 (19.2) 22 (28.2) 0.301 
Infectious 30 (57.7) 42 (53.8) 0.721 
Renal 5 (9.4) 22 (28.2) 0.014 
Gastrointestinal 9 (17.3) 18 (23.1) 0.511 
Cardiovascular 28 (53.8) 50 (64.1) 0.276 
Neurological 5 (9.6) 14 (17.9) 0.215 
Haematological 0 (0.0) 3 (3.8) 0.274 
Wound complication 4 (7.7) 5 (6.4) 1.000 
Pain 2 (3.8) 4 (5.1) 1.000 
 
POMS domain frequencies and post-operative morbidity risk on D15. Values shown are for the 
presence of the POMS morbidity and are n(%). Data available in n=30/48. 
D15: POMS domains Magovern score: 
low risk (n=11) 
Magovern score: 
high risk (n=19) 
p  
Pulmonary 0 (0.0) 7 (36.8) 0.029 
Infectious 8 (72.7) 10 (52.6) 0.442 
Renal 1 (9.1) 8 (42.1) 0.100 
Gastrointestinal 2 (18.2) 2 (10.5) 0.611 
Cardiovascular 7 (63.6) 12 (63.2) 1.000 
Neurological 1 (9.1) 4 (21.1) 0.626 
Haematological 1 (9.1) 0 (0.0) 0.367 
Wound complication 5 (45.5) 3 (15.8) 0.104 
Pain 0 (0.0) 2 (10.5) 0.520 
 
 
 
 
 
 
 
